

Risk Factors Comparison 2025-02-27 to 2024-03-28 Form: 10-K

Legend: **New Text** ~~Removed Text~~ ~~Unchanged Text~~ **Moved Text** **Section**

● Our business depends on license agreements with third parties to permit us to use patented technologies. The loss of any of our rights under these agreements could impair our ability to develop and market our products, if approved. ● If any of our pending patent applications do not issue, or are deemed invalid following issuance, we may lose valuable intellectual property protection. ● We rely on trade secret protection and other unpatented proprietary rights for important proprietary technologies, and any loss of such rights could harm our business, results of operations and financial condition. ● We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights. **Risks Related to Our Securities** ● The market price of our common stock may be significantly volatile. ● Our common stock may be delisted from The Nasdaq Capital Market if we fail to comply with continued listing standards. ● Future sales of our common stock in the public market could cause our stock price to fall. ● Our stockholders may experience significant dilution as a result of future equity offerings or issuances and exercise of outstanding options and warrants. ● Our ability to use net operating losses to offset future taxable income **are is** subject to certain limitations. ● We have never paid cash dividends on our common stock and do not anticipate paying dividends in the foreseeable future. **RISKS RELATED TO OUR BUSINESS AND OPERATIONS** We have a history of significant losses from operations and expect to continue to incur significant losses for the foreseeable future, and we may never achieve or maintain profitability. Since our inception, our expenses have substantially exceeded our revenue, resulting in continuing losses and an accumulated deficit of \$ ~~388.407~~ million at December 31, ~~2023~~ **2024**. For the years ended December 31, ~~2024 and 2023 and 2022~~, we incurred net losses of \$ ~~18.6 million and \$ 19.5 million and \$ 35.9 million~~, respectively. We currently have no product revenue and do not expect to generate any product revenue for the foreseeable future. Because we are committed to continuing our product research, development, clinical trial and commercialization programs, we will continue to incur significant operating losses unless and until we complete the development of IMNN- 001 and other new drug candidates and these drug candidates have been clinically tested, approved by the FDA and successfully marketed. The amount of future losses is uncertain. Our ability to achieve profitability, if ever, will depend on, among other things, the following, which we cannot guarantee: ~~us~~ or our collaborators successfully developing drug candidates, obtaining regulatory approvals to market and commercialize drug candidates, manufacturing any approved products on commercially reasonable terms, establishing a sales and marketing organization or suitable third- party alternatives for any approved product, generating sufficient sales revenue from our drug candidates, and raising sufficient funds to finance business activities. We might not be able to continue as a going concern, which could cause our stockholders to lose most or all of their investment. Our audited financial statements for the year ended December 31, ~~2023~~ **2024**, were prepared under the assumption that we would continue as a going concern. However, we have concluded that there is substantial doubt about our ability to continue as a going concern, therefore our independent registered public accounting firm included a “going concern” explanatory paragraph in its report on our financial statements for the year ended December 31, ~~2023~~ **2024**, indicating that, without additional sources of funding, our cash at December 31, ~~2023~~ **2024** is not sufficient for us to operate as a going concern for a period of at least one year from the date that the financial statements included in this Annual Report on Form 10- K are issued. Management’s plans concerning these matters, including our need to raise additional capital, are described in Note 2 of our financial statements included within this Annual Report on Form 10- K, however, management cannot assure you that its plans will be successful. If we cannot continue as a viable entity, our stockholders would likely lose most or all of their investment in us. We will need to raise additional capital to fund our planned future operations, and we may be unable to secure such capital without **significant** dilutive financing transactions. If we are not able to raise additional capital, we may not be able to complete the development, testing and commercialization of our drug candidates. We have not generated significant revenue and have incurred significant net losses in each year since our inception. For the year ended December 31, ~~2023~~ **2024**, we incurred a net loss of \$ ~~19.18~~ **5.6** million. We have incurred approximately \$ ~~388.407~~ million of cumulative net losses. As of December 31, ~~2023~~ **2024**, we had cash and cash equivalents ~~, short-term investments, interest receivable and net proceeds on the sale of net operating losses~~ of \$ ~~17.5~~ **0.9** million. We have substantial future capital requirements to continue our research and development activities and advance our drug candidates through various development stages **, including the Phase 3 registrational trial of IMNN- 001 in advanced ovarian cancer**. We are unable to estimate the duration and completion costs of our research and development projects or when, if ever, and to what extent we will receive cash inflows from the commercialization and sale of a product. Our inability to complete any of our research and development activities, preclinical studies or clinical trials in a timely manner or our failure to enter into collaborative agreements when appropriate could significantly increase our capital requirements and could adversely impact our liquidity. While our estimated future capital requirements are uncertain and could increase or decrease as a result of many factors, including the extent to which we choose to advance our research, development activities, preclinical studies and clinical trials, or if we are in a position to pursue manufacturing or commercialization activities, we will need significant additional capital to develop our drug candidates through development and clinical trials, obtain regulatory approvals and manufacture and commercialize approved products, if any. We do not know whether we will be able to access additional capital when needed or on terms favorable to us or our stockholders. Our inability to raise additional capital, or to do so on terms reasonably acceptable to us, would jeopardize the future success of our business. If we do not obtain or maintain FDA and foreign regulatory approvals for our drug candidates on a timely basis, or at all, or if the terms of any approval impose significant restrictions or limitations on use, we will be unable to sell those products and our business, results of operations and financial condition will be negatively affected. To obtain regulatory approvals from the FDA and foreign regulatory agencies, we must conduct clinical trials demonstrating that our drug candidates are safe and effective. We may need to amend ongoing trials, or the FDA and / or foreign regulatory agencies may require us to perform additional trials beyond those we planned. The testing and approval process requires substantial time, effort and resources, and generally takes a number of years to complete. The time to obtain approvals is also uncertain, and the FDA and foreign regulatory agencies have substantial discretion, at any phase of development, to terminate clinical studies, require additional clinical studies or other testing, delay or withhold approval, and mandate product withdrawals, including recalls. In addition, our drug candidates may have undesirable side effects or other unexpected characteristics that could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restricted label or the delay or denial of regulatory approval by regulatory authorities. Even if we receive regulatory approval of a product, the approval may limit the indicated uses for which the drug may be marketed. The failure to obtain timely regulatory approval of drug candidates, the imposition of marketing limitations, or a product withdrawal would negatively impact our business. Even if we receive approval, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and subject us to restrictions, withdrawal from the market, or penalties if we fail to comply with applicable regulatory requirements or if we experience unanticipated problems with our drug candidates, when and if approved. Finally, even if we obtain FDA approval of any of our drug candidates, we may never obtain approval or commercialize such products outside of the U. S., given that we may be subject to additional regulatory burdens in other markets. This could limit our ability to realize their full market potential. Drug development is an inherently uncertain process with a high risk of failure at every stage of development. Securing FDA or comparable foreign regulatory approval requires the submission of extensive preclinical and clinical data and supporting information for each therapeutic indication to establish the drug candidate’s safety and efficacy for its intended use. It takes years to complete the testing of a new drug or biological product and development delays and / or failure can occur at any stage of testing. Any of our present and future clinical trials may be delayed, halted, not authorized, or approval of any of our products may be delayed or may not be obtained due to any of the following: ● factors related to the ongoing effects of the COVID- 19 pandemic, including regulators or institutional review boards, or IRBs, or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; ● any preclinical test or clinical trial may fail to produce safety and efficacy results satisfactory to the FDA or comparable foreign regulatory authorities; ● preclinical and clinical data can be interpreted in different ways, which could delay, limit, or prevent marketing approval; ● negative or inconclusive results from a preclinical test or clinical trial or adverse events during a clinical trial could cause a preclinical study or clinical trial to be repeated or a development program to be terminated, even if other studies relating to the development program are ongoing or have been completed and were successful; ● the FDA or comparable foreign regulatory authorities can place a clinical hold on a trial if, among other reasons, it finds that subjects enrolled in the trial are or would be exposed to an unreasonable and significant risk of illness or injury; ● the facilities that we utilize, or the processes or facilities of third- party vendors, including without limitation the contract manufacturers who will be manufacturing drug substance and drug product for us or any potential collaborators, may not satisfactorily complete inspections by the FDA or comparable foreign regulatory authorities; and ● we may encounter delays or rejections based on changes in FDA policies or the policies of comparable foreign regulatory authorities during the period in which we develop a drug candidate, or the period required for review of any final marketing approval before we are able to market any drug candidate. In addition, information generated during the clinical trial process is susceptible to varying interpretations that could delay, limit, or prevent marketing approval. Moreover, early positive preclinical or clinical trial results may not be replicated in later clinical trials. As more drug candidates within a particular class of drugs proceed through clinical development to regulatory review and approval, the amount and type of clinical data that may be required by regulatory authorities may increase or change. Failure to demonstrate

adequately the quality, safety, and efficacy of any of our drug candidates would delay or prevent marketing approval. We cannot assure you that if clinical trials are completed, either we or our potential collaborators will submit applications for required authorizations to manufacture or market potential products or that any such application will be reviewed and approved by appropriate regulatory authorities in a timely manner, if at all. New gene- based products for therapeutic applications are subject to extensive regulation by the FDA and comparable agencies in other countries. The precise regulatory requirements with which we will have to comply, now and in the future, are uncertain due to the novelty of the gene- based products we are developing. The regulatory approval process for novel drug candidates such as ours can be significantly more expensive and take longer than for other, better known or more extensively studied drug candidates. Limited data exist regarding the safety and efficacy of DNA- based therapeutics compared with conventional therapeutics, and government regulation of DNA- based therapeutics is evolving. Regulatory requirements governing gene and cell therapy products have changed frequently and may continue to change in the future. The FDA has established the Office of Therapeutic Products within CBER, to consolidate the review of gene therapy and related products, and has established the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER in its review. It is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our drug candidates in either the U. S. or the European Union or how long it will take to commercialize our drug candidates. Adverse events or the perception of adverse events in the field of gene therapy generally, or with respect to our drug candidates specifically, may have a particularly negative impact on public perception of gene therapy and result in greater governmental regulation, including future bans or stricter standards imposed on gene- based therapy clinical trials, stricter labeling requirements and other regulatory delays in the testing or approval of our potential products. For example, if we were to engage an NIH- funded institution to conduct a clinical trial involving recombinant or nucleic acid molecules, we may be subject to review by an IBC and, in some cases, the NIH. Such review can delay the initiation of a clinical trial, even if the FDA has reviewed the trial design and details and approved its initiation. Conversely, the FDA can put an IND application on a clinical hold even if the IBC or the NIH has provided a favorable review. Such reviews and any new guidelines may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our drug candidates or lead to significant post- approval limitations or restrictions. Any increased scrutiny could delay or increase the costs of our product development efforts or clinical trials. Even if our products receive regulatory approval, they may still face future development and regulatory difficulties. Government regulators may impose ongoing requirements for potentially costly post- approval studies. This governmental oversight may be particularly strict with respect to gene- based therapies. If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected. We **have experienced and** may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. The enrollment of patients depends on many factors, including: ● the patient eligibility and exclusion criteria defined in the protocol; ● the size of the patient population required for analysis of the trial' s primary endpoints and the process for identifying patients; ● **delays in our research programs resulting from factors related to the COVID- 19 pandemic**; ● the willingness or availability of patients to participate in our trials; ● the proximity of patients to trial sites; ● the design of the trial; ● our ability to recruit clinical trial investigators with the appropriate competencies and experience; ● clinicians' and patients' perceptions as to the potential advantages and risks of the drug candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating; ● the availability of competing commercially available therapies and other competing drug candidates' clinical trials; ● our ability to obtain and maintain patient informed consents; and ● the risk that patients enrolled in clinical trials will drop out of the trials before completion. Our inability to enroll a sufficient number of patients for our clinical trials could result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our drug candidates, delay or halt the development of and approval processes for our drug candidates and jeopardize our ability to achieve our clinical development timeline and goals, including the dates by which we will commence, complete and receive results from clinical trials. Enrollment delays may also delay or jeopardize our ability to commence sales and generate revenues from our drug candidates. Any of the foregoing could cause the value of our company to decline and limit our ability to obtain additional financing, if needed. We rely on third parties to conduct all of our clinical trials. If these third parties are unable to carry out their contractual duties in a manner that is consistent with our expectations, comply with budgets and other financial obligations or meet expected deadlines, we may not receive certain development milestone payments or be able to obtain regulatory approval for or commercialize our drug candidates in a timely or cost- effective manner. We do not independently conduct clinical trials for our drug candidates. We rely, and expect to continue to rely, on third- party clinical investigators, CROs, clinical data management organizations and consultants to design, conduct, supervise and monitor our clinical trials. Because we do not conduct our own clinical trials, we must rely on the efforts of others and have reduced control over aspects of these activities, including the timing of such trials, the costs associated with such trials and the procedures that are followed for such trials. We do not expect to significantly increase our personnel in the foreseeable future and may continue to rely on third parties to conduct all of our future clinical trials. If we cannot contract with acceptable third parties on commercially reasonable terms or at all, if these third parties are unable to carry out their contractual duties or obligations in a manner that is consistent with our expectations or meet expected deadlines, if they do not carry out the trials in accordance with budgeted amounts, if the quality or accuracy of the clinical data they obtain is compromised due to their failure to adhere to our clinical protocols or for other reasons, or if they fail to maintain compliance with applicable government regulations and standards, our clinical trials may be extended, delayed or terminated or may become significantly more expensive, we may not receive development milestone payments when expected or at all, and we may not be able to obtain regulatory approval for or successfully commercialize our drug candidates. Despite our reliance on third parties to conduct our clinical trials, we are ultimately responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires clinical trials to be conducted in accordance with good clinical practices for conducting, recording and reporting the results of clinical trials and that the rights, integrity and confidentiality of clinical trial participants are protected. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government- sponsored database, ClinicalTrials. gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. Our reliance on third parties that we do not control does not relieve us of these responsibilities and requirements. If we or a third party we rely on fails to meet these requirements, we may not be able to obtain, or may be delayed in obtaining, marketing authorizations for our drug candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our drug candidates. This could have a material adverse effect on our business, financial condition, results of operations and prospects. Because we rely on third- party manufacturing and supply partners, our supply of research and development, preclinical and clinical development materials may become limited or interrupted or may not be of satisfactory quantity or quality. We rely on third- party supply and manufacturing partners to supply the materials and components for, and manufacture, our research and development, preclinical and clinical trial drug supplies. We do not own manufacturing facilities or supply sources for such components and materials. There can be no assurance that our supply of research and development, preclinical and clinical development drugs and other materials will not be limited, interrupted, or restricted in certain geographic regions or will be of satisfactory quality or will continue to be available at acceptable prices. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by FDA and foreign regulatory authorities in order to comply with regulatory standards, such as current cGMP. If we or any of our third- party manufacturers or testing contractors fail to maintain regulatory compliance, this could cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of our drug candidates, cause us to incur higher costs and prevent us from commercializing our products successfully. Furthermore, if our suppliers fail to meet contractual requirements, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed, or we could lose potential revenue. In the event that any of our suppliers or manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at all. The regulatory authorities also may, at any time following approval of a product for sale, inspect the manufacturing facilities of our third- party manufacturers. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and / or time- consuming for us or our third- party manufacturers to implement and that may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a manufacturing facility. Any such remedial measures imposed upon third parties with whom we contract could materially harm our business. If we fail to enter into and maintain successful strategic alliances for our drug candidates, we may have to reduce or delay our drug candidate development or increase our expenditures. To the extent we are able to enter into strategic transactions, we will be exposed to risks related to those collaborations and alliances. An important element of our strategy for developing, manufacturing and commercializing our drug candidates is entering into strategic alliances with pharmaceutical companies, research institutions or other industry participants to advance our programs and enable us to maintain our financial and operational capacity. We face significant competition in seeking appropriate alliances. We may not be able to negotiate alliances on acceptable terms, if at all. In addition, these alliances may be unsuccessful. If we fail to create and maintain suitable alliances, we may have to limit the size or scope of, or delay, one or more of our drug development or research

programs. If we elect to fund drug development or research programs on our own, we will have to increase our expenditures and will need to obtain additional funding, which may be unavailable or available only on unfavorable terms. We may not successfully engage in future strategic transactions, which could adversely affect our ability to develop and commercialize drug candidates, impact our cash position, increase our expenses and present significant distractions to our management. In the future, we may consider strategic alternatives intended to further the development of our business, which may include acquiring businesses, technologies, or products, out- or in-licensing drug candidates or technologies or entering into a business combination with another company. Any strategic transaction may require us to incur non-recurring or other charges, increase our near- and long-term expenditures and pose significant integration or implementation challenges or disrupt our management or business. These transactions would entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management's time and attention in order to manage a collaboration or develop acquired products, drug candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business. Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and have a material adverse effect on our business, results of operations, financial condition and prospects. Conversely, any failure to enter any strategic transaction that would be beneficial to us could delay the development and potential commercialization of our drug candidates and have a negative impact on the competitiveness of any drug candidate that reaches market. We have obtained Orphan Drug Designation for IMNN-001 and may seek Orphan Drug Designation for other drug candidates, but we may be unsuccessful or may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for market exclusivity. IMNN-001 has been granted orphan drug designation for ovarian cancer in both the U. S. and Europe. Regulatory authorities in some jurisdictions, including the U. S. and Europe, may designate drugs or biologics for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug or biologic as an orphan drug if the disease or condition for which the drug is intended affects fewer than 200,000 individuals in the U. S., or, if the drug is intended for a disease or condition affecting 200,000 or more people in the U. S., there is no reasonable expectation that the cost of developing and making available in the U. S. the drug or biologic for the disease or condition will be recovered from sales of the drug in the U. S. Even though we have obtained Orphan Drug Designation for IMNN-001 and may obtain such designation for other drug candidates in specific indications, we may not be the first to obtain marketing approval of these drug candidates for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. In addition, exclusive marketing rights in the U. S. may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties can be approved for the same indication. Even after an orphan product is approved, the FDA can subsequently approve a different sponsor's application for the same drug for the same indication if the FDA concludes that the later drug is safer, more effective or makes a major contribution to patient care. Orphan Drug Designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. Fast Track designation may not actually lead to a faster development or regulatory review or approval process. IMNN-001 received U. S. FDA Fast Track designation in 2021. However, we may not experience a faster development process, review, or approval compared to a product that lacks Fast Track designation. The FDA may withdraw our Fast Track designation if the FDA believes that the designation is no longer supported by data from our clinical or pivotal development program. Our Fast Track designation does not guarantee that we will qualify for or be able to take advantage of the FDA's expedited review procedures or that any application that we may submit to the FDA for regulatory approval will be accepted for filing or ultimately approved. Our relationships with healthcare providers and physicians and third-party payors will be subject to applicable false claims act, anti-kickback, transparency, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, administrative burdens, reputational harm and diminished profits and future earnings. Healthcare providers, physicians and third-party payors in the U. S. and elsewhere play a primary role in the recommendation and prescription of biopharmaceutical products. Arrangements with third-party payors and customers can expose biopharmaceutical manufacturers to broadly applicable fraud and abuse and other healthcare laws and regulations, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act, which may constrain the business or financial arrangements and relationships through which such companies sell, market and distribute biopharmaceutical products. In particular, the research of our drug candidates, as well as the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials. The distribution of biopharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage, and security requirements intended to prevent the unauthorized sale of biopharmaceutical products. The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company's attention from the business. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, reputational harm, possible exclusion from participation in federal and state funded healthcare programs, contractual damages and the curtailment or restricting of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Any action for violation of these laws, even if successfully defended, could cause a biopharmaceutical manufacturer to incur significant legal expenses and divert management's attention from the operation of the business. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect business in an adverse way. Ongoing legislative and regulatory changes affecting the healthcare industry could have a material adverse effect on our business. Political, economic and regulatory influences are subjecting the healthcare industry to potential fundamental changes that could substantially affect our results of operations by requiring, for example: (i) changes to our manufacturing arrangements; (ii) additions or modifications to product labeling; (iii) the recall or discontinuation of our products, if approved; or (iv) additional record-keeping requirements. We cannot predict what healthcare reform initiatives may be adopted in the future. Further, federal and state legislative and regulatory developments are likely, and we expect ongoing initiatives in the U. S. to increase pressure on drug pricing. Such reforms could have an adverse effect on anticipated revenues for any drug candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop drug candidates. We may fail to comply with evolving European and other privacy laws. We are subject to varying degrees of privacy regulation in the countries in which we operate **operations**, and the general trend is toward increasingly stringent regulation and enforcement. We are, for example, subject to costly and complex U. S. and foreign laws governing the collection, use, disclosure, and cross-border transfer of information about patients and other individuals that may materially adversely affect our financial condition and business operations. Since we have conducted and may conduct clinical trials in the European Economic Area ("EEA"), we are subject to additional data protection and clinical trial laws in the European Union. The General Data Protection Regulation, (EU) 2016 / 679 ("GDPR"), for example, governs the processing of personal data, and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing notices to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, alerting data subjects and authorities about data breaches, and taking specific measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the EEA, including the U. S., and confers on data subjects the right to lodge complaints with supervisory authorities, and seek certain judicial review for violations of the GDPR. In addition, the GDPR includes restrictions on cross-border data transfers. Under the GDPR, competent regulatory authorities have the power to impose fines up to EUR 20 million or 4% of the global annual turnover (whichever is higher), depending on the nature of the violation (see Art. 83, GDPR). Further consequences of non-compliance could be cease and desist claims by certain organizations / competitors, damage claims and reputational damage. Further, Regulation (EU) No 536 / 2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use and repealing Directive 2001 / 20 / EC governs how we conduct clinical trials in the European Union together

with Good Clinical Practices. As a result of Brexit, moreover, we also have independent obligations, similar to those already imposed on us by GDPR, under the United Kingdom's Data Protection Act, 2018. Additionally, there are other local data protection laws, industry-specific requirements, regulations, or applicable codes of conduct which may impact our operations. We have taken steps to implement privacy compliance programs and controls, but our business remains subject to potential risks of controls imposed on cross border data flows, unauthorized access, and loss of personal data through internal and external threats that could impact our business operations and research activities. The success of our products, if approved, may be harmed if the government, private health insurers and other third-party payers do not provide sufficient coverage or reimbursement. Our ability to commercialize our new cancer treatment systems successfully will depend in part on the extent to which reimbursement for the costs of such products, if approved, and related treatments will be available from third-party payors, which include government authorities such as Medicare, Medicaid, TRICARE, and the Veterans Administration, managed care providers, private health insurers, and other organizations. Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Patients are unlikely to use our drug candidates unless coverage is provided, and reimbursement is adequate to cover a significant portion of the cost. We cannot be sure that coverage and reimbursement will be available for, or accurately estimate the potential revenue from, our drug candidates. Our products, if approved, may not achieve sufficient acceptance by the medical community to sustain our business. The commercial success of our products, if approved, will depend upon their acceptance by the medical community and third-party payors as clinically useful, cost effective and safe. Any of our drug candidates or similar drug candidates being investigated by our competitors may prove not to be effective in trial or in practice, cause adverse events or other undesirable side effects. Our testing and clinical practice may not confirm the safety and efficacy of our drug candidates or even if further testing and clinical practice produce positive results, the medical community may view these new forms of treatment as effective and desirable or our efforts to market our new products, if approved, may fail. Market acceptance depends upon physicians and hospitals obtaining adequate reimbursement rates from third-party payors to make our products, if approved, commercially viable. Any of these factors could have an adverse effect on our business, financial condition and results of operations. We have no internal sales or marketing capability. If we are unable to create sales, marketing and distribution capabilities or enter into alliances with others possessing such capabilities to perform these functions, we will not be able to commercialize our products, if approved, successfully. We currently have no sales, marketing, or distribution capabilities. We intend to market our products, if and when such products are approved for commercialization by the FDA and foreign regulatory agencies, either directly or through other strategic alliances and distribution arrangements with third parties. If we decide to market our products directly, we will need to commit significant financial and managerial resources to develop a marketing and sales force with technical expertise and with supporting distribution, administration, and compliance capabilities, including providing adequate training on such topics. If we rely on third parties with such capabilities to market our products, we will need to establish and maintain partnership arrangements, and there can be no assurance that we will be able to enter into third-party marketing or distribution arrangements on acceptable terms or at all. To the extent that we do enter into such arrangements, we will be dependent on our marketing and distribution partners. In entering into third-party marketing or distribution arrangements, we expect to incur significant additional expenses and there can be no assurance that such third parties will establish adequate sales and distribution capabilities or be successful in gaining market acceptance for our products and services. Our success will depend in part on our ability to grow and diversify, which in turn will require that we manage and control our growth effectively. Our business strategy contemplates growth and diversification. Our ability to manage growth effectively will require that we continue to expend funds to improve our operational, financial and management controls, reporting systems and procedures. In addition, we must effectively expand, train and manage our employees. We will be unable to manage our business effectively if we are unable to alleviate the strain on resources caused by growth in a timely and successful manner. There can be no assurance that we will be able to manage our growth and a failure to do so could have a material adverse effect on our business. We face intense competition and the failure to compete effectively could adversely affect our ability to develop and market our products, if approved. There are many companies and other institutions engaged in research and development of various technologies for cancer treatment products that seek treatment outcomes similar to those that we are pursuing. We believe that the level of interest by others in investigating the potential of possible competitive treatments and alternative technologies will continue and may increase. Potential competitors engaged in all areas of cancer treatment research in the U. S. and other countries include, among others, major pharmaceutical, specialized technology companies, and universities and other research institutions. Most of our current and potential competitors have substantially greater financial, technical, human and other resources, and may also have far greater experience than we do we, both in pre-clinical testing and human clinical trials of new products and in obtaining FDA and other regulatory approvals. One or more of these companies or institutions could succeed in developing products or other technologies that are more effective than the products and technologies that we have been or are developing, or which would render our technology and products obsolete and non-competitive. Furthermore, if we are permitted to commence commercial sales of any of our products, we will also be competing, with respect to manufacturing efficiency and marketing, with companies having substantially greater resources and experience in these areas. We may be subject to significant product liability claims and litigation. Our business exposes us to potential product liability risks inherent in the testing, manufacturing and marketing of human therapeutic products. We presently have product liability insurance limited to \$ 10 million per incident and \$ 10 million annually. If we were to be subject to a claim in excess of this coverage or to a claim not covered by our insurance and the claim succeeded, we would be required to pay the claim with our own limited resources, which could have a severe adverse effect on our business. Whether or not we are ultimately successful in any product liability litigation, such litigation would harm the business by diverting the attention and resources of our management, consuming substantial amounts of our financial resources and by damaging our reputation. Additionally, we may not be able to maintain our product liability insurance at an acceptable cost, if at all. Our internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs. ~~Our~~ Despite the implementation of security measures, our internal computer systems and those of our CROs and other contractors and consultants are vulnerable to damage from computer viruses and malicious software that could attack our networks and data centers or those of our service providers; unauthorized parties may attempt to gain access to our systems, networks, or facilities, or those of third parties with whom we do business, through fraud, trickery, or other forms of deceiving our employees or contractors, direct social engineering, phishing, credential stuffing, ransomware, denial or degradation of service attacks and similar types of attacks against any or all of us, our patients and our services providers; inadvertent security breaches or theft, misuse, unauthorized access or other improper actions by our employees, patients, service providers and other business partners; natural disasters, terrorism, war and telecommunication and electrical failures. These extensive information security and cybersecurity threats, which affect companies globally, pose a risk to the security and availability of our systems and networks, and the confidentiality, integrity, and availability of our sensitive data. ~~We continually assess these threats and make investments to increase internal protection, detection, and response capabilities, as well as ensure that our third-party providers have required capabilities and controls, to address those risks. Even so, such~~ Such events could cause significant interruptions of our operations. For instance, the loss of preclinical data or data from any clinical trial involving our drug candidates could result in delays in our development and regulatory filing efforts and significantly increase our costs. To the extent that any disruption or privacy or security breach were to result in a loss of, or damage to, our data, or inappropriate disclosure of confidential or proprietary information, we could be subject to reputational harm, monetary fines, civil suits, civil penalties or criminal sanctions and requirements to disclose the breach, and other forms of liability and the development of our drug candidates could be delayed. In addition, such interruptions and cyber security incidents and faults can cause reputational damage. Our employees, independent contractors, consultants, collaborators and contract research organizations may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation. We are exposed to the risk that our employees, independent contractors, consultants, collaborators and contract research organizations may engage in fraudulent conduct or other illegal activity. Misconduct by those parties could include intentional, reckless and / or negligent conduct or disclosure of unauthorized activities to us that violates: (1) FDA regulations or similar regulations of comparable non-U. S. regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities, (2) manufacturing standards, (3) federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable non-U. S. regulatory authorities, and (4) laws that require the reporting of financial information or data accurately. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing, bribery and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee or collaborator misconduct could also involve the improper use of, including trading on, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. While we have a code of conduct and business ethics, it is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, additional reporting requirements and / or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, imprisonment, contractual damages,

reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could have a material adverse effect on our ability to operate our business and our results of operations. **Litigation and other legal proceedings against the Company, which may arise in the ordinary course of Company's business, could be costly and time consuming to defend. The Company is from time to time subject to legal proceedings and claims that arise in the ordinary course of business. From time to time, third parties may in the future assert intellectual property rights to technologies that are important to the Company's business and may in the future demand that we license their technology. Litigation may result in substantial costs and may divert management's attention and resources, which may seriously harm the Company's business, overall financial condition and operating results.**

RISKS RELATED TO OUR INTELLECTUAL PROPERTY Our business depends on license agreements with third parties to permit us to use patented technologies. The loss of any of our rights under these agreements could impair our ability to develop and market our products, if approved. Our success will depend, in a substantial part, on our ability to maintain our rights under license agreements granting us rights to use patented technologies. For instance, we are party to license agreements with Duke University, under which we have exclusive rights to commercialize medical treatment products and procedures based on Duke's thermo-sensitive liposome technology. The Duke University license agreement contains a license fee, royalty and / or research support provisions, testing and regulatory milestones, and other performance requirements that we must meet by certain deadlines. If we breach any provisions of the license and research agreements, we may lose our ability to use the subject technology, as well as compensation for our efforts in developing or exploiting the technology. Any such loss of rights and access to technology could have a material adverse effect on our business. Further, we cannot guarantee that any patent or other technology rights licensed to us by others will not be challenged or circumvented successfully by third parties, or that the rights granted will provide adequate protection. We may be required to alter any of our potential products or processes or enter into a license and pay licensing fees to a third party or cease certain activities. There can be no assurance that we can obtain a license to any technology that we determine we need on reasonable terms, if at all, or that we could develop or otherwise obtain alternate technology. If a license is not available on commercially reasonable terms or at all, our business, results of operations, and financial condition could be significantly harmed, and we may be prevented from developing and commercializing the product. Litigation, which could result in substantial costs, may also be necessary to enforce any patents issued to or licensed by us or to determine the scope and validity of another's claimed proprietary rights. If any of our pending patent applications are not issued, or are deemed invalid following issuance, we may lose valuable intellectual property protection. The patent positions of pharmaceutical and biotechnology companies, such as ours, are uncertain and involve complex legal and factual issues. We own various U. S. and international patents and have pending U. S. and international patent applications that cover various aspects of our technologies. There can be no assurance that patents that have been issued will be held valid and enforceable in a court of law through the entire patent term. Even for patents that are held valid and enforceable, the legal process associated with obtaining such a judgment is time-consuming and costly. Additionally, issued patents can be subject to opposition, interferences or other proceedings that can result in the revocation of the patent or maintenance of the patent in amended form (and potentially in a form that renders the patent without commercially relevant or broad coverage). Further, our competitors may be able to circumvent and otherwise design around our patents. Even if a patent is issued and enforceable because development and commercialization of pharmaceutical products can be subject to substantial delays, patents may expire early and provide only a short period of protection, if any, following the commercialization of products, if approved, encompassed by our patents. We may have to participate in interference proceedings declared by the U. S. Patent and Trademark Office, which could result in a loss of the patent and / or substantial cost to us. We have filed patent applications, and plan to file additional patent applications, covering various aspects of our technologies and our proprietary drug candidates. There can be no assurance that the patent applications for which we apply would actually issue as patents or do so with commercially relevant or broad coverage. The coverage claimed in a patent application can be significantly reduced before the patent is issued. The scope of our claim coverage can be critical to our ability to enter into licensing transactions with third parties and our right to receive royalties from our collaboration partnerships. Since publication of discoveries in scientific or patent literature often lags behind the date of such discoveries, we cannot be certain that we were the first inventor of inventions covered by our patents or patent applications. In addition, there is no guarantee that we will be the first to file a patent application directed to an invention. An adverse outcome in any judicial proceeding involving intellectual property, including patents, could subject us to significant liabilities to third parties, require disputed rights to be licensed from or to third parties or require us to cease using the technology in dispute. In those instances where we seek an intellectual property license from another, we may not be able to obtain the license on a commercially reasonable basis, if at all, thereby raising concerns on our ability to freely commercialize our technologies or products. We rely on trade secret protection and other unpatented proprietary rights for important proprietary technologies, and any loss of such rights could harm our business, results of operations and financial condition. We rely on trade secrets and confidential information that we seek to protect, in part, by confidentiality agreements with our corporate partners, collaborators, employees and consultants. We cannot assure you that these agreements are adequate to protect our trade secrets and confidential information or will not be breached or, if breached, we will have adequate remedies. Furthermore, others may independently develop substantially equivalent confidential and proprietary information or otherwise gain access to our trade secrets or disclose such technology. Any loss of trade secret protection or other unpatented proprietary rights could harm our business, results of operations and financial condition. We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights. Our commercial success depends on our ability to operate without infringing the patents and other proprietary rights of third parties. Although we currently are not involved in any material litigation involving patents, a third-party patent holder may assert a claim of patent infringement against us in the future. Alternatively, we may initiate litigation against the third-party patent holder to request that a court declare that we are not infringing the third party's patent and / or that the third party's patent is invalid or unenforceable. Any infringement action asserted against us, even if we are ultimately successful in defending against such action, would likely delay the regulatory approval process of our products, harm our competitive position, be expensive and require the time and attention of our key management and technical personnel. In addition, there is a risk that the court will decide that such patents are not valid and that we do not have the right to stop the other party from using the inventions.

RISKS RELATED TO OUR SECURITIES The market price of our common stock has been, and may continue to be volatile and fluctuate significantly, which could result in substantial losses for investors and subject us to securities class action litigation. The trading price for our common stock has been, and we expect it to continue to be, volatile. The price at which our common stock trades depends upon a number of factors, some of these factors are beyond our control. Broad market fluctuations may lower the market price of our common stock and affect the volume of trading in our stock, regardless of our financial condition, results of operations, business or prospects. In addition to the factors discussed in this "Risk Factors" section and elsewhere in this Annual Report, these factors include: ● disclosure of actual or potential clinical results with respect to drug candidates we are developing; ● regulatory developments in both the United States and abroad; ● developments concerning proprietary rights, including patents and litigation matters; ● public concern about the safety or efficacy of our drug candidates or technology, or related technology, or new technologies generally; ● concern about the safety or efficacy of our drug candidates or technology, or related technology, or new technologies generally; ● public announcements by our competitors or others; and ● general market conditions and comments by securities analysts and investors. Our common stock may be delisted from The Nasdaq Capital Market if we fail to comply with continued listing standards. Our common stock is currently traded on The Nasdaq Capital Market under the symbol "IMNN." If we fail to comply with Nasdaq's continued listing standards, we may be delisted and our common stock will trade, if at all, only on the over-the-counter market, such as the OTC Bulletin Board or OTCQX market, and then only if one or more registered broker-dealer market makers comply with quotation requirements. In addition, delisting of our common stock could depress our stock price, substantially limit liquidity of our common stock and materially adversely affect our ability to raise capital on terms acceptable to us, or at all. Further, delisting of our common stock would likely result in our common stock becoming a "penny stock" under the Exchange Act. On ~~December 26, 2023~~ ~~November 26, 2023~~ ~~2024~~, we received a notice from the staff of the Nasdaq Stock Market LLC (the "Staff") notifying us that, based upon the closing bid price of our common stock, for the 30 consecutive business days prior to the notice, we no longer met the requirement to maintain a minimum closing bid price of \$ 1.00 per share, as set forth in Nasdaq Listing Rule 5550 (a) (2). In accordance with Nasdaq Listing Rule 5810 (c) (3) (A), we were granted 180 calendar days, or until ~~June 24, 2024~~ ~~May 27, 2024~~ ~~2025~~, to regain compliance with the minimum bid price rule. To regain compliance, the closing bid price of our common stock must be \$ 1.00 per share or more for a minimum of 10 consecutive business days at any time before ~~June 24, 2024~~ ~~May 27, 2024~~ ~~2025~~. If we do not regain compliance with Rule 5550 (a) (2) by ~~June 24, 2024~~ ~~May 27, 2024~~ ~~2025~~, we may be eligible for an additional 180 calendar day compliance period. To qualify, we will be required to meet the continued listing requirement for market value of publicly held shares and all other Nasdaq initial listing standards, except the bid price requirement, and would need to provide written notice to Nasdaq of our intention to cure the deficiency during the second compliance period. If it appears to the Staff that we will not be able to cure the deficiency, or if we are otherwise not eligible, Nasdaq would notify us that our securities will be subject to delisting. In the event of such notification, we may appeal the Staff's determination to delist our securities, but there can be no assurance the Staff would grant our request for continued listing. If our common stock ~~is were to be~~ delisted by Nasdaq, it may be eligible for quotation on an over-the-counter quotation system or on the pink sheets. Upon any such delisting, our common stock would become subject to the regulations of the SEC relating to the market for penny stocks. A penny stock is any equity security not traded on a national securities exchange that has a market price of less than \$ 5.00 per share. The regulations applicable to penny stocks may severely affect the market liquidity for our common stock and could limit the ability of stockholders to sell securities in the secondary market. In such a case, an investor may find it more difficult to dispose of or obtain accurate quotations as to the market value of our common stock, and there can be no assurance that our

common stock will be eligible for trading or quotation on any alternative exchanges or markets. Delisting from Nasdaq could adversely affect our ability to raise additional financing through public or private sales of equity securities, would significantly affect the ability of investors to trade our securities and would negatively affect the value and liquidity of our common stock. Delisting could also have other negative results, including the potential loss of confidence by employees, the loss of institutional investor interest and fewer business development opportunities. Future sales of our common stock in the public market could cause our stock price to fall. Sales of a substantial number of shares of our common stock in the public market, or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. As of ~~March 26, February 21, 2024~~ **2025**, we had ~~9-14, 399-620, 789-732~~ shares of common stock outstanding, all of which, other than shares held by our directors and certain officers, were eligible for sale in the public market, subject in some cases to compliance with the requirements of Rule 144, including the volume limitations and manner of sale requirements. In addition, all of the shares of common stock issuable upon exercise of warrants will be freely tradable without restriction or further registration upon issuance. Our stockholders may experience significant dilution as a result of future equity offerings or issuances and exercise of outstanding options and warrants. In order to raise additional capital or pursue strategic transactions, we may in the future offer, issue or sell additional shares of our common stock or other securities convertible into or exchangeable for our common stock, including the issuance of common stock in relation to the achievement, if any, of milestones triggering our payment of earn-out consideration in connection with the EGEN acquisition. Our stockholders may experience significant dilution as a result of future equity offerings or issuances. Investors purchasing shares or other securities in the future could have rights superior to existing stockholders. As of December 31, ~~2023~~ **2024**, we had the following number of securities convertible into, or allowing the purchase of, our common stock, including ~~460-5, 155~~, 060 shares of common stock issuable upon exercise of warrants outstanding, 1, ~~095-645, 582-873~~ options to purchase shares of our common stock and restricted stock awards outstanding, and ~~1-420, 000-206, 342~~ shares of common stock reserved for future issuance under our stock incentive plan. Unstable global market and economic conditions may have serious adverse consequences on our business, financial condition and share price. The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, increases in inflation rates and uncertainty about economic stability. For example, the COVID-19 pandemic resulted in widespread unemployment, economic slowdown and extreme volatility in the capital markets. Similarly, the ongoing conflict between Ukraine and Russia **and the unrest in the Middle East** has created extreme volatility in the global capital markets and is expected to have further global economic consequences, including with respect to global supply chain and energy concerns. Any such volatility may have adverse consequences on us or the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive. Our ability to use net operating losses to offset future taxable income **are is** subject to certain limitations. On December 22, 2017, the then President of the U. S. signed into law the Tax Reform Act. The Tax Reform Act significantly changed U. S. tax law by, among other things, lowering corporate income tax rates, implementing a quasi-territorial tax system, providing a one-time transition toll charge on foreign earnings, creating a new limitation on the deductibility of interest expenses and modifying the limitation on officer compensation. The Tax Reform Act permanently reduced the U. S. corporate income tax rate from a maximum of 35 % to a flat 21 % rate, effective January 1, 2018. We currently have significant net operating losses (“NOLs”) that may be used to offset future taxable income. In general, under Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”), a corporation that undergoes an “ownership change” is subject to limitations on its ability to utilize its pre-change NOLs to offset future taxable income. During 2022, 2021 and years prior, we performed analyses to determine if there were changes in ownership, as defined by Section 382 of the Code, **that which** would limit our ability to utilize certain net operating loss and tax credit carry forwards. We determined we experienced ownership changes, as defined by Section 382, in connection with certain common stock offerings in 2011, 2013, 2015, 2017, 2018, 2020 **and 2021 and 2024**. As a result, the utilization of our federal tax net operating loss carry-forwards generated prior to the ownership changes is limited. Future changes in our stock ownership, some of which are outside of our control, could result in an ownership change under Section 382 of the Code, which would significantly limit our ability to utilize NOLs to offset future taxable income. Future changes in tax laws could also impair our corporate tax rate and / or our ability to utilize our NOLs. We have never paid cash dividends on our common stock in the past and do not anticipate paying cash dividends on our common stock in the foreseeable future. We have never declared or paid cash dividends on our common stock. We do not anticipate paying any cash dividends on our common stock in the foreseeable future. We currently intend to retain all available funds and any future earnings to fund the development and growth of our business. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for the foreseeable future for holders of our common stock. Anti-takeover provisions in our charter documents and Delaware law could prevent or delay a change in control. Our certificate of incorporation and bylaws may discourage, delay or prevent a merger or acquisition that a stockholder may consider favorable by authorizing the issuance of “blank check” preferred stock. This preferred stock may be issued by our Board of Directors on such terms as it determines, without further stockholder approval. Therefore, our Board of Directors may issue such preferred stock on terms unfavorable to a potential bidder in the event that our Board of Directors opposes a merger or acquisition. In addition, our staggered Board of Directors may discourage such transactions by increasing the amount of time necessary to obtain majority representation on our Board of Directors. Certain other provisions of our bylaws and of Delaware law may also discourage, delay or prevent a third party from acquiring or merging with us, even if such action were beneficial to some, or even a majority, of our stockholders. ITEM 1B. UNRESOLVED STAFF COMMENTSNone. ITEM 1C. CYBERSECURITYWe have processes for assessing, identifying and managing cybersecurity risks, which are built into our information technology (“IT”) function and are designed to help protect our information assets and operations from internal and external cyber threats, protect employee and clinical trial information from unauthorized access or attack, as well as secure our networks and systems. Such processes include physical, procedural and technical safeguards, response plans, and routine review of our policies and procedures to identify risks and refine our practices. We engage certain external parties, including a full-service managed IT service provider, to enhance our cybersecurity oversight. Our Audit Committee of the Board of Directors (the “Audit Committee”) is responsible for overseeing cybersecurity risk and periodically updates our Board of Directors on such matters. The Audit Committee receives periodic updates from management regarding cybersecurity matters and is notified between such updates regarding any significant new cybersecurity threats or incidents. We do not believe that there are currently any known risks from cybersecurity threats that are reasonably likely to materially affect us or our business strategy, results of operations or financial condition. Management is responsible for the operational oversight of company-wide cybersecurity strategy, policy, and standards across relevant departments to assess and help prepare us to address cybersecurity risks. In an effort to deter and detect cyber threats, we annually provide all employees with cybersecurity and prevention training, which covers timely and relevant topics, including social engineering, phishing, password protection, confidential data protection, and mobile security, and educates employees on the importance of reporting all incidents immediately. We also use technology-based tools to mitigate cybersecurity risks and to bolster our employee-based cybersecurity programs. ITEM 2. PROPERTIESWe own no real property and have no plans to acquire any real property in the future. Lawrenceville, NJ Lease In August 2023, the Company renewed its Lawrenceville office lease for a 24-month agreement for 9,850 square feet with monthly rent payments of approximately \$ 22,983 and \$ 23,394. Huntsville, AL Lease In January 2023, the Company renewed its Huntsville facility lease for a 60-month lease agreement for 11,420 square feet with monthly rent payments of approximately \$ 28,550 to \$ 30,903. We believe our existing facilities are suitable and adequate to conduct our business. Following is a table of future payments and maturity of our operating lease liabilities as of December 31, ~~2023~~ **2024**. For the year ending December 31, ~~2024~~ **2025** \$ 626,323 2025-543, 009 2026 362, 976 2027 370, 236 ~~235~~ 2028 and thereafter 30, 903 Subtotal future lease payments 1, 933-~~307, 447-123~~ Less imputed interest (~~308-167, 733-830~~) Total lease liabilities \$ 1, 624-~~139, 714-293~~ Weighted average remaining life ~~3-2, 5-7~~ years Weighted average discount rate 9.98 % For **2024, operating lease expense was \$ 651, 681 and cash paid for operating leases included in operating cash flows was \$ 659, 161. For 2023, operating lease expense was \$ 646, 633 and cash paid for operating leases included in operating cash flows was \$ 644, 593. For 2022, operating lease expense was \$ 587, 744 and cash paid for operating leases included in operating cash flows was \$ 601, 495.** ITEM 3. LEGAL PROCEEDINGSOn ~~PROCEEDINGS~~ **PROCEEDINGS** We are not currently October 29, 2020, a party putative securities class action was filed against the Company and certain of its officers and directors (the “Spar Individual Defendants”) in the U. S. District Court for the District of New Jersey, captioned Spar v. Celsion Corporation, et al., Case No. 1:20-cv-15228. The plaintiff alleged that the Company and Spar Individual Defendants made false and misleading statements regarding one of the Company’s drug candidates, ThermoDox®, and brought claims for damages under Section 10 (b) of the Exchange Act and Rule 10b-5 promulgated thereunder against all defendants, and under Section 20 (a) of the Exchange Act against the Spar Individual Defendants. On February 6, 2023, the U. S. District Court granted a Motion to Dismiss filed by the Company and Spar Individual Defendants and granted the plaintiff leave to file an amended complaint within 30 days. The plaintiff did not file an amended complaint within the 30-day deadline. In September 2023, the U. S. District Court issued an Order for Dismissal without prejudice. In February 2021, a derivative shareholder lawsuit was filed against the Company, as the nominal defendant, and certain of its directors and officers as defendants in the U. S. District Court for the District of New Jersey, captioned Fidler v. Michael H. Tardugno, et al., Case No. 3:21-cv-02662. The plaintiff alleged breach of fiduciary duty and other claims arising out of alleged statements made by certain of the Company’s directors and / or officers regarding ThermoDox®. The Company believes it has meritorious defenses to these claims and intends to vigorously contest this suit. At this stage of the case, neither the likelihood that a loss, if any **material legal proceedings**, will be realized, nor an estimate of possible loss or range of loss, if any, can be determined. ITEM 4.

MINE SAFETY DISCLOSURES Not Applicable. PART III ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES Market for Our Common Stock Our common stock trades on The Nasdaq Capital Market under the symbol "IMNN." Record Holders As of ~~March 28, 2024~~ **February 21, 2024**, there were approximately ~~28,200~~ **28,200** stockholders of record of our common stock. The actual number of stockholders may be greater than this number of record stockholders and ~~includes~~ **include** stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of stockholders of record also does not include stockholders whose shares may be held in trust by other entities. Dividend Policy We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain all of our future earnings for use in the operation of our business and to fund future growth and do not anticipate paying any cash dividends in the foreseeable future. Any future determination to declare cash dividends will be made at the discretion of our Board of Directors, subject to applicable law, and will depend on our financial condition, results of operations, capital requirements, general business conditions and other factors that our Board of Directors may deem relevant. Performance Graph Not required. Unregistered Sales of Equity Securities On ~~December 7, 2023~~ **October 7, 2023**, we granted: (i) an **inducement stock option** to purchase ~~80,600~~ **80,600** shares of the Company's common stock with an exercise price of ~~\$ 0.18~~ **\$ 0.18** per share **to one individual hired by the Company during the fourth quarter of 2024** and (ii) a **restricted stock award** of ~~20,000~~ **20,000** ~~restricted shares of the Company's common stock with an exercise price of \$ 1.02 per share~~ **to Dr. Sébastien Hazard, our Executive Vice President and an Chief Medical Officer** **exercise price of \$ 1.02 per share to Susan Eylward, our General Counsel, in each case** as an "inducement" grant pursuant to Rule 5635 (c) (4) of the Nasdaq Listing Rules. The grant of the option was exempt from registration under the Securities Act, pursuant to Section 4 (a) (2) thereof as a transaction by an issuer not involving a public offering. Issuer Purchases of Equity Securities ITEM 6. RESERVED. ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussions should be read in conjunction with the financial statements and related notes thereto included in this Annual Report. The following discussion contains forward-looking statements made pursuant to the safe harbor provisions of Section 27A of the Securities Act and Section 21E of the Exchange Act and the Private Securities Litigation Reform Act of 1995. These statements are based on the Company's beliefs and expectations about future outcomes and are subject to risks and uncertainties that could cause actual results to differ materially from anticipated results. Factors that could cause or contribute to such differences include those described under "Part I, Item 1A- Risk Factors" appearing in this Annual Report and factors described in other cautionary statements, cautionary language and risk factors set forth in other documents that the Company files with the SEC. The Company undertakes no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise. Overview On ~~September 19, 2022~~ **September 19, 2022**, Celsion Corporation announced a corporate name change to Imunon, Inc., reflecting the evolution of the Company's business focus and its commitment to developing cutting-edge immunotherapies and next-generation vaccines to treat cancer and infectious diseases. The Company's common stock continues to trade on the Nasdaq Stock Market under the new ticker symbol "IMNN." Imunon is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms with the aim to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. Imunon is developing its non-viral DNA technology across ~~four~~ **four** modalities. The first modality, TheraPlas®, is being developed for the coding of proteins and cytokines in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is being developed for the coding of viral antigens that can elicit a strong immunological response. This technology may represent a promising platform for the development of vaccines in infectious diseases. The ~~third~~ **third** modality, FixPlas®, concerns the application of Imunon's DNA technology to produce universal cancer vaccines, also called tumor-associated antigen cancer vaccines. The ~~fourth~~ **fourth** modality, IndiPlas®, is in the discovery phase and will focus on the development of personalized cancer vaccines, or neoepitope cancer vaccines. The Company's lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer ~~currently in~~ **that has completed** Phase II clinical development studies. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as ~~IL-12~~ **IL-12** and interferon gamma, at the tumor site. Additionally, the Company ~~has entered into~~ **is conducting** IND-enabling preclinical studies for the development of a ~~first-in-human~~ **first-in-human** study of its COVID-19 booster vaccine (IMNN-101) and a treatment for the Lassa virus (IMNN-102). ~~We~~ **The** Company has also initiated preclinical work to develop a ~~Trp2 tumor associated antigen cancer vaccine in melanoma (IMNN-201)~~ **Trp2 tumor associated antigen cancer vaccine in melanoma (IMNN-201)**. Imunon will continue to leverage these modalities and to advance the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. Business Plan and Going Concern Risk As a clinical-stage biopharmaceutical company, our business and our ability to execute our strategy to achieve our corporate goals are subject to numerous risks and uncertainties. Material risks and uncertainties relating to our business and our industry are described in "Part I, Item 1A. Risk Factors" in this Annual Report on Form 10-K. We have not generated and do not expect to generate any revenue from product sales in the next several years, if at all. An element of our business strategy has been to pursue, as resources permit, the research and development of a range of drug candidates for a variety of indications. We may also evaluate licensing products from third parties to expand our current product pipeline. This is intended to allow us to diversify the risks associated with our research and development expenditures. To the extent we are unable to maintain a broad range of drug candidates, our dependence on the success of one or a few drug candidates would increase and would have a more significant impact on our financial prospects, financial condition, and market value. We may also consider and evaluate strategic alternatives, including investment in, or acquisition of, complementary businesses, technologies, or products. Drug research and development is an inherently uncertain process and there is a high risk of failure at every stage prior to approval. The timing and the outcome of clinical results are extremely difficult to predict. The success or failure of any preclinical development and clinical trial can have a disproportionately positive or negative impact on our results of operations, financial condition, prospects, and market value. Our current business strategy includes the possibility of entering into collaborative arrangements with third parties to complete the development and commercialization of our drug candidates. In the event that third parties are contracted to manage the clinical trial process for one or more of our drug candidates, the estimated completion date would largely be under the control of that third party rather than us. We cannot forecast with any degree of certainty which proprietary products or indications, if any, will be subject to future collaborative arrangements, in whole or in part, and how such arrangements would affect our development plan or capital requirements. We may also apply for subsidies, grants or government or agency-sponsored studies that could reduce our development costs. However, we cannot forecast with any degree of certainty whether we will be selected to receive any subsidy, grant or governmental funding. Since inception, the Company has incurred substantial operating losses, principally from expenses associated with the Company's research and development programs, clinical trials conducted in connection with the Company's drug candidates, and applications and submissions to the FDA. The Company has not generated significant revenue and has incurred significant net losses in each year since our inception. As of December 31, ~~2023~~ **2023**, the Company has incurred approximately \$ ~~488.407~~ **488.407** million of cumulative net losses and had \$ ~~15.579~~ **15.579** million in cash and cash equivalents, ~~short-term investments and interest receivable~~ **short-term investments and interest receivable** to fund its operations. ~~The Company also has a \$ 1.3 million receivable from the sale of the Company's State of New Jersey net operating losses.~~ **The Company also has a \$ 1.3 million receivable from the sale of the Company's State of New Jersey net operating losses.** We have substantial future capital requirements to continue our research and development activities and advance our drug candidates through various development stages. The Company believes these expenditures are essential for the commercialization of its drug candidates and technologies. The Company's primary sources of cash have been proceeds from the issuance and sale of its common stock, **including** via its ATM program and other potential funding transactions. There can be no assurance that the Company will be able to do so in the future on a timely basis on terms acceptable to the Company, or at all. The Company has not yet commercialized any of its product candidates. Even if the Company commercializes one or more of its product candidates, it may not become profitable in the near term. The Company's ability to achieve profitability depends on several factors, including its ability to obtain regulatory approval for its product candidates, successfully complete any post-approval regulatory obligations and successfully commercialize its product candidates alone or in partnership. Given our development plans, we anticipate cash resources will **not** be sufficient to fund our operations **into for the next twelve months fourth quarter of 2024**. The Company has no committed sources of additional capital. As a result of the risks and uncertainties discussed in this Annual Report on Form 10-K, among others, we are unable to estimate the duration and completion costs of our research and development projects or when, if ever, and to what extent we will receive cash inflows from the commercialization and sale of a product. Our inability to complete any of our research and development activities, preclinical studies or clinical trials in a timely manner or our failure to enter into collaborative agreements when appropriate could significantly increase our capital requirements and could adversely impact our liquidity. While our estimated future capital requirements are uncertain and could increase or decrease as a result of many factors, including the extent to which we choose to advance our research, development activities, preclinical studies and clinical trials, or if we are in a position to pursue manufacturing or commercialization activities, we will need significant additional capital to develop our drug candidates through development and clinical trials, obtain regulatory approvals and manufacture and commercialized approved products, if any. We do not know whether we will be able to access additional capital when needed or on terms favorable to us or our stockholders. Our inability to raise additional capital, or to do so on terms reasonably acceptable to us, would jeopardize the future success of our business. Based on the above, management has determined there is substantial doubt regarding our ability to continue as a going concern. The report of our independent registered public accounting firm for the year ended December 31, ~~2023~~ **2023** includes an explanatory paragraph which expresses substantial doubt about our ability to continue as a going concern. Management's plan includes raising funds from outside investors, **including** via its ATM program and other potential funding sources ~~as mentioned~~. However, as mentioned above, there is no assurance such funding will be available to the Company or that it will be obtained on terms favorable to the Company or will provide

the Company with sufficient funds to meet its objectives. The Company's financial statements do not include any adjustments relating to the recoverability and classification of assets, carrying amounts or the amount and classification of liabilities that may be required should the Company be unable to continue as a going concern. The Company's ability to raise additional capital may also be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the U. S. and worldwide resulting from the ongoing **conflict between effects of the COVID-19 pandemic and the Russian invasion of Ukraine**. These disruptions may also disrupt the clinical trials process and **Russia and enrollment of patients**. This may delay commercialization efforts. The Company continues to monitor its operating activities in light of these **the unrest in events**, and it is reasonably possible that the **Middle East virus could have a negative effect on the Company's financial condition and results of operations**. The specific impact, if any, is not readily determinable as of the date of the financial statements included in this Annual Report. Financing Overview Equity, Debt and Other Forms of Financing Since 2018, the Company has annually submitted applications to sell a portion of the Company's State of New Jersey net operating losses ("NOLs") as part of the Technology Business Tax Certificate Program (the "NOL Program") sponsored by The New Jersey Economic Development Authority. Under the program, emerging biotechnology companies with unused NOLs and unused research and development credits are allowed to sell these benefits to other New Jersey-based companies. In 2018, 2019 and 2020, the Company sold cumulative NOLs from 2011 to 2019 totaling \$ 15 million and received net proceeds of \$ 14 million. **As part of the NOL Program, the Company sold \$ 1.3 million and \$ 1.6 million of its New Jersey NOLs in 2023 and 2022, respectively. The sale of these net operating losses resulted in net proceeds to the Company of approximately \$ 1.3 million in 2023 and \$ 1.6 million in 2022.** During 2021, the New Jersey State Legislature increased the maximum lifetime benefit per company from \$ 15 million to \$ 20 million. **As part of the expanded NOL Program, which will allow the Company sold \$ 4.6 million of its New Jersey NOLs in 2021, 2022 and 2023 resulting in net proceeds to the Company of approximately \$ 4.2 million. The Company can participate in this funding program in future years for up to an additional \$ 0.3-4 million in net operating losses under this the \$ 20 million maximum lifetime benefit limit.** As more fully discussed in Note 8 to our financial statements included in this Annual Report, in June 2021, the Company entered into a \$ 10 million loan facility with Silicon Valley Bank (the "SVB Loan Facility"). The Company immediately used \$ 6 million from this facility to retire all outstanding indebtedness with Horizon Technology Finance Corporation. The funding was in the form of money market secured indebtedness bearing interest at a calculated WSJ Prime-based variable rate. The SVB Loan Facility was repaid in full during the quarter ended June 30, 2023. **During 2024 and 2023, we issued a total of 5.1 million shares and 1.9 million shares of common stock, respectively, as discussed below for approximately \$ 9.0 million and approximately \$ 2.8 million, respectively, in net proceeds.** On ~~March 19~~ **May 15, 2021-2024**, the Company filed with the SEC a shelf registration statement on Form S-3 (the "~~2021-2024~~ **2021-2024** Registration Statement") that allows the Company to issue any combination of common stock, preferred stock or **for the offer warrants to purchase common stock or preferred stock in an and amount sale of up to \$ 100-75 million of its securities**. The ~~2021-2024~~ **2021-2024** Registration Statement was declared effective on ~~March 30~~ **May 22, 2021-2024**. The ~~2021-2024~~ **2021-2024** Registration Statement was ~~is~~ intended to provide us ~~the Company~~ with flexibility to raise capital in the future for general corporate purposes. However, ~~as of the Company's ability date of this filing and so long as our public float remains below \$ 75 million, we are subject to limitations with respect to offer and sell its securities in a primary offering on the use of the 2021-2024~~ **the Company's ability date of this filing and so long as our public float remains below \$ 75 million, we are subject to limitations with respect to offer and sell its securities in a primary offering on the use of the 2021-2024** Registration Statement ~~is limited by and any other shelf registration statement that we file with the SEC pursuant to General Instruction I. B. 6 of Form S-3 (the "Baby Shelf Limitation"), which limits the amount we that the Company can offer to up to one-third of our its public float during any trailing 12-month period. We The Company would be no longer be subject to the Baby Shelf Limitation if our its public float exceeds \$ 75 million. During 2022 and 2023, we issued a total of 3.5 million shares of common stock as discussed below for an aggregate \$ 9.5 million in gross proceeds.~~ **is limited by and any other shelf registration statement that we file with the SEC pursuant to General Instruction I. B. 6 of Form S-3 (the "Baby Shelf Limitation"), which limits the amount we that the Company can offer to up to one-third of our its public float during any trailing 12-month period. We The Company would be no longer be subject to the Baby Shelf Limitation if our its public float exceeds \$ 75 million. During 2022 and 2023, we issued a total of 3.5 million shares of common stock as discussed below for an aggregate \$ 9.5 million in gross proceeds.** ● On January 10, 2022, the Company entered into the Preferred Stock Purchase Agreement with several institutional investors, pursuant to which the Company agreed to issue and sell (i) 50,000 shares of Series A Preferred Stock and (ii) 50,000 shares of Series B Preferred Stock, in each case at an offering price of \$ 285 per share, representing a 5% original issue discount to the stated value of \$ 300 per share, for gross proceeds from each offering of \$ 14.25 million, or approximately \$ 28.50 million in the aggregate (the "Preferred Offerings"), before the deduction of the Placement Agent's (as defined below) fee and offering expenses. The shares of Series A Preferred Stock have a stated value of \$ 300 per share and are convertible, at a conversion price of \$ 13.65 per share, into 1,098,901 shares of common stock (subject in certain circumstances to adjustments). The shares of Series B Preferred Stock have a stated value of \$ 300 per share and are convertible, at a conversion price of \$ 15.00 per share, into 1,000,000 shares of common stock (subject in certain circumstances to adjustments). The closing of the Preferred Offerings occurred on January 13, 2022. On February 28, 2022, the Company effected a 15-for-1 reverse stock split of its common stock, which was made effective for trading purposes as of the commencement of trading on March 31, 2022. In connection with the Preferred Offerings, the Company entered into a placement agent agreement (the "Placement Agent Agreement") with AGP, as placement agent pursuant to which the Company agreed to pay AGP an aggregate cash fee equal to \$ 1,000,000 and reimburse AGP for certain of their expenses in an amount not to exceed \$ 110,000. On March 3, 2022, the Company redeemed for cash at a price equal to 105% of the \$ 300 stated value per share of all of its 50,000 outstanding shares of Series A Preferred Stock and its 50,000 outstanding Series B Preferred Stock. As a result, all shares of the Preferred Stock have been retired and are no longer outstanding and Imunon's only class of outstanding stock is its common stock. ● On April 6, 2022, the Company entered into a Securities Purchase Agreement (the "April 2022 Purchase Agreement") with several institutional investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering (the "April 2022 Offering"), an aggregate of 1,328,274 shares of the Company's common stock at an offering price of \$ 5.27 per share for gross proceeds of \$ 7.0 million before the deduction of the April 2022 Placement Agent (as defined below) fees and offering expenses. The closing of the April 2022 Offering occurred on April 8, 2022. In connection with the April 2022 Offering, the Company entered into a placement agent agreement with A. G. P. / Alliance Global Partners (the "April 2022 Placement Agent") pursuant to which the Company agreed to pay the April 2022 Placement Agent a cash fee equal to 6.5% of the aggregate gross proceeds raised from the sale of the securities sold in the April 2022 Offering and reimburse the April 2022 Placement Agent for certain of their expenses in an amount not to exceed \$ 50,000. ● On May 25, 2022, the Company entered into an At the Market Offering Agreement (~~On May 15, 2024, the "Company amended its ATM Agreement"~~ **On May 15, 2024, the "Company amended its ATM Agreement"**) with H. C. Wainwright & Co., LLC (~~"Wainwright"~~ **"Wainwright"**) as sales agent (~~"Wainwright"~~ **"Wainwright"**), pursuant to which the Company may offer and sell, from time to time, through Wainwright, shares of the Company's common stock having an aggregate offering price of up to \$ ~~7.5~~ **5,000,000**. The Company intends to use the net proceeds from the offering, if any, for general corporate purposes, including research and development activities, capital expenditures and working capital. ~~The On July 30, 2024, the Company did not sell any shares notified Wainwright that it was suspending its use of and terminating the "at the market offering" sales agreement prospectus (the "ATM Prospectus"), related to the potential issuance from time to time of the Company's common stock pursuant to the ATM Agreement, by and between the Company and Wainwright. Notwithstanding the termination of the ATM Prospectus, the ATM Agreement remains in full force and effect. On September 3, 2024, in connection with its intent to resume sales under the ATM Agreement, the Company filed a new prospectus supplement to the 2024 Registration Statement with the SEC for an aggregate offering price of up to \$ 5,500,000 related to the potential issuance from time to time of the Company's common stock pursuant to the ATM Agreement with Wainwright as sales agent in the first nine months of 2022. The From October 1, 2022 through December 31, 2022, the Company sold 336,888, 075-976 shares of common stock under the ATM Agreement for net proceeds of \$ 99,506 during 2024. During 2023, the Company sold 1,878,488 shares of common stock for net proceeds of \$ 603-2,750-798. During the year ended December 31, 658. July 2023-2024 Offering On July 30, 2024, the Company sold entered into the July 2024 Purchase Agreement with the Purchasers (as defined therein), 878 pursuant to which the Company issued, 488 in a registered direct offering, an aggregate of 5,000,000 shares of the Company's common stock for net proceeds at an offering price of \$ 2.8-00 per share for gross proceeds of \$ 10.0 million before the deduction of the placement agent fees and offering expenses. In a concurrent private placement (together with the registered direct offering, the "July 2024 Offering") and also pursuant to the July 2024 Purchase Agreement, the Company issued to the Purchasers unregistered warrants (the "Warrants") to purchase an aggregate of 5,000,000 shares of its common stock at a purchase price of \$ 2.00 per share. The Warrants were exercisable immediately after issuance for a term of five and one-half years following the date of issuance. The closing of the July 2024 Offering occurred on August 1, 2024. In connection with the July 2024 Offering, the Company entered into an engagement letter agreement with Wainwright pursuant to which the Company agreed to pay Wainwright and any other placement agents for the July 2024 Offering a cash fee equal to 7% of the aggregate gross proceeds raised from the sale of the securities sold in the July 2024 Offering and reimburse the placement agents for certain of their expenses in an amount not to exceed \$ 85,000. Brookline Capital Markets, a division of Arcadia Securities, LLC, acted as co-placement agent in the July 2024 Offering. Please refer to Note 2 to our financial statements included in this Annual Report. Also refer to Part I, Item 1A, Risk Factors, in this Annual Report, including, but not limited to, "We will need to raise substantial additional capital to fund our planned future operations, and we may be unable to secure such capital without significant dilutive financing transactions. If we are not able to raise additional capital, we may not be able to complete the development, testing and commercialization of our drug candidates." Critical Accounting Policies and Estimates Our financial statements included in this Annual Report have been prepared in accordance with accounting principles generally accepted in the U. S. ("GAAP"), which require that we make certain assumptions and estimates and, in connection therewith, adopt certain accounting policies. Our significant accounting policies are set forth in Note 1 to our financial statements included in this Annual Report. Of those policies, we believe that the policies discussed below may involve a higher degree of judgment and may be more critical to an accurate reflection of our financial condition and results of operations. ~~In-Process Research and Development Research~~ **Research**.~~

Other Intangible Assets and Goodwill During 2014, development costs are expensed as incurred. Supplies are consumable and recorded at cost and are charged to expense as they are used in operations. Equipment and facilities acquired certain assets of EGEN, Inc. As more fully described in Note 6 to our financial statements included in this Annual Report, the acquisition was accounted for under research and development activities that have alternative future uses are capitalized and charged to expense over their acquisition method of estimated useful lives. Warrant Accounting Accounting We which required the Company to perform an allocation of the purchase price to the assets acquired and liabilities assumed. Under the acquisition method of accounting account for warrants as either equity- classified or - the total purchase price is allocated to net tangible and intangible assets and liabilities liability - classified instruments based on an assessment of the warrants' specific terms and applicable authoritative guidance in ASC 480, "Distinguishing Liabilities from Equity" ("ASC 480"), and ASC 815 "Derivatives and Hedging" ("ASC 815"). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to our own ordinary shares and whether warrant holders could potentially require "net cash settlement" in a circumstance outside of our control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end- date while the warrants are outstanding. For issued or modified warrants that meet all the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair values- value of warrants classified as liabilities are recognized as a non- cash gain or loss on our statements of operations the acquisition date. As the warrants issued upon further discussed in Note 6 to our financings financial statements included in this Annual Report 2024 meet the criteria for equity classification under ASC 815, during the those year ended warrants were classified as equity as of December 31, 2022-2024, the Company recorded a \$13. No warrants were issued in 2023 4-million IPR & D impairment charge. We review our financial reporting and disclosure practices and accounting policies on an ongoing basis to ensure that our financial reporting and disclosure system provides accurate and transparent information relative to the current economic and business environment. As part of the process, the Company reviews the selection, application and communication of critical accounting policies and financial disclosures. The preparation of our financial statements in conformity with GAAP requires that our management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. We review our estimates and the methods by which they are determined on an ongoing basis. However, actual results could differ from our estimates. Results of Operations Comparison of Fiscal Year Ended December 31, 2023-2024 and Fiscal Year Ended December 31, 2022-2023. For the year ended December 31, 2023-2024, our net loss was \$ 19-18, 5-6 million compared to a net loss of \$ 35-19, 9-5 million for the year ended December 31, 2022-2023. The Company recognized \$ 1.3 million and \$ 1.6 million in tax benefits from the sale of its New Jersey NOLs under the NOL Program in each of the fourth quarters- quarter of 2023 and 2022, respectively. As of December 31, 2023-2024, the Company had \$ 15-5, 7-9 million in cash and cash equivalents, -short-term investments, and interest receivable to fund its operations. -The Company also has a \$ 1.3 million receivable from the sale of the Company's State of New Jersey NOLs. The Company's primary sources of cash have been proceeds from the issuance and sale of its common stock, including via its ATM program and other funding transactions. There can be no assurance that the Company will be able to do so in the future on a timely basis on terms acceptable to the Company, or at all. The Company has not yet commercialized any of its product candidates. Even if the Company commercializes one or more of its product candidates, it may not become profitable in the near term or at all. The Company's ability to achieve profitability depends on several factors, including its ability to obtain regulatory approval for its product candidates, successfully complete any post- approval regulatory obligations and successfully commercialize its product candidates alone or in partnership. Such conditions raise substantial doubts- doubt about the Company's ability to continue as a going concern. Based on the above, management has determined there is substantial doubt regarding our ability to continue as a going concern. The report of our independent registered public accounting firm for the year ended December 31, 2023-2024 includes an explanatory paragraph which expresses substantial doubt about our ability to continue as a going concern. Management's plan includes raising funds from the issuance and sale of its common stock, including via its ATM program and other funding transactions. However, as mentioned above, there is no assurance such funding will be available to the Company or that it will be obtained on terms favorable to the Company or will provide the Company with sufficient funds to meet its objectives. The Company's financial statements do not include any adjustments relating to the recoverability and classification of assets, carrying amounts or the amount and classification of liabilities that may be required should the Company be unable to continue as a going concern. The Company operates in one segment for the research and development of our product candidates. The Company's chief operating decision maker ("CODM") has been identified as the Chief Executive Officer and President, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company based on consolidated financial information. Consequently, we view the entire organization as one reportable segment and the strategic purpose of all operating activities (including general & administrative expenses) is to support that one segment. As a pre- revenue research and development company, the CODM evaluates company- wide performance and allocates resources based on non- financial research and development milestones achieved, and to a lesser extent, financial measures of performance such as clinical development (research and development expenses) and general and administrative expenses incurred. Our CODM does not generally evaluate our performance using asset or historical cash flow information. The table below provides a summary of the significant expense categories and consolidated net loss details provided to the CODM (in thousands):

	2024	2023	2022	Change Increase (Decrease)
Revenue: \$- \$500 \$(500) (100.0)%				
Operating Expenses: Clinical Research OVATION \$ 1,386 \$ 1,197 \$ 189 15.8%				
Vaccine 1,420 536 (339) (22.1)				
OPTIMA- 950 (950) (-100.0)%				
Other Clinical clinical and regulatory 2,434 1,793 641 35.1%				
Subtotal 5,240 2,990 4-2,250 75 392 (1,402)				
(31.3)%				
Non- Clinical R & D and CMC OVATION 1,819 1,504 315 20.3%				
PlacCine Vaccine 2,554 4,511 2(1,957) (43.9)				
43 2,072 85.0-0.4)%				
Manufacturing (CMC) 2,026 2,283 (257) (11.1)				
Subtotal 6,399 8,298 7(1,342) 956 (13.899) (22.0)				
9)%				
Research and development expenses 11,639 11,288 351 1.3%				
General and administrative expenses 7,493 9,742 13,688 (3-2,946) 249 (28.23)				
8.1)%				
Total operating expenses 19,132 21,030 25,422 (4-1,392) 898 (17.9)				
3.0)%				
Loss from operations \$ (19,132) \$ (21,030) \$ (24-1,922) 898 \$ (9-3,892) (15.6-0)				
6.0)%				
Licensing Revenue In January 2013, we entered into a technology development contract with Zhejiang Hisun Pharmaceutical Co. Ltd. ("Hisun"), pursuant to which Hisun paid us a non- refundable technology transfer fee of \$ 5.0 million to support our development of ThermoDox @ in the China territory. The \$ 5.0 million received as a non- refundable payment from Hisun in the first quarter 2013 has been recorded to deferred revenue and was amortized over the ten- year term of the agreement; therefore, we recognized revenue of \$ 500,000 in the year 2022. As of December 31, 2022, this contract has been fully amortized and recognized as revenue. Research and Development Expenses Research and development ("R & D") expenses decreased \$ 0.43 million to \$ 11.36 million in 2023-2024 from \$ 11.73 million in 2022-2023. Costs associated with the OVATION 2 Study were \$ 1.24 and \$ 1.52 million in 2024 and 2023 and 2022, respectively. Costs associated with the OPTIMA- PlacCine Vaccine Study were insignificant in 2023 compared to \$ 1.04 million in 2022-2024. Other clinical and regulatory costs were \$ 2.4 million in 2024 compared to \$ 1.8 million in 2023 compared to \$ 1.9 million in 2022. R & D costs associated with the development of IMN- 001 to support the OVATION 2 Study were \$ 1.58 million in 2023-2024, an decrease increase from \$ 0.37 million in same period of 2022-2023. The development of the PLACCINE DNA vaccine technology platform increased- decreased to \$ 2.6 million in 2024 compared to \$ 4.5 million in 2023 compared. CMC costs decreased to \$ 2.40 million in 2022-2024 compared. CMC costs increased to \$ 2.23 million in 2023 compared to \$ 1.2 million in 2022. General and Administrative Expenses General and administrative expenses decreased to \$ 7.5 million in 2024 compared to \$ 9.7 million in 2023 compared to \$ 13.7 million in 2022. This decrease is primarily attributable to lower the decrease in legal expenses of \$ 1.4 million, employee related costs of \$ 0.4 million, non- cash stock compensation expenses of \$ +0.3 million, insurance employee related costs of \$ 0.81 million, and franchise tax legal expenses of \$ 1.0 million, insurance costs of \$ 0.6 million, public company expenses of \$ 0.2 million offset by higher consulting fees of \$ 0.2 million. Change in Earn- out Milestone Liability The total aggregate purchase price for the acquisition of assets from EGEN included potential future earn- out payments contingent upon achievement of certain milestones. The difference between the aggregate \$ 30.4 million in future earn- out payments and the \$ 13.9 million included in the fair value of the acquisition consideration at June 20, 2014 was based on the Company's risk- adjusted assessment of each milestone and utilizing a discount rate based on the estimated time to achieve the milestone. The milestone liability is fair valued at the end of each quarter and any change in the value is recognized in our financial statements. On March 28, 2019, the Company and EGWU, Inc. entered into an amendment to the Asset Purchase Agreement discussed in Note 13 to our financial statements included in this Annual Report. Pursuant to the Amended Asset Purchase Agreement, payment of the earnout milestone liability related to the Ovarian Cancer Indication of \$ 12.4 million has been modified. The Company has the option to make the payment as follows: • \$ 7.0 million in cash within 10 business days of achieving the milestone; or • \$ 12.4 million in cash, common stock of the Company, or a combination of either, within one year of achieving the milestone. At December 31, 2022, the Company wrote off the earn- out milestone liability as a result of the requirements not being achieved and recognized a non- cash gain of \$ 5.4 million during 2022 as a result of the change in the fair value of the earn- out milestone liability. The Company fair value of the milestone liability was zero at December 31, 2023. Impairment of				

Goodwill and IPR & D Due to the continuing deterioration of public capital markets in the biotech industry and its impact on market capitalization rates in this sector, IPR & D was reviewed for impairment. Having conducted a quantitative analysis of the company's IPR & D assets, the Company concluded the IPR & D asset was impaired during the fourth quarter of 2022. As of December 31, 2022, the Company wrote off the \$ 13.4 million carrying value of this asset, thereby recognizing a non-cash charge of \$ 13.4 million in the fourth quarter of 2022. The Company fair value of the IPR & D was zero at December 31, 2023. Investment income and interest expense The Company recognized interest expense of \$ 0.2 million in 2023 compared to \$ 5.0 million in 2022. As more fully discussed in Note 9-7 to our financial statements included in this Annual Report, in June 2021, the Company entered into a \$ 10 million loan facility with Silicon Valley Bank. The Company immediately used \$ 6 million from this facility to retire all outstanding indebtedness with Horizon Technology Finance Corporation. In connection with the SVB Loan Facility, the Company incurred \$ 0.2 million in interest expense in 2023 compared to \$ 0.5 million in 2022. In connection with the termination of the SVB Loan Facility in the second quarter of 2023, the Company paid early termination and end-of-term charges to SVB and recognized \$ 0.3 million as a loss on debt extinguishment. As more fully discussed in Note 10 to our financial statements included in this Annual Report, in the first quarter of 2022, the Company incurred interest expense totaling \$ 4.6 million attributed to the Preferred Offerings. Investment income from the Company's short-term investments was \$ 0.5 million in 2024 compared to \$ 1.2 million in 2023 compared to \$ 0.5 million in 2022. Income Tax Benefit Annually, the State of New Jersey enables approved technology and biotechnology businesses with New Jersey NOLs the opportunity to sell these losses through the NOL Program, thereby providing cash to companies to help fund their research and development and business operations. During 2021, the New Jersey State Legislature increased the maximum lifetime benefit per company from \$ 15 million to \$ 20 million, which will allow the Company to participate in this innovative funding program in future years. After the cumulative NOL sales through 2023, the Company has approximately \$ 0.4 million remaining under the NOL Program. The Company entered into an agreement to sell the approved portion of the New Jersey NOLs applied for in 2023 for \$ 1.3 million. At December 31, 2023, the Company evaluated the valuation reserve for its NOLs associated with its New Jersey NOLs and reduced the valuation reserve and recognized \$ 1.3 million as a deferred tax asset and an income tax benefit. The Company completed the sale of these NOLs in March of 2024. During the fourth quarter of 2022, the Company entered into an agreement to sell the approved portion of the New Jersey NOLs applied for in 2022 for \$ 1.6 million. At December 31, 2022, the Company evaluated the valuation reserve for its tax net operating losses associated with its New Jersey NOLs and reduced the valuation reserve and recognized \$ 1.6 million as a deferred tax asset and an income tax benefit. The Company completed the sale of these NOLs in January of 2023. Financial Condition, Liquidity and Capital Resources Since inception, we have incurred significant losses and negative cash flows from operations. We have financed our operations primarily through the net proceeds from the sales of equity, credit facilities and amounts received under our product licensing agreement with Yakult and our technology development agreement with Hisun. The process of developing IMNN-001 and other drug candidates and technologies requires significant research and development work and clinical trial studies, as well as significant manufacturing and process development efforts. We expect these activities, together with our general and administrative expenses, to result in significant operating losses for the foreseeable future. Our expenses have significantly and regularly exceeded our revenue income, and we had an accumulated deficit of \$ 388,407 million at December 31, 2023-2024. At December 31, 2023-2024 we had total current assets of \$ 18.8, 2.0 million and current liabilities of \$ 7-4, 8 million, resulting in net working capital of \$ 10-3, 8.2 million. At On December 31, 2023-2024, we had cash and cash equivalents, short-term investments, interest receivable on short-term investments, net proceeds on the sale of net operating losses and money market investments of \$ 17-5, 0-9 million. At On December 31, 2022-2023, we had total current assets of \$ 37-18, 2 million and current liabilities of \$ 10-7, 1-4 million, resulting in net working capital of \$ 27-10, 1-8 million. We have substantial future capital requirements to continue our research and development activities and advance our drug candidates through various development stages. The Company believes these expenditures are essential for the commercialization of its technologies. Net cash used in operating activities for 2023-2024 was \$ 19-18, 0-9 million. Our net loss of \$ 19-18, 5-6 million for 2023-2024 included the following non-cash transactions of \$ 0.8-5 million in non-cash stock-based compensation expense. At On December 31, 2023-2024, we had cash and cash equivalents, short-term investments, interest receivable on short-term investments, receivable from the sale of New Jersey NOLs and money market investments of \$ 17-5, 0-9 million. See Financing Overview. The Company may seek additional capital through further public or private equity offerings, debt financing, additional strategic alliance and licensing arrangements, collaborative arrangements, or some combination of these financing alternatives. If we raise additional funds through the issuance of equity securities, the percentage ownership of our stockholders could be significantly diluted, and the newly issued equity securities may have rights, preferences, or privileges senior to those of the holders of our common stock. If we raise funds through the issuance of debt securities, those securities may have rights, preferences, and privileges senior to those of our common stock. If we seek strategic alliances, licenses, or other alternative arrangements, such as arrangements with collaborative partners or others, we may need to relinquish rights to certain of our existing or future technologies, drug candidates, or products we would otherwise seek to develop or commercialize on our own, or to license the rights to our technologies, drug candidates, or products on terms that are not favorable to us. The overall status of the economic climate could also result in the terms of any equity offering, debt financing, or alliance, license, or other arrangement being even less favorable to us and our stockholders than if the overall economic climate were stronger. We also will continue to look for government sponsored research collaborations and grants to help offset future anticipated losses from operations and, to a lesser extent, interest income. If adequate funds are not available through either the capital markets, strategic alliances, or collaborators, we may be required to delay or, reduce the scope of, or terminate our research, development, clinical programs, manufacturing, or commercialization efforts, or effect additional changes to our facilities or personnel, or obtain funds through other arrangements that may require us to relinquish some of our assets or rights to certain of our existing or future technologies, drug candidates, or products on terms not favorable to us. Such conditions raise substantial doubts about the Company's ability to continue as a going concern. Management's plan includes raising funds from the issuance and sale of its common stock via its ATM program and other funding transactions. However, as mentioned above, there is no assurance such funding will be available to the Company or that it will be obtained on terms favorable to the Company or will provide the Company with sufficient funds to meet its objectives. The Company's financial statements do not include any adjustments relating to the recoverability and classification of assets, carrying amounts or the amount and classification of liabilities that may be required should the Company be unable to continue as a going concern. Off-Balance Sheet Arrangements We do not utilize off-balance sheet financing arrangements as a source of liquidity or financing. ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item. ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA The financial statements, supplementary data and report of independent registered public accounting firm required to be filed pursuant to this Item 8 are appended to this Annual Report beginning on page F- 1. ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE ITEM 9A. CONTROLS AND PROCEDURES (a) Disclosure Controls and Procedures We have conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a- 15 (e) and 15d- 15 (e) under the Exchange Act under the supervision, and with the participation, of our management, including our principal executive officer and principal financial officer. Based on that evaluation, our principal executive officer and principal financial officer concluded that as of December 31, 2023-2024, which is the end of the period covered by this Annual Report, our disclosure controls and procedures were effective. (b) Management's Report on Internal Control over Financial Reporting Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a- 15 (f) and 15d- 15 (f) under the Exchange Act. Our internal control over financial reporting is a process designed by, or under the supervision of, our chief executive officer and chief financial officer, or persons performing similar functions, and effected by our Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. Our internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and disposition of the assets of the Company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP and that receipts and expenditures of the Company are being made only in accordance with authorization of management and directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements. Management assessed the effectiveness of the Company's internal control over financial reporting as of December 31, 2023-2024. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in the 2013 Internal Control-Integrated Framework. Based on its evaluation, management has concluded that the Company's internal control over financial reporting is effective as of December 31, 2023-2024. Pursuant to Regulation S- K Item 308 (b), this Annual Report does not include an attestation report of the Company's registered public accounting firm regarding internal control over financial reporting. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate. A control system, no matter how well designed and operated can provide only reasonable, but not absolute, assurance that the control system's objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their cost. (c) Changes in Internal Control over Financial Reporting There have been no changes in our internal control over financial reporting in the fiscal quarter ended December 31, 2023-

2024 that were identified in connection with our management's evaluation required by paragraph (d) of rules 13a-15 and 15d-15 under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. ITEM 9B. OTHER INFORMATION Rule 10b5-1 Trading Plans During the year ended December 31, 2023-2024, no directors or executive officers entered into, modified or terminated, contracts, instructions or written plans for the sale or purchase of the Company's securities that were intended to satisfy the affirmative defense conditions of Rule 10b5-1. ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS Not applicable. PART III ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE Our Board of Directors currently consists of six members and is divided into three classes of directors serving staggered three-year terms. Directors for each class are elected at the Annual Meeting of Stockholders held in the year in which the term for their class expires and hold office for a three-year term and until their successors are duly elected and qualified, or their earlier death, resignation or removal. In accordance with our amended and restated certificate of incorporation and bylaws, our Board may fill any vacancy on the Board by appointment. Set forth below is certain information regarding our Company's current directors, as well as our non-director executive officers. NAME AGE POSITION (S) CLASS Frederick J. Fritz Director I Christine Pellizzari Director I James E. Dentzer Director II Stacy R. Lindborg, Ph. D. **President, Chief Executive Officer and** Director II Donald P. Braun, Ph. D. Director III Michael H. Tardugno Executive Chairman III Khurshed Anwer, Ph. D. Executive Vice President and Chief Scientific Officer **Susan Eylward General Counsel** **Sébastien Hazard, M. D. Executive Vice President and Corporate Secretary** **Douglas Faller, MD** Chief Medical Officer **David Gaiero** **Jeffrey W. Church Executive Vice President and Chief Financial Officer** 57-Class I Directors (Term expires in 2026) Mr. Frederick J. Fritz. Mr. Fritz was appointed to our Board of Directors in July 2011. Mr. Fritz has served as CEO and Founder of NeuroDx, a development stage diagnostic device company focused on the neurosurgery market, since 2006. Mr. Fritz joined NeuroDx from Valeo Medical, a biotechnology company he founded in 2003 to develop the world's first non-invasive diagnostic test for endometriosis. Prior to that, Mr. Fritz was President and CEO of Songbird Hearing, Inc., a medical device company spun out of Sarnoff Corporation. Mr. Fritz began his career in marketing management and new product development. He joined Schering Plough's Wesley Jessen in 1985 as VP Marketing and Sales in 1986. He was promoted to general manager of Schering's Over the Counter pharmaceutical business in 1988 and of the podiatric products business in 1990. He was President of Coleman North America from 1995 to 1997. Mr. Fritz holds a bachelor's degree in engineering (summa cum laude) from University of Illinois and an MBA degree from Harvard University. Ms. Christine A. Pellizzari. Ms. Pellizzari was appointed to our Board of Directors in June 2021. Ms. Pellizzari **has most recently** served as the Chief Legal Officer **and Human Resources Officer** of Science 37 **since July (formerly Nasdaq: SNCE), a developer of leading decentralized clinical trial solutions, where she had global responsibility for both the legal and human resource functions and also oversaw quality and privacy from 2021 through 2024. Immediately Prior** prior to joining Science 37, Ms. Pellizzari served as the General Counsel and Corporate Secretary of Inmed, Inc., (Nasdaq: INSM) a publicly traded biotech company focused on serious and rare diseases, from 2013 to 2018 and as Chief Legal Officer from 2018 to 2021. From 2007 through 2012 Ms. Pellizzari held various legal positions of increasing responsibility at Aegerion Pharmaceuticals, most recently as Executive Vice President, General Counsel and Corporate Secretary. Prior to Aegerion, Ms. Pellizzari was Senior Vice President, General Counsel and Secretary at Dendrite International, Inc., a formerly publicly traded company that provided sales effectiveness, promotional and compliance solutions to the pharmaceutical industry. Ms. Pellizzari joined Dendrite from the law firm of Wilentz, Goldman & Spitzer, where she specialized in health care transactions and related regulatory matters. Ms. Pellizzari has nearly three decades of relevant experience, including having served for over 25 years as Chief Legal Officer and General Counsel of publicly traded companies in biopharmaceutical and related industries. Ms. Pellizzari also serves on the board of directors of Tempest Therapeutics (Nasdaq: TPST), a public clinical-stage oncology company and Neurosense Therapeutics (Nasdaq: NRSN), a public clinical-stage development company advancing treatments for severe neurodegenerative diseases. Ms. Pellizzari received her Bachelor of Arts, cum laude, from the University of Massachusetts (Amherst) and her Juris Doctor degree from the University of Colorado School of Law. She is a member of Global Leaders in Law, Executive Women in Bio, Women Corporate Directors, National Association of Corporate Directors, Association of Corporate Counsel, Society for Corporate Governance and National Association of Stock Plan Professionals. Class II Directors (Term expires in 2024-2027) Mr. James E. Dentzer. Mr. Dentzer was appointed to our Board of Directors in September 2022. He has been President and Chief Executive Officer and a member of the Board of Directors of Curis, Inc. (Nasdaq: CRIS) since September 2018. From March 2018 to September 2018, Mr. Dentzer served as Curis' Chief Operating Officer and Chief Financial Officer. From March 2016 to March 2018, Mr. Dentzer served as Curis' Chief Administrative Officer and Chief Financial Officer. Mr. Dentzer has also held the positions of secretary and treasurer from March 2016 to March 2019. Prior to joining Curis, Mr. Dentzer served as Chief Financial Officer of Dicerca Pharmaceuticals, Inc., a formerly publicly traded biotechnology company, from December 2013 to December 2015. Prior to that, he was the Chief Financial Officer of Valeritas, Inc., a formerly publicly traded medical technology company, from March 2010 to December 2013. Prior to joining Valeritas, Inc., he was the Chief Financial Officer of Amicus Therapeutics, Inc. (Nasdaq: FOLD), a biotechnology company, from October 2006 to October 2009. In prior positions, he spent six years as Corporate Controller of Biogen Inc. (Nasdaq: BILB), a biotechnology company, and six years in various senior financial roles at E. I. du Pont de Nemours and Company, a chemical, petroleum and biotechnology company, in the U. S. and Asia. Mr. Dentzer holds a B. A. degree in Philosophy from Boston College and an M. B. A. from the University of Chicago. Dr. Stacy R. Lindborg. Dr. Lindborg, **a was appointed to our Board of Directors- director since in June 2021, has served as President and Chief Executive Officer of the Company since May 2024.** Dr. Lindborg, **a globally recognized biostatistician,** brings to Immunon **nearly 30 more than 25** years of pharmaceutical **and biotech** industry experience with a particular focus on R & D, **regulatory affairs,** executive management and strategy. She has worked with biologics, small molecules and cell therapies to address a broad range of diseases and disorders, including multiple Orphan drug products, along with extensive experience in early-stage development having taken molecules from first **in-man-human** studies into the clinic, through **regulatory** approval and **commercial** launch. **Prior to joining the Company,** Dr. Lindborg **held** **s holds** the position of co-Chief Executive Officer at Brainstorm Cell Therapeutics (Nasdaq: BCLI), which she joined in 2020, **and where she also currently serves as an independent director since May 2024.** From 2012 to 2020, she held positions of increasing responsibility at Biogen, **where she worked in biostatistics and biometrics,** and served as Vice President for Global Analytics and Data Sciences. **Prior to her time at Biogen, Dr. Lindborg joined had worked at** Eli Lilly and Company (NYSE: LLY) **in since** 1996 **moving advancing** through the organization to serve from 2010 to 2012 as Head of R & D Strategy with responsibility for characterizing the productivity of the portfolio and **driving advancing** key R & D strategy projects **including the annual by connecting individual drug- development decisions to portfolio risk practices and driving fundamental R & D Long-Range Plan decisions to increase the number of drug launches.** Dr. Lindborg **is received an M. A. and a graduate of Ph. D. in statistics from** Baylor University **where she received a Ph. D. and M. A. in statistics and a B. A. in psychology with a minor in mathematics.** She has authored more than **fifty 50** abstracts, 200 presentations and **45 40** manuscripts that have been published in peer-reviewed journals. She **has held numerous positions within the American serves on several industry advisory boards related to statistics Statistical Association and biotechnology- International Biometric Society and was elected Fellow in 2008.** 58-Class III Directors (Term expires in 2025) Dr. Donald P. Braun. Dr. Braun was appointed to our Board of Directors in December 2015. Dr. Braun has over 35 years of research experience in oncology, cancer immunology, cancer immunotherapy, and inflammatory diseases. He is the author of more than 120 published peer-reviewed manuscripts, twenty-five reviews and book chapters, and co-editor of a book on the role of prostaglandins and other COX 2 metabolites in cancer patient immunity and immunotherapy. He served from 2006 to 2014 as Vice President Clinical Research, after which he served as Vice President Translational Research and Chief Science Officer at the Cancer Treatment Centers of America until his retirement in May 2016. Prior to this role, he was the Scientific Director of the Cancer Center and Professor of Medicine and Immunology at Rush Medical College in Chicago from 1978 to 1999, and the Administrative Director of the Cancer Institute and a Professor of Surgery with tenure at the Medical College of Ohio from 1999 to 2006. He received his Ph. D. in Immunology and Microbiology from the University of Illinois at the Medical Center in Chicago. Dr. Braun has served as an advisor to numerous public agencies and private corporations concerned with cancer therapeutics and diagnostics. At the National Cancer Institute, Dr. Braun served as a member of the Experimental Therapeutics Study Section; the Small Business Innovation Grant Review Study Section; and the Experimental Therapy program for "Molecular Targets in Lung Cancer." He served as a member of the Immunology and Immunotherapy Study Section of the American Cancer Society- National Division; as a Member of the Ohio Cancer Incidence Surveillance System; as a Member of the Biomedical Research Technology Transfer Commission for the State of Ohio; and as an advisor to the State of Arizona's Disease Research Control Commission. Dr. Braun has also served as a consultant to numerous pharmaceutical and biotechnology companies developing cancer treatments and diagnostics including Pfizer Inc. (NYSE: PFE), Sterling Winthrop, Abbott Laboratories (NYSE: ABT), Boehringer Mannheim, Serono Corporation, Biomira Inc., Centocor and Merck KGA. Mr. Michael H. Tardugno. Mr. Tardugno was appointed President and Chief Executive Officer of the Company on January 3, 2007, and was elected to the Board of Directors on January 22, 2007. In October of 2014, Mr. Tardugno was appointed by our Board of Directors as our Chairman. Effective July 18, 2022, Mr. Tardugno transitioned from the roles of President, Chief Executive Officer and Chairman to the position of Executive Chairman of the Board. **From March 15, 2024, Mr. Tardugno served as interim Chief Executive Officer until the appointment of Dr. Lindborg effective May 13, 2024.** Prior to joining the Company and for the period from February 2005 to December 2006, Mr. Tardugno served as Senior Vice President and General Manager of Mylan Technologies, Inc., a subsidiary of Mylan Inc. From 1998 to 2005, Mr. Tardugno was Executive Vice President of Songbird Hearing, Inc., a medical device company spun out of Sarnoff Corporation. From 1996 to 1998, he was Senior Vice President of Technical Operations worldwide for a division of Bristol-Myers Squibb (NYSE: BMY), and from 1977 to 1995, he held

increasingly senior executive positions including Senior Vice President of Worldwide Technology Development with Bausch & Lomb (NYSE, TSX: BLCO) and Abbott Laboratories (NYSE: ABT). Mr. Tardugno holds a B. S. degree from St. Bonaventure University and completed the Harvard Business School Program for Management Development. Executive Officers The following are the biographical summaries for each of our executive officers, **other than Dr. Stacy R. Lindborg, whose biographical summary is described above**. Each executive officer is elected by and serves at the pleasure of our Board of Directors.

Khursheed Anwer, Ph. D. Dr. Anwer joined us in June 2014 as Executive Vice President and Chief Scientific Officer, in connection with our acquisition of all the assets of EGWU, Inc. (formerly known as Egen, Inc.), an Alabama corporation (or “EGEN”). Before joining the Company, Dr. Anwer served as EGEN’s President and Chief Scientific Officer, a position he held since 2009. He joined EGEN in July 2002 as Vice President of Research and Development and directed EGEN’s clinical and research and development functions. Before joining EGEN, Dr. Anwer was Director of Pre-Clinical Development at Valentis, Inc. from July 2000 to June 2002. From 1993 to 1999, he served in several positions at GeneMedicine, Inc., where he led several research projects in the area of non-viral gene therapy. He has authored more than 40 publications in the area of non-viral gene therapy, resulting from his active career in research and development. Dr. Anwer holds a Ph. D. in physiology / pharmacology from Ohio University and received post-doctoral training from the University of Texas Health Science Center at Houston. Dr. Anwer also has a master’s in business administration from the University of Alabama.

Susan Eylward Ms 59 Sébastien Hazard, M. D. On December 7, Eylward joined the Company in October 2023-2024. Dr. as General Counsel and Corporate Secretary. Hazard Prior to her position with the Company, Ms. Eylward served as Senior Counsel at Science 37, Inc. (formerly Nasdaq: SNCE), a solutions organization focused on decentralized clinical trials, from January 2022 through April 2024, where she was appointed responsible for a variety of complex legal matters, including, among others, corporate governance, securities compliance, executive compensation, and acquisitions. Prior to that, Ms. Eylward served as Executive corporate counsel and Vice President at the Allstate Corporation (NYSE: ALL) during 2021, at National General Holdings Corp. (formerly Nasdaq: NGHC) from September 2014 through December 2020, and at Tower Group International, Ltd. (formerly Nasdaq: TWGP) from May 2009 through September 2014, and at each of the foregoing, she had responsibility for various corporate legal matters including governance, securities law, alternative investments and transactions. From 2004 through 2009, Ms. Eylward practiced law at Dewey & LeBoeuf LLP, where she represented public and private companies for equity and debt offerings, as well as mergers and acquisitions. Ms. Eylward received a Juris Doctor from New York Law School and a Bachelor of Arts in Accounting from Boston College.

Douglas Faller, MD Dr. Faller, and an internationally recognized oncologist / hematologist and scientist, has nearly 30 years of pharmaceutical and biotech industry experience with a particular focus on clinical R & D, discovery, regulatory affairs, and strategy development. He has worked with small molecules, gene therapies, biologics and cell therapies to address a range of malignant and non-malignant diseases and disorders, including rare and genetic diseases, and neurological and neuropsychiatric disorders. He has extensive experience in early-stage development as well as global late-stage development and world-wide marketing approvals. He has taken molecules (including those discovered in his own academic laboratories) from first-in-human studies in the clinic, through registrational trials, international regulatory approvals and commercial launch. Prior to his position with the Company, Dr. Faller served as Chief Medical Officer of Skyhawk Therapeutics beginning in 2024, where he led the development Company, effective as of December 11, splicing modulators for the treatment of oncological and neurological disorders. From 2023-2022 through 2024, immediately prior to joining the Company, Dr. Hazard served as Chief Medical Officer Senior Vice President, Head of Clinical Oryzon Genomics, leading the development of epigenetic-modifying small molecules in oncology and neuropsychiatric disorders, and prior to that role, from 2015 through 2022, Dr. Faller was Executive Medical Director at Takeda Pharmaceuticals, where he led multiple programs in hematologic oncology, solid tumor malignancies and rare diseases, from first-in-human to global registrational trials and post-marketing trials. He was also extensively involved in Business Development for oncology, hematology and rare diseases. Dr. Faller was the scientific founder and CMO / CSO of Viracta Therapeutics, which he joined in 2019 and remained through 2021, after it became publicly traded and launched a pivotal trial of his therapeutic. Dr. Faller is the scientific founder or co-founder of four biopharma companies. Prior to working full-time in the biopharmaceutical industry, Dr. Faller was a professor at Bicyele Therapeutics (Nasdaq: BCYC) from April 2021 through September 2023. Prior to joining Bicyele Therapeutics, Dr. Hazard Harvard served as Clinical Development Lead, Medical School, and an attending physician at GSK from June 2019 to April 2021-Brigham and Women’s Hospital, Boston Children’s Hospital and Dana-Farber Cancer Institute. He founded and directed the Comprehensive Cancer Center at Boston University, where he also served as Senior first Grunebaum Professor for Cancer Research, Vice-Chairman of the Department of Medicine, and Professor of Medicine, Biochemistry, Pediatrics, Microbiology, Pathology and Laboratory Medicine. Dr. Faller received a B. S. in biochemistry from the Massachusetts Institute of Technology, an MD from Harvard Medical School, and a PhD from the Massachusetts Institute of Technology July 2018 to May 2019, and Senior Medical Director of Technology Global Medical Affairs from August 2016 to July 2018 at TESARO, Inc. Dr. Hazard held various positions within Genentech, including Medical Director in Lung Cancer cancer of U-molecular biology. He S-Medical Affairs from November 2012 to July 2016. Earlier in his career Dr. Hazard served as has authored more than 300 abstracts, 230 presentations and 375 manuscripts that have been published advisor to the head of the French Drug Agency and to the French Health Minister’s cabinet. Dr. Hazard holds a Doctorate in Medicine, peer-reviewed journals. He is certified in Internal Medicine and Public Health from Paris VI Pitie Salpetriere, Hematology and Oncology, Executive M. B. A. from INSEAD and is a Fellow of the American College of Physicians master’s degree in epidemiology and statistics applied to clinical research from Paris VI University. David Gaiero Mr. Gaiero Jeffrey W. Church Mr. Church joined us the Company in July 2010-May 2024 as Vice President, Chief Financial Officer pursuant to a professional agreement (the “Agreement”) between the Company and Corporate Secretary Monomoy Advisors, LLC, a financial advisory services firm (“Monomoy”). He currently serves as a partner with Monomoy. Prior to joining Monomoy in May 2024, Mr. Gaiero Church was appointed as our Senior Vice President, Corporate Strategy and Investor Relations in July 2011. In July 2013, Mr. Church was reappointed as Senior Vice President and Chief Financial Officer. In December 2018, Mr. Church was promoted to Executive Vice President. Immediately prior to joining the Company, Mr. Church served as Chief Financial Officer of Cyteir Therapeutics, Inc. Prior to joining Cyteir Therapeutics in December 2020, Mr. Gaiero served in various roles at Wave Life Sciences (Nasdaq: WVE) from July 2017 to December 2020, most recently serving as Interim Chief Financial Officer and prior to that, serving as Vice President and Corporate Controller. Prior to joining Wave Secretary of Alba Therapeutics Corporation, a privately held life-science company, from September 2007 until 2010-2015 to July. From 2006 until 2007-2017, he Mr. Gaiero served as Vice President, Chief Financial Officer and Corporate Secretary for Novavax Controller of OvaScience, Inc. (Nasdaq: NVAX), a vaccine development company listed on The Nasdaq Global Select Market. From 1998 until 2006, he served as Vice President, CFO and Corporate Secretary for GenVec, Inc., a biotechnology company formerly listed on The Nasdaq Capital Market. Prior to that, he Mr. Gaiero held various senior financial positions of increasing responsibility and scope in finance and accounting at BioSpherics iRobot Corporation and Meridian Medical Technologies, both formerly publicly traded companies. He started Mr. Gaiero began his career in public accounting at PricewaterhouseCoopers LLP with Pricewaterhouse from 1979 until 1986. Mr. Church holds Gaiero received a B. S. B. degree A. in accounting Accounting from the University of Maryland Massachusetts, Amherst, and is a Certified Public Accountant in Massachusetts. Delinquent Section 16 (a) Beneficial Ownership Reporting Reports Compliance Section 16 (a) of the Exchange Act requires our executive officers, directors and persons who own more than 10% of our common stock to file reports of ownership and reports of changes in ownership of common stock and other equity securities of the Company with the SEC. Executive officers, directors and greater than 10% stockholders are required by SEC regulations to furnish us with copies of all Section 16 (a) forms they file. We have identified the following reports required to be filed by insiders under Section 16 (a) of the Exchange Act that were not filed in a timely manner: one late report by Stacy Lindborg relating to one transaction and one late report by Donald Braun relating to one transaction. To our knowledge, based solely on a review of the copies of reports furnished to us, we believe that during the year ended December 31, 2023-2024, our executive officers, directors and greater than 10% stockholders complied with all Section 16 (a) filing requirements. Code of Ethics Our Code of Ethics and Business Conduct is applicable to all employees, including the principal executive officer, principal financial officer and principal accounting officer or controller, or persons performing similar functions. The Code of Ethics and Business Conduct is posted on our website at www.imunon.com. Corporate Governance Audit Committee Our Audit Committee consists of Mr. James A. Dentzer (Chair), Mr. Frederick J. Fritz and Ms. Christine Pellizzari. Our Audit Committee operates under a written charter as amended and restated effective January 24, 2023. A copy of that charter, as may be amended from time to time, is available on our web site, located at http://www.imunon.com. Additional copies of the charter are available upon written request to us. 60 Our Audit Committee assists our Board of Directors in fulfilling its responsibility to oversee management’s implementation of our financial reporting process. In discharging its oversight role, the Audit Committee reviewed and discussed the audited financial statements contained in our 2023-2024 Annual Report on Form 10-K with our management and independent registered public accounting firm. Management is responsible for the financial statements and the reporting process, including the system of internal controls. Our independent registered public accounting firm is responsible for expressing an opinion on the conformity of those financial statements with accounting principles generally accepted in the U. S. Our Board has determined that all members of the Audit Committee meet the independence standards established by the SEC and Nasdaq. Our Board has determined that Mr. Dentzer is qualified to serve as the “audit committee financial expert” as defined by Item 407 (d) (5) of Regulation S-K and that Mr. Fritz and Ms. Pellizzari meet the financial literacy requirements under applicable Nasdaq rules. Nomination of Directors There have been no changes to the

procedures by which stockholders may recommend nominees to our Board of Directors. Insider Trading Policy Our board of directors has adopted an insider trading policy which governs the purchase, sales, and / or other dispositions of our securities by directors, officers, and employees. Our insider trading policy is attached hereto as Exhibit 19 and incorporated herein. Our insider trading policy is designed to promote compliance with insider trading laws, rules and regulations and, among other things, prohibits our officers, directors, and employees from, among other things, engaging in short sales, transactions in derivative securities (including put and call options) or other forms of hedging transactions (i. e., zero- cost collars, equity swaps, exchange funds and forward sale contracts) that are designed to hedge or offset any decrease in the market value of equity securities (1) granted to the executive officer or director by the Company as part of the compensation of such individual, or (2) held, directly or indirectly, by the executive officer or director.

ITEM 11. EXECUTIVE COMPENSATION

COMPENSATION Compensation of Executive Officers This section discusses the material components of the executive compensation program for our executive officers who are named in the “ 2024 Summary Compensation Table ” below. In 2024, our “ named executive officers ” and their positions were as follows: • Stacy Lindborg, our President and Chief Executive Officer; • Michael Tardugno, our Executive Chairman and former President and Chief Executive Officer; • Corinne Le Goff, our former President and Chief Executive Officer; • Khurshed Anwer, our Executive Vice President and Chief Scientific Officer; • David Gaiero, our Chief Financial Officer; and • Jeffrey Church, our former Executive Vice President, Chief Financial Officer and Corporate Secretary

The following table sets forth information regarding the total compensation for services rendered in all capacities during the years ended December 31, 2024 and 2023, awarded to, paid to, or earned by each “ Named Executive Officer ” serving as of December 31, 2023. All compensation awarded to, earned by, or paid to IMUNON ’ s Named Executive Officers are included in the table below for the years ended December 31, 2024 and 2023 and 2022: Name and Principal Position Year Salary Bonus Stock Awards (1) Option Awards (H)(2) Non- Equity Incentive Plan Compensation (2-3) All Other Compensation (3-4) Total (\$) Stacy Lindborg (5) 2024 \$ 341, 954 \$ - \$ 26, 500 \$ 335, 641 \$ - \$ 1, 745 \$ 705, 839 President & CEO Michael Tardugno (6) 2024 \$ 336, 639 \$ - \$ 213, 072 \$ - \$ 10, 099 \$ 559, 810 Executive Chairman & former interim CEO Corinne Le Goff (4-7) 2024 \$ 148, 869 \$ - \$ - \$ - \$ - \$ - \$ 148, 869 Former President and CEO 2023 \$ 658, 080 \$ - \$ - \$ 107, 775 \$ 274, 959 \$ 15, 000 \$ 1, 055, 814 President & CEO 2022 \$ 264, 000 \$ - \$ 97, 500 \$ 308, 564 \$ 157, 250 \$ 56, 480 \$ 883, 794 Khurshed Anwer (5-8) 2023-2024 \$ 412, 385, 760 \$ 610 \$ - \$ - \$ 47, 900 \$ 87, 678 \$ - \$ 149, 125 \$ 281 \$ 94, 622 \$ 413 \$ 218 \$ 680 \$ 159 Executive VP & CSO 2022-2023 \$ 382, 412, 629 \$ 760 \$ - \$ - \$ 19, 500 \$ 118, 47, 286 \$ 900 \$ 139, 125, 737 \$ 281 \$ 94, 18, 218 \$ 506 \$ 678 \$ 680, 658 \$ 159 David Gaiero (9) 2024 \$ 280, 000 \$ - \$ - \$ - \$ 280, 000 CFO Jeffrey Church (6-10) 2023-2024 \$ 441, 251, 296 \$ 337 \$ - \$ - \$ 47, 900 \$ 816 \$ 115, 726 \$ 75, 498, 000 \$ 615 \$ 679 \$ 759, 922 \$ 768 Former Executive VP & CFO 2022-2023 \$ 409, 441, 822 \$ 296 \$ - \$ - \$ 87, 47, 715 \$ 900 \$ 139, 115, 094 \$ 726 \$ - \$ 75, 000 \$ 636 \$ 679, 631 \$ 922 (1)

The value reported for restricted stock awards is the aggregate grant date fair value of restricted stock granted to the Named Executive Officer in the year shown, determined in accordance with FASB ASC Topic 718. (2) The value reported for option awards is the aggregate grant date fair value of stock options granted to the Named Executive Officers in the years shown, determined in accordance with FASB ASC Topic 718, disregarding adjustments for forfeiture assumptions. The assumptions for making the valuation determinations are set forth in Note 12-11 to the Company ’ s financial statements for the year years ended December 31, 2022-2024 and December 31, 2023 included in the Company ’ s Annual Reports on Form 10- K for each of those years. With respect to Dr. Lindborg, the column includes the annual grant of options to Dr. Lindborg as part of the non- employee director compensation program. (2-3) Executives ’ bonuses under our annual incentive program are based on the achievement of specific performance measures established at the beginning of the fiscal year by our Compensation Committee. Historically, our Compensation Committee has awarded the annual incentive bonus for each year in the first quarter of the following year.

Our Compensation Committee has not approved the amount and the payment of the incentive bonus for 2023-2024 for each of the Named Executive Officers in the form of stock awards and Non- Equity (Cash) Incentive Plan Compensation and stock awards. (3-4) This column includes other compensation as indicated below and matching and discretionary contributions made by the Company for the Named Executive Officers under our 401 (k) plan. Our matching contribution is equal to 50 % of the employee ’ s deferrals under the plan up to 6 % of the employee ’ s compensation, subject to applicable IRS limitations, and are made in shares of our common stock. (4-5) Dr. Le Goff Lindborg, a director since 2021, joined the Company as President and Chief Executive Officer and, effective as of May 13, 2024, Dr. Lindborg became a Named Executive Officer for the first time in 2024. For Dr. Lindborg, the amount in the “ Salary ” column reflects \$ 14, 838 that Dr. Lindborg received as her cash retainer for her service as a non- employee director effective prior to becoming the Company ’ s President and CEO in May 2024, as well as of July 18, 2022 and stepped down from these -- the base salary amount received by Dr. Lindborg during fiscal year 2024, which was pro- rated for the time served in her employee positions during fiscal year, effective March 15, 2024. For Dr. Lindborg Le Goff, “ All Other Compensation ” for 2023-2024 consists of a 401 (k)- plan matching contribution of \$ 15, 000-745 in our common stock. (5-6) Mr. Tardugno, the Company ’ s Executive Chairman, served as the Company ’ s interim Chief Executive Officer from March 15, 2024 until May 13, 2024. For Dr. Mr Anwer Tardugno, “ All Other Compensation ” for 2023-2024 consists of a 401 (k)- plan matching contribution of \$ 75-10, 099 in our common stock. (7) Dr. Le Goff joined the Company as President and Chief Executive Officer and as a director, effective as of July 18, 2022, and stepped down from these positions, effective March 15, 2024. For Dr. Le Goff, the amount in the “ Salary ” column reflects the base salary amount received by Dr. Le Goff during fiscal year 2024, which was pro- rated for the time served in her employee positions during fiscal year 2024. (8) For Dr. Anwer, “ All Other Compensation ” for 2024 consists of \$ 133, 000 for a retention bonus paid in July 2023-2024. (6-5) 237-775 for discretionary spending allowance and a 401 (k)- plan matching contribution of \$ 12-10, 981-350 in our common stock. (6-9) Mr. Gaiero joined the Company as Chief Financial Officer, effective as of June 1, 2024. For Mr. Gaiero, the amount in the “ Salary ” column reflects the pro- rated amount received by Monomoy Advisors, LLC for the time served by Mr. Gaiero in his position of CFO during fiscal year 2024. (10) Mr. Church retired from the positions of Executive Vice President and Chief Financial Officer, effective as of June 1, 2024. For Mr. Church, the amount in the “ Salary ” column reflects the base salary amount received by Mr. Church during fiscal year 2024, which was pro- rated for the time served in his employee positions during fiscal year 2024. For Mr. Church “ All Other Compensation ” for 2023-2024 consists of \$ 75-428, 615 in severance paid, in connection with his retirement, and \$ 70, 000 for a retention bonus paid consulting services he provided in July 2023-2024 post-retirement.

62-Narrative Disclosure to 2023-2024 Summary Compensation Table Potential Payments Upon Termination or Change in Control Employment Arrangements Employment Agreement with Stacy R. Lindborg, Ph. D. The Company and Dr. Lindborg entered into an employment agreement effective as of May 31, 2024, in connection with her appointment as President and Chief Executive Officer. Pursuant to the Employment Agreement, the Company agreed to pay Dr. Lindborg an initial salary of \$ 567, 000 and a targeted annual performance bonus of 100 % of her annual base salary (pro- rated for the year ended December 31, 2024). Dr. Lindborg also received (i) an option to purchase 112, 500 shares of the Company ’ s common stock and (ii) an additional option to purchase 112, 500 shares of the Company ’ s common stock following the Company ’ s 2024 annual meeting of stockholders. Both stock options will vest in equal fourths over four years, with the first 28, 125 options vesting on the first anniversary of the date of grant and the remaining three-fourths vesting in equal parts on subsequent anniversaries of the grant date. Dr. Lindborg is eligible to receive a sign- on bonus from the Company of \$ 200, 000 subject to certain conditions. Dr. Lindborg ’ s initial term of employment pursuant to the Employment Agreement is one year, to be extended automatically by an additional year at the end of such term and each subsequent one- year term absent three months ’ prior written notice by Dr. Lindborg or the Company. Following the effective date of her employment with the Company, Dr. Lindborg did not receive any additional compensation for her service on the Board. Dr. Lindborg ’ s employment agreement provides that, upon a termination of Dr. Lindborg ’ s employment by the Company without “ cause ” or by Dr. Lindborg for “ good reason, ” as each such term is defined in her employment agreement: (x) outside the Change in Control Protection Period (as defined in the employment agreement), (i) Dr. Lindborg will be entitled to receive an amount equal to 12 months of her then- current base salary, payable in equal monthly installments during the 12- month period following such termination and reimbursement of her COBRA premiums for up to 12 months, and (ii) all of her options and similar awards would generally remain exercisable for the remainder of the original term of the award, and (y) during the Change in Control Protection Period, (i) Dr. Lindborg will be entitled to receive an amount equal to 24 months of her then- current base salary, payable in equal monthly installments during the 12- month period following such termination and reimbursement of her COBRA premiums for up to 12 months, (ii) full acceleration of then- unvested portions of the options awarded to Dr. Lindborg in connection with her appointment as CEO and (iii) all of her options and similar awards would generally remain exercisable for the remainder of the original term of the award.

Employment Agreement with Corinne Le Goff The Company and Dr. Le Goff entered into an employment agreement effective as of July 18, 2022, in connection with her appointment as President and Chief Executive Officer. Pursuant to the employment agreement, the Company agreed to pay Dr. Le Goff an initial salary of \$ 624, 000 and a signing bonus \$ 50, 000. Dr. Le Goff ’ s targeted annual performance bonus was 72 % of her annual base salary (pro- rated for the year ended December 31, 2022). Dr. Le Goff also received (i) an option to purchase 177, 000 shares of the Company ’ s common stock that vested with respect to 25 % of the subject shares on July 18, 2023 and the remaining 75 % percent to vest in equal quarterly installments thereafter such that the stock option would be fully vested and exercisable as of the fourth anniversary of July 18, 2022, and (ii) a restricted stock award of 53, 000 restricted shares that vested on July 18, 2023. Dr. Le Goff did not receive any additional compensation for her service on the Board. The agreement had no set term of employment and provided that in the event of termination by the Company other than for cause, Dr. Le Goff would receive an amount equal to one year ’ s salary as a severance payment. Effective March 15, 2024, Dr. Le Goff resigned from her

62-Narrative Disclosure to 2023-2024 Summary Compensation Table Potential Payments Upon Termination or Change in Control Employment Arrangements Employment Agreement with Stacy R. Lindborg, Ph. D. The Company and Dr. Lindborg entered into an employment agreement effective as of May 31, 2024, in connection with her appointment as President and Chief Executive Officer. Pursuant to the Employment Agreement, the Company agreed to pay Dr. Lindborg an initial salary of \$ 567, 000 and a targeted annual performance bonus of 100 % of her annual base salary (pro- rated for the year ended December 31, 2024). Dr. Lindborg also received (i) an option to purchase 112, 500 shares of the Company ’ s common stock and (ii) an additional option to purchase 112, 500 shares of the Company ’ s common stock following the Company ’ s 2024 annual meeting of stockholders. Both stock options will vest in equal fourths over four years, with the first 28, 125 options vesting on the first anniversary of the date of grant and the remaining three-fourths vesting in equal parts on subsequent anniversaries of the grant date. Dr. Lindborg is eligible to receive a sign- on bonus from the Company of \$ 200, 000 subject to certain conditions. Dr. Lindborg ’ s initial term of employment pursuant to the Employment Agreement is one year, to be extended automatically by an additional year at the end of such term and each subsequent one- year term absent three months ’ prior written notice by Dr. Lindborg or the Company. Following the effective date of her employment with the Company, Dr. Lindborg did not receive any additional compensation for her service on the Board. Dr. Lindborg ’ s employment agreement provides that, upon a termination of Dr. Lindborg ’ s employment by the Company without “ cause ” or by Dr. Lindborg for “ good reason, ” as each such term is defined in her employment agreement: (x) outside the Change in Control Protection Period (as defined in the employment agreement), (i) Dr. Lindborg will be entitled to receive an amount equal to 12 months of her then- current base salary, payable in equal monthly installments during the 12- month period following such termination and reimbursement of her COBRA premiums for up to 12 months, and (ii) all of her options and similar awards would generally remain exercisable for the remainder of the original term of the award, and (y) during the Change in Control Protection Period, (i) Dr. Lindborg will be entitled to receive an amount equal to 24 months of her then- current base salary, payable in equal monthly installments during the 12- month period following such termination and reimbursement of her COBRA premiums for up to 12 months, (ii) full acceleration of then- unvested portions of the options awarded to Dr. Lindborg in connection with her appointment as CEO and (iii) all of her options and similar awards would generally remain exercisable for the remainder of the original term of the award.

Employment Agreement with Corinne Le Goff The Company and Dr. Le Goff entered into an employment agreement effective as of July 18, 2022, in connection with her appointment as President and Chief Executive Officer. Pursuant to the employment agreement, the Company agreed to pay Dr. Le Goff an initial salary of \$ 624, 000 and a signing bonus \$ 50, 000. Dr. Le Goff ’ s targeted annual performance bonus was 72 % of her annual base salary (pro- rated for the year ended December 31, 2022). Dr. Le Goff also received (i) an option to purchase 177, 000 shares of the Company ’ s common stock that vested with respect to 25 % of the subject shares on July 18, 2023 and the remaining 75 % percent to vest in equal quarterly installments thereafter such that the stock option would be fully vested and exercisable as of the fourth anniversary of July 18, 2022, and (ii) a restricted stock award of 53, 000 restricted shares that vested on July 18, 2023. Dr. Le Goff did not receive any additional compensation for her service on the Board. The agreement had no set term of employment and provided that in the event of termination by the Company other than for cause, Dr. Le Goff would receive an amount equal to one year ’ s salary as a severance payment. Effective March 15, 2024, Dr. Le Goff resigned from her

62-Narrative Disclosure to 2023-2024 Summary Compensation Table Potential Payments Upon Termination or Change in Control Employment Arrangements Employment Agreement with Stacy R. Lindborg, Ph. D. The Company and Dr. Lindborg entered into an employment agreement effective as of May 31, 2024, in connection with her appointment as President and Chief Executive Officer. Pursuant to the Employment Agreement, the Company agreed to pay Dr. Lindborg an initial salary of \$ 567, 000 and a targeted annual performance bonus of 100 % of her annual base salary (pro- rated for the year ended December 31, 2024). Dr. Lindborg also received (i) an option to purchase 112, 500 shares of the Company ’ s common stock and (ii) an additional option to purchase 112, 500 shares of the Company ’ s common stock following the Company ’ s 2024 annual meeting of stockholders. Both stock options will vest in equal fourths over four years, with the first 28, 125 options vesting on the first anniversary of the date of grant and the remaining three-fourths vesting in equal parts on subsequent anniversaries of the grant date. Dr. Lindborg is eligible to receive a sign- on bonus from the Company of \$ 200, 000 subject to certain conditions. Dr. Lindborg ’ s initial term of employment pursuant to the Employment Agreement is one year, to be extended automatically by an additional year at the end of such term and each subsequent one- year term absent three months ’ prior written notice by Dr. Lindborg or the Company. Following the effective date of her employment with the Company, Dr. Lindborg did not receive any additional compensation for her service on the Board. Dr. Lindborg ’ s employment agreement provides that, upon a termination of Dr. Lindborg ’ s employment by the Company without “ cause ” or by Dr. Lindborg for “ good reason, ” as each such term is defined in her employment agreement: (x) outside the Change in Control Protection Period (as defined in the employment agreement), (i) Dr. Lindborg will be entitled to receive an amount equal to 12 months of her then- current base salary, payable in equal monthly installments during the 12- month period following such termination and reimbursement of her COBRA premiums for up to 12 months, and (ii) all of her options and similar awards would generally remain exercisable for the remainder of the original term of the award, and (y) during the Change in Control Protection Period, (i) Dr. Lindborg will be entitled to receive an amount equal to 24 months of her then- current base salary, payable in equal monthly installments during the 12- month period following such termination and reimbursement of her COBRA premiums for up to 12 months, (ii) full acceleration of then- unvested portions of the options awarded to Dr. Lindborg in connection with her appointment as CEO and (iii) all of her options and similar awards would generally remain exercisable for the remainder of the original term of the award.

Employment Agreement with Corinne Le Goff The Company and Dr. Le Goff entered into an employment agreement effective as of July 18, 2022, in connection with her appointment as President and Chief Executive Officer. Pursuant to the employment agreement, the Company agreed to pay Dr. Le Goff an initial salary of \$ 624, 000 and a signing bonus \$ 50, 000. Dr. Le Goff ’ s targeted annual performance bonus was 72 % of her annual base salary (pro- rated for the year ended December 31, 2022). Dr. Le Goff also received (i) an option to purchase 177, 000 shares of the Company ’ s common stock that vested with respect to 25 % of the subject shares on July 18, 2023 and the remaining 75 % percent to vest in equal quarterly installments thereafter such that the stock option would be fully vested and exercisable as of the fourth anniversary of July 18, 2022, and (ii) a restricted stock award of 53, 000 restricted shares that vested on July 18, 2023. Dr. Le Goff did not receive any additional compensation for her service on the Board. The agreement had no set term of employment and provided that in the event of termination by the Company other than for cause, Dr. Le Goff would receive an amount equal to one year ’ s salary as a severance payment. Effective March 15, 2024, Dr. Le Goff resigned from her

62-Narrative Disclosure to 2023-2024 Summary Compensation Table Potential Payments Upon Termination or Change in Control Employment Arrangements Employment Agreement with Stacy R. Lindborg, Ph. D. The Company and Dr. Lindborg entered into an employment agreement effective as of May 31, 2024, in connection with her appointment as President and Chief Executive Officer. Pursuant to the Employment Agreement, the Company agreed to pay Dr. Lindborg an initial salary of \$ 567, 000 and a targeted annual performance bonus of 100 % of her annual base salary (pro- rated for the year ended December 31, 2024). Dr. Lindborg also received (i) an option to purchase 112, 500 shares of the Company ’ s common stock and (ii) an additional option to purchase 112, 500 shares of the Company ’ s common stock following the Company ’ s 2024 annual meeting of stockholders. Both stock options will vest in equal fourths over four years, with the first 28, 125 options vesting on the first anniversary of the date of grant and the remaining three-fourths vesting in equal parts on subsequent anniversaries of the grant date. Dr. Lindborg is eligible to receive a sign- on bonus from the Company of \$ 200, 000 subject to certain conditions. Dr. Lindborg ’ s initial term of employment pursuant to the Employment Agreement is one year, to be extended automatically by an additional year at the end of such term and each subsequent one- year term absent three months ’ prior written notice by Dr. Lindborg or the Company. Following the effective date of her employment with the Company, Dr. Lindborg did not receive any additional compensation for her service on the Board. Dr. Lindborg ’ s employment agreement provides that, upon a termination of Dr. Lindborg ’ s employment by the Company without “ cause ” or by Dr. Lindborg for “ good reason, ” as each such term is defined in her employment agreement: (x) outside the Change in Control Protection Period (as defined in the employment agreement), (i) Dr. Lindborg will be entitled to receive an amount equal to 12 months of her then- current base salary, payable in equal monthly installments during the 12- month period following such termination and reimbursement of her COBRA premiums for up to 12 months, and (ii) all of her options and similar awards would generally remain exercisable for the remainder of the original term of the award, and (y) during the Change in Control Protection Period, (i) Dr. Lindborg will be entitled to receive an amount equal to 24 months of her then- current base salary, payable in equal monthly installments during the 12- month period following such termination and reimbursement of her COBRA premiums for up to 12 months, (ii) full acceleration of then- unvested portions of the options awarded to Dr. Lindborg in connection with her appointment as CEO and (iii) all of her options and similar awards would generally remain exercisable for the remainder of the original term of the award.

Employment Agreement with Corinne Le Goff The Company and Dr. Le Goff entered into an employment agreement effective as of July 18, 2022, in connection with her appointment as President and Chief Executive Officer. Pursuant to the employment agreement, the Company agreed to pay Dr. Le Goff an initial salary of \$ 624, 000 and a signing bonus \$ 50, 000. Dr. Le Goff ’ s targeted annual performance bonus was 72 % of her annual base salary (pro- rated for the year ended December 31, 2022). Dr. Le Goff also received (i) an option to purchase 177, 000 shares of the Company ’ s common stock that vested with respect to 25 % of the subject shares on July 18, 2023 and the remaining 75 % percent to vest in equal quarterly installments thereafter such that the stock option would be fully vested and exercisable as of the fourth anniversary of July 18, 2022, and (ii) a restricted stock award of 53, 000 restricted shares that vested on July 18, 2023. Dr. Le Goff did not receive any additional compensation for her service on the Board. The agreement had no set term of employment and provided that in the event of termination by the Company other than for cause, Dr. Le Goff would receive an amount equal to one year ’ s salary as a severance payment. Effective March 15, 2024, Dr. Le Goff resigned from her

62-Narrative Disclosure to 2023-2024 Summary Compensation Table Potential Payments Upon Termination or Change in Control Employment Arrangements Employment Agreement with Stacy R. Lindborg, Ph. D. The Company and Dr. Lindborg entered into an employment agreement effective as of May 31, 2024, in connection with her appointment as President and Chief Executive Officer. Pursuant to the Employment Agreement, the Company agreed to pay Dr. Lindborg an initial salary of \$ 567, 000 and a targeted annual performance bonus of 100 % of her annual base salary (pro- rated for the year ended December 31, 2024). Dr. Lindborg also received (i) an option to purchase 112, 500 shares of the Company ’ s common stock and (ii) an additional option to purchase 112, 500 shares of the Company ’ s common stock following the Company ’ s 2024 annual meeting of stockholders. Both stock options will vest in equal fourths over four years, with the first 28, 125 options vesting on the first anniversary of the date of grant and the remaining three-fourths vesting in equal parts on subsequent anniversaries of the grant date. Dr. Lindborg is eligible to receive a sign- on bonus from the Company of \$ 200, 000 subject to certain conditions. Dr. Lindborg ’ s initial term of employment pursuant to the Employment Agreement is one year, to be extended automatically by an additional year at the end of such term and each subsequent one- year term absent three months ’ prior written notice by Dr. Lindborg or the Company. Following the effective date of her employment with the Company, Dr. Lindborg did not receive any additional compensation for her service on the Board. Dr. Lindborg ’ s employment agreement provides that, upon a termination of Dr. Lindborg ’ s employment by the Company without “ cause ” or by Dr. Lindborg for “ good reason, ” as each such term is defined in her employment agreement: (x) outside the Change in Control Protection Period (as defined in the employment agreement), (i) Dr. Lindborg will be entitled to receive an amount equal to 12 months of her then- current base salary, payable in equal monthly installments during the 12- month period following such termination and reimbursement of her COBRA premiums for up to 12 months, and (ii) all of her options and similar awards would generally remain exercisable for the remainder of the original term of the award, and (y) during the Change in Control Protection Period, (i) Dr. Lindborg will be entitled to receive an amount equal to 24 months of her then- current base salary, payable in equal monthly installments during the 12- month period following such termination and reimbursement of her COBRA premiums for up to 12 months, (ii) full acceleration of then- unvested portions of the options awarded to Dr. Lindborg in connection with her appointment as CEO and (iii) all of her options and similar awards would generally remain exercisable for the remainder of the original term of the award.

Employment Agreement with Corinne Le Goff The Company and Dr. Le Goff entered into an employment agreement effective as of July 18, 2022, in connection with her appointment as President and Chief Executive Officer. Pursuant to the employment agreement, the Company agreed to pay Dr. Le Goff an initial salary of \$ 624, 000 and a signing bonus \$ 50, 000. Dr. Le Goff ’ s targeted annual performance bonus was 72 % of her annual base salary (pro- rated for the year ended December 31, 2022). Dr. Le Goff also received (i) an option to purchase 177, 000 shares of the Company ’ s common stock that vested with respect to 25 % of the subject shares on July 18, 2023 and the remaining 75 % percent to vest in equal quarterly installments thereafter such that the stock option would be fully vested and exercisable as of the fourth anniversary of July 18, 2022, and (ii) a restricted stock award of 53, 000 restricted shares that vested on July 18, 2023. Dr. Le Goff did not receive any additional compensation for her service on the Board. The agreement had no set term of employment and provided that in the event of termination by the Company other than for cause, Dr. Le Goff would receive an amount equal to one year ’ s salary as a severance payment. Effective March 15, 2024, Dr. Le Goff resigned from her

positions as President, Chief Executive Officer and Director of the Company. Employment Agreements – Agreement with Other Named Michael H. Tardugno Effective July 18, 2022, Mr. Tardugno transitioned from his roles as Chairman, President and Chief Executive Officers – Officer Jeffrey Church The to the position of Executive Chairman of the Board. Mr. Tardugno and the Company and Mr. Church entered into an employment offer letter agreement, effective as of July 18, 2022, that superseded the previous employment agreement with Mr. Tardugno. The agreement has a term ending on June 15 December 31, 2016 2024, with the option for a one-year extension that was exercised. Under the agreement, the Company agreed to pay Mr. Church Tardugno a base salary of \$ 500, 000 (prorated to \$ 240, 000) for 2022 and a base salary of \$ 350, 000 for 2023 and 2024, and to reimburse him for all reasonable business expenses. Mr. Tardugno remains eligible for annual performance bonuses and equity awards and may participate in all compensation and benefit programs generally made available to other senior executives. In the event of termination by the Company other than for cause, Mr. Tardugno will receive an amount equal to one year 's employment is salary as a severance payment. Consulting Agreement with Monomoy Advisors, LLC The Company and Monomoy Advisors, LLC (" Monomoy at -with;" however), subject to Mr. Church a financial advisory services firm, entered into a professional consulting agreement, effective as of June 1, 2024, in connection with the appointment of David Gaiero as the Company 's promotion -Chief Financial Officer. Pursuant to the Agreement, the Company agreed to pay Monomoy \$ 35, 000 per month for Mr. Gaiero 's service as the Company 's Chief Financial Officer. Retirement and Consulting Agreement with Jeffrey Church Effective June 1, 2024, Mr. Church retired from his roles as Executive Vice President in January 2019, if we terminate Chief Financial Officer and Corporate Secretary. On May 17, 2024, the Company and Mr. Church 's entered into a retirement and consulting agreement (the " Retirement and Consulting Agreement ") that superseded the previous employment agreement with Mr. Church, pursuant to which he agreed to provide the Company consulting services for a term ending on December 31, 2024, with any - an reason -option for an agreed upon extension (other - the than just cause " Consulting Period "). During the Consulting Period, we will the Company agreed to pay Mr. Church a monthly retainer of \$ 10, 000, plus an additional \$ 250 for each hour of services performed in excess of 40 hours per month. In addition, pursuant to the Retirement and Consulting Agreement, Mr. Church received (i) within 30 days following his Retirement Date, any accrued but unpaid salary continuation and COBRA premiums any unreimbursed business expenses incurred prior to his Retirement Date and (ii) a retirement bonus in the amount of \$ 428, 615. Mr. Church also remained eligible to receive a pro-rated bonus for 2024 up to twelve months. The salary and COBRA premiums will cease at the end of the twelve-month period or if he finds new employment -Employment Offer Letter with Khursheed Anwer prior to the twelve-month period, the benefit will be reduced by the amount of compensation which he will receive from any new employer. Mr. Church 's right to receive these severance benefits is subject to his providing a release of claims in favor of the Company. -The Company and Dr. Anwer entered into an employment offer letter effective as of June 20, 2014. Dr. Anwer 's employment with us is " at-will "; however, subject to the retention and severance agreement between the Company and Dr. Anwer dated as of May 28, 2014, if we terminate Dr. Anwer 's employment without cause (as such term is defined in the retention and severance agreement), he will be entitled to receive cash severance equal to 12 months of his base salary and reimbursement of his COBRA premiums for up to 12 months. Dr. Anwer 's right to receive these severance benefits is subject to his providing a release of claims in favor of the Company. CIC Agreements - Agreement We have entered into an amended and restated double-trigger change in control severance agreements - agreement (CIC Agreements - Agreement) with Mr each of the Named Executive Officers (other than Dr. Tardugno Anwer, who is not subject to such an agreement) to provide severance benefits to him these executives should their his employment terminate in certain circumstances in connection with a change in control of the Company (a " CIC "). Under the amended and restated CIC Agreements, in the event that, on or within two years after a CIC, we terminate the executive 's employment without cause or in the event that the executive terminates his employment for good reason, the executive would be entitled to receive a cash lump sum payment equal to two (2) times the sum of (1) the executive 's annual base salary and (2) the executive 's target annual bonus for the fiscal year in which the termination occurs. (For these purposes, the terms " cause, " " good reason " and " change in control " are each defined in the CIC Agreement.) In addition, we will pay or reimburse the executive for the cost of COBRA premiums and life insurance coverage for the executive and his eligible dependents, in each case for a period of up to two years following the termination. The executive would also be entitled to full acceleration of his then-outstanding equity awards granted to him by us. However, as to any equity award agreement that is subject to performance-based vesting requirements, the vesting of such an award will continue to be governed by its terms. In the case of options or similar awards, the award would generally remain exercisable for the remainder of the original term of the award (or, in the case of awards that vested after the date of the CIC, for the lesser of 12 months following the last day such award would have been exercisable under the applicable award agreement and the remainder of the original term). The benefits provided under the CIC Agreement are in addition to, and not in lieu of, any severance benefits the executive may be entitled to receive in connection with the termination of his employment under any other agreement with the Company. The executive 's right to benefits under the CIC Agreement is subject to his execution of a release of claims in favor of the Company upon the termination of his employment. The CIC Agreements do not provide for any tax gross ups. Material Terms of Equity Grants During 63 Potential Payments Upon Termination or Change In Control As described above under " Narrative Disclosure to 2023 2024 Summary Compensation Table, " the Company entered into agreements with each Each of the equity awards granted to the Named Executive Officers providing for benefits payable to the executives in connection with a termination of their employment. The Company also entered into agreements with Dr. Le Goff and Mr. Church providing for benefits payable to the executives in connection with a termination of employment following a CIC of the Company. If in the event the Named Executive Officer is entitled to receive severance benefits in connection with a termination of employment under both their severance agreement and their CIC agreement, the executive shall be entitled to receive the benefits from both agreements. The first table below indicates the benefits that would have been payable to each executive if a termination of employment in the circumstances described above had occurred on December 31, 2023 2024, outside of a CIC. The second table below indicates the benefits that would have been payable to each executive if a change in control of the Company and such a termination of employment had occurred on that date. Severance Benefits (Outside of a Change in Control) Name Cash Severance Continuation of Health /Life Benefit Equity Acceleration Total Corinne Le Goff \$ 477, 360 \$ 30, 189 - \$ 507, 549 Khursheed Anwer \$ 400, 899 \$ 28, 242 - \$ 429, 141 Jeffrey W. Church \$ 428, 615 \$ 12, 921 - \$ 441, 536 Change of Control Severance Benefits Name Cash Severance Continuation of Health /Life Benefit Equity Acceleration Total Corinne Le Goff \$ 477, 360 \$ 30, 189 - \$ 507, 549 Jeffrey W. Church \$ 1, 242, 984 \$ 25, 842 - \$ 1, 268, 826 Material Terms of Option Grants During 2023 Each of the stock options awarded to the Named Executive Officers in 2023 was granted under, and is subject to, the terms of the IMUNON, INC. 2018 Stock Incentive Plan (the " 2018 Plan "). The 2018 Plan is administered by the Compensation Committee, which has authority to interpret the plan provisions and make all required determinations under the plan. This authority includes making required proportionate adjustments to outstanding awards upon the occurrence of certain corporate events such as reorganizations, mergers, and stock splits, and making provision to ensure that any tax withholding obligations incurred in respect of awards are satisfied. Awards granted under the plan are generally only transferable to a beneficiary of a Named Executive Officer upon his death. Under the terms of the 2018 Plan, if there is a change in control of the Company, each Named Executive Officer 's outstanding awards granted under the plan will generally terminate, unless the Compensation Committee provides for the substitution, assumption, exchange or other continuation or settlement (in cash, securities, or property) of the outstanding awards. The Compensation Committee has the discretion to provide for outstanding awards to become vested in connection with a change in control. The Compensation Committee does not take material nonpublic information into account when determining the timing and terms of equity awards. The Company does not time the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation. Each option granted to the Named Executive Officers in 2023 2024 was granted with a per-share exercise price equal to the closing price of our common stock on the grant date. Each option is scheduled to vest in three installments, with one-third half vesting on the date of grant and the balance one-fourth vesting on in equal annual installments over each of the next two years -first and second anniversary of the date of the grant, subject in each case to the executive 's continued employment through the applicable vesting date and has a maximum term of ten years. However, vested options may terminate earlier in connection with a change in control transaction or a termination of the Named Executive Officer 's employment. Subject to any accelerated vesting that may apply in the circumstances, the unvested portion of the option will immediately terminate upon a termination of the Named Executive Officer 's - employment. 64 Each share of restricted stock granted to Dr. Lindborg in 2024 is scheduled to fully vest on the first anniversary of the grant date, subject to the executive 's continued employment through the applicable vesting date. Subject to any accelerated vesting that may apply in the circumstances, the unvested portion of the restricted stock will immediately terminate upon the termination of the Named Executive Officer 's employment. The following table sets forth the stock options and restricted stock shares granted to our named executive officers in the 2024 fiscal year. Named Executive Officer 2024 Stock Options Granted 2024 Restricted Stock Shares Granted Stacy Lindborg 293, 102 25, 000 Michael Tardugno 207, 926 Corinne Le Goff - Khursheed Anwer 90, 653 David Gaiero - Jeff Church 12, 500 - Outstanding Equity Awards at Year-End The following table summarizes the unexercised number of shares of the Company 's common stock options held by underlying outstanding equity incentive plan awards for each of the Named Executive Officers - Officer as of December 31, 2023 2024. None of the Named Executive Officers held any other outstanding stock awards as of December 31, 2023 2024. Option Awards Name Grant Date Number of Shares or Units of Stock No. of Securities Underlying Unexercised Options (#) Exercisable No. of Securities Underlying Unexercised Options (#) Unexercisable Option Exercise Price (\$) Option Expiration Date Michae H Corinne Le Goff 7/18/2022 44, 250 132, 750 (2) \$ 1. Tardugno 9/5/7/18 /2032 (3) 3/17/2023 30, 000 60, 000 (1) \$ 1. 32 3/17/2033 (3) Khursheed Anwer 10/3/2019 2-4, 832 333 - \$ 25. 80 10/3/2029 3/04/2022 43 80, 000.

333-6-667 (1) \$ 4.60 3 / 04 / 2032 6 / 13 / 2022 43-90, 000-333-6-667 (1) \$ 1.93 6 / 13 / 2032 3 / 17 / 2023 43-16, 334-26-667 8, 666-333 (1) \$ 1.32 3 / 17 / 2033 3 / 15 / 2024 6, 250 6, 250 (2) \$ 0.86 3 / 15 / 2034 6 / 12 / 2024 50, 000 50, 000 (2) \$ 1.22 6 / 12 / 2034 9 / 6 / 2024 41, 463 41, 463 (2) \$ 1.04 9 / 6 / 2034 12 / 18 / 2024 6, 250 6, 250 (2) \$ 0.83 12 / 18 / 2034 Stacy R. Lindborg PhD 6 / 4 / 2021 2, 666- \$ 18.60 6 / 4 / 2031 3 / 4 / 2022 2, 500- \$ 4.60 3 / 4 / 2034 6 / 13 / 2022 2, 500- \$ 1.93 6 / 13 / 2032 3 / 17 / 2023 1, 333 667 (1) \$ 1.32 3 / 17 / 2033 3 / 15 / 2024 2, 250 2, 250 (2) \$ 0.86 3 / 15 / 2034 5 / 13 / 2024- 112, 500 (2) \$ 1.48 5 / 13 / 2034 6 / 12 / 2024- 112, 500 (2) \$ 1.22 6 / 12 / 2034 9 / 6 / 2024 31, 801 31, 801 (2) \$ 1.04 9 / 6 / 2034 9 / 6 / 2024 25, 000 (3) Jeffrey W. Church 10 / 3 / 2019 2, 334- \$ 25.80 10 / 3 / 2029 6 / 13 / 2022 33, 333- 46-6673 (1) \$ 1.93 6 / 13 / 2032 3 / 17 / 2023 43-334-26, 667-666 (1) \$ 1.32 3 / 17 / 2033 3 / 15 / 2024 12, 500- \$ 0.86 3 / 15 / 2034 Khurshed Anwer 10 / 3 / 2019 2, 832- \$ 25.80 10 / 3 / 2029 3 / 04 / 2022 20, 000- \$ 4.60 3 / 04 / 2032 6 / 13 / 2022 20, 000- \$ 1.93 6 / 13 / 2032 3 / 17 / 2023 26, 667 13, 333 (1) \$ 1.32 3 / 17 / 2033 3 / 15 / 2024 12, 500 12, 500 (2) \$ 0.86 3 / 15 / 2034 6 / 12 / 2024 12, 500 12, 500 (2) \$ 1.22 6 / 12 / 2034 9 / 6 / 2024 20, 327 20, 327 (2) \$ 1.04 9 / 6 / 2034 (1) Each of these stock option grants vest in three equal installments, with one-third of the grant vesting each immediately, on the first anniversary, and on the second anniversary of the date of grant. (2) Each of these stock option grants vest in four equal installments, with one-half-fourth of the grant vesting each on date of grant and one-fourth on the first, and second, third, and fourth anniversary of the date of grant. (3) Dr. Lindborg received a restricted stock grant. Le Goff served as President and Chief Executive Officer of the Company until March 15, 2024. All of the equity awards held by Dr. Le Goff that had vested prior to March 15, 2024 may be exercised by Dr. Le Goff until September 11, 2024, at which time vests fully on the first anniversary will automatically be forfeited if not exercised. All stock options and stock awards (and similar equity rights) that had not vested as of date of the grant March 15, 2024 were forfeited by Dr. Le Goff. Director Compensation Non-Employee Director Compensation Table The following table sets forth the cash and non-cash compensation paid to the Company's directors who were not employed by the Company or any of its subsidiaries ("Non-Employee Directors") for the year ended December 31, 2023-2024. Other than as set forth in the table, we did not pay any compensation, make any equity awards or non-equity awards to, or pay any other compensation to any of the Non-Employee Directors in 2023-2024. The compensation paid to any director who was also one of our employees during fiscal year 2023-2024 is presented in the "2023-2024 Summary Compensation Table" and the information that follows that table. Such employee directors did not receive separate compensation for their service on the Board of Directors or any of its Committees (other than Dr. Lindborg prior to her appointment as CEO and President of the Company as described in Footnote (1) below). Name (1) Fees Earned (\$) Option Awards (\$) (2) Total (\$) James E. Dentzer 51, 839 12, 144 63, 983 Frederick J. Fritz 93, 419 13, 309 106, 728 Donald P. Braun 58, 949 12, 651 71, 600 Christine A. Pellizzari 41, 039 13, 456 54, 495 (1) Dr. Lindborg did not participate in the non-employee director compensation program following her appointment as CEO and President of the Company. The compensation received by Dr. Lindborg during 2024, including the compensation received solely for her service as a non-employee director, is reported in the Summary Compensation Table above. Mr. Tardugno and Dr. Le Goff are not shown in this table because they were compensated as officers for the years shown and did not receive any additional director compensation. Name Fees Earned (\$) Option Awards (\$) (1) Total (\$) James E. Dentzer 58, 800 2, 395 61, 195 Frederick J. Fritz 103, 800 2, 395 106, 195 Donald P. Braun 70, 500 2, 395 72, 895 Stacy R. Lindborg 41, 700 2, 395 44, 095 Christine A. Pellizzari 45, 300 2, 395 47, 695 (1) The value reported for Option Awards is the aggregate grant date fair value of stock options granted to each Director in 2023-2024, determined in accordance with FASB ASC Topic 718. The assumptions for making the valuation determinations are set forth in Note 12-11 to our financial statements. As of December 31, 2023-2024, Mr. Dentzer had 4-17, 667-301 option awards outstanding; Mr. Fritz had 48-32, 333-070 option awards outstanding; Dr. Braun had 15-28, 833-905 option awards outstanding; and Dr. Lindborg and Ms. Pellizzari each had 9-23, 666-630 option awards outstanding. 65-The following table sets forth stock option grants awarded to the Company's Non-Employee Directors for the year ended December 31, 2023-2024. Employee directors do not receive separate equity awards for service on the Board of Directors or any of the Board committees. Dr. Lindborg did not participate in the non-employee director compensation program following her appointment as CEO and President of the Company. Equity awards received by Dr. Lindborg during 2024 for her service as a non-employee director are reported in the Summary Compensation Table above. Non-Employee Director Stock Option and Grant Awards Table Name Number of Options Granted (#) (1) Exercise Price (\$) Grant Date Expiration Date Grant Date Fair Value (\$) James E. Dentzer 2-4, 000-500 \$ 0.86 3 / 15 / 2024 3 / 15 / 2034 \$ 0.79 4, 500 \$ 1.32-22 6 / 12 / 2024 6 / 12 / 2034 \$ 1.12 3, 634 \$ 1.04 9 / 6 / 2024 9 / 6 / 2034 \$ 0.99 Frederick J. Fritz 3, 500 \$ 0.86 3 / 17-15 / 2023-2024 3 / 17-15 / 2033-2034 \$ 0.79 3, 500 \$ 1.20 Donald P. Braun 2, 000-22 6 / 12 / 2024 6 / 12 / 2034 \$ 1.32-12 6, 737 \$ 1.04 9 / 6 / 2024 9 / 6 / 2034 \$ 0.99 Donald P. Braun 3, 500 \$ 0.86 3 / 17-15 / 2023-2024 3 / 17-15 / 2033-2034 \$ 0.79 3, 500 \$ 1.20 Christine A. Pellizzari 4, 500 \$ 0.86 3 / 17-15 / 2023-2024 3 / 17-15 / 2033-2034 \$ 0.79 4, 500 \$ 1.20 Stacy R. Lindborg 2, 000-22 6 / 12 / 2024 6 / 12 / 2034 \$ 1.12 4, 964 32-3 / 17 / 2023-3 / 17 / 2033 \$ 1.20 Christine A. Pellizzari 2, 000-04 9 / 6 / 2024 9 / 6 / 2034 \$ 1-0, 99 32-3 / 17 / 2023-3 / 17 / 2033 \$ 1-20 (1) Each of these stock option grants vest vests in three equal installments, with one-third-half of the grant vesting on the date of grant and one-third-fourth of the grant vesting on each of the first and second anniversary of the date of grant, subject to the applicable director's continued service as a member of our Board through each applicable vesting date. During the year ended December 31, 2023-2024, each Non-Employee Director of the Company received annual cash compensation in the amount of \$ 30-27, 500-450 payable in quarterly installments, and an additional \$ 2-1, 200-980 for attendance at regular meetings of the Board of Directors and \$ 1, 200-080 for each meeting of a committee of the Board of Directors that was not held in conjunction with a meeting of the Board of Directors. Each Non-Employee director is reimbursed for the out-of-pocket costs of attending meetings of the Board of Directors and of committees of the Board of Directors. In 2023-2024, the Chairman of the Audit Committee received an additional annual cash fee of \$ 43-12, 500-150 and the Chairman of the Compensation Committee received an additional annual cash fee of \$ 40-9, 500-450. 66-Acting on behalf of the Board of Directors, Mr. Fritz also received fees totaling \$ 48-43, 000-200 in 2023-2024 for his role as a Board Liaison to our Board of Directors. Mr. Fritz's responsibilities as Board Liaison include the following: (i) serve as an initial sounding board for our management regarding issues, matters, or communications to be brought or potentially to be brought before the Board of Directors; (ii) provide input and feedback to management regarding strategic matters, business matters, major scientific, clinical, collaboration, or corporate development matters, key personnel matters, or other items of significance regarding which management would like to obtain initial or further Board guidance, including, but not limited to, guidance regarding timing and content of communications regarding such matters or items with the full Board or any of its committees; (iii) remain accessible to management to provide guidance on business or strategy issues or other issues of significance on an as-needed basis; (iv) participate in meetings and relevant discussions as requested by management; (v) conduct general advisory or liaison services to the Board, including relaying to management requests from other members of the Board regarding desired additional information or clarification or suggestions or feedback regarding improvement in Board processes or communications; (vi) serve as a conduit for informal communications between management and the Board; and (vii) any other such services established by the Board from time to time. Acting on behalf of our Board of Directors, Dr. Braun also received fees totaling \$ 30-22, 000-500 in 2023-2024 for his role as a strategic advisor to our Executive Chairman and our Chief Executive Officer. Dr. Braun's responsibilities as a strategic advisor include the following: (i) provide strategic and tactical advice to our Chief Executive Officer; (ii) evaluate international subsidiary options; (iii) develop strategies to secure business relationships other than in the U. S.; and (iv) having done both (ii) and (iii), develop high potential ex-US market strategies that address the objectives for broad and profitable sales of its commercial products. Stock Ownership Guidelines for Non-Employee and Executive Directors Our Board of Directors believes that, as a matter of sound corporate governance, non-employee and executive directors should have a significant personal financial stake in our performance. Consequently, in February 2011, our Board of Directors adopted stock ownership guidelines for non-employee and executive directors. Our corporate governance guidelines require that each non-employee director acquire and hold shares of our common stock having an aggregate value equal to two times the director's total compensation in the first year of service and that our executive director acquire and hold shares of our common stock having an aggregate value equal to the executive director's total compensation in the first year of service. Each director is expected to satisfy the applicable ownership guideline within three years after his or her appointment to the Board. Shares of our common stock that count toward satisfaction of these ownership guidelines include, unless beneficial ownership therein is disclaimed: (i) shares owned outright by the director or executive officer or their immediate family members residing in the same household, whether held individually or jointly; (ii) shares held in a trust, family limited partnership or similar entity solely for the benefit of the director or executive officer and / or their immediate family members; (iii) shares of restricted stock and restricted stock units awarded under our equity incentive plans, including vested and unvested awards; and (iv) shares acquired upon stock option exercise, but not shares underlying unexercised stock options. 67-ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS The following table is furnished by the Company and sets forth certain information known to the Company regarding the beneficial ownership of the Company's common stock as of March 26-February 21, 2024-2025 by: • each person or group known by us to own beneficially more than 5 % of the Company's outstanding common stock; • each of our directors, as well as each executive officer named in the Summary Compensation Table appearing under the heading "Executive Compensation;" and • our directors and executive officers as a group. We determine beneficial ownership in accordance with the rules of the SEC. Under SEC rules, beneficial ownership for purposes of this table takes into account shares as to which the individual has voting or investment power (including shares held indirectly through the Imunon, Inc. 401 (k) Plan), as well as shares that may be acquired within 60 days of March 26-February 21, 2024-2025. Shares of common stock subject to options that are currently exercisable or that become exercisable within 60 days of March 26-February 21, 2024-2025, are treated as outstanding and beneficially owned by the holder of such options. However, these shares are not treated as

outstanding for purposes of computing the percentage ownership of any other person. Unless otherwise indicated or as to the interests of spouses, the persons included in the table have sole voting and investment power with respect to all shares beneficially owned thereby. Percentage ownership calculations are based on 9,141,399,620,789,732 shares outstanding as of March 26, February 21, 2024, 2025. NAME OF BENEFICIAL OWNER NUMBER OF SHARES OF COMMON STOCK BENEFICIALLY OWNED (1) PERCENT OF SHARES OF COMMON STOCK OUTSTANDING (2) Ayrton Capital LLC (3) 1,250,000 7.88 % James E. Dentzer * (1-4) 5-12, 361,361 ** Stacy R. Lindborg * (2) 10-109,416 ** Frederick J. Fritz * (3-5) 28-37, 682-843 ** Donald P. Braun * (4-6) 15-48, 430-841 ** Christine Pellizzari * (5-7) 10-17, 416-773 ** Michael H. Tardugno * (6-8) 183-375, 763-1562 2, 95-57 % Stacy Lindborg Corinne Le Goff * (7-9) 127-72, 898 ** 250-1,35 % Khurshed Anwer * (8-10) 78-147, 188-265 1.01 % Jeffrey Church * (11) 77, 172 ** Susan Eylward Jeffrey W. Church * ** Douglas Faller MD * ** David Gaiero * ** Corrine LeGoff * (9-12) 78-53, 450-000 ** Directors and Executive Officers as a group (9-12 persons) (10-13) 410-842, 707-4463 5, 37-76 % * The address of each of the individuals named is c/o IMUNON, INC., 997 Lenox Drive, Suite 100, Lawrenceville, NJ 08648. ** Less than one percent. (1) Beneficial Ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. Except as indicated by footnote, and subject to community property laws where applicable, the persons named in the table above have sole voting and investment power with respect to all shares of common stock shown as beneficially owned by them. (2) Based on 14,620,732 shares of common stock outstanding as of February 21, 2025 (3) Based on the Schedule 13G filed by Ayrton Capital, LLC ("Ayrton Capital") on February 13, 2025, reporting beneficial ownership as of December 31, 2024 and represents shares of Common Stock issuable on the exercise of certain warrants held by the reporting persons. The Schedule 13G provides information only as of December 31, 2024, and, consequently, the beneficial ownership of the abovementioned reporting person may have changed between December 31, 2024 and February 21, 2025. Shares reported herein were held by Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B, a Cayman Islands exempted company (the "Fund"). The Fund is a private investment vehicle for which Ayrton Capital LLC, a Delaware limited liability company (the "Investment Manager"), serves as the investment manager. Waqas Khatri serves as the managing member of the Investment Manager. The address of the principal business and office of Ayrton Capital LLC and its affiliates is 55 Post Rd West, 2nd Floor, Westport Ct, 06880. (4) Includes 5-12, 361-109 shares of common stock underlying options currently exercisable or exercisable within 60 days of March 26, February 21, 2024, 2025. (5) Includes 11,766 shares of common stock and 26,077 2024. (2) Includes 10,416 shares of common stock underlying options currently exercisable or exercisable within 60 days of March 26, February 21, 2024, 2025. (3-6) Includes 11-25, 766-597 shares of common stock and 16-23, 916-244 shares of common stock underlying options currently exercisable or exercisable within 60 days of March 26, February 21, 2024, 2025. (4-7) Includes 17-597 shares of common stock (reflecting the reverse stock split effected by the Company on February 28, 2022 at a ratio of 15:1) and 14,833 shares of common stock underlying options currently exercisable or exercisable within 60 days of March 26, February 21, 2024, 2025. (5-8) Includes 10-69, 416-141 shares of common stock and 306,421 shares of common stock underlying options currently exercisable or exercisable within 60 days of March 26, February 21, 2024, 2025. (6-9) Includes 16-28, 513-056 shares of common stock and 167-44, 250-842 shares of common stock underlying options currently exercisable or exercisable within 60 days of March 26, February 21, 2024, 2025. (7-10) Includes 53-12, 000-855 shares of common stock and 74-134, 250-410 shares of common stock underlying options currently exercisable or exercisable within 60 days of March 26, February 21, 2024, 2025. (Dr. Le Goff served as President and Chief Executive Officer of the Company until March 15, 2024. All of the options held by Dr. Le Goff that had vested prior to March 15, 2024 may be exercised by Dr. Le Goff until September 11, 2024, at which time they will automatically be forfeited if not exercised. All stock options and stock awards (and similar equity rights) that had not vested as of March 15, 2024 were forfeited by Dr. Le Goff. (8) Includes 2,855-338 shares of common stock (reflecting the reverse stock split effected by the Company on February 28, 2022 at a ratio of 15:1) and 75-74, 333-834 shares of common stock underlying options currently exercisable or exercisable within 60 days of March 26, February 21, 2024, 2025. (9-12) Includes 3-53, 617-000 shares of common stock (reflecting the reverse 13) Includes 202,753 of common stock split effected by the Company on February 28, 2022 at a ratio of 15:1) and 74-639, 833-710 shares of common stock underlying options currently exercisable or exercisable within 60 days of March 26, February 21, 2024, 2025. (10) Includes 375,359 shares of common stock underlying options currently exercisable or exercisable within 60 days of March 26, 2024. Equity Compensation Plan Information as of December 31, 2023 Plan 2024 Plan Category Number of securities to be issued upon exercise of outstanding options, warrants and rights (a) Weighted-average exercise price of outstanding options, warrants and rights (b-1) Number of Securities remaining available for future issuance under equity compensation plans (excluding securities reflected in first column (a)-(c) Equity compensation plans approved by securityholders 772,297 (1), 555,073 (2) \$ 2.03 420,000 (3) -09-1,202,776 (2) Equity compensation plans not approved by securityholders 294,130, 751-500 (3-4) 1.59-07 - Total 1,067-685, 048-573 (1) 1.95 420,000 (1) Represents the weighted average exercise price of outstanding stock options and does not take into account restricted stock awards, which do not have an exercise price. (2) -68-1,202,776 (1) Includes both vested and unvested options to purchase common stock and unvested stock grants under the 2018 Plan. These awards have a weighted average remaining term of 8.7 years. (2-3) Represents shares available for award grant purposes under the 2018 Plan. Subject to certain express limits of the plan, shares available under the plan generally may be used for any type of award authorized under that plan including options, stock appreciation rights, restricted stock and other forms of awards granted or denominated in shares of our common stock or units of our common stock. (3-4) Includes both vested and unvested options to purchase common stock and unvested stock grants under inducement grants provided certain employees as an inducement to accept employment with the Company. These awards have a weighted average remaining term of 9.0-5 years. These grants are similar to those granted under the 2018 Plan. 69-ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE Related Person Transactions Our Code of Ethics requires all of our directors, officers and employees to give their complete loyalty to the best interests of the Company and to avoid any action that may involve, or that even may appear to involve, a conflict of interest with the Company. The Code of Ethics also requires any of our directors, officers or employees who become aware of a conflict or potential conflict to bring it to the attention of supervisor, manager or other appropriate personnel or consult the compliance procedures provided in the Code of Ethics. The Board of Directors reviews and approves or ratifies all relationships and transactions between us and (i) any of our directors or executive officers, (ii) any nominee for election as a director, (iii) any securityholder who is known to us to own beneficially or of record more than five percent of our common stock or (iv) any member of the immediate family of any of the foregoing. On November 16, 2022, the Company entered into a Convertible Note Purchase Agreement with Transomic Technologies, Inc. ("Transomic") whereby the Company purchased \$ 375,000 of convertible notes secured by certain assets held by Transomic and warrants. As a result of this investment in Transomic, Imunon's executive chairman, Mr. Michael Tardugno, was appointed to the Board of Directors of Transomic. The Company is disclosing the notes receivable as a related party transaction. In December 2023, Transomic filed a formal certificate of dissolution of the company resulting in a complete write off of the convertible note and related warrants. Director Independence In accordance with the rules of the SEC and Nasdaq, the Company requires that at least a majority of the directors serving at any time on the Board of Directors be independent. The Board has determined that of the six currently serving directors, five-four directors (Drs- Dr. Braun and Lindborg, Messrs. Dentzer and Fritz and Ms. Pellizzari) are independent under applicable SEC and Nasdaq rules. ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES Withum, Brown Smith PC ("Withum") has served as our independent accountants since 2017 and has advised us that neither Withum nor any of its members has, or has had in the past three years, any financial interest in the Company or any relation to the Company other than as auditors and accountants. The following table presents fees as invoiced for professional audit services rendered for the fiscal years ended December 31, 2023-2024 and December 31, 2022-2023, and fees for other services rendered during those periods: 2024 2023 2022-FEE CATEGORY AMOUNT % OF TOTAL AMOUNT % OF TOTAL Audit Fees \$ 144,240 68 % \$ 150,000 60 % \$ 158,500 81 % Audit Related Fees 10,200 5 9,705 4 14,246 7 Tax Fees 12,272 6 13,750 5 10,800 6 All Other Fees 45,240 21 78,885 31 11,850 6 Total Fees \$ 252,211, 340-952 100 % \$ 195-252, 396-340 \$ 100 % 70-Audit fees consist of fees for professional services rendered by Withum for the audits of our annual financial statements in our Annual Reports on Form 10-K and for reviews of the quarterly financial statements included in the Company's Quarterly Reports on Form 10-Q. Audit -related fees pertain to the work performed during our equity offerings in 2024 and 2023 and 2022. Tax fees consist of fees for preparation of the Company's federal and state tax returns. All other fees consist of fees for attendance at the Company's annual meetings, review of registration statements and similar matters. Services by Employees of Withum No part of Withum's engagement to audit the Company's financial statements for the years ended December 31, 2024 and 2023 and 2022 was attributable to work performed by persons other than Withum's full-time, permanent employees. Audit Committee Policy on Approval of Audit and Non-Audit Services It is the policy of the Audit Committee to pre-approve all audit and permissible non-audit services provided by our independent accountants, in accordance with rules prescribed by the SEC. These services may include audit services, audit-related services, tax services, and other services. Pre-approval is based on a written proposal, accompanied by a cost estimate, and estimated budget. The Audit Committee has delegated to its chairman the authority to pre-approve audit and non-audit services with an estimated cost of up to \$ 25,000, provided the exercise of such authority is reported to the Audit Committee at its next regular meeting. The Audit Committee reserves the right, from time to time, to delegate pre-approval authority to other of its members, so long as such members are independent directors. All audit and permissible non-audit services during 2024 and 2023 and 2022 were approved by the Audit Committee in accordance with its pre-approval policy and the approval requirements of the SEC. PART IV ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES (a) The following documents are filed as part of this Annual Report: 1. FINANCIAL STATEMENTS The following is a list of the consolidated financial statements of Imunon, Inc. filed with this Annual Report, together with the reports of our independent registered

public accountants and Management's Report on Internal Control over Financial Reporting. Page REPORTS Reports of Independent Registered Public Accounting Firm F- 1 FINANCIAL STATEMENTS Consolidated Balance Sheets F- 3 Consolidated Statements of Operations F- 5 Consolidated Statements of Comprehensive Loss F- 6 Consolidated Statements of Cash Flows F- 7 Consolidated Statements of Changes in Stockholders' Equity F- 9 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS F- 112. FINANCIAL STATEMENT SCHEDULES All financial statement schedules are omitted because the information is inapplicable or presented in the notes to the consolidated financial statements. 74-3. EXHIBITS The following documents are included as exhibits to this report: EXHIBIT NO. DESCRIPTION 2. 1 * Asset Purchase Agreement dated as of June 6, 2014, by and between Imunon, Inc. and EGEN, Inc., incorporated herein by reference to Exhibit 2. 1 to the Quarterly Report on Form 10-Q of the Company for the quarter ended June 30, 2014 (SEC File No. 001- 15911). 2. 2 Amendment to Asset Purchase Agreement between Celsion Corporation and EGWU, Inc., dated March 28, 2019 incorporated herein by reference to Exhibit 10. 1 to the Current Report on Form 8- K of the Company filed on April 1, 2019 (SEC File No. 001- 15911). 3. 1 Amended and Restated Certificate of Incorporation of Imunon, dated March 24, 2023, incorporated herein by reference to Exhibit 3. 1 to the Current Report on Form 8- K of the Company filed on March 24, 2023 (SEC File No. 001- 15911). 3. 2 Amended and Restated Bylaws of the Company, effective on March 15, 2024, incorporated by reference to Exhibit 3. 1 to the Current Report on Form 8- K of the Company, filed on March 18, 2024 (SEC File No. 001- 15911). 4. 1 Form of Representative's Common Stock Purchase Warrant, incorporated herein by reference to Exhibit 4. 2 to the Current Report on Form 8- K of the Company, filed on October 31, 2017 (SEC File No. 001- 15911). 4. 2 Form of Placement Agent Common Stock Purchase Warrant incorporated herein by reference to Exhibit 4. 4 to the Current Report on Form 8- K of the Company, filed on July 11, 2017 (SEC File No. 001- 15911). 4. 3 Form of Amended and Restated Warrant (issued under First Amendment of Venture Loan and Security Agreement, dated as of August 1, 2020, by and among Imunon, Inc., Horizon Funding I, LLC, Horizon Funding Trust 2019- 1, and Horizon Technology Finance Corporation, as Collateral Agent), incorporated herein by reference to Exhibit 4. 1 to the Current Report on Form 8- K of the Company, filed on September 4, 2020 (SEC File No. 001- 15911). 4. 4 Form of Exchange Warrant, incorporated herein by reference to Exhibit 4. 1 to the Current Report on Form 8- K of the Company, filed on March 13, 2020 (SEC File No. 001- 15911). 4. 5 Warrant to purchase Shares of Common Stock of Celsion Corporation between Celsion Corporation and EGWU, Inc., dated March 28, 2019, incorporated herein by reference to Exhibit 4. 1 to the Quarterly Report on Form 10- Q of the Company for the quarter ended March 31, 2019 (SEC File No. 001- 15911). 4. 6 **Description Form of Warrant Securities of the Registrant**, incorporated herein by reference to Exhibit 4. **5-1** to the **Annual Current** Report on Form **10-8**- K of the Company **filed on July for the fiscal year ended December 31, 2019-2024 (SEC file No. 10-001- 15911)**. 4. 7 **Description of Securities of the Registrant**10. 1 * * * Imunon, Inc. 2007 Stock Incentive Plan, as amended, incorporated herein by reference to Exhibit 10. 1 to the Current Report on Form 8- K of the Company, filed on May 16, 2017 (SEC File No. 001- 15911). 10. 2 Form Inducement Offer to Exercise Common Stock Purchase Warrants, incorporated herein by reference to Exhibit 10. 3 to the Quarterly Report on Form 10- Q of the Company for the quarter ended September 30, 2017 (SEC File No. 001- 15911). 10. 3 * * * Imunon, Inc. 2018 Stock Incentive Plan, incorporated by reference to Exhibit 10. 1 to the Current Report on Form 8- K of the Company filed May 15, 2018 (SEC File No. 001- 15911). 10. 4 * * * First Amendment to the Imunon, Inc. 2018 Stock Incentive Plan, incorporated by reference to Exhibit 10. 1 to the Current Report on Form 8- K of the Company, filed on May 15, 2019 (SEC File No. 001- 15911). 10. 5 * * * Second Amendment to the Imunon, Inc. 2018 Stock Incentive Plan, incorporated by reference to Exhibit 10. 1 to the Current Report on Form 8- K of the Company, filed on June 16, 2020 (SEC File No. 001- 15911). 10. 6 * * * Third Amendment to the Celsion Corporation 2018 Stock Incentive Plan, incorporated herein by reference to Exhibit 10. 1 to the Current Report on Form 8- K of the Company, filed with the Commission on June 10, 2021 (SEC File No. 001- 15911). 72-10. 7 * * * **Form of Incentive Stock Option Grant Agreement under the 2018 Stock Incentive Plan, incorporated herein by reference to Exhibit 10. 1 to the Quarterly Report on Form 10- Q of the Company for the quarter ended March 31, 2024 (SEC File No. 001- 15911)**. 10. 8 * * * **Form of Restricted Stock Agreement under the 2018 Stock Incentive Plan, incorporated herein by reference to Exhibit 10. 2 to the Quarterly Report on Form 10- Q of the Company for the quarter ended March 31, 2024 (SEC File No. 001- 15911)**. 10. 9 * * * **Form of Nonqualified Stock Option and Restricted Stock Grant Agreement for employment inducement awards, incorporated by reference to Exhibit 99. 1 to the Company's Registration Statement on Form S- 8 filed on August 29, 2024 (No. 333- 281833)**. 10. 10 * * * Employment Offer Letter, entered into on June 15, 2010, between the Company and Jeffrey W. Church, incorporated herein by reference to Exhibit 10. 1 to the Current Report on Form 8- K of the Company filed on June 18, 2010 (SEC File No. 001- 15911). 10. **8-11** * * * Employment Offer Letter effective as of June 2, 2014, between the Company and Khurshed Anwer incorporated herein by reference to Exhibit 10. 27 to the Annual Report of the Company for the year ended December 31, 2014 (SEC File No. 001- 15911). 10. **9-12** * * * Employment Agreement between the Company and Michael H. Tardugno, effective as of July 18, 2022, incorporated herein by reference to Exhibit 10. 2 to the Current Report on Form 8- K of the Company filed with the Commission on July 19, 2022 (SEC File No. 001- 15911). 10. **10-13** * * * Employment Agreement between the Company Corporation and Corinne Le Goff, effective as of July 18, 2022 incorporated herein by reference to Exhibit 10. 1 to the Current Report on Form 8- K of the Company filed with the Commission on July 19, 2022 (SEC File No. 001- 15911). 10. **11-14** * * * Amended and Restated Change in Control Agreement dated as of September 6, 2016, by and between the Company and Michael H. Tardugno, incorporated herein by reference to Exhibit 10. 1 to the Quarterly Report on Form 10- Q of the Company for the quarter ended September 30, 2016 (SEC File No. 001- 15911). 10. **12-15** * * * **Employment Amended and Restated Change in Control Agreement**, dated as of **September 6 May 3, 2016-2024**, by and between the Company and **Jeffrey W- Stacy Lindborg, Ph. Church D.**, incorporated herein by reference to Exhibit 10. **3-1** to the **Current Report on Form 8- K of the Company filed on May 8, 2024 (SEC File No. 001- 15911)**. 10. **16** * * * **Retirement and Consulting Agreement, dated May 17, 2024, between Imunon, Inc. and Jeffrey Church, incorporated by reference to Exhibit 10. 1 to the Current Report on Form 8- K of the Company filed on May 20, 2024 (SEC File No. 001- 15911)**. 10. **17** * * * **Consulting Agreement, dated April 15, 2024, by and between Imunon, Inc. and Monomoy Advisors, LLC incorporated by reference to Exhibit 10. 2 to the Current Report on Form 8- K of the Company filed on May 20, 2024 (SEC File No. 001- 15911)**. 10. **18** * * * **Offer Letter of Employment, dated October 2, 2024, between Imunon, Inc. and Susan Eylward, incorporated by reference to Exhibit 10. 1 to the Current Report on Form 8- K of the Company filed on October 7, 2024 (SEC File No. 001- 15911)**. 10. **19** * * * **Separation Agreement, dated August 9, 2024 by and between the Company and Sébastien Hazard, M. D., incorporated by reference to Exhibit 10. 5 to the Quarterly Report on Form 10- Q of the Company for the quarter ended September 30, 2016-2024 (SEC File file No. 001- 15911)**. 10. **13-20** * Development, Product Supply and Commercialization Agreement, effective December 5, 2008, by and between the Company and Yakult Honsha Co., Ltd., incorporated herein by reference to Exhibit 10. 15 to the Annual Report of the Company for the year ended December 31, 2008 (SEC File No. 001- 15911). 10. **14-21** * The 2nd Amendment to The Development, Product Supply and Commercialization Agreement, effective January 7, 2011, by and between the Company and Yakult Honsha Co., Ltd. incorporated herein by reference to Exhibit 10. 1 to the Current Report on Form 8- K of the Company filed on January 18, 2011 (SEC File No. 001- 15911). 10. **15-22** * Technology Development Agreement effective as of May 7, 2012, by and between Imunon, Inc. and Zhejiang Hisun Pharmaceutical Co. Ltd., incorporated herein by reference to Exhibit 10. 2 to the Quarterly Report on Form 10- Q of the Company for the quarter ended June 30, 2012 (SEC File No. 001- 15911). 10. **16-23** * Technology Development Contract dated as of January 18, 2013, by and between Imunon, Inc. and Zhejiang Hisun Pharmaceutical Co. Ltd., incorporated herein by reference to Exhibit 10. 1 to the Quarterly Report on Form 10- Q of the Company for the quarter ended March 31, 2013 (SEC File No. 001- 15911). 73-10. **17-24** Lease Agreement, executed July 21, 2011, by and between Imunon, Inc. and Brandywine Operating Partnership, L. P., incorporated herein by reference to Exhibit 10. 1 to the Current Report on Form 8- K of the Company filed on July 25, 2011 (SEC File No. 001- 15911). 10. **18-25** First Amendment to Lease Agreement, executed April 20, 2017, by and between Imunon, Inc. and Lenox Drive Office Park, LLC, incorporated herein by reference to Exhibit 10. 1 to the Current Report on Form 10- Q of the Company filed on November 14, 2017 (SEC File No. 001- 15911). 10. **19-26** Second Amendment to Lease Agreement, dated January 9, 2019, by and between Celsion Corporation and Lenox Drive Office Park, LLC, successor in interest to Brandywine Operating Partnership, L. P., incorporated herein by reference to Exhibit 10- Q to the Current Report on Form 10- Q of the Company for the quarter ended March 31, 2019 (SEC File No. 001- 15911). 10. **20-27** Lease Agreement dated January 15, 2018, by and between Imunon, Inc. and HudsonAlpha Institute of Biotechnology for office and lab space located in Huntsville, Alabama incorporated herein by reference to Exhibit 10. 1 to the Quarterly Report on Form 10- Q of the Company for the quarter ended March 31, 2018 (SEC File No. 001- 15911). 10. **21-28** Settlement Agreement and Release, by and between the plaintiff to the shareholder action captioned O' Connor v. Braun, et al., N. J. Super., Dkt. No. MERC- 00068- 19, William J. O' Connor, derivatively on behalf of Imunon, Inc. and individually on behalf of himself and all other similarly situated stockholders of Imunon, Inc. and defendants, incorporated herein by reference to Exhibit 10. 2 to the Current Report on Form 8- K of the Company, filed on June 16, 2020 (SEC File No. 001- 15911). 10. **22-29** Form of Exercise Agreement, incorporated by reference to Exhibit 10. 1 to the Current Report on Form 8- K of the Company, filed on March 13, 2020 (SEC File No. 001- 15911). 10. **23-30** At the Market Offering Agreement, dated May 25, 2022 by and between Celsion Corporation and H. C. Wainwright & Co. LLC, incorporated by reference to Exhibit 10. 1 to the Current Report on Form 8- K of the Company, filed on May 25, 2022, (SEC File No. 001- 15911). **10. 31 Amendment No. 1, dated May 15, 2024, to At the Market Offering Agreement, by and between Imunon, Inc. and H. C. Wainwright & Co. LLC, incorporated by reference to Exhibit 1. 3 to the Company's Registration Statement on Form S- 3 (No. 333- 279425) filed on May 15, 2024. 10. 32 Form of Securities Purchase Agreement, dated as of July 30, 2024, by and among the company and each purchaser party thereto, incorporated by reference to Exhibit 10. 1 to the Current Report on Form 8- K of the Company, filed on July 31, 2024 (SEC File o. 001- 15911)**. 10. **33** * * * Imunon, Inc. 2018 Stock Incentive Plan, as amended as of June 14, 2023, incorporated herein by reference to Exhibit 10. 1 to the

Current Report on Form 8-K of the Company, filed with the Commission on June 15, 2023 (SEC File 001- 15911). 19 Insider Trading Policy 21. 1

Subsidiaries of Imunon, Inc. 23. 1 Consent of WithumSmith Brown, PC, independent registered public accounting firm for the Company. 31. 1 Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes- Oxley Act of 2002. 31. 2 Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes- Oxley Act of 2002. 32. 1 Certification of Chief Executive Officer pursuant to 18 U. S. C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002. 32. 2 Certification of Chief Financial Officer pursuant to 18 U. S. C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002. **97-Compensation Recovery Policy, incorporated herein by reference to Exhibit 97 to the Annual Report of the Company for the year ended December 31, 2023 (SEC File No. 001- 15911).** 101. INS Inline XBRL Instance Document 101. SCH Inline XBRL Taxonomy Extension Schema Document 101. CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101. DEF Inline XBRL Taxonomy Extension Definition Linkbase Document 101. LAB Inline XBRL Taxonomy Extension Label Linkbase Document 101. PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document Cover Page Interactive Data File (embedded within the Inline XBRL document) 101 * * The following materials from the Company’ s Annual Report for the fiscal year ended December 31, **2023-2024**, formatted in XBRL (Extensible Business Reporting Language): (i) the audited Consolidated Balance Sheets, (ii) the audited Consolidated Statements of Operations, (iii) the audited Consolidated Statements of Comprehensive Loss, (iv) the audited Consolidated Statements of Cash Flows, (v) the audited Consolidated Statements of Changes in Stockholders’ Equity and (vi) Notes to Financial Statements. * Portions of this exhibit have been omitted pursuant to a request for confidential treatment under Rule 24b- 2 of the Securities Exchange Act of 1934, amended, and the omitted material has been separately filed with the Securities and Exchange Commission. Filed herewith. Furnished herewith. * * XBRL information is filed herewith. * * * Management contract or compensatory plan or arrangement. ITEM 16. FORM 10-K. **SUMMARY SIGNATURES SUMMARY 74 SIGNATURES** Pursuant to the requirements of Section 13 or 15 (d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. IMUNON, INC. Registrant **March 28 February 27, 2024-2025** By: / s / **Michael H. Stacy Lindborg, Ph. D. Tardugno Michael H. Tardugno Stacy Lindborg, Ph. D. Chief Executive Officer Pursuant Chairman of the Board Pursuant** to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated: Name Position Date / s / **MICHAEL H. TARDUGNO Executive Chairman of the Board March 28 February 27, 2024-2025** (Michael H. Tardugno) / s / **JEFFREY W. STACY R. CHURCH-LINDBORG, Ph. D. President, Chief Executive Vice President and Chief March 28, 2024 (Jeffrey W. Church) Financial Officer and Director February 27, 2025 (Stacy R Lindborg, Ph. D.) (Principal Executive Officer)** / s / **DAVID GAIERO Chief KIMBERLY A. GRAPER Vice President of Finance Financial Officer February 27, & Controller March 28, 2024-2025 (Kimberly A. Graper David Gaiero) (Principal Financial Officer and Principal Accounting Officer)** / s / **FREDERICK J. FRITZ Director March 28 February 27, 2024-2025** (Frederick J. Fritz) / s / **JAMES E. DENTZER Director March 28 February 27, 2024-2025** (James E. Dentzer) / s / **DONALD BRAUN Director March 28 February 27, 2024-2025** (Donald Braun, Ph. D.) / s / **CHRISTINE PELLIZZARI Director March 28 February 27, 2024-2025** (Christine A. Pellizzari) / s / **STACY R. LINDBORG Director March 28, 2024 (Dr. Stacy R Lindborg) 75** Report of Independent Registered Public Accounting Firm Board of Directors and Stockholders of Imunon Inc. ; Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated balance sheets of Imunon Inc. as of December 31, **2024 and 2023 and 2022**, and the related consolidated statements of operations, comprehensive loss, changes in stockholders’ equity, and cash flows for each of the two years in the period ended December 31, **2023-2024**, and the related notes (collectively referred to as the “ financial statements ”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of Imunon Inc. as of December 31, **2024 and 2023 and 2022**, and the results of its operations and its cash flows for each of the two years in the period ended December 31, **2023-2024**, in conformity with accounting principles generally accepted in the United States of America. Substantial Doubt Regarding Going Concern The accompanying consolidated financial statements have been prepared assuming that the entity will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the entity has suffered recurring losses from operations, has **negative cash flows experienced cash used** from operations, and has **an a significant** accumulated deficit, that raise substantial doubt about its ability to continue as a going concern. Management’ s plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Basis for Opinion These consolidated financial statements are the responsibility of the entity’ s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“ PCAOB ”) and are required to be independent with respect to Imunon Inc. in accordance with the U. S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Imunon Inc. is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the entity’ s internal control over financial reporting. Accordingly, we express no such opinion. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. Critical Audit Matters The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate. **F-1**
Going Concern Evaluation Classification of Warrants Critical Audit Matter Description of Matter As described further in Note 2-10 and 12 to the consolidated financial statements, in July 2024, the Company sold 5 has suffered recurring losses from operations, has 000, 000 shares of common stock at an accumulated deficit, offering price of \$ 2. 00 per share and warrants expects its operating losses to continue purchase up to 5, 000, 000 shares of common stock, at a exercise price of \$ 2. 00 per share, for the foreseeable future net proceeds of approximately \$ 9 million. The Accordingly, the Company has determined that these -- the factors raise substantial doubt as to Warrants met all the criteria for equity classification and recorded the them Company’ s ability to continue as a component going concern for a period of additional paid- one year from the issuance of these financial statements. Management intends to seek opportunities to fund its business by way of public or private offerings of the Company’ s stock in capital upon order to satisfy the Company’ s obligations as they- the closing of come due for at least one year from the consolidated transaction in July 2024. We identified the determination of the financial statement classification of issuance date. Further, there -- the Warrants is no guarantee that the Company will be successful in these endeavors. Auditing management’ s conclusions about whether there are conditions and events that raise substantial doubt about the entity’ s ability to continue as a going concern within one year after the consolidated financial statements are issued is subjective and requires especially challenging auditor judgment. How We Addressed the Matter in Our Audit We obtained an understanding of controls over the Company’ s process for determining their ability to continue as a going concern. We determined the Company’ s ability to continue as a going concern is a critical audit matter. Our principal considerations included the existence of accounting complexities related to certain provisions of the warrant agreement, including settlement provisions and derivative elements in applying the accounting standard. Auditing these elements involved especially complex auditor judgment due to the estimation terms of the applicable agreement, including the extent of specialized knowledge and uncertainty regarding skills needed. How We Addressed the Matter in Our Audit • Evaluating the appropriateness of management’ s application of the accounting guidance in determining the classification of the warrants in the financial statement by i) reviewing the relevant terms of the warrant agreement, (ii) evaluating the completeness and accuracy of the Company’ s available capital- technical accounting analysis and the risk of bias in management’ s judgments and assumptions in their-- the application determination. Our audit procedures related to considering whether the results of our audit procedures, when considered in the aggregate, indicate whether there -- the is substantial doubt about relevant accounting literature. • Utilizing personnel with specialized knowledge and skills in technical accounting to assist in: (i) evaluating the terms of the warrant agreement in relation to the relevant accounting literature, and (ii) assessing the appropriateness of conclusions reached by the Company’ s ability to continue as a going concern for reasonable period of time included the following procedures, among other procedures: • Evaluating the financial condition of the Company, including liquidity sources as of the date of the auditor’ s opinion (the “ assessment date ”). • Examining and evaluating underlying evidence with respect to this assessment date evaluation. • Evaluating conditional and unconditional obligations due or anticipated to become due during the period of 12 months from the date of the filing of these financial statements (the “ look forward period ”) and examining and evaluating underlying evidence with respect to this evaluation. • Evaluating the Company’ s assessment of its cash flows during the look forward period and examining and evaluating underlying evidence with respect to this evaluation. • Inquiring of Company management as to whether there are any other adverse conditions or events which could raise substantial doubt regarding the Company’ s ability to continue as a going concern and evaluating such events, as applicable. •

Performing an assessment regarding management's plans to alleviate substantial doubt regarding the Company's ability to continue as a going concern and examining and evaluating underlying evidence with respect to this assessment, as applicable. • Evaluated the adequacy of the Company's financial statements disclosures regarding liquidity and going concern to determine in which such disclosures were in accordance with U.S. generally accepted accounting principles. / s / WithumSmith Brown, PC WithumSmith Brown, PC We have served as Imunon Inc.'s auditor since 2017. East Brunswick, New Jersey **March 27 February 26, 2024 2025** PCAOB ID Number 100 F- 2 IMUNON, INC. CONSOLIDATED BALANCE SHEETS **2024** 2023 2022 December 31, **2024** 2023 2022-ASSETS Current assets: Cash and cash equivalents \$ **5, 872, 767 \$ 5,** 838, 566 \$ **11, 492, 841** Investment in debt securities- available for sale, at fair value **9, 857, 087 21, 254, 485** Accrued interest receivable on investment securities **128, 932** Money market investments, restricted cash **1, 500, 000** Advances and deposits on clinical programs and other current assets **2, 136, 192 2,** 545, 051 **2, 403, 433** Total current assets **8, 008, 959** 18, 240, 704 **36, 779, 691** Property and equipment (at cost, less accumulated depreciation and amortization) **541, 272** 751, 906 **548, 301** Other assets: Money market investments, restricted cash **4, 500, 000** Deferred income tax asset **1, 280, 385 1, 567, 026** Operating lease right- of- use assets, net **1, 117, 133 1,** 595, 074 **155, 876** Deposits and other assets **50, 000 425 50,** 000 Total other assets **1, 167, 133 2,** 925, 459 **6, 647, 902** Total assets \$ **9, 717, 364 \$ 21,** 918, 069 \$ **43, 975, 894** See accompanying notes to the consolidated financial statements. F-3 (Continued) December 31, **2024** 2023 2022-LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable – trade \$ **3-1, 515 300,** 192 **102 3,** 586 **515,** 623 **192** Other accrued liabilities **3, 033, 747 3,** 390, 521 **4, 794, 936** Notes payable – current portion, net of deferred financing costs **1, 424, 774** Operating lease liabilities- current portion **452, 358** 485, 421 **230, 749** Total current liabilities **4, 786, 131** 7, 391, 134 **10, 037, 082** Notes payable – non-current portion, net of deferred financing costs **4, 610, 946** Operating lease liabilities- non-current portion **686, 935** 1, 139, 293 – Total liabilities **5, 473, 066 \$** 8, 530, 427 **14, 648, 028** Commitments and contingencies – Stockholders' equity: Preferred Stock- \$ 0.01 par value (100,000 shares authorized, and no shares issued or outstanding at December 31, **2024 and** 2023 **and** 2022) – Common stock- \$ 0.01 par value (112,500,000 shares authorized; **14, 500, 707 and** 9, 399, 811 **and** 7, 436, 219 shares issued at December 31, **2024 and** 2023 **and** 2022, respectively) **145, 007** 93, 998 **74, 362** Additional paid- in capital **410, 987, 523** 401, 500, 838 **397, 980, 023** Accumulated other comprehensive income **60, 796 26, 494** Accumulated deficit **(406, 803, 044)** (388, 182, 802) **(368, 667, 825)** Total stockholders' equity before treasury stock **4, 329, 486** 13, 472, 830 **29, 413, 054** Treasury stock, at cost (22 shares at December 31, **2024 and** 2023 **and** 2022) (85, 188) (85, 188) Total stockholders' equity **4, 244, 298** 13, 387, 642 **29, 327, 866** Total liabilities and stockholders' equity \$ **9, 717, 364 \$ 21,** 918, 069 \$ **43, 975, 894** F- 4 CONSOLIDATED STATEMENTS OF OPERATIONS **2024** 2023 2022 Years Ended December 31, **2024** 2023 2022 Licensing revenue \$ **500, 000** Operating expenses: Research and development \$ **11, 639, 411 \$ 11,** 287, 691 **11, 733, 666** General and administrative **7, 493, 035 9,** 742, 739 **13, 687, 899** Total operating expenses **19, 132, 446** 21, 030, 430 **25, 421, 565** Loss from operations **(19, 132, 446)** (21, 030, 430) **(24, 921, 565)** Other income (expense): Investment income **Gain from change in earn- out milestone liability- 5, 396 net 512,** 204 **1 000** Impairment of in- process research and development **(13, 366 157,** 625 **234)** Loss on debt extinguishment **(329, 158)** - Investment income, net **1, 457, 625 453, 356** Interest expense **(197, 080)** (5, 028, 618) Other expense **(loss) income** (396, 319) **1, 801** Total other income (expense), net **512, 204 235, 068** (12, 543, 695) Loss before income tax benefit **(18, 620, 242)** (20, 795, 362) **(37, 465, 260)** Income tax benefit **1, 280, 385 1,** 567, 026 Net loss \$ **(18, 620, 242)** \$ **(19, 514, 977)** \$ **(35, 898, 234)** Net loss per common share- basic and diluted \$ **(1. 62)** \$ **(2. 16)** \$ **(5. 03)** Weighted average common shares outstanding- basic and diluted **11, 508, 159 9,** 045, 320 **7, 142, 970** F- 5 CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS **2024** 2023 2022 Years Ended December 31, **2024** 2023 2022 Other comprehensive loss Changes in: Realized gains on investment securities recognized in investment income, net **431, 801 49, 222** Unrealized losses on investment securities, net **(397, 499)** (14, 754) Change in realized and unrealized gains on available for sale securities, net **\$- 34, 302 34, 468** Net loss **(18, 620, 242)** (19, 514, 977) **(35, 898, 234)** Total comprehensive loss \$ **(18, 620, 242)** \$ **(19, 480, 675)** \$ **(35, 862, 766)** F- 6 CONSOLIDATED STATEMENTS OF CASH FLOWS **2024** 2023 2022 Years Ended December 31, **2024** 2023 2022 Cash flows from operating activities: Net loss \$ **(18, 620, 242)** \$ **(19, 514, 977)** \$ **(35, 898, 234)** Adjustments to reconcile net loss to net cash used in operating activities: Depreciation **240, 175** 248, 154 **196, 510** Amortization of right- of- use assets **477, 941** 471, 851 **535, 119** Recognition of deferred revenue **(500, 000)** Realized and unrealized **(gains) and** losses, net, on investment securities **(61, 983)** 34, 302 **34, 468** Change in fair value of earn- out milestone liability **(5, 396, 000)** Stock- based compensation **477, 256** 759, 013 **Realization 2, 673, 047** Change of deferred income tax asset **1, 280, 385** 286, 641 **(183, 580)** Loss on extinguishment of debt **329, 158** - Write- off of note receivable (Transomic) **375, 000** - Impairment of in- process research and development **13, 366, 234** Amortization of deferred finance charges and debt discount associated with note payable **55, 122 181, 259** Net changes in: Accrued interest receivable on investment securities **68, 136** (20, 088) Advances, deposits, and other current assets **408, 859** (141, 619) **43, 980** Other assets **(241, 511)** Accounts payable and accrued liabilities **(3, 057, 361)** (1, 992, 929) **2, 111, 901** Net cash used in operating activities **(18, 854, 970)** (19, 022, 148) **(23, 096, 895)** Cash flows from investing activities: Purchases of investment securities **(57, 174)** (13, 541, 806) **(48, 226, 390)** Proceeds from sale and maturity of investment securities **9, 915, 448** 25, 000 **6, 775, 000** Purchases of property and equipment **(29, 541)** (451, 759) **(267, 800)** Net cash provided by investing activities **9, 828, 733** 11, 006, 435 **8, 280, 810** Cash flows from financing activities: Proceeds from redeemable convertible preferred stock offering **28, 500, 000** Payment upon redemption of redeemable convertible preferred stock **(28, 500, 000)** Proceeds from sale of common stock equity, net of issuance costs **9, 060, 438** 2, 781, 438 **6, 722, 654** Payoff of the SVB loan and accrued end- of- term fees **(6, 420, 000)** - Net cash used in (provided by) financing activities **9, 060, 438** (3, 638, 562) **6, 722, 654** Net change in cash, cash equivalents and restricted cash **34, 201** (11, 654, 275) **(8, 093, 431)** Cash, cash equivalents and restricted cash at beginning of year **5, 838, 566** 17, 492, 841 **25, 586, 272** Cash **and** cash equivalents **and** restricted cash at end of year \$ **5, 872, 767 \$ 5,** 838, 566 \$ **17, 492, 841** F- 7 Years Ended December 31, **2024** 2023 2022 Supplemental disclosure of cash flow information: Cash paid for: Income taxes paid \$ **2, 500 2, 000** Interest \$ **179, 542 4, 847, 359** Non- Cash Investing and Financing Activities Recognition of right of use asset and liability \$ **1, 911, 049 \$- 8** CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY YEAR ENDED DECEMBER 31, **2023-2024** Shares Amount Capital Shares Amount (Loss) Deficit Total Common Stock Outstanding Additional Paid- in Treasury Stock Accum. Other Compr. Income Accumulated Shares Amount Capital Shares Amount (Loss) Deficit Total Balance at January 1, **2024** 9, 399, 811 \$ 93, 998 \$ 401, 500, 838 **22 \$ (85, 188) \$ 60, 796 \$ (388, 182, 802) \$ 13, 387, 642** Net loss----- **(18, 620, 242)** **(18, 620, 242)** Sale of equity through equity financing facilities **5, 088, 796 50, 888 9, 009, 550----- 9, 060, 438** Issuance of stock upon vesting of restricted shares **12, 100 121----- 121** Realized and unrealized gains, net, on investment securities----- **(60, 796) (60, 796)** Stock- based compensation expense-- **477, 135----- 477, 135** Balance at December 31, **2024** 14, 500, 707 \$ 145, 007 \$ 410, 987, 523 **22 \$ (85, 188) \$- \$ (406, 803, 044) \$ 4, 244, 298** YEAR ENDED DECEMBER 31, **2023** Common Stock Outstanding Additional Paid- in Treasury Stock Accum. Other Compr. Income Accumulated Shares Amount Capital Shares Amount (Loss) Deficit Total Balance at January 1, **2023** 7, 436, 219 \$ 74, 362 \$ 397, 980, 023 **22 \$ (85, 188) \$ 26, 494 \$ (368, 667, 825) \$ 29, 327, 866** Balance **7, 436, 219 \$ 74, 362 \$ 397, 980, 023 22 \$ (85, 188) \$ 26, 494 \$ (368, 667, 825) \$ 29, 327, 866** Net loss----- **(19, 514, 977)** (19, 514, 977) Sale of equity through equity financing facilities **1, 904, 142 19, 041 2, 762, 397----- 2, 781, 438** Issuance of common stock upon exercise vesting of restricted shares options-- **59, 450 595----- 595** Realized and unrealized gains, net, on investment securities----- **34, 302- 34, 302** Stock- based compensation expense-- **758, 418----- 758, 418** Balance at December 31, **2023** -9, 399, 811 \$ 93, 998 \$ 401, 500, 838 **22 \$ (85, 188) \$ 60, 796 \$ (388, 182, 802) \$ 13, 387, 642** Balance F- 9 YEAR ENDED DECEMBER 31, **399** 2022 Shares Amount Capital Shares Amount (Loss) Deficit Total Series A & B Preferred Common Stock Outstanding Additional Paid- in Treasury Stock Accum. Other Compr. Income Accumulated Shares Amount Capital Shares Amount (Loss) Deficit Total Balance at January 1, **811** 2022- \$ **93 -5, 998** 770, 516 \$ **57 401, 500** 705 \$ **388, 838** 600, 979- **22 \$ (85, 188) \$ 60 (7, 796 974) \$ (332 388, 769 182, 591 802)** \$ **55, 795, 931** Balance- \$ **5, 770, 516 \$ 57, 705 \$ 388, 600, 979 22 \$ (85, 188) \$ (7, 974) \$ (332, 769, 591) \$ 55, 795, 931** Net loss----- **(35, 898, 234)** (35, 898, 234) Effect of reverse stock split **(27)** - Issuance of preferred stock upon financing **100, 000 28, 500, 000** - **285,000, 000** Redemption of preferred stock (100,000) **(28, 500, 000)** - **(28, 500, 000)** Sale of equity through equity financing facilities **1, 664, 349 16, 644 6, 706, 010----- 6, 722, 654** Issuance of common stock for restricted options **1, 381 13** - **13** Realized and unrealized gains, net **387, 642** on investment securities **34, 468** - **34, 468** Stock- based compensation expense **477, 135** - **477, 135** Balance at December 31, **2022** - \$ **7, 436, 219 \$ 74, 362 \$ 397, 980, 023 22 \$ (85, 188) \$ 26, 494 \$ (368, 667, 825) \$ 29, 327, 866** Balance- \$ **7, 436, 219 \$ 74, 362 \$ 397, 980, 023 22 \$ (85, 188) \$ 26, 494 \$ (368, 667, 825) \$ 29, 327, 866** See accompanying notes to the consolidated financial \$ statements. F- 10 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, **2023-2024** 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Description of Business On September 19, 2022, Celsion Corporation announced a corporate name change to Imunon, Inc. ("Imunon" or the "Company") reflecting the evolution of the Company's business focus and its commitment to developing cutting- edge immunotherapies and next- generation vaccines to treat cancer and infectious diseases. The Company's common stock continues to trade on the Nasdaq Stock Market under the ticker symbol "IMNN." Imunon is a fully integrated, clinical- stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms with the aim to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. Imunon is developing its non- viral DNA technology across four its modalities. The first modality, TheraPlas®, is developed for the coding of proteins and cytokines in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the coding of viral antigens that can elicit a strong immunological response. This technology may represent a promising platform for the development of vaccines in infectious diseases. The third modality, FixPlas®, concerns the application of Imunon's DNA

technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, IndiPlas®, is in the discovery phase and will focus on the development of personalized cancer vaccines, or neoepitope cancer vaccines. The Company's lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in **that has completed Phase 2 development II clinical studies**. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company **has entered is conducting IND-enabling preclinical studies for the development of a first-in-human study of its COVID-19 booster vaccine (IMNN-101) and a treatment for the Lassa virus (IMNN-102)**. The Company has also initiated preclinical work to develop a Trp2 tumor associated antigen cancer vaccine in melanoma (IMNN-201). Imunon will continue to leverage these modalities and to advance the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. Basis of Presentation The accompanying consolidated financial statements ("Financial Statements") of Imunon have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company and CLSN Laboratories, Inc. The Company **in 2023 dissolved Celsion GmbH in 2023**. All significant intercompany balances and transactions have been eliminated in consolidation. **Accounting Standards Events and conditions arising subsequent to the most recent balance sheet date Update through the date of the issuance of: Improvements to Reportable Segment Disclosures In November 2023, these-- the Financial Statements FASB issued ASU No. 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures". The disclosure requirements are required on an annual and interim basis and are applicable to entities with a single reportable segment. The amendments in the ASU require disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker ("CODM"), a description of other segment items by reportable segment, and any additional measures of a segment's profit or loss used by the CODM when deciding how to allocate resources. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods for fiscal years beginning after December 31, 2024, with early adoption allowed. We adopted this guidance as of January 1, 2024 on a retrospective basis and the adoption did not have a material been evaluated for their possible impact on the our consolidated Financial financial Statements statements and accompanying notes. Refer No events and conditions would give rise to any information that required accounting recognition Note 3, "Segment Performance Measures and Expenses," or for new disclosure disclosures resulting from in the Financial Statements other-- the adoption than those arising in the ordinary course of business ASU 2023-07. Use of Estimates The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation, the fair value of the earn-out milestone liabilities, estimates for contingent liabilities, if any, and accounting for impairment of in-process research and development assets. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates. F-11 Revenue Recognition The Company's sole did not generate any revenue stream was related to the Hisun agreement described in Note 18, 2024 or 2023, and whose contract has expired. There there were no accounts receivable as of December 31, 2024 and 2023 and 2022. Cash and Cash Equivalents Cash and cash equivalents include cash on hand and investments purchased with an original maturity of three months or less. A portion of these funds are not covered by FDIC insurance. Fair Value of Financial Instruments The carrying values of financial instruments approximate their respective fair values. Management believes that the carrying amounts of the Company's financial instruments, including cash and cash equivalents and accounts payable approximate fair value due to the short-term nature of those instruments. Short-term investments are recorded at their estimated fair value. Short-Term Investments The Company classifies its investments in debt securities with readily determinable fair values as investments available-for-sale in accordance with Accounting Standards Codification ("ASC") 320, Investments-Debt and Equity Securities. Available-for-sale securities consist of debt securities not classified as trading securities or as securities to be held to maturity. The Company has classified all of its investments as available-for-sale. Unrealized holding gains and losses on available-for-sale securities are reported as a net amount in accumulated other comprehensive gain or loss in stockholders' equity until realized. Gains and losses on the sale of available-for-sale securities are determined using the specific identification method. The Company's short-term investments consist of corporate bonds. Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is provided over the estimated useful lives of the related assets, ranging from three to seven years, using the straight-line method. Amortization is recognized over the lesser of the life of the asset or the lease term. Major renewals and improvements are capitalized at cost and ordinary repairs and maintenance are charged against operating expenses as incurred. Depreciation expense was approximately \$ 240,000 and \$ 248,000 and \$ 197,000 for the years ended December 31, 2024 and 2023 and 2022, respectively. The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An asset is considered impaired if its carrying amount exceeds the future net undiscounted cash flows that the asset is expected to generate. If such asset is considered to be impaired, the impairment recognized is the amount by which the carrying amount of the asset, if any, exceeds its fair value determined using a discounted cash flow model. There was no impairment of property or equipment during 2024 or 2023. Advances and Deposits on Clinical Programs and Other Current Assets Supplies are consumable items kept on hand to support the Company's R & D and manufacturing operations which includes prepaid expense, raw materials, clinical supplies and consumable items or for 2022 clinical trials with alternate uses that are capitalized. Supplies are recorded at cost and are charged to expense as they are used in operations. The Company regularly reviews the quality and utilization of supplies to determine if future use of these supplies is probable. Due to the generic use of these supplies, they can be used in multiple projects other than those currently being studied. Deposits include real property security deposits and other deposits which are contractually required and of a long-term nature. During 2014, the Company acquired certain assets of EGEN, Inc. As more fully described in Note 6, the acquisition was accounted for under the acquisition method of accounting which required the Company to perform an allocation of the purchase price to the assets acquired and liabilities assumed. Under the acquisition method of accounting, the total purchase price is allocated to net tangible and intangible assets and liabilities based on their estimated fair values as of the acquisition date. F-12 Impairment or Disposal of Long-Lived Assets The Company assesses the impairment of its long-lived assets under accounting standards for the impairment or disposal of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and fair value. See Note 5 for information on impairment losses of its in-process research and development. Comprehensive Income (Loss) ASC 220, Comprehensive Income, establishes standards for the reporting and display of comprehensive income (loss) and its components in the Company's consolidated financial statements. The objective of ASC 220 is to report a measure of comprehensive income (loss) of all changes in equity of an enterprise that result from transactions and other economic events in a period other than transactions with owners. Comprehensive gains (losses) result from changes in unrealized gains and losses from investment in debt securities. Research and development costs are expensed as incurred. Equipment and facilities acquired for research and development activities that have alternative future uses are capitalized and charged to expense over their estimated useful lives. Net Loss per Share of Common Stock Basic and diluted net loss per common share was computed by dividing net loss for the year by the weighted average number of shares of common stock outstanding, both basic and diluted, during each period. The impact of common stock equivalents has been excluded from the computation of diluted weighted average common shares outstanding in periods where there is a net loss, as their effect is anti-dilutive. For the years ended December 31, 2024 and 2023 and 2022, the total number of shares of common stock issuable upon exercise of warrants and equity awards was 6,840,633 and 1,255,642 and 988,389, respectively. For the years ended December 31, 2024 and 2023 and 2022, diluted loss per common share is the same as basic loss per common share as all other warrants that were convertible into shares of the Company's common stock were excluded from the calculation of diluted earnings attributable to common stockholders per common share as their effect would be anti-dilutive. Income Taxes Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in results of operations in the period that the tax rate change occurs. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. In accordance with ASC 740, Income Taxes, a tax position is recognized as a benefit only if it is "more likely than not" that the tax position taken would be sustained in a tax examination, presuming that a tax examination will occur. The Company recognizes interest and / or penalties related to income tax matters in the income tax expense category. As more fully discussed in Note 10, on November 28, 2023, the Company received approval from the New Jersey Economic Development Authority to sell \$ 1.3 million of its New Jersey net operating losses ("NOLs"), recognizing a tax benefit for the year ended December 31, 2023 for the net proceeds (approximately \$ 1.3 million) by reducing the net operating loss valuation allowance. As more fully discussed in Note 10, on November 28, 2023, the Company was notified by the New Jersey Economic Development Authority that its application was approved and the Company entered into an agreement to sell this NOL. On March 22, 2024, the Company received approximately \$ 1.3 million upon completion of the sale of the 2023 NOLs. During 2022, the Company received approval to sell \$ 1.6 million of its New Jersey NOLs, receiving**

net proceeds of approximately \$ 1.6 million. As part of the Technology Business Tax Certificate Program sponsored by The New Jersey Economic Development Authority, emerging biotechnology companies with unused NOLs and unused research and development credits are allowed to sell these benefits to other New Jersey-based companies. During 2021, the New Jersey State Legislature increased the maximum lifetime benefit per company from \$ 15 million to \$ 20 million, which will allow the Company to participate in this innovative funding program in future years for up to an additional \$ 0.4 million in net operating losses under this maximum lifetime benefit (see Note 2). F- 13 Stock- Based Compensation In March 2016 The Company accounts for all share- based payment awards granted to employees and non- employees as stock- based compensation expense at grant date fair value. The Company's share- based payments include stock options and grants of common stock, including common stock subject to vesting. The measurement date for employee awards is the Financial Accounting Standards Board ("FASB") issued date of grant, and stock- based compensation costs are recognized as expense over the employees' requisite service period, which is the vesting period, on a straight- line basis. Prior to the adoption of Accounting Standards Update ("ASU") No. 2016- 09- 07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share- Based Payment Accounting ("ASU No. 2016- 07") on January 1, 2020, the measurement date for non- employee awards was generally the date the services were completed, resulting in financial reporting period adjustments to stock- based compensation during the vesting terms for changes in the fair value of the awards. Since the adoption of ASU 2016- 07, the measurement date for non- employee awards is the date of grant without changes in the fair value of the award. There was no material impact as a result of adopting this new standard. Stock- based compensation costs for non- employees are recognized as expense over the vesting period on a straight- line basis. Stock- based compensation expense is classified in the accompanying consolidated statements of operations based on the function to which the related services simplify various aspects of accounting for share- based payments. The areas for simplification involve several aspects of the accounting for share- based payment transactions, including the income tax consequences and classification on the statements of cash flows. The Company recognizes the effect of forfeitures Forfeitures are recorded as in compensation cost when they occur. The fair value of each stock option grant is estimated on the date of grant using the Black- Scholes option- pricing model. Since there is limited historical data of the Company's share price on the public market, the Company estimates its expected stock volatility based on the historical volatility of a publicly traded set of representative companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company's stock options has been determined utilizing the "simplified" method for awards that qualify as "plain- vanilla" options. The risk- free interest rate is determined by reference to the U. S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued accounting pronouncements will not have a material impact on the Company's consolidated financial position, results of operations, and cash flows, or do not apply to its operations. F- 14 In December 2023, the FASB issued ASU No. 2023- 09, Improvements to Income Tax Disclosures, which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax- related disclosures. ASU No. 2023- 09 is effective for fiscal years beginning after December 15, 2024 and allows for adoption on a prospective basis, with a retrospective option. Early adoption is permitted. The Company is currently evaluating the impact of the ASU on the income tax disclosures within the consolidated financial statements. In November 2024, the FASB issued Accounting Standards Update No. 2024- 03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses ("ASU 2024- 03"). ASU 2024- 03 will require more detailed information about the types of expenses in commonly presented income statement captions such as "Cost of sales" and "Selling, general and administrative expenses". The new guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027 with early adoption permitted. The Company is currently evaluating the impact that this change will have on the Company's disclosures.

2. FINANCIAL CONDITION AND GOING CONCERN UNCERTAINTY Since inception, the Company has incurred substantial operating losses, principally from expenses associated with the Company's research and development programs, clinical trials conducted in connection with the Company's drug candidates, and applications and submissions to the FDA. The Company has not generated significant revenue and has incurred significant net losses in each year since inception. For the year ended December 31, 2023- 2024, the Company had a net loss of \$ 49.18, 5.6 million and used \$ 49.18, 0.9 million to fund operations. As of December 31, 2023- 2024, the Company has incurred approximately \$ 388.407 million of cumulative net losses. As of December 31, 2023- 2024, the Company had \$ 15.5, 7.9 million in cash and cash equivalents, and short- term investments, and interest receivable and \$ 1.3 million net proceeds from the sale of its New Jersey net operating losses. The Company has substantial future capital requirements to continue its research and development activities and advance its drug candidates through various development stages. The Company believes these expenditures are essential for the commercialization of its drug candidates and technologies. The Company expects its operating losses to continue for the foreseeable future as it continues its product development efforts, and when it undertakes marketing and sales activities. The Company's ability to achieve profitability is dependent upon its ability to obtain governmental approvals, manufacture, and market and sell its new drug candidates. There can be no assurance that the Company will be able to commercialize its technology successfully or that profitability will ever be achieved. The Company expects that its operating results will fluctuate significantly in the future and will depend on a number of factors, many of which are outside the Company's control. The Company's ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the U. S. and worldwide resulting from the COVID- 19 pandemic, the Russian invasion of Ukraine and the unrest in the Middle East. The Company continues to monitor its operating activities in light of these events, and it is possible that these events could result in a variety of risks to the business. The specific impact, if any, is not readily determinable as of the date of these consolidated Financial Statements. F- 14 The Company has based its estimates on assumptions that may prove to be wrong. The Company may need to obtain additional funds sooner or in greater amounts than it currently anticipates. Potential sources of financing include strategic relationships, public or private sales of the Company's shares or debt, the sale of the Company's New Jersey NOLs and other sources. If the Company raises funds by selling additional shares of common stock or other securities convertible into common stock, the ownership interest of existing stockholders may be diluted. The actual amount of funds the Company will need to operate is subject to many factors, some of which are beyond the Company's control. These factors include the progress of research activities; the number and scope of research programs; the progress of preclinical and clinical development activities; the progress of the development efforts of parties with whom the Company has entered into research and development agreements; the costs associated with additional clinical trials of drug candidates; the ability to maintain current research and development licensing arrangements and to establish new research and development and licensing arrangements; the ability to achieve milestones under licensing arrangements; the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; and the costs and timing of regulatory approvals. F- 15 The consolidated financial statements have been prepared on the going concern basis. In making this assessment, management conducted a comprehensive review of the Company's business plan including, but not limited to: • the Company's financial position for the year ended December 31, 2023- 2024; • significant events and transaction- transactions the Company has entered into since December 31, 2023- 2024; • the Company's cash flow and cash usage forecasts for the period one year from the issuance date of this Annual Report on Form 10- K; • the Company's capitalization structure including common stock outstanding and common stock issuable on exercise of warrants and equity awards, and other common stock issuable under equity plans; and • continued support of the Company's stockholders. As a result of the uncertainties involved in our business, we are unable to estimate the duration and completion costs of our research and development projects or when, if ever, and to what extent we will receive cash inflows from the commercialization and sale of a product. Our inability to complete our research and development projects in a timely manner or our failure to enter into collaborative agreements, when appropriate, could significantly increase our capital requirements and could adversely impact our liquidity. These uncertainties could force us to seek additional, external sources of financing from time to time in order to continue with our business strategy. Our inability to raise additional capital, or to do so on terms reasonably acceptable to us, would jeopardize the future success of our business. Our estimated future capital requirements are uncertain and could change materially as a result of many factors, including the progress of our research, development, clinical, manufacturing, and commercialization activities. Management has determined the Company has suffered recurring losses from operations and has an accumulated deficit that raises substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance date of this Annual Report on Form 10- K. The report of our independent registered public accounting firm for the year ended December 31, 2023- 2024, includes an explanatory paragraph, which expresses substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of the uncertainty. A fundamental component of the ability to continue as a going concern is the Company's ability to raise capital as required, as to which no assurances can be provided. To address the additional funding requirements of the Company, management has undertaken the following initiatives: • it has assessed its current expenditures and will be reducing the current spending requirements where necessary; • it will pursue additional capital funding in the public and private markets through equity sales and / or debt facilities; • it will pursue possible partnerships and collaborations; and • it will pursue potential out licensing for its drug candidates. F- 15 Our ability to continue as a going concern may depend on our ability to raise additional capital, attain further operating efficiencies, reduce

expenditures, and, ultimately, to generate revenue. There are no assurances that these future funding and operating efforts will be successful. If management is unsuccessful in these efforts, our current capital is not expected to be sufficient to fund our operations for the next twelve months. **F-16 3. SEGMENT PERFORMANCE MEASURES AND EXPENSES SCHEDULE OF SIGNIFICANT EXPENSE CATEGORIES AND CONSOLIDATED NET LOSS FOR THE YEAR ENDED DECEMBER 31, (IN THOUSANDS) CHANGE INCREASE (DECREASE) 2024 2023 Operating Expenses: Clinical Research OVATION \$ 1,386 \$ 1,197 \$ 189 15.8 % Vaccine 1,420-1,420 100.0 % Other clinical and regulatory 2,434 1,793 641 35.8 % Subtotal 5,240 2,990 2,250 75.3 % Non-Clinical R & D and CMC OVATION 1,819 1,504 315 20.9 % PlacCCine Vaccine 2,554 4,511 (1,957) (43.4) % Manufacturing (CMC) 2,026 2,283 (257) (11.3) % Subtotal 6,399 8,298 (1,899) (22.9) % Research and development expenses 11,639 11,288 351 3.1 % General and administrative expenses 7,493 9,742 (2,249) (23.1) % Total operating expenses 19,132 21,030 (1,898) (9.0) % Loss from operations \$ (19,132) \$ (21,030) \$ (1,898) (9.0) % 4.**

INVESTMENTS IN DEBT SECURITIES AVAILABLE FOR SALE Investments in debt securities available for sale with a fair value of \$ 0 and \$ 9,857,087 and \$ 21,254,485 as of December 31, 2024 and 2023 and 2022, respectively, consisted of U. S. Treasury securities and corporate debt securities. These investments are valued at estimated fair value, with unrealized gains and losses reported as a separate component of stockholders' equity in accumulated other comprehensive loss. The Company reviews its debt securities classified as short-term investments on a regular basis for impairment. For debt securities in unrealized loss positions, the Company determines whether any portion of the decline in fair value below the amortized cost basis is due to credit-related factors if it neither intends to sell nor anticipates that it is more likely than not that it will be required to sell prior to recovery of the amortized cost basis. The Company considers factors such as the extent to which the market value has been less than the cost, any noted failure of the issuer to make scheduled payments, changes to the rating of the security and other relevant credit-related factors in determining whether or not a credit loss exists. During fiscal 2024 and 2023 and 2022, the Company did not recognize an allowance for credit-related losses on any of our investments. **F-17** A summary of the cost, fair value and maturities of the Company's short-term investments is as follows: SCHEDULE OF COST, FAIR VALUE AND MATURITIES OF SHORT TERM INVESTMENTS December 31, 2023-2024 December 31, 2022-2023 Cost Fair Value Cost Fair Value Short-term investments U. S. Treasury securities \$ - \$ - \$ 9,796,291 \$ 9,857,087 \$ - \$ - Corporate debt securities - 21,227,991 21,254,485 Total \$ 9,796,291 \$ 9,857,087 \$ 21,227,991 \$ 21,254,485 December 31, 2023-2024 December 31, 2022-2023 Cost Fair Value Cost Fair Value Short-term investment maturities Within 3 months \$ - \$ - \$ 2,467,518 \$ 2,490,775 \$ 4,005,559 \$ 3,994,590 Between 3- 12 months - 7,328,773 7,366,312 17,222,432 17,259,895 Total \$ - \$ - \$ 9,796,291 \$ 9,857,087 \$ 21,227,991 \$ 21,254,485 The following table shows the Company's investment in debt securities available for sale gross unrealized gains (losses) and fair value by investment category and length of time that individual securities have been in a continuous unrealized loss position at December 31, 2024 and 2023 and 2022. The Company has reviewed individual securities to determine whether a decline in fair value below the amortizable cost basis is other than temporary. **SUMMARY SCHEDULE OF INVESTMENT SECURITIES GROSS UNREALIZED GAINS (LOSSES) December 31, 2023-2024 December 31, 2022-2023 Available for sale securities (all unrealized holding gains and losses are less than 12 months at date of measurement) Fair Value Unrealized Holding Gains (Losses) Fair Value Unrealized Holding Gains (Losses) Investments in debt securities with unrealized gains \$ - \$ - \$ 9,857,087 \$ 60,796 \$ 13,278,505 \$ 43,508 Investments in debt securities with unrealized losses \$ - \$ - \$ 7,975,980 \$ (17,014) Total \$ 9,857,087 \$ 60,796 \$ 21,254,485 \$ 26,494 **F-16** Investment income, net, which includes net realized losses on sales of available for sale securities and investment income interest and dividends, is summarized as follows: **SUMMARY SCHEDULE OF NET REALIZED LOSSES ON SALES OF AVAILABLE FOR SALE SECURITIES AND INVESTMENT INCOME INTEREST AND DIVIDENDS 2024 2023 2022** Interest and dividends accrued and paid \$ 450,221 \$ 725,824 \$ 502,578 Realized losses **61,983** 431,801 (49,222) Realized gains (losses) 431,801 (49,222) Investment income, net \$ 512,204 \$ 1,157,625 \$ 453,356 4. **RESTRICTED CASH** As a condition of the SVB Loan Facility entered into on June 18, 2021, as further discussed in Note 9, the Company was required at all times to maintain on deposit with SVB as cash collateral in a segregated money market bank account in the name of the Company, unrestricted and unencumbered cash (other than a lien in favor of SVB) in an amount of at least 100% of the aggregate outstanding amount of the SVB loan facility. SVB could restrict withdrawals or transfers by or on behalf of the Company that would violate this requirement. The loan was repaid in full during the quarter ended June 30, 2023, thus removing this requirement. The required reserve totaled \$ 6.0 million as of December 31, 2022. This amount is presented in part as restricted cash in current and other non-current assets on the accompanying consolidated balance sheets. The following table reconciles cash and cash equivalents and restricted cash per the consolidated balance sheets to the consolidated statements of cash flows: **SCHEDULE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH December 31, 2023 December 31, 2022** Cash and cash equivalents \$ 5,838,566 \$ 11,492,841 Money market investments, restricted - 6,000,000 Total \$ 5,838,566 \$ 17,492,841 5. **FAIR VALUES OF FINANCIAL INSTRUMENTS** FASB ASC Section 820, Fair Value Measurements and Disclosures, establishes a three-level hierarchy for fair value measurements which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows: Level 1: Quoted prices (unadjusted) or identical assets or liabilities in active markets that the entity has the ability to access as of the measurement date; Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data; and Level 3: Significant unobservable inputs that reflect a reporting entity's own assumptions that market participants would use in pricing an asset or liability. **F-17** Cash and cash equivalents and accounts payable are reflected in the consolidated balance sheets at their approximate estimated fair values primarily due to their short-term nature. The fair values of securities available for sale are determined by relying on the securities' relationship to other benchmark quoted securities and classified its investments as Level 2 items in both 2024 and 2023 and 2022. There were no transfers of assets or liabilities between Level 1 and Level 2 and no transfers in or out of Level 3 during the years ended December 31, 2024 and 2023 and 2022. **F** The changes in Level 3 liabilities were the result of changes in the fair value of the earn-out milestone liability included in earnings and in-process R & D. The earn-out milestone liability is valued using a risk-adjusted assessment of the probability of payment of each milestone, discounted to present value using an estimated time to achieve the milestone (see Note 13). Assets and liabilities measured at fair value are summarized below: **SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS Total Fair Value Quoted Prices in Active Markets for Identical Assets / Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Recurring items as of December 31, 2024 U. S. treasury obligations, available for sale \$ - \$ - \$ - \$ - Recurring items as of December 31, 2023 Corporate debt securities U. S. treasury obligations, available for sale \$ 9,857,087 \$ 9,857,087 \$ - \$ - Recurring items as of December 31, 2022 Corporate debt securities and U. S. treasury obligations, available for sale \$ 21,254,485 \$ 21,254,485 \$ - \$ - Non-recurring items as of December 31, 2022 In-process R & D \$ - \$ - \$ - \$ - Liabilities: Recurring items as of December 31, 2022 Earn-out milestone liability \$ - \$ - \$ - \$ - 6. **INTANGIBLE ASSETS** In June 2014, the Company completed the acquisition of substantially all of the assets of EGEN, Inc., an Alabama corporation ("EGEN"), which changed its company name to EGWU, Inc. after the closing of the acquisition (the "EGEN Acquisition"). The Company acquired all of EGEN's right, title and interest in and to substantially all of the assets of EGEN, including cash and cash equivalents, patents, trademarks and other intellectual property rights, clinical data, certain contracts, licenses and permits, equipment, furniture, office equipment, furnishings, supplies and other tangible personal property. In addition, CLSN Laboratories assumed certain specified liabilities of EGEN, including the liabilities arising out of the acquired contracts and other assets relating to periods after the closing date. **F-18** Acquired In-process Research and Development. Acquired in-process research and development ("IPR & D") consists of EGEN's drug technology platforms: TheraPlas and TheraSilence. The fair value of the IPR & D drug technology platforms was estimated to be \$ 24.2 million as of the acquisition date. As of the closing of the acquisition, the IPR & D was considered indefinite lived intangible assets and will not be amortized. IPR & D was reviewed for impairment at least annually as of the third quarter ended September 30, and whenever events or changes in circumstances indicate that the carrying value of the assets might not be recoverable. The Company's IPR & D consisted of three core elements, its RNA delivery system, its glioblastoma multiforme cancer ("GBM") drug candidate and its ovarian cancer indication. As of December 31, 2022, the Company assessed whether there were indicators of impairment for the Company's IPR & D and determined that the IPR & D asset was impaired during that period. Due to the continuing deterioration of public capital markets in the biotech industry in 2022 and 2021 and its impact on market capitalization rates in this sector, IPR & D was reviewed for impairment. Having conducted a quantitative analysis of the company's IPR & D assets, the Company concluded the IPR & D asset was impaired during the fourth quarter of 2022. As of December 31, 2022, the Company wrote off the \$ 13.4 million carrying value of this asset, thereby recognizing a non-cash charge of \$ 13.4 million in the fourth quarter of 2022. The following is a summary of the net fair value of the assets acquired in the EGEN Acquisition for the year ended December 31, 2022: **SCHEDULE OF FAIR VALUE OF ASSETS ACQUIRED IPR & D Balance at January 1, 2022, net \$ 13,366,234 Balance \$ 13,366,234 Impairment charge (13,366,234) Balance at December 31, 2022, net \$ - Balance \$ - 7. **PROPERTY AND EQUIPMENT** Property and equipment at December 31, 2024 and 2023 and 2022 consist of the following: **SUMMARY SCHEDULE OF PROPERTY AND EQUIPMENT 2023-2022 December 31, 2024 2023 2022** Machinery and equipment (5- 7 year life) \$ 951 2,055, 192 \$ 2,468 055, 388 Machinery 192 Furniture and equipment fixtures (3- 5 year life) 167, 351 191, 932 Leasehold improvements (5- 7 year life) 619 2, 024 055, 192 2, 468, 388 Furniture and fixtures (3- 5 year life) 191, 932 350, 481 Leasehold improvements (5- 7 year life) 607, 054 373, 194 Property and equipment gross 1, 737, 567 2, 854, 178 3, 192, 063 Less accumulated depreciation and amortization (1, 196, 295) (2, 102, 272) (2, 643, 762) Total \$ 541, 272 \$ 751, 906 \$ 548, 301 8. **OTHER ACCRUED LIABILITIES** Other accrued liabilities at December 31, 2024 and 2023 and 2022 include the following: **SCHEDULE OF OTHER ACCRUED LIABILITIES 2023-2022 December 31, 2024 2023 2022********

Amounts due to contract research organizations and other contractual agreements \$ 1,048,036 \$ 1,442,659 \$ 2,196,711-Accrued payroll and related benefits 1,945,111 1,693,383 2,139,927-Accrued interest 37,583-Accrued professional fees 20,600 234,479 215,402-Other 20,000 205 20 313,000 Total \$ 3,033,747 \$ 3,390,521 \$ 4,794,936 F-19-9. NOTES PAYABLE The SVB Loan Facility On June 18, 2021, the Company entered into a \$ 10 million loan facility (the "SVB Loan Facility") with Silicon Valley Bank ("SVB"). Imunon immediately drew down \$ 6 million from the SVB Loan Facility and used the funds to retire all outstanding indebtedness with Horizon Technology Finance Corporation pursuant to a loan agreement entered into on June 27, 2018, under which the Company had drawn down \$ 10 million and repaid \$ 5 million in August 2020. Concurrently with this transaction, the Company used \$ 6.0 million of other available funds to establish a restricted cash account which served as security for the SVB Loan Facility. F-19 The SVB Loan Facility was in the form of money market secured indebtedness bearing interest at a calculated WSJ Prime- based variable rate. A final payment equal to 3 % of the total \$ 10 million commitment amount was due upon maturity or prepayment of the SVB Loan Facility. There was no facility commitment fee, and no stock or warrants were issued to SVB. Payments under the loan agreement were interest only for the first 24 months after loan closing, followed by a 24- month amortization period of principal and interest through the scheduled maturity date. In connection with the SVB Loan Facility, the Company incurred financing fees and expenses totaling \$ 243,370 which was recorded and classified as debt discount and was amortized as interest expense using the effective interest method over the life of the loan. Also, in connection with the SVB Loan Facility, the Company was required to pay an end- of- term fee equal to 3.0 % of the original loan amount at time of maturity. Therefore, these amounts totaling \$ 300,000 were amortized as interest expense using the effective interest method over the life of the loan. During the years- year ended December 31, 2023 and 2022, the Company incurred interest expense of \$ 197,080 and \$ 295,792 and amortized \$ 329,158 and \$ 181,259, respectively, as interest expense for debt discounts and end- of- term fee in connection with the SVB Loan Facility. On April 21, 2023, the Company repaid the outstanding principal balance, an early termination fee and the end- of- term charges in full satisfaction of the SVB Loan Facility. The following is a schedule of the amounts paid to SVB on April 21, 2023: SCHEDULE OF DEBT Principal balance at April 21, 2023 \$ 6,000,000 Early termination fees 120,000 End of term charges 300,000 Total payoff amount \$ 6,420,000 During the year ended December 31, 2023, the Company recorded a loss of \$ 329,158 on the early termination of the SVB Loan Facility which represented the early termination fee and the end of the term fees, net of previously amortized interest expense totaling \$ 334,212 on the date of its payoff. F-9. INCOME TAXES The income tax benefit for the years ended December 31, 2024 and 2023 and 2022 consists of the following: SCHEDULE OF INCOME TAX PROVISION (BENEFIT) 2024 2023 2022-Federal Current \$- \$- Deferred-- State and Local-- Current-- Deferred - (1,280,385) (1,567,026) Total \$ - \$ (1,280,385) \$ (1,567,026) F-20 A reconciliation of the Company' s statutory tax rate to the effective rate for the years ended December 31, 2024 and 2023 and 2022 is as follows: SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION 2024 2023 2022-Federal statutory rate 21.0 21.0 % 21.0 % State taxes, net of federal tax benefit 7.8 4.40 7.1 Permanent differences (2.74) (3.1) 29.8-True- Up (0.07) (105.0) -Other 0.11 (2.9) -Rate Change 0.57- Deferred vs statutory rate (0.75)- Expiration of NOLs (17.51)-Change in valuation allowance and deferred rate change, net (9.01) 89.0 (53.8) Effective tax rate - % 6.1 % F-20 4.1 % The components of the Company' s deferred tax asset as of December 31, 2024 and 2023 and 2022 are as follows: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES 2023 2022-December 31, 2024 2023 2022-Net operating loss carryforwards \$ 66,141,490 \$ 67,310,000 \$ 79,800,000 Section 174 6,482,099 4,929,000 - Other deferred tax assets, net 2,010,744 2,016,000 13,287,000 Subtotal 74,634,333 74,255,000 93,087,000 Valuation allowance (74,634,333) (72,974,615) (91,519,974) Total deferred tax asset \$ - 1,280,385 \$ 1,567,280, 026 385 The evaluation of the realizability of such deferred tax assets in future periods is made based upon a variety of factors that affect the Company' s ability to generate future taxable income, such as intent and ability to sell assets and historical and projected operating performance. The As of December 31, 2024, based on the Company has established a valuation reserve for' s history of earnings and its assessment of future earnings, management believes that it is more likely than not future taxable income will not be sufficient to realize the deferred income tax assets other than those related. Therefore, full valuation allowance has been applied to deferred tax assets its New Jersey NOLs. At December 31, 2023, after its evaluation of its New Jersey NOLs as discussed more fully below, the Company reduced the valuation reserve and recognized \$ 1.3 million as a deferred income tax asset. Such tax assets are available to be recognized and benefit future periods. As of December 31, 2023-2024, the Company had federal net operating loss carry carryforwards ---- forwards of approximately \$ 307-303 million. If , net of net operating losses utilized in prior years of which \$ 218 million, if unused, will expire starting in 2024-2025 through 2037. The federal NOLs generated for the years ended after 2017 of approximately \$ 78-101 million can be carried forward indefinitely. As of December 31, 2023-2024, the Company had state net operating loss carryforwards of approximately \$ 44-40 million, net of net operating losses utilized in prior years, and, if unused, will expire starting in 2029 through 2042-2043-likely- than- not to be sustained upon examination by taxing authorities.As of December 31, 2024-and-2023 ,and 2022, there were no unrecognized tax benefits.The Company recognizes accrued interest and penalties as income tax expense.No amounts were accrued for the payment of interest and penalties at December 31, 2024-and-2023 and 2022 .The Company is currently not aware of any issues under review that could result in significant payments,accruals or material deviation from its position in the next year.Sections 382 and 383 of the Internal Revenue Code provide for a limitation on the annual use of NOL and tax credit carryforwards following certain ownership changes that could limit the Company' s ability to utilize these carryforwards.The Company has completed an analysis to determine if such ownership changes have occurred and concluded it was more likely than not that there were changes in ownership.Due to the existence of full valuation allowance,limitations under Section 382 and 383 will not impact the Company' s effective tax rate.Further analyses will be performed prior to recognizing the benefits of any losses or credits in the financial statements . Effective for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental to research and experimentation (" R & E ") activities under IRC Section 174. While taxpayers historically had the option of deducting these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R & E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection with R & E activities in the US must be amortized over a 5- year period if incurred, and R & E expenses incurred outside the US must be amortized over a 15- year period. R & E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2023-2024, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R & E expenses. The Company will continue to monitor this issue for future developments, but it does not expect R & E capitalization and amortization to require it to pay cash taxes now or in the near future. The Company' s income tax returns for 2019 to 2022-2020 to 2023 are still open and subject to audit. In addition, net operating losses arising from prior years are also subject to examination at the time they are utilized in future years. F-ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more- 21 likely- than- not to be..... or credits in the financial statements. Sale of New Jersey Net Operating Losses Since 2018, the Company has annually submitted applications to sell a portion of the Company' s New Jersey NOLs as part of the Technology Business Tax Certificate Program sponsored by The New Jersey Economic Development Authority. Under the program, emerging biotechnology companies with unused NOLs and unused research and development credits are allowed to sell these benefits to other New Jersey- based companies. As part of the Technology Business Tax Certificate Program, the Company sold \$ 1.3 million and \$ 1.6 million of its New Jersey NOLs in 2023 and 2022, respectively. The sale of these net operating losses resulted in net proceeds to the Company of approximately \$ 1.3 million in 2023-2024 and \$ 1.6 million in 2022. During 2021, the New Jersey State Legislature increased the maximum lifetime benefit per company from \$ 15 million to \$ 20 million, which will allow the Company to participate in this funding program in future years for up to an additional \$ 0.3 million in net operating losses under this maximum lifetime benefit. F-21-11. STOCKHOLDERS' EQUITY On March 19-May 15, 2021-2024, the Company filed with the SEC a shelf registration statement on Form S-3 (the "2021 Registration Statement") that allows the Company to issue any combination of common stock, preferred stock or warrants to purchase common stock or preferred stock in an amount up to \$ 100 million. The 2021 Registration Statement was declared effective on March 30, 2021. The 2021 Registration Statement was intended to provide the Company with flexibility to raise capital in the future for general corporate purposes. However, as of the date of these financial statements and so long as the Company' s public float remains below \$ 75 million, it is subject to limitations with respect to the use of the 2021 Registration Statement and any other shelf registration statement that files with the SEC pursuant to General Instruction I. B-6 of Form S-3 (the "Baby Shelf Limitation"), which limits the amount that the Company can offer to up to one- third of its public float during any trailing 12- month period. The Company would be no longer subject to the Baby Shelf Limitation if its public float exceeds \$ 75 million. On September 19, 2022, the Company announced a corporate name change to Imunon, Inc. The Company' s common stock will continue to trade on the Nasdaq Stock Market under the new ticker symbol "IMNN" effective as of the opening of trading on September 21, 2022, and its CUSIP number (15117N602) remained unchanged. The Company filed an amendment- amended to its Articles of Incorporation to effect the new corporate name. Reverse Stock Split On February 28, 2022, the Company effected a 15- for- 1 reverse stock split of its common stock which was made effective for trading purposes as of the commencement of trading on March 31, 2022. As of that date, each 15 shares of issued and outstanding common stock and equivalents was consolidated into one share of common stock. All shares have been restated to reflect the effects of the 15- for- 1 reverse stock split. In addition, at the market open on March 1, 2022, the Company' s common stock started trading under a new CUSIP number 15117N602 although the Company' s ticker symbol, CLSN, remained unchanged. The reverse stock split was previously approved by the Company' s stockholders at the 2022 Special Meeting held on February 24, 2022, and the Company subsequently filed a Certificate of Amendment to its Certificate of Incorporation to effect the stock consolidation. The primary reasons for the reverse stock split and the

amendment were: ● To provide the Company with the ability to support its future anticipated growth and would provide greater flexibility to consider and respond to future business opportunities and needs as they arise, including equity financings and stock-based acquisitions of new technology and product development candidates. The availability of additional shares of common stock would permit the Company to undertake certain of the foregoing actions without delay and expense associated with holding a Special Meeting of Stockholders to obtain stockholder approval each time such an opportunity arises that would require the issuance of shares of common stock; and ● To continue listing on The NASDAQ Capital Market, which requires that the Company comply with the applicable listing requirements under NASDAQ Marketplace Rules, which requirements include, among others, a minimum bid price of at least \$ 1.00 per share. On December 2, 2021, the Company received a letter from NASDAQ indicating that the closing bid price of the Company's common stock fell below \$ 1.00 per share for the previous 30 consecutive business days, and that the Company was therefore not in compliance with the minimum bid price requirement for continued inclusion on The NASDAQ Capital Market. The Company had 180 calendar days, until May 31, 2022, to regain compliance with this requirement, which occurs when the closing bid price of the Company's common stock is at least \$ 1.00 per share for a minimum of ten consecutive business days during the 180-day compliance period. F-22 Immediately prior to the reverse stock split, the Company had 86,557,736 shares of common stock outstanding which consolidated into 5,770,516 shares of the Company's common stock. No fractional shares were issued in connection with the reverse stock split. Holders of fractional shares have been paid out in cash for the fractional portion with the Company's overall exposure for such payouts consisting of a nominal amount. The amount of the Company's outstanding convertible preferred stock were not affected by the reverse stock split. The number of outstanding options, stock awards and warrants were adjusted accordingly, with outstanding options and stock awards being reduced from approximately 6.6 million to approximately 0.4 million and outstanding warrants being reduced from approximately 2.5 million to approximately 0.2 million. At the Market Offering Agreement On, dated as of May 25, 2022, (the "ATM Company entered into an At the Market Offering Agreement") with H. C. Wainwright & Co., LLC, ("Wainwright") as sales agent ("Wainwright"), pursuant Pursuant to which the terms of the amended ATM Agreement, the Company may offer and sell, from time to time, through Wainwright, shares of the Company's common stock having an aggregate offering price of up to \$ 7.5, 500,000. During 2022 the Company sold 336,075 shares of stock for net proceeds of \$ 503,798. The Company intends to use the net proceeds from the any offering, if any, under the amended ATM Agreement for general corporate purposes, including research and development activities, capital expenditures and working capital. In On September 3, 2023-2024, the Company filed a new prospectus supplement to the 2024 Registration Statement with the SEC for an aggregate offering price of up to \$ 5,500,000 related to the potential issuance from time to time of the Company's common stock pursuant to the ATM Agreement with Wainwright has as sales agent. The Company sold 188,796,904,142 shares of common stock under the ATM Agreement for net proceeds of \$ 99,506 during 2024. During 2023, the Company sold 1,878,488 shares of common stock under the ATM Agreement for net proceeds of \$ 2,781,750, 438,658 Series A and Series B Convertible Redeemable Preferred. The Company sold 120,047 shares of common Stock stock Offering under the ATM Agreement for net proceeds of \$ 105,693 from January 1, 2025 through February 21, 2025. On January 10 July 30, 2022-2024, the Company entered into a Securities the July 2024 Purchase Agreement (the "Preferred Stock Purchase Agreement") with the Purchasers several institutional investors, pursuant to which the Company agreed to issue issued and sell, in concurrent registered direct offerings (the "Preferred Offerings"), (i) 50,000 shares of the Company's Series A Convertible Redeemable Preferred Stock, par value \$ 0.01 per share (the "Series A Preferred Stock"), and (ii) 50,000 shares of the Company's Series B Convertible Redeemable Preferred Stock, par value \$ 0.01 per share (the "Series B Preferred Stock" and together with the Series A Preferred Stock, the "Preferred Stock"), in each case at an offering price of \$ 285 per share, representing a 5% original issue discount to the stated value of \$ 300 per share, for gross proceeds of each Preferred Offering of \$ 14.25 million, or approximately \$ 28.50 million in the aggregate for the Preferred Offerings, before the deduction of the Placement Agent's (as defined below) fee and offering expenses. The shares of Series A Preferred Stock have a stated value of \$ 300 per share and are convertible, at a conversion price of \$ 13.65 per share, into 1,098,901 shares of common stock (subject in certain circumstances to adjustments). The shares of Series B Preferred Stock have a stated value of \$ 300 per share and are convertible, at a conversion price of \$ 15.00 per share, into 1,000,000 shares of common stock (subject in certain circumstances to adjustments). The closing of the Preferred Offerings occurred on January 13, 2022. On March 3, 2022, the Company redeemed for cash at a price equal to 105% of the \$ 300 stated value per share all of its 50,000 outstanding shares of Series A Preferred Stock and its 50,000 Series B Preferred Stock. As a result, all shares of the Preferred Stock have been retired and are no longer outstanding and Imunon's only class of outstanding stock is its common. In connection with the Preferred Offerings, the Company entered into a placement agent agreement (the "Placement Agent Agreement") with AGP pursuant to which the Company agreed to pay AGP an aggregate cash fee equal to \$ 1,000,000 and reimburse the AGP for certain of their expenses in an amount not to exceed \$ 110,000. April 2022 Registered Direct Offering On April 6, 2022, the Company entered into a Securities Purchase Agreement (the "April 2022 Purchase Agreement") with several institutional investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering (the "April 2022 Offering"), an aggregate of 15,328,000, 274,000 shares of the Company's common stock at an offering price of \$ 5.2, 27.00 per share for gross proceeds of \$ 7.10 million before the deduction of the April 2022 Placement Agent agent (as defined below) fees and offering expenses. In a concurrent private placement and also pursuant to the July 2024 Purchase Agreement, the Company issued to the Purchasers the Warrants to purchase an aggregate of 5,000,000 shares of its common stock at an exercise price of \$ 2.00 per share. The Warrants became exercisable immediately after issuance for a term of five and one-half years following the date of issuance. The closing of the April July 2022-2024 Offering occurred on April 8 August 1, 2022-2024. In connection with the April 2022 Offering, the Company entered into a placement agent agreement with A. G. P. / Alliance Global Partners (the "April 2022 Placement Agent") pursuant to which the Company agreed to pay the April 2022 Placement Agent a cash fee equal to 6.5% of the aggregate gross proceeds raised from the sale of the securities sold in the April 2022 Offering and reimburse the April 2022 Placement Agent for certain of their expenses in an amount not to exceed \$ 50,000. F-23-12-22 11. STOCK-BASED COMPENSATION The Company has long-term compensation plans that permit the granting of equity-based awards in the form of stock options, restricted stock, restricted stock units, stock appreciation rights, other stock awards, and performance awards. At the 2018 Annual Stockholders Meeting of the Company held on May 15, 2018, stockholders approved the Imunon, Inc. 2018 Stock Incentive Plan (the "2018 Plan"). The 2018 Plan, as adopted, permits the granting of 180,000 shares of Imunon common stock as equity awards in the form of incentive stock options, nonqualified stock options, restricted stock, restricted stock units, stock appreciation rights, other stock awards, performance awards, or in any combination of the foregoing. At the 2019 Annual Stockholders Meeting of the Company held on May 14, 2019, stockholders approved an amendment to the 2018 Plan whereby the Company increased the number of common stock shares available by 80,000 to a total of 260,000 under the 2018 Plan, as amended. At the 2020 Annual Stockholders Meeting of the Company held on June 15, 2020, stockholders approved an amendment to the 2018 Plan, as previously amended, whereby the Company increased the number of shares of common stock available by 166,667 to a total of 426,667 under the 2018 Plan, as amended. At the 2021 Annual Stockholders Meeting of the Company held on June 10, 2021, stockholders approved an amendment to the 2018 Plan, as previously amended, whereby the Company increased the number of shares of common stock available by 513,333 to a total of 940,000 under the 2018 Plan, as amended. At the 2023 Annual Stockholders Meeting of the Company held on June 14, 2023, stockholders approved an amendment to the 2018 Plan, as previously amended, whereby the Company increased the number of shares of common stock available by 1,030,000 to a total of 1,970,000 under the 2018 Plan, as amended. The Company has issued stock awards to employees and directors in the form of stock options and restricted stock. Options are generally granted with strike prices equal to the fair market value of a share of Imunon common stock on the date of grant. Incentive stock options may be granted to purchase shares of common stock at a price not less than 100% of the fair market value of the underlying shares on the date of grant, provided that the exercise price of any incentive stock option granted to an eligible employee owning more than 10% of the outstanding stock of Imunon must be at least 110% of such fair market value on the date of grant. Only officers and key employees may receive incentive stock options. Option and restricted stock awards vest upon terms determined by the Compensation Committee of the Board of Directors and are subject to accelerated vesting in the event of a change of control or certain terminations of employment. The Company issues new shares to satisfy its obligations from the exercise of options or the grant of restricted stock awards. As of December 31, 2023-2024, the Compensation Committee of the Board of Directors approved the grant of (i) inducement stock options (the "Inducement Option Grants") to purchase a total of 294,110, 000 751 shares of Imunon common stock and (ii) inducement restricted stock awards (the "Inducement Stock Grants") totaling 91,350 shares of Imunon common stock. Each award has a grant date of the date of grant. Each Inducement Option Grant has a weighted exercise price of \$ 1.59-02 per share. Each Inducement Option Grant vests over three-four years, with one-third-fourth vesting on the one-year anniversary of the employee's first day of employment with the Company and one-third-fourth vesting on the second and, third and fourth anniversaries thereafter, subject to the new employee's continued service relationship with the Company on each such date. Each Inducement Option Grant has a ten-year term and is subject to the terms and conditions of the applicable stock option agreement. Each of Inducement Stock Grant vested on the one-year anniversary of the employee's first day of employment with the Company is subject to the new employee's continued service relationship with the Company through such date and is subject to the terms and conditions of the applicable restricted stock agreement. As of December 31, 2023-2024, there were a total of 1,975,073 shares of Imunon common stock reserved for issuance under the 2018 Plan, which were comprised of 768-1, 731-555, 073 shares of Imunon common stock subject to equity awards previously granted under the 2018 Plan and 2007 Plan and 1-420, 000 206, 342 shares of Imunon common stock available for future issuance under the 2018 Plan. As of December 31, 2023-2024, there are a total of 294-130, 751-500 shares of Imunon common stock subject to outstanding inducement awards. Total compensation cost related to stock

options and restricted stock awards was approximately \$ 0. ~~5 million and \$ 0.8 million and \$ 2.7 million~~ during ~~2024 and 2023 and 2022~~, respectively. Of these amounts, \$ 0. ~~2.3 million and \$ 0.92 million~~ were charged to research and development expenses during ~~2024 and 2023 and 2022~~, respectively, and \$ 0. ~~2 million and \$ 0.6 million and \$ 1.8 million~~ were charged to general and administrative expenses during ~~2024 and 2023 and 2022~~, respectively. F- ~~24-23~~ A summary of stock option awards as of December 31, ~~2023-2024~~ and changes during the two- year period ended December 31, ~~2023-2024~~ is presented below: SUMMARY OF STOCK OPTIONSAwards Number Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at January 1, ~~2022-2023~~ ~~441, 425 \$ 38.50~~ Options granted ~~716, 156 \$ 2.72~~ Options canceled or expired (~~397, 361~~) \$ ~~39.06~~ Outstanding at December 31, ~~2022-760, 220 \$ 4.55~~ Options granted ~~432, 500 \$ 1.23~~ Options canceled or expired (~~129, 238~~) \$ ~~9.37~~ Outstanding at December 31, ~~2023~~ 1, 063, 482 \$ ~~2.61~~ Options granted ~~1, 051, 835 \$ 1.12~~ Options canceled or expired (~~469, 444~~) \$ ~~1.58~~ Outstanding at December 31, ~~2024~~ 1, 645, 873 \$ ~~1.95~~ 8.8 \$ - ~~13, 476~~ Exercisable at December 31, ~~2023-2024~~ ~~453-907, 766-723~~ \$ ~~2.58~~ 8.3 - ~~64.8-5.5~~ - ~~7, 299~~ A summary of the status of the Company's non- vested restricted stock awards as of December 31, ~~2023-2024~~ and changes during the two- year period ended December 31, ~~2023-2024~~ is presented below: SUMMARY OF NON-VESTED RESTRICTED STOCK AWARDSRestricted Stock Number Outstanding Weighted Average Grant Date Fair Value Non- vested stock awards outstanding at January 1, ~~2022-2023~~ ~~1, 481 \$ 12.36~~ Granted ~~69, 650 \$ 1.92~~ Granted ~~22, 100 \$ 0.92~~ Vested and issued (~~59, 450~~) \$ ~~1, 381, 91~~ Forfeited (~~200~~) \$ ~~4.4~~ ~~60.04~~ Forfeited (~~100~~) \$ ~~9.45~~ Non- vested stock awards outstanding at December 31, ~~2022-2023~~ ~~69-32, 650-100~~ \$ ~~1.92-23~~ Granted ~~22-39, 400-700~~ \$ ~~0.92-99~~ Vested and issued (~~59-12, 450-100~~) \$ ~~1.91-84~~ Forfeited (~~200-20, 000~~) \$ ~~4.0-60.88~~ Non- vested stock awards outstanding at December 31, ~~2023-2024~~ ~~32-39, 400-700~~ \$ ~~1.0-23.99~~ A summary of stock options outstanding at December 31, ~~2023-2024~~ by price range is as follows: SUMMARY OF STOCK OPTIONS OUTSTANDING Options Outstanding Options Exercisable Range of Exercise Prices Number Weighted Average Remaining Contractual Term (in years) Weighted Average Exercise Price Number Weighted Average Remaining Contractual Term (in years) Weighted Average Exercise Price Up to \$ 1. ~~95-689-501, 413-250, 252-9.3~~ \$ ~~1.15-513, 433~~ 9.1 \$ ~~1.13-74-315, 867-8.8~~ \$ ~~1.71-51 to \$ 4.50-207, 345-7.5~~ \$ ~~1.96 to \$ 93-206, 289-7.5~~ \$ ~~10-1, 00-347, 975-8.4~~ \$ ~~3.27-113, 936-93~~ Above ~~8.2~~ \$ ~~4.63~~ Above ~~51-188, 276-6.9~~ \$ ~~10-7, 28-188, 01-001~~ ~~26, 394-6.3-9~~ \$ ~~23-7, 27-69-23, 963-6.1~~ \$ ~~645, 873-907, 723~~ F- ~~24-29~~ 1, 063, 482-453, 766 F- ~~25~~ The fair values of stock options granted were estimated at the date of grant using the Black- Scholes option pricing model. The Black- Scholes model was originally developed for use in estimating the fair value of traded options, which have different characteristics from Imunon's stock options. The model is also sensitive to changes in assumptions, which can materially affect the fair value estimate. The Company used the following assumptions for determining the fair value of options granted under the Black- Scholes option pricing model: SCHEDULE OF ASSUMPTIONS USED TO DETERMINE FAIR VALUE OF OPTIONS GRANTED Year Ended December 31, ~~2024-2023~~ 2022-Risk- free interest rate 3. ~~72 % to 4.50 %~~ 3.39 % to 4.81 % ~~1.74 % to 3.97 %~~ Expected volatility ~~101.7 % to 115.8 %~~ 100.0 % to 113.6 % ~~100.0 % to 113.9 %~~ Expected life (in years) 7.5 to 10 ~~-0.7.5 to 10~~ -0-Expected dividend yield 0.0 % 0.0 % Expected volatilities utilized in the model are based on historical volatility of the Company's stock price. As of December 31, ~~2023-2024~~, there was \$ 0. ~~4.5~~ million of total unrecognized compensation cost related to non- vested stock- based compensation arrangements. That cost is expected to be recognized over a weighted- average period of 1. ~~8-4~~ years. ~~13-12~~ WARRANTS EARN- OUT MILESTONE LIABILITY-The Company accounts total aggregate purchase price for warrants the EGEN Acquisition included potential future earn- out payments contingent upon achievement of certain milestones. The difference between the aggregate \$ ~~30.4~~ million in future earn- out payments and the \$ ~~13.9~~ million included in the fair value of the acquisition consideration at June 20, 2014 was ~~as either equity- classified or liability- classified instruments based on an assessment of the warrant's specific terms and applicable authoritative guidance in FASB ASC 480, Distinguishing Liabilities from Equity ("ASC 480"), and ASC 815, Derivatives and Hedging ("ASC 815").~~ The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company's risk- adjusted own common stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each milestone (10% subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as 67%) and utilizing a discount rate based component of additional paid- in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date estimated time to achieve the milestone (1.5 to 2.5 years). The earn- out milestone liability is fair valued at the end of issuance, and each balance sheet date thereafter quarter and any change in their value will be recognized in the Financial Statements. On March 28, 2019, the Company and EGWU, Inc., entered into the Amended Asset Purchase Agreement. Pursuant to the Amended Asset Purchase Agreement, payment of the earnout milestone liability related to the Ovarian Cancer Indication of \$ ~~12.4~~ million has been modified. The Company had has analyzed the Warrants issued in the July 2024 Offering and determined the they option are considered to make the payment upon achievement be freestanding instruments and do not exhibit any of the milestones characteristics in ASC 480 and therefore are not classified as follows: a) \$ 7.0 million in cash within 10 business days of achieving the milestone; or b) \$ ~~12.4~~ million in cash, common stock of the Company, or a combination of either, within one year of achieving the milestone. At December 31, 2022, the Company wrote off the earn- out milestone liability liabilities under ASC 480. The Warrants meet all of the requirements for equity classification under ASC 815 and therefore are classified as equity a result of the requirements not being achieved and recognized a non- cash gain of \$ ~~5.4~~ million during 2022 as a result of the change in the fair value of the earn- out milestone liability. The Company fair value of the milestone liability is zero at December 31, 2023. The following is a summary of the changes in the earn- out milestone liability for 2022: SCHEDULE OF CHANGES IN EARN- OUT MILESTONE LIABILITY Balance at January 1, 2022 \$ ~~5, 396, 000~~ Non- cash gain from the adjustment for the change in fair value included in 2022 net loss (~~5, 396, 000~~) Balance at December 31, 2022 \$ ~~F- 26-14~~ WARRANTS Following is a summary of all warrant activity for the two years ended December 31, ~~2023-2024~~: SUMMARY OF WARRANT ACTIVITY Warrants Number of Warrants Issued Weighted Average Exercise Price Warrants outstanding at January 1, ~~2022-2023~~ ~~175-168, 792-519~~ \$ ~~20-19, 96-78~~ Warrants issued during 2024 ~~5, 000, 000-2, 000~~ Warrants expired during ~~2022-2023~~ (~~7-8, 273-459~~) \$ ~~48-37, 30-29~~ Warrants outstanding and exercisable at December 31, ~~2022-2023~~ ~~168-160, 519-060~~ \$ ~~19-18, 78-86~~ Warrants issued during 2024 ~~5, 000, 000-2, 000~~ Warrants expired during ~~2023-2024~~ (~~8-5, 459-000~~) \$ ~~37-11, 29-85~~ Warrants outstanding and exercisable at December 31, ~~2023-2024~~ ~~160-5, 155, 060~~ \$ ~~18-2, 86-51~~ Aggregate intrinsic value of outstanding warrants at December 31, ~~2023-2024~~ \$ ~~-~~ Weighted average remaining contractual terms (years) ~~2-5, 2-15-0~~ F- ~~25-13~~ IMUNON EMPLOYEE BENEFIT PLANS Imunon maintains a defined- contribution plan under Section 401 (k) of the Code. The plan covers substantially all employees over the age of twenty- one. Participating employees may defer a portion of their pretax earnings, up to the IRS annual contribution limit. The Company makes a matching contribution up to a maximum of 3 % of an employee's annual salary. The Company's total matching contributions for the year ended December 31, ~~2024 and 2023 and 2022~~ were \$ ~~62, 000 and \$ 142, 000 and \$ 117, 000~~, respectively. ~~16-14~~ LEASES Lawrenceville, New Jersey Lease In August 2023, the Company renewed its Lawrenceville office lease for a 24- month agreement for 9, 850 square feet with monthly rent payments of approximately \$ 22, 983 to \$ 23, 394. Huntsville, Alabama Lease The following is a table of the lease payments and maturity of the Company's operating lease liabilities as of December 31, ~~2023-2024~~: SCHEDULE OF LEASE PAYMENTS AND MATURITY OF OPERATING LEASE LIABILITIES For the year ending December 31, ~~2024-2025~~ \$ ~~626, 323-2025-543, 009-2026-362, 976-2027-370, 236-2028 and Thereafter thereafter~~ ~~30, 903-904~~ Subtotal future lease payments 1, ~~933-307, 447-124~~ Less imputed interest (~~308-167, 733-831~~) Total lease liabilities \$ ~~1, 624-139, 714-293~~ Weighted average remaining life ~~3-2, 5-7~~ years Weighted average discount rate 9.98 % The discount rate used was the Company's incremental borrowing rate, which is 9.98 %, as the Company could not determine the rate implicit in the lease. For 2024, operating lease expense was \$ 652, 166 and cash paid for operating leases included in operating cash flows was \$ 659, 646. For 2023, operating lease expense was \$ 646, 633 and cash paid for operating leases included in operating cash flows was \$ 644, 593. For 2022, operating lease expense was \$ 587, 744 and cash paid for operating leases included in operating cash flows was \$ 601, 495. Amortization expense was approximately \$ 478, 000 and \$ 472, 000 and \$ 535, 000 for the years ended December 31, ~~2024 and 2023 and 2022~~, respectively. ~~15~~ F- ~~27-17~~ COMMITMENTS AND CONTINGENCIES ~~16~~ On October 29, 2020, a putative securities class action was filed against the Company and certain of its officers and directors (the "Spar Individual Defendants") in the U. S. District Court for the District of New Jersey, captioned Spar v. Celston Corporation, et al., Case No. 1:20- cv- 15228. The plaintiff alleged that the Company and Spar Individual Defendants made false and misleading statements regarding one of the Company's drug candidates, ThermoDox ®, and brought claims for damages under Section 10 (b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and Rule 10b- 5 promulgated thereunder against all defendants, and under Section 20 (a) of the Exchange Act against the Spar Individual Defendants. On February 6, 2023, the U. S. District Court granted a Motion to Dismiss filed by the Company and Spar Individual Defendants and granted the plaintiff leave to file an amended complaint within 30 days. The plaintiff did not file an amended complaint within the 30- day deadline. In September 2023, the U. S. District Court issued an Order for Dismissal without prejudice. ~~18~~ TECHNOLOGY DEVELOPMENT AND LICENSING AGREEMENTS On May 7, 2012, the Company entered into a long- term commercial supply agreement with Zhejiang Hisun Pharmaceutical Co. Ltd. ("Hisun") for the production of ThermoDox ® in mainland China, Hong Kong and Macau (the "China territory"). In accordance with the terms of the agreement, Hisun is responsible for providing all of the technical and regulatory support services, including the costs of all technical transfer, registration and bioequivalence studies, technical transfer costs, Imunon consultative support costs and the purchase of any necessary equipment and additional facility costs necessary to support capacity requirements for the manufacture

of ThermoDox®. Imunon is obligated to repay Hisun for the aggregate amount of these development costs and fees commencing on the successful completion of three registration batches of ThermoDox®. Hisun is also obligated to meet certain performance requirements under the agreement. The agreement was initially limited to a percentage of the production requirements of ThermoDox® in the China territory with Hisun retaining an option for additional global supply after local regulatory approval in the China territory. In addition, the agreement provided that Hisun would collaborate with Imunon around the regulatory approval activities for ThermoDox® with the China State Food and Drug Administration. On January 18, 2013, the Company entered into a technology development contract with Hisun, pursuant to which Hisun paid Imunon a non-refundable research and development fee of \$ 5 million to support development of ThermoDox® in the China territory. Following the Company's announcement on January 31, 2013 that the HEAT study failed to meet its primary endpoint, Imunon and Hisun agreed that the Technology Development Contract entered into on January 18, 2013 would remain in effect while the parties continued to collaborate and evaluate the next steps in relation to ThermoDox®, which include the sub-group analysis of patients in the Phase III HEAT Study for the HCC clinical indication and other activities to further the development of ThermoDox® for the Greater China market. The \$ 5.0 million received as a non-refundable payment from Hisun in the first quarter 2013 was recorded to deferred revenue and was amortized over the 10-year term of the agreement, until such time as the parties would find a mutually acceptable path forward on the development of ThermoDox® based on findings of the ongoing post-study analysis of the HEAT study data. The Hisun agreement has expired.

19. RELATED PARTY TRANSACTION On November 16, 2022, the Company entered into a convertible note purchase agreement with Transomic Technologies, Inc. (" Transomic ") whereby the Company purchased \$ 375,000 of convertible notes secured by certain assets held by Transomic and warrants. Imunon purchased product products from Transomic for research and development purposes – primarily delivery vectors for its vaccine program. As a result of this investment in Transomic, Imunon's executive chairman, Mr. Michael Tardugno, was appointed to the Board of Directors of Transomic. The Company disclosed the notes receivable as a related party transaction. In December 2023, Transomic filed a formal certificate of dissolution of the company resulting in a complete write-off of the convertible note and related warrants.

20-17. SUBSEQUENT EVENTS On March 6, 2024, the Company has evaluated its subsequent events from December 31, 2023, through the date these condensed consolidated financial statements were issued. Pharm determining all subsequent events have been disclosed.

D-F- 26 EXHIBIT 4. 7 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, informed AS AMENDED DESCRIPTION OF CAPITAL STOCK The following summary of the general terms and provisions of the capital stock of Imunon, Inc. (" Imunon ", " we ", " our ") does not purport to be complete and is subject to, and qualified in its entirety by, reference to our Amended and Restated Certificate of Incorporation (" certificate of incorporation ") our Amended and Restated Bylaws (" bylaws ") each of which is incorporated by reference as an exhibit to our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, and applicable provisions of the Delaware General Corporation Law (the " DGCL "). Our common stock, par value \$ 0.01 per share is registered pursuant to Section 12 (b) of the Securities and Exchange Act of 1934 and trades on the Nasdaq Capital Market under the symbol IMNN. The summaries below do not purport to be complete statements of the relevant provisions of the certificate of incorporation, the bylaws or the DGCL.

Authorized Capital Stock Our authorized capital stock consists of 112,500,000 shares of common stock, par value \$ 0.01 per share and 100,000 shares of preferred stock, par value \$ 0.01 per share, all of which preferred stock is undesignated. Common Stock Holders of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders and do not have cumulative voting rights. Subject to any preferential rights of any outstanding preferred stock, holders of common stock are entitled to receive ratably such dividends, if any, as may be declared from time to time by our board of directors out of funds legally available therefor. In the event of a dissolution, liquidation or winding-up of the Company, holders of common stock are entitled to share ratably in all assets remaining after payment of liabilities and any preferential rights of any outstanding preferred stock. Holders of common stock have no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to our common stock. All outstanding shares of common stock are fully paid and non-assessable. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock which may be designated and issued in the future. Our Common Stock is listed on the Nasdaq Capital Market under the symbol " IMNN. " Transfer Agent and Registrar The transfer agent and registrar for our Common Stock is Equiniti Trust Company, LLC. Equiniti Trust Company, LLC is located at 6201 15th Avenue, Brooklyn, NY 11219. Their telephone number is (888) 999-0032. Preferred Stock Undesignated Preferred Stock Pursuant to our certificate of incorporation, our board of directors has the authority, without further action by the stockholders (unless such stockholder action is required by applicable law or NASDAQ rules), to designate and issue shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the designations, powers (including voting), privileges, preferences and relative participating, optional or other rights, if any, of the shares of each such series and the qualifications, limitations or restrictions thereof and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. We will fix the designations, powers (including voting), privileges, preferences and relative participating, optional or other rights, if any, of the preferred stock of each series, as well as the qualifications, limitations or restrictions thereof, in the certificate of designation relating to that series. The certificate of designation will describe the terms of the series of preferred stock. This description will include: • the title and stated value; • the number of shares we are offering; • the liquidation preference per share; • the purchase price; • the dividend rate, period and payment date and method of calculation for dividends; • whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate; • the procedures for any auction or remarketing, if any; • the provisions for a sinking fund, if any; • the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase rights; • any listing of the preferred stock on any securities exchange or market; • whether the preferred stock will be convertible into or exchangeable for other securities and, if applicable, the conversion price, or how it will be calculated, and the conversion period; • voting rights, if any, of the preferred stock; • preemptive rights, if any; • restrictions on transfer, sale or other assignment, if any; • liability as to further calls or to assessment by the Company, if any; • a discussion of any material United States federal income tax considerations applicable to the preferred stock; • the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; • any limitations on the issuance of any class or series of preferred stock ranking senior to or on a parity with the series of preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; and • any other specific terms, preferences, rights or limitations of, or restrictions on, the preferred stock. The DGCL provides that the holders of preferred stock will have the right to vote separately as a class or, in some cases, as a series on an amendment to our certificate of incorporation if the amendment would change the par value or, unless our certificate of incorporation provides otherwise, the number of authorized shares of the class or the powers, preferences or special rights of the class or series so as to adversely affect the class or series, as the case may be. This right is in addition to any voting rights that may be provided in the applicable certificate of designation. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our common stock or other securities. Preferred stock could be issued quickly with terms designed to delay or prevent a change in control of our Company or make removal of management more difficult. Additionally, the issuance of preferred stock may have the effect of decreasing the market price of our common stock. Anti-Takeover Considerations and Special Provisions of Our Certificate of Incorporation, Our Bylaws and the Delaware General Corporation Law Certificate of Incorporation and Bylaws A number of provisions of our certificate of incorporation and bylaws concern matters of corporate governance and the rights of our stockholders. Provisions that grant our board of directors the ability to issue shares of preferred stock and to set the voting rights, preferences and other terms thereof may discourage takeover attempts that are not first approved by our board of directors, including takeovers that may be considered by some stockholders to be in their best interests, such as those attempts that might result in a premium over the market price for the shares held by stockholders. Certain provisions could delay or impede the removal of incumbent directors even if such removal would be beneficial to our stockholders, such as the classification of our board of directors and the lack of cumulative voting. Since our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. These provisions may have the effect of deterring hostile takeovers or delaying changes in our control or in our management. These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and in the policies they implement and to discourage certain types of transactions that may involve an actual or threatened change of our control. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal. The provisions also are intended to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and, as a consequence, they also may inhibit fluctuations in the market price of our shares that could result from actual or rumored takeover attempts. These provisions also could discourage or make more difficult a merger, tender offer or proxy contest, even if they could be favorable to the interests of stockholders, and could potentially depress the market price of our common stock. Our board of directors believes that these provisions are appropriate to protect our interests and the interests of our stockholders. Classification of Board ; No Cumulative Voting. Our certificate of incorporation and bylaws provide for our board of directors to be divided into three classes, with staggered three-

year terms. Only one class of directors is elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Because our stockholders do not have cumulative voting rights, our stockholders representing a majority of the shares of common stock outstanding will be able to elect all of our directors due to be elected at each annual meeting of our stockholders. Meetings of and Actions by Stockholders. Our bylaws provide that annual meetings of our stockholders may take place at the time and place designated by our board of directors. A special meeting of our stockholders may be called at any time by our board of directors, the chairman of our board of directors or the president. Our bylaws provide that (i) our board of directors can fix separate record dates for determining stockholders entitled to receive notice of a stockholder meeting and for determining stockholders entitled to vote at the meeting; (ii) we may hold a stockholder meeting by means of remote communications; (iii) any stockholder seeking to have the stockholders authorize or take corporate action by written consent shall, by written notice to the secretary of the Company, request that the board fix a record date and the board shall adopt a resolution fixing the record date in all events within ten calendar days after a request is received; and (iv) a written consent of stockholders shall not be effective unless a written consent signed by a sufficient number of stockholders to take such action is received by us within 60 calendar days of the earliest dated written consent received. Advance Notice Requirements for Stockholder Proposals and Directors. Director Nominations. Our bylaws provide that stockholders seeking to bring business before an annual meeting of her resignation from her position stockholders or to nominate candidates for election as President directors at and an annual meeting Chief Executive Officer of stockholders must provide timely notice in writing the Company and from the Board, effective as of March 15, 2024. Dr. Le Goff To be timely, a stockholder's resignation notice must be delivered to, or mailed and received by, the secretary of the Company at our principal executive offices not later than the result close of business any disagreement with the Company on the 90th calendar day any matter relating to its operations, policies or nor earlier than the close of business on the 120th calendar day in advance of the date specified in practices. The Company is conducting a search for Dr. Le Goff's successor as Chief Executive Officer. Michael H. Tardugno, the Company's Executive Chairman proxy statement released to stockholders in connection with the previous year's annual meeting of stockholders. If the date of the annual meeting is more than 30 calendar days before or after such anniversary date, notice by the stockholder to be timely must be so not earlier than the close of business on the 120th calendar day in advance of such date of annual meeting and not later than the close of business on the later of the 90th calendar day in advance of such date of annual meeting or the tenth calendar day following the date on which public announcement of the date of the meeting is made. In no event shall the public announcement of and an Chief Executive Officer prior to Dr adjournment or postponement of an annual meeting commence a new time period (or extend any time period) for the giving of an advance notice by any stockholder. Le Goff Any stockholder that proposes director nominations or other business must be a stockholder of record at the time the advance notice is delivered by such stockholder to us and entitled to vote at the meeting. Our bylaws also specify requirements as to the form and content of a stockholder's notice. These provisions may preclude stockholders from bringing matters before an annual meeting of stockholders or from making nominations for the election of directors at an annual meeting of stockholders. Unless otherwise required by law, any director nomination or other business shall not be made or transacted if the stockholder (or a qualified representative of the stockholder) does not appear at the meeting to present the director nominee or other proposed business. Filling of Board Vacancies. Our certificate of incorporation and bylaws provide that the authorized size of our board of directors shall be determined by the board by board resolution from time to time and that our board of directors has assumed day the exclusive power to day leadership fill any vacancies and newly created directorships resulting from any increase in the authorized number of directors and the stockholders do not have the power to fill such vacancies. Vacancies in our board of directors and newly created directorships resulting from any increase in the authorized number of directors on our board of directors may be filled by a majority of the directors remaining in office, even though that number may be less than a quorum of our board of directors, or by a sole remaining director. A director so elected to fill a vacancy shall serve for the remaining term of the predecessor the he Company or she replaced and until such his or her successor is named and has qualified, or until his or her earlier resignation, removal or death. Amendment of the Certificate of Incorporation. Our certificate of incorporation may be amended, altered, changed or repealed at a meeting of our stockholders entitled to vote thereon by the affirmative vote of a majority of the outstanding stock entitled to vote thereon and a majority of the outstanding stock of each class entitled to vote thereon as a class, in the manner prescribed by the DGCL. Amendment of the Bylaws. Our bylaws may be amended or repealed, or new bylaws may be adopted, by either our board of directors or the affirmative vote of at least 66 2 / 3 percent of the voting power of our outstanding shares of capital stock. Section 203 of the Delaware General Corporation Law We are subject to Section 203 of the DGCL, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became and an interested stockholder, with the following exceptions: • before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder; • upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85 percent of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (i) by persons who are directors and also officers and (ii) pursuant to employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will continue to be tendered in a tender or exchange offer; and • on or after such date, the business combination his is role directing Company strategy approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2 / 3 percent of the outstanding voting stock that is not owned by the interested stockholder. F-28 In general, Section 203 defines a business combination to include the following: • any merger or consolidation involving the corporation and the interested stockholder; • any sale, lease, transfer, pledge or other disposition of ten percent or more of the assets of the corporation to or with the interested stockholder; • subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; • any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; and • the receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges or other financial benefits by or through the corporation. In general, Section 203 of the DGCL defines an "interested stockholder" as an entity or person who, together with the entity's or person's affiliates and associates, beneficially owns, or is an affiliate of the corporation and within three years prior to the time of determination of interested stockholder status did own, 15 percent or more of the outstanding voting stock of the corporation. A Delaware corporation may "opt out" of these provisions with an express provision in its certificate of incorporation. We have not opted out of these provisions, which may as a result, discourage or prevent mergers or other takeover or change of control attempts of us. Exhibit 21. 1 Subsidiaries of Imunon, Inc. Name Jurisdiction of Incorporation CLSN Laboratories, Inc. Delaware Exhibit 23. 1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements of Imunon, Inc. on Form S- 1 (333- 221543, 333- 219414, 333- 217156, 333- 214353 and 333- 234603 and 333- 281834), Form S- 3 (Nos. 333- 174960, 333- 183286, 333- 198786, 333- 193936, 333- 205608, 333- 206789 and 333- 227236, 333- 240271, 333- 249420 and 333- 279425) and on Form S- 8 (Nos. 33 139784, 333- 145680, 333- 183288, 333- 207864 and 333- 281833) of Imunon, Inc. of our report dated March February 27, 2024 2025 (which includes an explanatory paragraph relating to the Imunon, Inc.'s ability to continue as a going concern), relating to the consolidated financial statements as of and for the years ended December 31, 2024 and 2023 and 2022, which appear in this Form 10- K. / s / WithumSmith Brown, PC East Brunswick, New Jersey March 27 February 26, 2024 2025 Exhibit 31. 1 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECURITIES EXCHANGE ACT OF 1934 RULES 13a- 14 (a) AND 15d- 14 (a) AS ADOPTED PURSUANT TO § 302 OF THE SARBANES- OXLEY ACT OF 2002 I, Michael H. Tardugno- Stacy Lindborg, PhD, certify that: 1. I have reviewed this Annual Report of Imunon, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a- 15 (e) and 15d- 15 (e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a- 15 (f) and 15d- 15 (f)) for the Registrant and have: (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c) Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d) Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the registrant's most

recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and 5. The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's Board of Directors (or persons performing the equivalent functions): (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting. Date: **March 28 February 27, 2024 2025** / s/ **Michael H. Tardugno Michael H. Lindborg, Ph. Tardugno Chairman of the Board Exhibit D. Stacy R. Lindborg, Ph. D. President and Chief Executive Officer Exhibit 31. 2 CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO I. David Gaiero Jeffrey W. Church**, certify that: (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c) Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d) Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and 5. The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent functions): Date: **March 28 February 27, 2024 2025** / s/ **David Gaiero David Gaiero Jeffrey W. Church Jeffrey W. Church Executive Vice President and Chief Financial Officer Exhibit 32. 1 PURSUANT TO 18 UNITED STATES CODE § 1350 § 906 OF THE SARBANES- OXLEY ACT OF 2002** In connection with the Annual Report of Imunon, Inc. (the "Company") for the year ended December 31, **2023 2024**, as filed with the Securities and Exchange Commission on or about **March 28 February 27, 2024 2025** (the "Report"), I, **Michael H. Tardugno Stacy Lindborg, Ph.D.** President and Chief Executive Officer of the Company, certify, pursuant to 18 U. S. C. § 1350, as adopted pursuant to § 906 of the Sarbanes- Oxley Act of 2002, that, to my knowledge: 1. The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934, as amended; and 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. This certification accompanies each Report pursuant to § 906 of the Sarbanes- Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes- Oxley Act of 2002, be deemed filed by the Company for purposes of § 18 of the Securities Exchange Act of 1934, as amended. A signed original of this written statement required by § 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. Exhibit 32. 2 In connection with the Annual Report of Imunon, Inc. (the "Company") for the year ended December 31, **2023 2024**, as filed with the Securities and Exchange Commission on or about **February 27 March Date: March 28, 2024 2025** (the "Report"), I, **David Gaiero Jeffrey W. Church. Executive Vice President and Chief Financial Officer** of the Company, certify, pursuant to 18 U. S. C. § 1350, as adopted pursuant to § 906 of the Sarbanes- Oxley Act of 2002, that, to my knowledge: **Exhibit Imunon, Inc. Executive Officer Incentive Compensation Recovery Policy I. Purpose The Board of Directors (the "Board") of Imunon, Inc., a Delaware corporation (the "Company"), has adopted this policy (this "Policy") which requires the recovery of certain executive compensation in the event that the Company is required to prepare an Accounting Restatement (as defined below). References herein to the Company also include all of its consolidated direct and indirect subsidiaries. This Policy is designed to comply with Section 10D of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), Rule 10D-1 thereunder, and The Nasdaq Stock Market ("Nasdaq") Listing Rule 5608 ("Rule 5608") and will be interpreted and applied accordingly. II. Administration This Policy will be administered by the Compensation Committee of the Board (the "Committee"). The Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy. Any determinations made by the Committee will be final and binding on all affected individuals. III. Covered Persons This Policy applies to the Company's current and former executive officers, as determined pursuant to Rule 16a-1 (f) promulgated under the Exchange Act and including executive officers identified under Item 401 (b) of Regulation S- K ("Executive Officers," and together with any former Executive Officer, the "Covered Persons"). IV. Recoupment upon an Accounting Restatement If the Company is required to prepare an Accounting Restatement, the Company will recover reasonably promptly all Erroneously Awarded Compensation from each Covered Person, unless the Committee determines in accordance with Section VI below that such recovery is impracticable. For purposes of the foregoing: • "Accounting Restatement" means an accounting restatement of any of the Company's financial statements due to the Company's material noncompliance with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or to correct an error that is not material to previously issued financial statements, but would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period, within the meaning of Rule 10D-1 and Rule 5608. For the avoidance of doubt, an Accounting Restatement will not be deemed to occur in the event of a restatement of the Company's financial statements due to an out- of- period adjustment or due to a retrospective (i) application of a change in accounting principles; (ii) revision to reportable segment information due to a change in the structure of the Company's internal organization; (iii) reclassification due to a discontinued operation; (iv) application of a change in reporting entity, such as from a reorganization of entities under common control; or (v) revision for stock splits, reverse stock splits, stock dividends, or other changes in capital structure. • "Covered Incentive Compensation" means Incentive Compensation Received on or after October 2, 2023 by a person: (i) after beginning service as an Executive Officer, (ii) who served as an Executive Officer at any time during the performance period for that Incentive Compensation, and (iii) while the Company has a class of securities listed on a national securities exchange or a national securities association, and (iv) during the three completed fiscal years immediately preceding the date that the Company is required to prepare the Accounting Restatement (or such longer period as required under Rule 5608 in the event the Company changes its fiscal year). The date that the Company is required to prepare the Accounting Restatement will be the earlier of (x) the date the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes or reasonably should have concluded that the Accounting Restatement is required, and (y) the date a court, regulator or other authorized body directs the Company to prepare the Accounting Restatement. • "Erroneously Awarded Compensation" means the amount of Covered Incentive Compensation that was Received by each Covered Person in excess of the Covered Incentive Compensation that would have been Received by the Covered Person had such Covered Incentive Compensation been determined based on the restated Financial Reporting Measure following an Accounting Restatement, computed without regard to taxes paid. For this purpose, if the amount of Covered Incentive Compensation that is Received by a Covered Person was based on the Company's stock price or total shareholder return and is not subject to mathematical recalculation directly from the Accounting Restatement, the amount to be recovered as Erroneously Awarded Compensation shall be based on a reasonable estimate of the effect of the Accounting Restatement on the Financial Reporting Measure upon which the Covered Incentive Compensation was Received. The Company's Chief Financial Officer shall, on behalf of the Committee, obtain and maintain all documentation of the determination of any such reasonable estimate and provide such documentation to Nasdaq when required. • "Financial Reporting Measure" means (i) any measure that is determined and presented in accordance with the accounting principles used in preparing the Company's financial statements and any measure that is derived wholly or in part from any such measure, and (ii) the Company's stock price and the total stockholder return of the Company. A measure, however, need not be presented within the financial statements or included in a filing with the U. S. Securities and Exchange Commission ("SEC") to constitute a Financial Reporting Measure. • "Incentive Compensation" means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure. For the avoidance of doubt, Incentive Compensation shall also be deemed to include any amounts which were determined based on (or were otherwise calculated by reference to) Incentive Compensation (including, without limitation, any amounts under any long- term disability, life insurance or supplemental retirement plan or any notional account that is based on Incentive Compensation, as well as any earnings accrued thereon). • "Received" Incentive Compensation is deemed "Received" in the Company's fiscal period during which the Financial Reporting Measure specified in such Incentive Compensation is attained, even if the payment or grant of Incentive Compensation occurs after the end of the period. Recoupment of Erroneously Awarded Compensation pursuant to this Policy is made on a "no fault" basis, without regard to whether any misconduct occurred or whether any Covered Person has responsibility for the noncompliance that resulted in the Accounting Restatement. V. Method of Recoupment The Committee will determine, in its sole discretion, the method for recouping Erroneously Awarded Compensation hereunder, which may include, without limitation, any of the following: • Requiring reimbursement of cash Incentive Compensation previously paid; • Seeking recovery of any gain realized on or since the vesting, exercise, settlement, sale, transfer, or other disposition of any equity- based awards; • Offsetting the recouped amount from any compensation otherwise owed by the Company to the Covered Person (including, without limitation, any severance otherwise payable by the Company to the Covered Person); • Making a deduction from the Covered Person's salary; • Requiring the Covered Person to transfer back to the Company any shares he or she received pursuant to an equity award; • Surrendering to the Company any shares**

being held pursuant to stock ownership guidelines; ● Cancelling, or reducing the number of shares subject to, or the value of, outstanding vested or unvested equity awards; and / or ● Taking any other remedial and recovery action permitted by law, as determined by the Committee. The Committee will consider Section 409A of the U. S. Internal Revenue Code of 1986, as amended, prior to offsetting recouped amounts against future payments of deferred compensation. In addition, the Committee may, in its sole discretion, determine whether and to what extent additional action is appropriate to address the circumstances surrounding the noncompliance so as to minimize the likelihood of any recurrence. VI. Impracticability The Committee will recover any Erroneously Awarded Compensation in accordance with this Policy unless the Committee determines that such recovery would be impracticable because (i) the direct expense paid to a third party to assist in enforcing the Policy would exceed the amount to be recovered, (ii) recovery would violate an applicable home country law adopted prior to November 28, 2022, or (iii) recovery would likely cause an otherwise tax-qualified, broad-based retirement plan of the Company to fail to meet the requirements of 26 U. S. C. 401 (a) (13) or 26 U. S. C. 411 (a) and regulations thereunder. Before concluding that it would be impracticable to recover any Erroneously Awarded Compensation based on the expense of enforcement, the Company shall make a reasonable attempt to recover such Erroneously Awarded Compensation, and the Company's Chief Financial Officer, on behalf of the Committee, shall document such reasonable attempt (s) to recover and provide that documentation to the Nasdaq when required. Before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on violation of law, the Committee shall engage legal counsel experienced and qualified to practice law in the applicable jurisdiction (if such counsel is acceptable to the Nasdaq) to render an opinion that recovery would result in a violation of law and shall provide such opinion to the Nasdaq. The Company shall provide funding for the fees and expenses of such legal counsel as approved by the Committee. VII. No Indemnification or Insurance Neither the Company nor any of its subsidiaries or affiliates shall indemnify any Covered Person against the loss of any Erroneously Awarded Compensation. Further, neither the Company nor any of its subsidiaries or affiliates shall pay or reimburse any Covered Person for any insurance policy entered into by a Covered Person that provides for full or partial coverage of any recoupment obligation under this Policy. VIII. Amendment; Termination The Board or the Committee may amend this Policy from time to time in its discretion in any manner consistent with applicable law and regulation. The Board or Committee may terminate this Policy at any time when the Company does not have a class of securities listed on a national securities exchange or a national securities association. IX. Other Recoupment Rights The Board intends that this Policy will be applied to the fullest extent of the law. Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company (a) under applicable law, regulation or rule, (b) pursuant to the terms of, any similar policy or recoupment provision in any employment agreement, severance agreement, equity award agreement, bonus plan, or similar agreement or plan, and (c) any other legal remedies available to the Company. Further, the provisions of this Policy are in addition to (and not in lieu of) any rights to repayment the Company may have under Section 304 of the Sarbanes-Oxley Act of 2002. X. Successors This Policy shall be binding and enforceable against all Covered Persons and their beneficiaries, heirs, executors, administrators, or other legal representatives. XI. Disclosure The circumstances of any recoupment pursuant to this Policy will be publicly disclosed where required by Rule 10D-1, Item 402 of Regulation S-K and Rule 5608. In accordance with Rule 10D-1, the Policy shall be filed with the SEC as an exhibit to the Company's Form 10-K, as provided in Item 601 (b) of Regulation S-K. XII. Change of Listing In the event that the Company lists its securities on any national securities exchange or national securities association other than the Nasdaq, all references to Nasdaq in this Policy shall mean each national securities exchange or national securities association upon which the Company has a class of securities then listed. v3.24.1 Cover USD (\$) \$ in Millions 12 Months Ended Dec. 31, 2023 Mar. 26, 2024 Jun. 30, 2023 Cover [Abstract] Document Type 10-K Amendment Flag false Document Annual Report true Document Transition Report false Document Period End Date Dec. 31, 2023 Document Fiscal Period Focus FY Document Fiscal Year Focus Current Fiscal Year End Date 12-31 Entity File Number 001-15911 Entity Registrant Name IMUNON, INC. Entity Central Index Key Entity Tax Identification Number 52-1256615 Entity Incorporation, State or Country Code DE Entity Address, Address Line One LENOX DRIVE Entity Address, Address Line Two SUITE 100 Entity Address, City or Town LAWRENCEVILLE Entity Address, State or Province NJ Entity Address, Postal Zip Code City Area Code (609) Local Phone Number 896-9100 Title of 12 (b) Security Common Stock, Par Value \$ 0.01 Per Share Trading Symbol IMNN Security Exchange Name NASDAQ Entity Well-known Seasoned Issuer No Entity Voluntary Filers No Entity Current Reporting Status Yes Entity Interactive Data Current Yes Entity Filer Category Non-accelerated Filer Entity Small Business true Entity Emerging Growth Company false Entity Shell Company false Entity Public Float \$ 11.9 Entity Common Stock, Shares Outstanding 9,399,789 Documents Incorporated by Reference None ICFR Auditor Attestation Flag false Document Financial Statement Error Correction [Flag] false Auditor Name WithumSmithBrown, PC Auditor Location East Brunswick, New Jersey Auditor Firm ID X-Definition Boolean flag that is true when the XBRL content amends previously-filed or accepted submission. References No definition available. Details Name: dei_AmendmentFlag Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: durationX-Definition PCAOB issued Audit Firm Identifier References Reference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Form 10-K-Number 249-Section 310 Reference 2: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Form 20-F-Number 249-Section 220-Subsection f Reference 3: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Form 40-F-Number 249-Section 240-Subsection f Details Name: dei_Auditor Firm ID Namespace Prefix: dei_Data Type: dei:nonemptySequenceNumberItem Type Balance Type: na Period Type: durationX-References Reference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Form 10-K-Number 249-Section 310 Reference 2: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Form 20-F-Number 249-Section 220-Subsection f Reference 3: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Form 40-F-Number 249-Section 240-Subsection f Details Name: dei_Auditor Location Namespace Prefix: dei_Data Type: dei:internationalNameItem Type Balance Type: na Period Type: durationX-References Reference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Form 10-K-Number 249-Section 310 Reference 2: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Form 20-F-Number 249-Section 220-Subsection f Reference 3: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Form 40-F-Number 249-Section 240-Subsection f Details Name: dei_CityAreaCode Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: durationX-Definition Cover page. References No definition available. Details Name: dei_CoverAbstract Namespace Prefix: dei_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-Definition End date of current fiscal year in the format--MM-DD. References No definition available. Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: durationX-Definition Boolean flag that is true only for a form used as an annual report. References Reference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Form 10-K-Number 249-Section 310 Reference 2: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Form 20-F-Number 249-Section 220-Subsection f Reference 3: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Form 40-F-Number 249-Section 240-Subsection f Details Name: dei_DocumentAnnualReport Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: durationX-Definition Indicates whether any of the financial statement period in the filing include a restatement due to error correction. References Reference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Regulation S-K-Number 229-Section 402-Subsection w Reference 2: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Form 10-K-Number 249-Section 310 Reference 3: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Form 20-F-Number 249-Section 220-Subsection f Reference 4: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Form 40-F-Number 249-Section 240-Subsection f Details Name: dei_DocumentFinStmntErrorCorrectionFlag Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: durationX-Definition Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. References No definition available. Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_Data Type: dei:fiscalPeriodItem Type Balance Type: na Period Type: durationX-Definition This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. References No definition available. Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_Data Type: xbrli:gYearItemType Balance Type: na Period Type: durationX-Definition For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. References No definition available. Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_Data Type: xbrli:dateTimeItemType Balance Type: na Period Type: durationX-Definition Boolean flag that is true only for a form used as a transition report. References Reference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Exchange Act-Number 240-Section 12-Subsection b-23 Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: durationX-Definition The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. References No definition available. Details Name: dei_DocumentType Namespace Prefix: dei_Data Type: dei:submissionTypeItem Type Balance Type: na Period Type: durationX-Definition Documents incorporated by reference. References Reference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Exchange Act-Number 240-Section 12-Subsection b-23 Details Name: dei_DocumentsIncorporatedByReferenceTextBlock Namespace Prefix: dei_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: durationX-

DefinitionAddress Line 1 such as Attn, Building Name, Street Name ReferencesNo definition available. Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: durationX-DefinitionAddress Line 2 such as Street or Suite number ReferencesNo definition available. Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: durationX-DefinitionName of the City or Town ReferencesNo definition available. Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: durationX-DefinitionCode for the postal or zip code ReferencesNo definition available. Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: durationX-DefinitionName of the state or province. ReferencesNo definition available. Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_Data Type: dei:stateOrProvinceCodeItemType Balance Type: na Period Type: durationX-DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameExchangeAct-Number240-Section12-Subsectionb-2> Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: durationX-DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class / interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. ReferencesNo definition available. Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instantX-DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports); and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. ReferencesNo definition available. Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_Data Type: dei:yesNoItemType Balance Type: na Period Type: durationX-DefinitionIndicate if registrant meets the emerging growth company criteria. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameExchangeAct-Number240-Section12-Subsectionb-2> Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: durationX-DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. ReferencesNo definition available. Details Name: dei_EntityFileNumber Namespace Prefix: dei_Data Type: dei:fileNumberItemType Balance Type: na Period Type: durationX-DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameExchangeAct-Number240-Section12-Subsectionb-2> Details Name: dei_EntityFilerCategory Namespace Prefix: dei_Data Type: dei:filerCategoryItemType Balance Type: na Period Type: durationX-DefinitionTwo-character EDGAR code representing the state or country of incorporation. ReferencesNo definition available. Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: durationX-DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameRegulationS-T-Number232-Section405> Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_Data Type: dei:yesNoItemType Balance Type: na Period Type: durationX-DefinitionThe aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter. ReferencesNo definition available. Details Name: dei_EntityPublicFloat Namespace Prefix: dei_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameExchangeAct-Number240-Section12-Subsectionb-2> Details Name: dei_EntityRegistrantName Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: durationX-DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameExchangeAct-Number240-Section12-Subsectionb-2> Details Name: dei_EntityShellCompany Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: durationX-DefinitionIndicates that the company is a Smaller Reporting Company (SRC). ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameExchangeAct-Number240-Section12-Subsectionb-2> Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: durationX-DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameExchangeAct-Number240-Section12-Subsectionb-2> Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_Data Type: dei:employerIdItemType Balance Type: na Period Type: durationX-DefinitionIndicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15 (d) of the Act. ReferencesNo definition available. Details Name: dei_EntityVoluntary Filers Namespace Prefix: dei_Data Type: dei:yesNoItemType Balance Type: na Period Type: durationX-DefinitionIndicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameSecuritiesAct-Number230-Section405> Details Name: dei_EntityWellKnownSeasonedIssuer Namespace Prefix: dei_Data Type: dei:yesNoItemType Balance Type: na Period Type: durationX-ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameForm10-K-Number249-Section310> Reference 2: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameForm20-F-Number249-Section220-Subsectionf> Details Name: dei_IcfrAuditorAttestationFlag Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: durationX-DefinitionLocal phone number for entity. ReferencesNo definition available. Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: durationX-DefinitionTitle of a 12 (b) registered security. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameExchangeAct-Number240-Section12-Subsectionb> Details Name: dei_Security12bTitle Namespace Prefix: dei_Data Type: dei:securityTitleItemType Balance Type: na Period Type: durationX-DefinitionName of the Exchange on which a security is registered. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameExchangeAct-Number240-Section12-Subsectiond1-1> Details Name: dei_SecurityExchangeName Namespace Prefix: dei_Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: durationX-DefinitionTrading symbol of an instrument as listed on an exchange. ReferencesNo definition available. Details Name: dei_TradingSymbol Namespace Prefix: dei_Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: durationConsolidated Balance Sheets USD (\$) Dec. 31, 2023-Dec. 31, 2022Current assets: Cash and cash equivalents \$ 5, 838, 566 \$ 11, 492, 841Investment in debt securities - available for sale, at fair value 9, 857, 087 21, 254, 485Accrued interest receivable on investment securities 128, 932Money market investments, restricted cash 1, 500, 000Advances and deposits on clinical programs and other current assets 2, 545, 051 2, 403, 433Total current assets 18, 240, 704 26, 779, 691Property and equipment (at cost, less accumulated depreciation and amortization) 751, 906 548, 301Other assets: Money market investments, restricted cash 4, 500, 000Deferred income tax asset 1, 280, 385 1, 567, 026Operating lease right-of-use assets, net 1, 595, 074 155, 876Deposits and other assets 50, 000 425, 000Total other assets 2, 925, 459 6, 647, 902Total assets 21, 918, 069 43, 975, 894Current liabilities: Accounts payable - trade 3, 515, 192 3, 586, 623Other accrued liabilities 3, 390, 521 4, 794, 936Notes payable - current portion, net of deferred financing costs 1, 424, 774Operating lease liabilities - current portion 485, 421 230, 749Total current liabilities 7, 390, 892 134, 100, 037 082Notes payable - non-current portion, net of deferred financing costs 4, 610, 946Operating lease liabilities - non-current portion 1, 139, 293 Total liabilities 8, 530, 427 14, 648, 028Commitments and contingencies Stockholders' equity: Preferred Stock - \$ 0. 01 par value (100, 000 shares authorized, and no shares issued or outstanding at December 31, 2023 and 2022) Common stock - \$ 0. 01 par value (112, 500, 000 shares authorized; 9, 399, 811 and 7, 436, 219 shares issued at December 31, 2023 and 2022, respectively, and 9, 399, 789 and 7, 436, 197 shares outstanding at December 31, 2023 and 2022, respectively) 93, 998 74, 362Additional paid-in capital 401, 500, 838 397, 980, 023Accumulated other comprehensive income 60, 796 26, 494Accumulated deficit (388, 182, 802) (368, 667, 825) Total stockholders' equity before treasury stock 13, 472, 830 29, 413, 054Treasury stock, at cost (22 shares at December 31, 2023 and 2022) (85, 188) (85, 188) Total stockholders' equity 13, 387, 642 29, 327, 866Total liabilities and stockholders' equity \$ 21, 918, 069 \$ 43, 975, 894X-DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic852-SubTopic10-NameAccountingStandardsCodification-Section55-Paragraph10-PublisherFASB-URIhttps://asc>

fasb.org//1943274/2147481372/852-10-55-10Reference 2:

Paragraph 3-Subparagraph (bb)-Publisher FASB-URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 4-08 \(g\) \(1\) \(iii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 4-08 (g) (1) (iii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(e\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (e)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 6: <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147483467/210-10-45-1>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 5-02 \(9\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 5-02 (9))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210. 13-01 \(a\) \(4\) \(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210. 13-01 (a) (4) (i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 10: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210. 13-01 \(a\) \(4\) \(iii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210. 13-01 (a) (4) (iii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210. 13-01 \(a\) \(4\) \(iii\) \(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210. 13-01 (a) (4) (iii) (A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210. 13-01 \(a\) \(4\) \(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210. 13-01 (a) (4) (iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210. 13-01 \(a\) \(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210. 13-01 (a) (5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210. 13-02 \(a\) \(4\) \(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210. 13-02 (a) (4) (i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210. 13-02 \(a\) \(4\) \(ii\) \(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210. 13-02 (a) (4) (ii) (A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210. 13-02 \(a\) \(4\) \(iii\) \(B\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210. 13-02 (a) (4) (iii) (B))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210. 13-02 \(a\) \(4\) \(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210. 13-02 (a) (4) (iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210. 13-02 \(a\) \(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210. 13-02 (a) (5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210. 13-02 \(a\) \(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210. 13-02 (a) (5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 20: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7)Details Name: us-gaap-AssetsCurrentNamespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-ReferencesNo definition available. Details Name: us-gaap-AssetsCurrentAbstractNamespace Prefix: us-gaap-Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147481830/320-10-45-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 326-SubTopic 30-Name Accounting Standards Codification-Section 45-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147479130/326-30-45-1>Details Name: us-gaap-AvailableForSaleSecuritiesDebtSecuritiesCurrentNamespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 5-02 \(11\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 5-02 (11))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/exampleRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483467/210-10-45-1](http://www.xbrl.org/2003/role/exampleRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483467/210-10-45-1)Reference 3: <http://asc.fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 45-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-4>Details Name: us-gaap-CashAndCashEquivalentsAtCarryingValueNamespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 7-03 \(a\) \(19\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 7-03 (a) (19))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 6-04 \(15\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 6-04 (15))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1)Reference 3: [http://asc.fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 942-SubTopic 210-Section S99-Paragraph 1-Subparagraph \(SX 210. 9-03.17\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1](http://asc.fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 942-SubTopic 210-Section S99-Paragraph 1-Subparagraph (SX 210. 9-03.17)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1)Reference 4: [http://asc.fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph \(SX 210. 5-02.25\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://asc.fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph (SX 210. 5-02.25)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Details Name: us-gaap-CommitmentsAndContingenciesNamespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 7-03 \(a\) \(22\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 7-03 (a) (22))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1)Reference 3: [http://asc.fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 5-02 \(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://asc.fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 5-02 (29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Details Name: us-gaap-CommonStockValueNamespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-DefinitionAmount, after allowance for credit loss, of accrued interest on investment in debt security measured at amortized cost (held-to-maturity). ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 5C-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5C>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 326-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 5-Publisher FASB-URI https://asc.fasb.org/1943274/2147479344/326-20-45-5>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 326-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 3A-Publisher FASB-URI https://asc.fasb.org/1943274/2147479319/326-20-50-3A>Details Name: us-gaap-DebtSecuritiesHeldToMaturityAccruedInterestAfterAllowanceForCreditLossNamespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-DefinitionAmount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/740-10-45-4>

org//1943274/2147482525/740-10-45-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 6-Publisher FASB-URI https://asc.fasb.org//1943274/2147482525/740-10-45-6-Details Name: us-gaap-DeferredIncomeTaxAssetsNet-namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: debit-Period Type: instantX-Definition Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer. ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(17))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1-Details Name: us-gaap-DepositsAssetsNonecurrent-namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: debit-Period Type: instantX-Definition Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer. ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(3)(a)(4))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1-Details Name: us-gaap-GrantsReceivableCurrent-namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: debit-Period Type: instantX-Definition Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (bb)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 7: http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 12-Publisher FASB-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(14))-Publisher FASB-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 22: http://asc.fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph (SX 210.5-02.19-26)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1-Details Name: us-gaap-Liabilities-namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit-Period Type: instantX-Definition Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-03(a)(25))-Publisher FASB-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 6: http://asc.fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-03(23))-Publisher FASB-URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 7: http://asc.fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(32))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1-Details Name: us-gaap-LiabilitiesAndStockholdersEquity-namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit-Period Type: instantX-Definition Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (bb)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 7: http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph

5-Publisher FASB-URI <https://asc.fasb.org//1943274/2147483467/210-10-45-5>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i)))-Publisher FASB-URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1A>Reference 10: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii)))-Publisher FASB-URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1A>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A)))-Publisher FASB-URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1A>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv)))-Publisher FASB-URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1A>Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5)))-Publisher FASB-URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1A>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i)))-Publisher FASB-URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1B>Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A)))-Publisher FASB-URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1B>Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B)))-Publisher FASB-URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1B>Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv)))-Publisher FASB-URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1B>Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(5\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5)))-Publisher FASB-URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1B>Reference 19: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(a\)-Publisher FASB-URI <https://asc.fasb.org//1943274/2147481404/852-10-50-7>Reference 20: \[http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \\(b\\)-Publisher FASB-URI <https://asc.fasb.org//1943274/2147481404/852-10-50-7>Reference 21: \\[http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph \\\(SX 210.5-02.21\\\)-Publisher FASB-URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>Details Name: us-gaap-LiabilitiesCurrentNamespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-ReferencesNo definition available. Details Name: us-gaap-LiabilitiesCurrentAbstract Namespace Prefix: us-gaap-Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionCarrying value as of the balance sheet date of notes payable \\\(with maturities initially due after one year or beyond the operating cycle if longer\\\), excluding current portion. ReferencesReference 1: \\\[http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph \\\\(SX 210.5-02.22\\\\)-Publisher FASB-URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>Details Name: us-gaap-LongTermNotesPayable Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-DefinitionSum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer. ReferencesReference 1: \\\\[http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph \\\\\(SX 210.5-02.19,20\\\\\)-Publisher FASB-URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>Details Name: us-gaap-NotesPayableCurrentNamespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. ReferencesReference 1: \\\\\[http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph \\\\\\(b\\\\\\)-Publisher FASB-URI <https://asc.fasb.org//1943274/2147479041/842-20-45-1>Details Name: us-gaap-OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. ReferencesReference 1: \\\\\\[http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph \\\\\\\(b\\\\\\\)-Publisher FASB-URI <https://asc.fasb.org//1943274/2147479041/842-20-45-1>Details Name: us-gaap-OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-DefinitionAmount of lessee's right to use underlying asset under operating lease. ReferencesReference 1: \\\\\\\[http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph \\\\\\\\(a\\\\\\\\)-Publisher FASB-URI <https://asc.fasb.org//1943274/2147479041/842-20-45-1>Details Name: us-gaap-OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-ReferencesNo definition available. Details Name: us-gaap-OtherAssetsAbstract Namespace Prefix: us-gaap-Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionAmount of noncurrent assets classified as other. ReferencesReference 1: \\\\\\\\[http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \\\\\\\\\(SX 210.5-02\\\\\\\\\(17\\\\\\\\\)\\\\\\\\\)-Publisher FASB-URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>Details Name: us-gaap-OtherAssetsNoncurrent Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-DefinitionAmount of long-term investments classified as other. ReferencesReference 1: \\\\\\\\\[http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \\\\\\\\\\(SX 210.7-03\\\\\\\\\\(a\\\\\\\\\\)\\\\\\\\\\(1\\\\\\\\\\)\\\\\\\\\\(f\\\\\\\\\\)\\\\\\\\\\)-Publisher FASB-URI <https://asc.fasb.org//1943274/2147479440/944-210-S99-1>Reference 2: \\\\\\\\\\[http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \\\\\\\\\\\(SX 210.5-02\\\\\\\\\\\(12\\\\\\\\\\\)\\\\\\\\\\\)-Publisher FASB-URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>Details Name: us-gaap-OtherLongTermInvestments Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-DefinitionAmount of short-term investments classified as other. ReferencesReference 1: \\\\\\\\\\\[http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \\\\\\\\\\\\(SX 210.7-03\\\\\\\\\\\\(a\\\\\\\\\\\\)\\\\\\\\\\\\(1\\\\\\\\\\\\)\\\\\\\\\\\\(g\\\\\\\\\\\\)\\\\\\\\\\\\)-Publisher FASB-URI <https://asc.fasb.org//1943274/2147479440/944-210-S99-1>Reference 2: \\\\\\\\\\\\[http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \\\\\\\\\\\\\(SX 210.5-02\\\\\\\\\\\\\(8\\\\\\\\\\\\\)\\\\\\\\\\\\\)-Publisher FASB-URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>Reference 3: \\\\\\\\\\\\\[http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 942-SubTopic 210-Section S99-Paragraph 1-Subparagraph \\\\\\\\\\\\\\(SX 210.9-03.5\\\\\\\\\\\\\\)-Publisher FASB-URI <https://asc.fasb.org//1943274/2147479853/942-210-S99-1>Details Name: us-gaap-OtherShortTermInvestments Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-DefinitionAggregate par or stated value of issued nonredeemable preferred stock \\\\\\\\\\\\\\(or preferred stock redeemable solely at the option of the issuer\\\\\\\\\\\\\\). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. ReferencesReference 1: \\\\\\\\\\\\\\[http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI <https://asc.fasb.org//1943274/2147481372/852-10-55-10>Reference 2: \\\\\\\\\\\\\\\[http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \\\\\\\\\\\\\\\\(SX 210.7-03\\\\\\\\\\\\\\\\(a\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\(21\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\)-Publisher FASB-URI <https://asc.fasb.org//1943274/2147479440/944-210-S99-1>Reference 3: \\\\\\\\\\\\\\\\[http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \\\\\\\\\\\\\\\\\(SX 210.5-02\\\\\\\\\\\\\\\\\(28\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\\)-Publisher FASB-URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>Details Name: us-gaap-PreferredStockValue Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. ReferencesReference 1: \\\\\\\\\\\\\\\\\[http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 1-SubTopic 10-Topic 360-Publisher FASB-URI <https://asc.fasb.org//1943274/2147482099/360-10-50-1>Reference 2: \\\\\\\\\\\\\\\\\\[http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI <https://asc.fasb.org//1943274/2147481372/852-10-55-10>Reference 3: \\\\\\\\\\\\\\\\\\\[http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \\\\\\\\\\\\\\\\\\\\(SX 210.7-03\\\\\\\\\\\\\\\\\\\\(a\\\\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\\\\\(8\\\\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\\\\\)-Publisher FASB-URI <https://asc.fasb.org//1943274/2147479440/944-210-S99-1>Reference 4: \\\\\\\\\\\\\\\\\\\\[http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 360-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph 1-Publisher FASB-URI <https://asc.fasb.org//1943274/2147480842/942-360-50-1>Details Name: us-gaap-PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-DefinitionAmount of accumulated undistributed earnings \\\\\\\\\\\\\\\\\\\\\(deficit\\\\\\\\\\\\\\\\\\\\\). ReferencesReference 1: \\\\\\\\\\\\\\\\\\\\\[http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI <https://asc.fasb.org//1943274/2147481372/852-10-55->\\\\\\\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\\\\\\\(http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org//1943274/2147481372/852-10-55-\\\\\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\\\\\\(http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 360-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph 1-Publisher FASB-URI https://asc.fasb.org//1943274/2147480842/942-360-50-1\\\\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\\\\\(http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \\\\\\\\\\\\\\\\\\\(SX 210.7-03\\\\\\\\\\\\\\\\\\\(a\\\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\\\\(8\\\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\\\\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1\\\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\\\\(http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10\\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\\\(http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 1-SubTopic 10-Topic 360-Publisher FASB-URI https://asc.fasb.org//1943274/2147482099/360-10-50-1\\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\\(http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \\\\\\\\\\\\\\\\(SX 210.5-02\\\\\\\\\\\\\\\\(28\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1\\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\]\\\\\\\\\\\\\\\(http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \\\\\\\\\\\\\\\(SX 210.7-03\\\\\\\\\\\\\\\(a\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\(21\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1\\\\\\\\\\\\\\\)\\\\\\\\\\\\\\]\\\\\\\\\\\\\\(http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10\\\\\\\\\\\\\\)\\\\\\\\\\\\\]\\\\\\\\\\\\\(http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 942-SubTopic 210-Section S99-Paragraph 1-Subparagraph \\\\\\\\\\\\\(SX 210.9-03.5\\\\\\\\\\\\\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1\\\\\\\\\\\\\)\\\\\\\\\\\\]\\\\\\\\\\\\(http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \\\\\\\\\\\\(SX 210.5-02\\\\\\\\\\\\(8\\\\\\\\\\\\)\\\\\\\\\\\\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1\\\\\\\\\\\\)\\\\\\\\\\\]\\\\\\\\\\\(http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \\\\\\\\\\\(SX 210.7-03\\\\\\\\\\\(a\\\\\\\\\\\)\\\\\\\\\\\(1\\\\\\\\\\\)\\\\\\\\\\\(g\\\\\\\\\\\)\\\\\\\\\\\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1\\\\\\\\\\\)\\\\\\\\\\]\\\\\\\\\\(http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \\\\\\\\\\(SX 210.5-02\\\\\\\\\\(12\\\\\\\\\\)\\\\\\\\\\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1\\\\\\\\\\)\\\\\\\\\]\\\\\\\\\(http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \\\\\\\\\(SX 210.7-03\\\\\\\\\(a\\\\\\\\\)\\\\\\\\\(1\\\\\\\\\)\\\\\\\\\(f\\\\\\\\\)\\\\\\\\\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1\\\\\\\\\)\\\\\\\\]\\\\\\\\(http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \\\\\\\\(SX 210.5-02\\\\\\\\(17\\\\\\\\)\\\\\\\\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1\\\\\\\\)\\\\\\\]\\\\\\\(http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph \\\\\\\(a\\\\\\\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479041/842-20-45-1\\\\\\\)\\\\\\]\\\\\\(http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph \\\\\\(b\\\\\\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479041/842-20-45-1\\\\\\)\\\\\]\\\\\(http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph \\\\\(b\\\\\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479041/842-20-45-1\\\\\)\\\\]\\\\(http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph \\\\(SX 210.5-02.19,20\\\\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1\\\\)\\\]\\\(http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph \\\(SX 210.5-02.22\\\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1\\\)\\]\\(http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph \\(SX 210.5-02.21\\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1\\)\]\(http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481404/852-10-50-7\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481404/852-10-50-7)

10Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(g\)\(2\)\(i\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (g)(2)(i)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(h\)\(2\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (h)(2)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 11-Publisher FASB-URI https://asc.fasb.org//1943274/2147480990/946-20-50-11>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-03\(a\)\(23\)\(a\)\(4\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-03(a)(23)(a)(4))-Publisher FASB-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(17\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(17))-Publisher FASB-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1)Reference 7: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1)Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(30\)\(a\)\(3\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(30)(a)(3))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1)Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10>Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 12-Publisher FASB-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(19\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(19))-Publisher FASB-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.6-05\(4\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.6-05(4))-Publisher FASB-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2)Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(4\)\(b\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b))-Publisher FASB-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(6\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(6))-Publisher FASB-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(7\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(7))-Publisher FASB-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3)Reference 8: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1)Reference 9: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3)Reference 10: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28)Reference 11: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1)Reference 12: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(31\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(31))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1)Reference 13: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(30\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(30))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1)Reference 14: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SAB Topic 4.E\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SAB Topic 4.E)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2)Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-ReferencesNo definition available. Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionTotal amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock. ReferencesNo definition available. Details Name: us-gaap_StockholdersEquityBeforeTreasuryStock Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-DefinitionThe amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 505-SubTopic 30-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org//1943274/2147481520/505-30-50-4>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 505-SubTopic 30-Section 45-Paragraph 1-Publisher FASB-URI https://asc.fasb.org//1943274/2147481549/505-30-45-1>Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02.29,30\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph (SX 210.5-02.29,30)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1)Details Name: us-gaap_TreasuryStockValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-Consolidated Balance Sheets (Parenthetical)-\$/shares Dec. 31, 2023-Dec. 31, 2022Statement of Financial Position [Abstract] Preferred stock, par value \$ 0.01 \$ 0.01Preferred stock, shares authorized 100,000 100,000Preferred stock, shares issuedPreferred stock, shares outstandingCommon stock, par value \$ 0.01 \$ 0.01Common stock, shares authorized 112,500,000 112,500,000Common stock, shares issued 9,399,811 7,436,219Common stock, shares outstanding 9,399,789 7,436,197Treasury stock, sharesX-DefinitionFace amount or stated value per share of common stock. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1)Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instantX-DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(16\)\(a\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(16)(a))-Publisher FASB-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1)Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instantX-DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1)Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instantX-DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-2>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.6-05\(4\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.6-05(4))-Publisher FASB-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(4\)\(b\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b))-Publisher FASB-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(16\)\(a\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(16)(a))-Publisher FASB-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1)Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(7\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(7))-Publisher FASB-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3)Reference 6: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1)Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instantX-DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. ReferencesReference 1: <http://>

www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02 (28))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1-Details Name: us-gaap-PreferredStockParOrStatedValuePerShare-namespace Prefix: us-gaap-Data Type: dtr-types: perShareItem Type: Balance Type: na Period Type: instantX-Definition The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. References Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04 (16) (a))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1-Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02 (28))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1-Details Name: us-gaap-PreferredStockSharesAuthorized-namespace Prefix: us-gaap-Data Type: xbrli:sharesItem Type: Balance Type: na Period Type: instantX-Definition Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt. References Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02 (28))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1-Details Name: us-gaap-PreferredStockSharesIssued-namespace Prefix: us-gaap-Data Type: xbrli:sharesItem Type: Balance Type: na Period Type: instantX-Definition Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. References Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.6-05 (4))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479617/946-210-S99-2-Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09 (4) (b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3-Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04 (16) (a))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1-Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09 (7))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3-Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02 (28))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1-Details Name: us-gaap-PreferredStockSharesOutstanding-namespace Prefix: us-gaap-Data Type: xbrli:sharesItem Type: Balance Type: na Period Type: instantX-References No definition available. Details Name: us-gaap-StatementOfFinancialPosition-namespace Prefix: us-gaap-Data Type: xbrli:stringItem Type: Balance Type: na Period Type: durationX-Definition Number of previously issued common shares repurchased by the issuing entity and held in treasury. References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02 (28))-Publisher FASB-URI https://asc.fasb.org/1943274/2147481549/505-30-45-1-Details Name: us-gaap-TreasuryStockCommonShares-namespace Prefix: us-gaap-Data Type: xbrli:sharesItem Type: Balance Type: na Period Type: instant Consolidated Statements of Operations-USD (\$)-12-Months Ended Dec. 31, 2023-Dec. 31, 2022 Income Statement [Abstract] License revenue \$ 500,000 Operating expenses: Research and development 11,287,691-11,733,666 General and administrative 9,742,739-13,687,899 Total operating expenses 21,030,430-25,421,565 Loss from operations (21,030,430) (24,921,565) Other income (expense): Gain from change in earn-out milestone liability 5,396,000 Impairment of in-process research and development (13,366,234) Loss on debt extinguishment (329,158) Investment income, net 1,157,625-453,356 Interest expense (197,080) (5,028,618) Other (loss) income (396,319) 1,801 Total other income (expense), net 235,068 (12,543,695) Loss before income tax benefit (20,795,362) (37,465,260) Income tax benefit 1,280,385 1,567,026 Net loss \$ (19,514,977) \$ (35,898,234) Net loss per common share-Basic \$ (2.16) \$ (5.03) Net loss per common share-Diluted \$ (2.16) \$ (5.03) Weighted average common shares outstanding-Basic 9,045,320-7,142,970 Weighted average common shares outstanding-Diluted 9,045,320-7,142,970X-Definition Gain loss from change in earnout milestone liability. References No definition available. Details Name: IMNN-GainLossFromChangeInEarnoutMilestoneLiability-namespace Prefix: IMNN-Data Type: xbrli:monetaryItem Type: Balance Type: credit Period Type: durationX-Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. References Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3-Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 15-Publisher FASB-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15-Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (e) (4)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1-Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1-Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11-Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11-Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7-Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2-Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B-Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4-Reference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1-Reference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10-Reference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03 (25))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2-Reference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04 (27))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483589/942-220-S99-1-Reference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04 (23))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1-Reference 16: http://www.xbrl.org/2003/role/exampleRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 52-Publisher FASB-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52-Reference 17: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7-Details Name: us-gaap-EarningsPerShareBasic-namespace Prefix: us-gaap-Data Type: dtr-types: perShareItem Type: Balance Type: na Period Type: durationX-Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. References Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3-Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 15-Publisher FASB-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15-Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (e) (4)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1-Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1-Reference 5: http://www.xbrl.org/2003/role/

disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (a)-Publisher FASB-URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7)Reference 8: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 6B-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 6B-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 10: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-50-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(25\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(25))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-04\(27\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483589/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04(27))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483589/942-220-S99-1)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(23\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(23))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1)Reference 15: <http://www.xbrl.org/2003/role/exampleRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 52-Publisher FASB-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7>Details Name: us-gaap-EarningsPerShareDiluted Namespace Prefix: us-gaap-Data Type: dtr-Items: perShareItem Type Balance Type: na Period Type: durationX-Definition Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(b\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (b)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 470-SubTopic 50-Section 40-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147481303/470-50-40>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 470-SubTopic 50-Section 40-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147481303/470-50-40-4>Details Name: us-gaap-GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: durationX-Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-07\(2\)\(a\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-07(2)(a))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03.4\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03.4)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Details Name: us-gaap-GeneralAndAdministrativeExpense Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: durationX-Definition Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value. References Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482665/350-30-50-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482665/350-30-50-3)Details Name: us-gaap-ImpairmentOfIntangibleAssetsIndefinitelyLivedExcludingGoodwill Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: durationX-Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(11\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(11))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 5: <http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 31-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 235-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-05\(b\)\(2\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479557/942-235-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 235-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-05(b)(2))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479557/942-235-S99-1)Reference 8: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 25-Paragraph 1-SubTopic 20-Topic 940-Publisher FASB-URI https://asc.fasb.org/1943274/2147481913/940-20-25-1>Reference 9: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(10\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(10))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 10: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-04\(15\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483589/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04(15))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483589/942-220-S99-1)Details Name: us-gaap-IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: durationX-References No definition available. Details Name: us-gaap-IncomeStatementAbstract Namespace Prefix: us-gaap-Data Type: xbrli:stringItem Type Balance Type: na Period Type: durationX-Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SAB TOPIC 6.1.7\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SAB TOPIC 6.1.7)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph \(h\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph (h)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(9\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(9))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 45-Paragraph 2-Subparagraph \(a\)-SubTopic 20-Topic 740-Publisher FASB-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 45-Paragraph 2-Subparagraph (a)-SubTopic 20-Topic 740-Publisher FASB-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(h\)\)-SubTopic 10-Topic 235-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(h))-SubTopic 10-Topic 235-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Details Name: us-gaap-IncomeTaxExpenseBenefit Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: durationX-Definition Amount of the cost of borrowed funds accounted for as interest expense. References Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147480167/946-830-55-10>Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 45-Paragraph 3-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483581/946-220-45-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 45-Paragraph 3-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483581/946-220-45-3)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-07\(3\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-07(3))-Publisher FASB-URI https://asc.fasb.org/1943274/)

2147483575/946-220-S99-1Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22)Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 835-SubTopic 30-Section 45-Paragraph 3-Publisher FASB-URI https://asc.fasb.org//1943274/2147482925/835-30-45-3>Reference 6: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-04.9\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04.9)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(210.5-03\(11\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (210.5-03(11))-Publisher FASB-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 835-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483013/835-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 835-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483013/835-20-50-1)Details-Name: us-gaap-InterestExpense-namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType-Balance Type: debit-Period Type: durationX-Definition: Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03.8\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03.8)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03.7\(a\),\(b\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03.7(a),(b))-Publisher FASB-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2)Details-Name: us-gaap-InvestmentIncomeNet-namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType-Balance Type: credit-Period Type: durationX-Definition: The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\)\(2\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b)(2)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1)Reference 8: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11)Reference 12: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4>Reference 13: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7>Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(18\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(18))-Publisher FASB-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22>Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-07\(9\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-07(9))-Publisher FASB-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(1\)\(d\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(1)(d))-Publisher FASB-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A)Reference 20: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30)Reference 30: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32)Reference 31: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B)Reference 32: <http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 31-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31>Reference 33: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(e\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (e)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32)Reference 34: <http://www.xbrl.org/2003/role/disclosureRef-Topic 205-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 7-Publisher FASB-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7>Reference 35: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28>Reference 36: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A)Reference 37: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B)Reference 38: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(20\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(20))-Publisher FASB-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2)Reference 39: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-04\(22\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04(22))-Publisher FASB-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1)

URI <https://asc.fasb.org/1943274/2147483589/942-220-S99-1> Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-\(SX-210-5-03-7\)-Publisher-FASB-URI](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-(SX-210-5-03-7)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147483621/220-10-S99-2> Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. References No definition available. Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- References No definition available. Details Name: us-gaap_OperatingExpenses Abstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- Definition The net result for the period of deducting operating expenses from operating revenues. References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-22-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147482810/280-10-50-22> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-30-Subparagraph-\(b\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-30-Subparagraph-(b)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147482810/280-10-50-30> Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-\(f\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-(f)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147482810/280-10-50-32> Reference 4: <http://www.xbrl.org/2003/role/exampleRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-31-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147482810/280-10-50-31> Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-\(c\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-(c)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147482810/280-10-50-32> Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX- Definition Amount of revenue and income classified as other. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-320-Name-Accounting-Standards-Codification-Section-S99-Paragraph-6-Subparagraph-\(SX-210-12-14-\(Column-E\)-\(2\)\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-320-Name-Accounting-Standards-Codification-Section-S99-Paragraph-6-Subparagraph-(SX-210-12-14-(Column-E)-(2))-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147480032/946-320-S99-6> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-320-Name-Accounting-Standards-Codification-Section-S99-Paragraph-6-Subparagraph-\(SX-210-12-14-\(Column-E\)-\(Footnote-4\)\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-320-Name-Accounting-Standards-Codification-Section-S99-Paragraph-6-Subparagraph-(SX-210-12-14-(Column-E)-(Footnote-4))-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147480032/946-320-S99-6> Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-320-Name-Accounting-Standards-Codification-Section-S99-Paragraph-6-Subparagraph-\(SX-210-12-14-\(Column-E\)-\(Footnote-6\)-\(b\)\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-320-Name-Accounting-Standards-Codification-Section-S99-Paragraph-6-Subparagraph-(SX-210-12-14-(Column-E)-(Footnote-6)-(b))-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147480032/946-320-S99-6> Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-7-04-\(4\)\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-7-04-(4))-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147483586/944-220-S99-1> Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-6-07-\(1\)-\(e\)\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-6-07-(1)-(e))-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147483575/946-220-S99-1> Details Name: us-gaap_OtherIncome Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX- References No definition available. Details Name: us-gaap_OtherIncomeAndExpenses Abstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-730-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147482916/730-10-50-1> Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic-912-SubTopic-730-Name-Accounting-Standards-Codification-Section-25-Paragraph-1-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147482517/912-730-25-1> Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-985-SubTopic-20-Section-50-Paragraph-1-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147481283/985-20-50-1> Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-924-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SAB-Topic-11-L\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-924-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SAB-Topic-11-L)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147479941/924-10-S99-1> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-5-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147479806/606-10-50-5> Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-30-Subparagraph-\(a\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-30-Subparagraph-(a)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147482810/280-10-50-30> Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-42-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147482810/280-10-50-42> Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-22-Subparagraph-\(b\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-22-Subparagraph-(b)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147482810/280-10-50-22> Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-\(b\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-(b)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147482810/280-10-50-32> Reference 7: <http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-40-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147482810/280-10-50-40> Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-22-Subparagraph-\(a\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-22-Subparagraph-(a)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147482810/280-10-50-22> Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-\(a\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-(a)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147482810/280-10-50-32> Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-41-Subparagraph-\(a\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-41-Subparagraph-(a)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147482810/280-10-50-41> Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Subparagraph-\(a\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Subparagraph-(a)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147479806/606-10-50-4> Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(a\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(a)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147482662/260-10-50-1> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-16-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147482689/260-10-45-16> Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: durationX- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(a\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(a)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147482662/260-10-50-1> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-10-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147482689/260-10-45-10> Details Name: us-gaap_WeightedAverageNumberOfSharesOutstanding Basic Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: durationX- Definition Consolidated Statements of Comprehensive Loss-USD (\$) 12 Months Ended Dec. 31, 2023 Dec. 31, 2022 Changes in: Realized gains on investment securities recognized in investment income, net \$ 431, 801 \$ 49, 222 Unrealized losses on investment securities, net (397, 499) (14, 754) Change in realized and unrealized gains on available for sale securities, net 34, 302 34, 468 Net loss (19, 514, 977) (35, 898, 234) Total comprehensive loss \$(19, 480, 675) \$(35, 863, 766) X- Definition Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and

distributions to owners. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210. 5-03 \(24\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210. 5-03 (24))) Publisher FASB-URI <https://asc.fasb.org//1943274/2147483621/220-10-S99-2>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 9-04 \(26\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 9-04 (26))) Publisher FASB-URI <https://asc.fasb.org//1943274/2147483589/942-220-S99-1>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 7-04 \(22\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 7-04 (22))) Publisher FASB-URI <https://asc.fasb.org//1943274/2147483586/944-220-S99-1>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B)Reference 6: <http://asc.fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 220-SubTopic 10-Section 45-Paragraph 5-Publisher FASB-URI https://asc.fasb.org//1943274/2147482790/220-10-45-5-Details Name: us-gaap-ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.>ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 4-08 \(g\) \(1\) \(ii\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 4-08 (g) (1) (ii))) Publisher FASB-URI <https://asc.fasb.org//1943274/2147480678/235-10-S99-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\) \(2\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b) (2)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1)Reference 8: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11)Reference 12: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4>Reference 13: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7>Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 7-04 \(18\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 7-04 (18))) Publisher FASB-URI <https://asc.fasb.org//1943274/2147483586/944-220-S99-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22>Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 6-07 \(9\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 6-07 (9))) Publisher FASB-URI <https://asc.fasb.org//1943274/2147482575/946-220-S99-1>Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210. 6-09 \(1\) \(d\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210. 6-09 (1) (d))) Publisher FASB-URI <https://asc.fasb.org//1943274/2147483575/946-220-S99-3>Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210. 13-01 \(a\) \(4\) \(ii\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210. 13-01 (a) (4) (ii))) Publisher FASB-URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1A>Reference 20: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210. 13-01 \(a\) \(4\) \(ii\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210. 13-01 (a) (4) (ii))) Publisher FASB-URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1A>Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210. 13-01 \(a\) \(4\) \(iii\) \(A\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210. 13-01 (a) (4) (iii) (A))) Publisher FASB-URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1A>Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210. 13-01 \(a\) \(4\) \(iv\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210. 13-01 (a) (4) (iv))) Publisher FASB-URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1A>Reference 23: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210. 13-01 \(a\) \(5\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210. 13-01 (a) (5))) Publisher FASB-URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1A>Reference 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210. 13-02 \(a\) \(4\) \(ii\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210. 13-02 (a) (4) (ii))) Publisher FASB-URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1B>Reference 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210. 13-02 \(a\) \(4\) \(iii\) \(A\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210. 13-02 (a) (4) (iii) (A))) Publisher FASB-URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1B>Reference 26: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210. 13-02 \(a\) \(4\) \(iii\) \(B\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210. 13-02 (a) (4) (iii) (B))) Publisher FASB-URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1B>Reference 27: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210. 13-02 \(a\) \(4\) \(iv\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210. 13-02 (a) (4) (iv))) Publisher FASB-URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1B>Reference 28: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210. 13-02 \(a\) \(5\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210. 13-02 (a) (5))) Publisher FASB-URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1B>Reference 29: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30)Reference 30: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32)Reference 31: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B)Reference 32: <http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 31-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31>Reference 33: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32)Reference 34: <http://www.xbrl.org/2003/role/disclosureRef-Topic 205-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 7-Publisher FASB-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7>Reference 35: <http://asc.fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28>Reference 36: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A)Reference 37: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B)Reference 38: [http://asc.fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210. 5-03 \(20\)\)](http://asc.fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210. 5-03 (20))) Publisher FASB-URI <https://asc.fasb.org//1943274/2147483621/220-10-S99-2>Reference 39: [http://asc.fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 9-04 \(22\)\)](http://asc.fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 9-04 (22))) Publisher FASB-URI <https://asc.fasb.org//1943274/2147483589/942-220-S99-1>Details Name: us-gaap-NetIncomeLoss Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-ReferencesNo definition available. Details Name: us-gaap-OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent Abstract Namespace Prefix: us-gaap-Data Type:

xbrl: stringItemType Balance Type: na Period Type: durationX-DefinitionAmount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. ReferencesReference 1:

Section 45-Paragraph 28-Subparagraph (b)-SubTopic 10-Topic 230-Publisher FASB-URI <https://asc.fasb.org//1943274/2147482740/230-10-45-28>Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 4-08 \(h\) \(1\) \(Note 1\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 4-08 (h) (1) (Note 1))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SAB Topic 6.1.Fact. 1\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SAB Topic 6.1.Fact. 1)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SAB Topic 6.1.Fact. 1\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SAB Topic 6.1.Fact. 1)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SAB Topic 6.1.7\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SAB Topic 6.1.7)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 9-Subparagraph \(b\)-SubTopic 10-Topic 740-Publisher FASB-URI https://asc.fasb.org//1943274/2147482685/740-10-50-9](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 9-Subparagraph (b)-SubTopic 10-Topic 740-Publisher FASB-URI https://asc.fasb.org//1943274/2147482685/740-10-50-9)Details Name: us-gaap_DeferredIncomeTaxExpenseBenefit Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(b\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (b)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 360-SubTopic 10-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482099/360-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 360-SubTopic 10-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482099/360-10-50-1)Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(b\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (b)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28)Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 470-SubTopic 50-Section 40-Paragraph 4-Publisher FASB-URI https://asc.fasb.org//1943274/2147481303/470-50-40-4>Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-DefinitionAmount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482665/350-30-50-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482665/350-30-50-3)Details Name: us-gaap_ImpairmentOfIntangibleAssetsIndefinitelyLivedExcludingGoodwill Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-DefinitionThe amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org//1943274/2147482913/230-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 45-Paragraph 25-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-25](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 45-Paragraph 25-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-25)Details Name: us-gaap_IncomeTaxesPaid Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-DefinitionChange in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(a\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (a)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28)Details Name: us-gaap_IncreaseDecreaseInAccountsPayableTrade Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-DefinitionThe increase (decrease) during the reporting period in investment income that has been earned but not yet received in cash. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(a\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (a)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28)Details Name: us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-ReferencesNo definition available. Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionAmount of increase (decrease) in operating assets classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(a\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (a)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28)Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(a\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (a)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28)Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 17-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-17](http://www.xbrl.org/2003/role/disclosureRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 17-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-17)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-25](http://www.xbrl.org/2003/role/disclosureRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-25)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org//1943274/2147482913/230-10-50-2>Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 24-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-24>Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-ReferencesNo definition available. Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 24-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-24>Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-ReferencesNo definition available. Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 24-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-25>Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: na Period Type: durationX-ReferencesNo definition available. Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the

parent. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-4-08-\(g\)-\(1\)-\(ii\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-4-08-(g)-(1)-(ii))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-323-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-\(e\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic-323-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-(e))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-825-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-28-Subparagraph-\(f\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic-825-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-28-Subparagraph-(f))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-6-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(b\)-\(2\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(b)-(2))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic-815-SubTopic-10-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-\(f\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-815-SubTopic-10-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-(f))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 8: <http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-8-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-9-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-\(a\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-(a))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-\(b\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-(b))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 12: <http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 13: <http://www.xbrl.org/2003/role/exampleRef-Topic-946-SubTopic-830-Name-Accounting-Standards-Codification-Section-55-Paragraph-10-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480167/946-830-55-10>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-45-Paragraph-7-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483581/946-220-45-7>Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-7-04-\(18\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483586/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-7-04-(18))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483586/944-220-S99-1)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-22-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-6-07-\(9\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483575/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-6-07-(9))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483575/946-220-S99-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-\(SX-210-6-09-\(1\)-\(d\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483575/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-(SX-210-6-09-(1)-(d))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483575/946-220-S99-3)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-\(SX-210-13-01-\(a\)-\(4\)-\(i\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(4)-(i))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 20: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-\(SX-210-13-01-\(a\)-\(4\)-\(ii\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(4)-(ii))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-\(SX-210-13-01-\(a\)-\(4\)-\(iii\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(4)-(iii))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-\(SX-210-13-01-\(a\)-\(4\)-\(iv\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(4)-(iv))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-\(SX-210-13-01-\(a\)-\(5\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(5))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-\(SX-210-13-02-\(a\)-\(4\)-\(i\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02-(a)-(4)-(i))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-\(SX-210-13-02-\(a\)-\(4\)-\(ii\)-\(A\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02-(a)-(4)-(ii)-(A))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-\(SX-210-13-02-\(a\)-\(4\)-\(ii\)-\(B\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02-(a)-(4)-(ii)-(B))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-\(SX-210-13-02-\(a\)-\(4\)-\(iv\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02-(a)-(4)-(iv))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-\(SX-210-13-02-\(a\)-\(5\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02-(a)-(5))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-30-Subparagraph-\(b\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-30-Subparagraph-(b))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 30: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-\(f\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-(f))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 31: [http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-60B-Subparagraph-\(a\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-60B-Subparagraph-(a))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 32: <http://www.xbrl.org/2003/role/exampleRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-31-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-31>Reference 33: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-\(c\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-(c))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 34: <http://www.xbrl.org/2003/role/disclosureRef-Topic-205-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-7-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 35: <http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic-230-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-28-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 36: [http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1A-Subparagraph-\(a\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1A-Subparagraph-(a))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482790/220-10-45-1A)Reference 37: [http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1B-Subparagraph-\(a\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1B-Subparagraph-(a))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482790/220-10-45-1B)Reference 38: [http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-\(SX-210-5-03-\(20\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-(SX-210-5-03-(20))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 39: [http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic-942-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-9-04-\(22\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483589/942-220-S99-1](http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic-942-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-9-04-(22))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483589/942-220-S99-1)Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX-ReferencesNo definition available. Details Name: us-gaap_NoneashInvestingAndFinancingItemsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na-Period Type: durationX-DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-230-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-28-Subparagraph-\(b\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-230-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-28-Subparagraph-(b))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-28)Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX-DefinitionThe cash outflow to reacquire callable preferred stock which is identified as being convertible to another type of financial security. ReferencesReference 1: [http://www.fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-230-SubTopic-10-Section-45-Paragraph-15-Subparagraph-\(a\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-15](http://www.fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-230-SubTopic-10-Section-45-Paragraph-15-Subparagraph-(a))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-15)Details Name: us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX-DefinitionAmount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-320-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-11-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481830/320-10-45-11>Reference 2: [http://www.fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-230-SubTopic-10-Section-45-Paragraph-13-Subparagraph-\(a\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-13](http://www.fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-230-SubTopic-10-Section-45-Paragraph-13-Subparagraph-(a))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-13)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-230-SubTopic-10-Section-45-Paragraph-13-Subparagraph-\(a\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-13](http://www.xbrl.org/2003/role/disclosureRef-Topic-230-SubTopic-10-Section-45-Paragraph-13-Subparagraph-(a))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-13)

SubTopic 10 Name Accounting Standards Codification Section 45 Paragraph 11 Publisher FASB URI <https://asc.fasb.org/1943274/2147482740/230-10-45-11> Details Name: us-gaap-PaymentsToAcquireAvailableForSaleSecuritiesDebt Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX Definition The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 13-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-13](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 13-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-13) Details Name: us-gaap-PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX Definition The cash inflow from the additional capital contribution to the entity. Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 14-Subparagraph \(a\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 14-Subparagraph (a)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14) Details Name: us-gaap-ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX Definition The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder. Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 14-Subparagraph \(a\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 14-Subparagraph (a)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14) Details Name: us-gaap-ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX Definition Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale). Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 11-Publisher FASB-URI https://asc.fasb.org/1943274/2147481830/320-10-45-11> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 11-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-11> Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 12-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-12](http://www.xbrl.org/2003/role/disclosureRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 12-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-12) Details Name: us-gaap-ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX Definition Amount of non-cash expense for share-based payment arrangement. Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(a\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (a)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) Details Name: us-gaap-ShareBasedCompensation Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX Reference No definition available. Details Name: us-gaap-SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX Definition Amount of unrealized gain (loss) on investment. Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(b\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (b)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) Details Name: us-gaap-UnrealizedGainLossOnInvestments Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration Consolidated Statements of Changes in Stockholders' Equity-USD (\$) Series A and B Preferred Stock [Member] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Treasury Stock-Common [Member] AOCI Attributable to Parent [Member] Retained Earnings [Member] Total Balance at Dec. 31, 2021 \$ 57,705 \$ 388,600,979 \$ (85,188) \$ (7,974) \$ (332,769,591) \$ 55,795,931 Balance, shares at Dec. 31, 2021 5,770,516 Net loss (35,898,234) (35,898,234) Sale of equity through equity financing facilities \$ 16,644,670,010,672,654 Sale of equity through equity financing facilities, shares 1,664,349 Realized and unrealized gains, net, on investment securities 34,468,346,468 Stock-based compensation expense 2,673,034 2,673,034 Effect of reverse stock split Effect of reverse stock split, shares (27) Issuance of preferred stock upon financing \$ 28,500,000 28,500,000 Issuance of preferred stock upon financing, shares 100,000 Redemption of preferred stock \$ (28,500,000) (28,500,000) Redemption of preferred stock, shares (100,000) Issuance of common stock for restricted options \$ 13 Issuance of common stock for restricted options, shares 1,381 Balance at Dec. 31, 2022 \$ 74,362,397,080,023 \$ (85,188) 26,494 (368,667,825) 29,327,866 Balance, shares at Dec. 31, 2022 7,436,219 Net loss (19,514,977) (19,514,977) Sale of equity through equity financing facilities \$ 19,041,276,397,278,438 Sale of equity through equity financing facilities, shares 1,904,142 Issuance of common stock upon exercise of restricted options \$ 595 Issuance of common stock upon exercise of restricted options, shares 59,450 Realized and unrealized gains, net, on investment securities 34,302,34,302 Stock-based compensation expense 758,418 \$ 758,418 Effect of reverse stock split, shares (5,770,516) Balance at Dec. 31, 2023 \$ 93,998 \$ 401,500,838 \$ (85,188) \$ 60,796 \$ (388,182,802) \$ 13,387,642 Balance, shares at Dec. 31, 2023 9,399,811 X-Definition Issuance of preferred stock upon financing, shares Reference No definition available. Details Name: IMNN_StockIssuedDuringPeriodIssuanceOfPreferredStockUponFinancingShares Namespace Prefix: IMNN Data Type: xbrli:sharesItemType Balance Type: na Period Type: durationX Definition Issuance of preferred stock upon financing. Reference No definition available. Details Name: IMNN_StockIssuedDuringPeriodValueIssuanceOfPreferredStockUponFinancing Namespace Prefix: IMNN Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX Definition Stock issued during period value reverse stock splits. Reference No definition available. Details Name: IMNN_StockIssuedDuringPeriodValueReverseStockSplits Namespace Prefix: IMNN Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX Definition Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 35-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147480483/718-10-35-2> Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 20-Section 55-Paragraph 13-Publisher FASB-URI https://asc.fasb.org/1943274/2147481089/718-20-55-13> Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 20-Section 55-Paragraph 12-Publisher FASB-URI https://asc.fasb.org/1943274/2147481089/718-20-55-12> Details Name: us-gaap-AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08 \(g\) \(1\) \(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08 (g) (1) (ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1) Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3) Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28) Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6> Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3> Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\) \(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b) (2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1) Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1) Reference 8: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8> Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9> Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11) Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11) Reference 12: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4> Reference 13: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147480167/946-830-55-10> Reference 14: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147483581/946-220-45-7> Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04 \(18\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04 (18))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1) Reference 16: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting>

Standards Codification—Section 50—Paragraph 22—Publisher FASB—URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-6-07-\(9\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-6-07-(9)))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147483575/946-220-S99-1>Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-\(SX-210-6-09-\(1\)-\(d\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-(SX-210-6-09-(1)-(d)))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147483575/946-220-S99-3>Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-\(SX-210-13-01-\(a\)-\(4\)-\(i\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(4)-(i)))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 20: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-\(SX-210-13-01-\(a\)-\(4\)-\(ii\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(4)-(ii)))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-\(SX-210-13-01-\(a\)-\(4\)-\(iii\)-\(A\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(4)-(iii)-(A)))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-\(SX-210-13-01-\(a\)-\(4\)-\(iv\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(4)-(iv)))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 23: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-\(SX-210-13-01-\(a\)-\(5\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(5)))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-\(SX-210-13-02-\(a\)-\(4\)-\(i\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02-(a)-(4)-(i)))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-\(SX-210-13-02-\(a\)-\(4\)-\(iii\)-\(A\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02-(a)-(4)-(iii)-(A)))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 26: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-\(SX-210-13-02-\(a\)-\(4\)-\(iii\)-\(B\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02-(a)-(4)-(iii)-(B)))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 27: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-\(SX-210-13-02-\(a\)-\(4\)-\(iv\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02-(a)-(4)-(iv)))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 28: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-\(SX-210-13-02-\(a\)-\(5\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02-(a)-(5)))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 29: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-30-Subparagraph-\(b\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-30-Subparagraph-(b)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147482810/280-10-50-30>Reference 30: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-\(f\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-(f)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 31: [http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-60B-Subparagraph-\(a\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-60B-Subparagraph-(a)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147482810/280-10-45-60B>Reference 32: <http://www.xbrl.org/2003/role/exampleRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-31-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147482810/280-10-50-31>Reference 33: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-\(c\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-(c)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 34: <http://www.xbrl.org/2003/role/disclosureRef-Topic-205-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-7-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 35: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic-230-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-28-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 36: [http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1A-Subparagraph-\(a\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1A-Subparagraph-(a)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147482790/220-10-45-1A>Reference 37: [http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1B-Subparagraph-\(a\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1B-Subparagraph-(a)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147482790/220-10-45-1B>Reference 38: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-\(SX-210-5-03-\(20\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-(SX-210-5-03-(20)))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 39: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-942-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-9-04-\(22\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-942-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-9-04-(22)))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147483589/942-220-S99-1>Details Name: us-gaap_NetIncomeLossNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-Definition Amount after tax of other comprehensive income (loss) attributable to parent entity. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic-810-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-19-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147481231/810-10-45-19>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-20-SubTopic-10-Topic-810-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147481231/810-10-45-20>Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-50-Paragraph-1A-Subparagraph-\(c\)-\(3\)-SubTopic-10-Topic-810-Publisher-FASB-URI](http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-50-Paragraph-1A-Subparagraph-(c)-(3)-SubTopic-10-Topic-810-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147481203/810-10-50-1A>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1B-Subparagraph-\(b\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1B-Subparagraph-(b)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147482790/220-10-45-1B>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1A-Subparagraph-\(b\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1A-Subparagraph-(b)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147482790/220-10-45-1A>Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-Definition Number of shares issued which are neither cancelled nor held in the treasury. ReferencesNo definition available. Details Name: us-gaap_SharesOutstandingNamespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instantX-Definition Number of new stock issued during the period. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-SubTopic-10-Topic-505-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-505-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(a\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-505-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(a)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147481004/946-505-50-2>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-\(SX-210-6-09-\(4\)-\(b\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-(SX-210-6-09-(4)-(b)))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147483575/946-220-S99-3>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-\(SX-210-6-03-\(i\)-\(1\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-(SX-210-6-03-(i)-(1)))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147479886/946-10-S99-3>Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-5-02-\(28\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-5-02-(28)))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 6: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-3-04\)-Publisher-FASB-URI](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-3-04)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147480008/505-10-S99-1>Reference 7: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-5-02-\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-5-02-(29)))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssuesNamespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: durationX-Definition Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-SubTopic-10-Topic-505-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-3-04\)-Publisher-FASB-URI](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-3-04)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147480008/505-10-S99-1>Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGrossNamespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: durationX-Definition Reduction in the number of shares during the period as a result of a reverse stock split. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-SubTopic-10-Topic-505-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Details Name: us-gaap_StockIssuedDuringPeriodSharesReverseStockSplitsNamespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: durationX-Definition Number of share options (or share units) exercised during the current period. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(c\)-\(1\)-\(iv\)-\(02\)-Publisher-FASB-URI](http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(c)-(1)-(iv)-(02)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-5-02-\(28\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-5-02-(28)))

Publisher FASB URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1) Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: durationX-Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2> Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 11-Publisher FASB-URI https://asc.fasb.org/1943274/2147480167/946-830-55-11> Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 205-Name Accounting Standards Codification-Section 45-Paragraph 4-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480767/946-205-45-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 205-Name Accounting Standards Codification-Section 45-Paragraph 4-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480767/946-205-45-4) Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 505-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481004/946-505-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 505-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481004/946-505-50-2) Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(4\)\(b\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3) Reference 6: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(28\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) Reference 7: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1) Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: durationX-Definition Aggregate value of stock related to Restricted Stock Awards issued during the period. References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2> Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(28\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1) Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) Details Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: durationX-Definition Value of stock issued as a result of the exercise of stock options. References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2> Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1) Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2> Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: durationX-Definition Number of stock bought back by the entity at the exercise price or redemption price. References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2> Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1) Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2> Details Name: us-gaap_StockRedeemedOrCalledDuringPeriodShares Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: durationX-Definition Equity impact of the value of stock bought back by the entity at the exercise price or redemption price. References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2> Details Name: us-gaap_StockRedeemedOrCalledDuringPeriodValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: durationX-Definition Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. References Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10> Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 12-Publisher FASB-URI https://asc.fasb.org/1943274/2147480167/946-830-55-12> Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(19\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(19))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1) Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.6-05\(4\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479617/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.6-05(4))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479617/946-210-S99-2) Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(4\)\(b\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(6\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(6))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3) Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(7\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(7))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3) Reference 8: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(iii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1) Reference 9: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3) Reference 10: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28) Reference 11: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) Reference 12: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(31\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(31))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) Reference 13: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(30\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(30))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2) Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant Pay vs Performance Disclosure-USD (\$)-12-Months Ended Dec. 31, 2023 Dec. 31, 2022 Pay vs Performance Disclosure [Table] Net Income (Loss) Attributable to Parent \$ (19,514,977) \$ (35,898,234) X-References Reference 1: [http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Regulation S-K-Number 229-Section 402-Subsection v-Paragraph 1-Details Name: ecd-PvpTable Namespace Prefix: ecd_Data Type: xbrli:stringItem Type Balance Type: na Period Type: durationX-Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. References Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Regulation S-K-Number 229-Section 402-Subsection v-Paragraph 1-Details Name: ecd-PvpTable Namespace Prefix: ecd_Data Type: xbrli:stringItem Type Balance Type: na Period Type: durationX-Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. References Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1) Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3) Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28) Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6> Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3> Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3> Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>

will focus on the development of personalized cancer vaccines, or neoepitope cancer vaccines. The Company's lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company is conducting IND-enabling preclinical studies for the development of a COVID-19 booster vaccine (IMNN-101) and a treatment for the Lassa virus (IMNN-102). The Company has also initiated preclinical work to develop a Trp2 tumor associated antigen cancer vaccine in melanoma (IMNN-201). Imunon will continue to leverage these modalities and to advance the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions.

Basis of Presentation The accompanying consolidated financial statements ("Financial Statements") of Imunon have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company and CLSN Laboratories, Inc. The Company in 2023 dissolved Celsion GmbH. All significant intercompany balances and transactions have been eliminated in consolidation. Events and conditions arising subsequent to the most recent balance sheet date through the date of the issuance of these Financial Statements have been evaluated for their possible impact on the Financial Statements and accompanying notes. No events and conditions would give rise to any information that required accounting recognition or disclosure in the Financial Statements other than those arising in the ordinary course of business.

Use of Estimates The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation, the fair value of the earn-out milestone liabilities, estimates for contingent liabilities, if any, and accounting for impairment of in-process research and development assets. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.

Revenue Recognition The Company's sole revenue stream was related to the Hisun agreement described in Note 18, and whose contract has expired. There were no accounts receivable as of December 31, 2023 and 2022.

Cash and Cash Equivalents Cash and cash equivalents include cash on hand and investments purchased with an original maturity of three months or less. A portion of these funds are not covered by FDIC insurance.

Fair Value of Financial Instruments The carrying values of financial instruments approximate their respective fair values. Management believes that the carrying amounts of the Company's financial instruments, including cash and cash equivalents and accounts payable approximate fair value due to the short-term nature of those instruments. Short-term investments are recorded at their estimated fair value.

Short-Term Investments The Company classifies its investments in debt securities with readily determinable fair values as investments available-for-sale in accordance with Accounting Standards Codification ("ASC") 320, Investments-Debt and Equity Securities. Available-for-sale securities consist of debt securities not classified as trading securities or as securities to be held to maturity. The Company has classified all of its investments as available-for-sale. Unrealized holding gains and losses on available-for-sale securities are reported as a net amount in accumulated other comprehensive gain or loss in stockholders' equity until realized. Gains and losses on the sale of available-for-sale securities are determined using the specific identification method. The Company's short-term investments consist of corporate bonds.

Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is provided over the estimated useful lives of the related assets, ranging from three to seven years, using the straight-line method. Amortization is recognized over the lesser of the life of the asset or the lease term. Major renewals and improvements are capitalized at cost and ordinary repairs and maintenance are charged against operating expenses as incurred. Depreciation expense was approximately \$ 248, 000 and \$ 197, 000 for the years ended December 31, 2023 and 2022, respectively. The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An asset is considered impaired if its carrying amount exceeds the future net undiscounted cash flows that the asset is expected to generate. If such asset is considered to be impaired, the impairment recognized is the amount by which the carrying amount of the asset, if any, exceeds its fair value determined using a discounted cash flow model. There was no impairment of property or equipment during 2023 or 2022.

Deposits Deposits include real property security deposits and other deposits which are contractually required and of a long-term nature.

In-Process Research and Development, Other Intangible Assets and Goodwill During 2014, the Company acquired certain assets of EGEN, Inc. As more fully described in Note 6, the acquisition was accounted for under the acquisition method of accounting which required the Company to perform an allocation of the purchase price to the assets acquired and liabilities assumed. Under the acquisition method of accounting, the total purchase price is allocated to net tangible and intangible assets and liabilities based on their estimated fair values as of the acquisition date.

Impairment or Disposal of Long-Lived Assets The Company assesses the impairment of its long-lived assets under accounting standards for the impairment or disposal of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and fair value. See Note 5 for information on impairment losses of its in-process research and development.

Comprehensive Income (Loss) ASC 220, Comprehensive Income, establishes standards for the reporting and display of comprehensive income (loss) and its components in the Company's consolidated financial statements. The objective of ASC 220 is to report a measure of comprehensive income (loss) of all changes in equity of an enterprise that result from transactions and other economic events in a period other than transactions with owners. Comprehensive gains (losses) result from changes in unrealized gains and losses from investment in debt securities. Research and Development Research and development costs are expensed as incurred. Equipment and facilities acquired for research and development activities that have alternative future uses are capitalized and charged to expense over their estimated useful lives.

Net Loss per Share of Common Stock Basic and diluted net loss per common share was computed by dividing net loss for the year by the weighted average number of shares of common stock outstanding, both basic and diluted, during each period. The impact of common stock equivalents has been excluded from the computation of diluted weighted average common shares outstanding in periods where there is a net loss, as their effect is anti-dilutive. For the years ended December 31, 2023 and 2022, the total number of shares of common stock issuable upon exercise of warrants and equity awards was 1, 255, 642 and 988, 389, respectively. For the years ended December 31, 2023 and 2022, diluted loss per common share is the same as basic loss per common share as all options and all other warrants that were convertible into shares of the Company's common stock were excluded from the calculation of diluted earnings attributable to common stockholders per common share as their effect would be anti-dilutive.

Income Taxes Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in results of operations in the period that the tax rate change occurs. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. In accordance with ASC 740, Income Taxes, a tax position is recognized as a benefit only if it is "more likely than not" that the tax position taken would be sustained in a tax examination, presuming that a tax examination will occur. The Company recognizes interest and/or penalties related to income tax matters in the income tax expense category. As more fully discussed in Note 10, on November 28, 2023, the Company received approval from the New Jersey Economic Development Authority to sell \$ 1. 3 million of its New Jersey net operating losses ("NOLs"), recognizing a tax benefit for the year ended December 31, 2023 for the net proceeds (approximately \$ 1. 3 million) by reducing the net operating loss valuation allowance. As more fully discussed in Note 10, on November 28, 2023, the Company was notified by the New Jersey Economic Development Authority that its application was approved and the Company entered into an agreement to sell this NOL. On March 22, 2024, the Company received approximately \$ 1. 3 million upon completion of the sale of the 2023 NOLs. During 2022, the Company received approval to sell \$ 1. 6 million of its New Jersey NOLs, receiving net proceeds of approximately \$ 1. 6 million. As part of the Technology Business Tax Certificate Program sponsored by The New Jersey Economic Development Authority, emerging biotechnology companies with unused NOLs and unused research and development credits are allowed to sell these benefits to other New Jersey-based companies. During 2021, the New Jersey State Legislature increased the maximum lifetime benefit per company from \$ 15 million to \$ 20 million, which will allow the Company to participate in this innovative funding program in future years for up to an additional \$ 0. 4 million in net operating losses under this maximum lifetime benefit (see Note 2).

Stock-Based Compensation In March 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-09, Compensation-Stock Compensation, which simplifies various aspects of accounting for share-based payments. The areas for simplification involve several aspects of the accounting for share-based payment transactions, including the income tax consequences and classification on the statements of cash flows. The Company recognizes the effect of forfeitures in compensation cost when they occur.

Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued accounting pronouncements will not have a material impact on the Company's consolidated financial position, results of operations, and cash flows, or do not apply to its operations. In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures, which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. ASU No. 2023-09 is effective for fiscal years beginning after December 15, 2024 and allows for adoption on a prospective basis, with a retrospective option. Early adoption

is permitted. The Company is currently evaluating the impact of the ASU on the income tax disclosures within the consolidated financial statements. X-ReferencesNo definition available. Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org//1943274/2147483426/235-10-50-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 235-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org//235/tableOfContentDetails> Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: durationFINANCIAL CONDITION AND GOING CONCERN UNCERTAINTY 12 Months Ended Dec. 31, 2023 Organization, Consolidation and Presentation of Financial Statements [Abstract] FINANCIAL CONDITION AND GOING CONCERN UNCERTAINTY 2. FINANCIAL CONDITION AND GOING CONCERN UNCERTAINTY Since inception, the Company has incurred substantial operating losses, principally from expenses associated with the Company's research and development programs, clinical trials conducted in connection with the Company's drug candidates, and applications and submissions to the FDA. The Company has not generated significant revenue and has incurred significant net losses in each year since inception. For the year ended December 31, 2023, the Company had a net loss of \$ 19.5 million and used \$ 19.0 million to fund operations. As of December 31, 2023, the Company has incurred approximately \$ 388 million of cumulative net losses. As of December 31, 2023, the Company had \$ 15.7 million in cash and cash equivalents, short-term investments, and interest receivable and \$ 1.3 million net proceeds from the sale of its New Jersey net operating losses. The Company has substantial future capital requirements to continue its research and development activities and advance its drug candidates through various development stages. The Company believes these expenditures are essential for the commercialization of its drug candidates and technologies. The Company expects its operating losses to continue for the foreseeable future as it continues its product development efforts, and when it undertakes marketing and sales activities. The Company's ability to achieve profitability is dependent upon its ability to obtain governmental approvals, manufacture, and market and sell its new drug candidates. There can be no assurance that the Company will be able to commercialize its technology successfully or that profitability will ever be achieved. The Company expects that its operating results will fluctuate significantly in the future and will depend on a number of factors, many of which are outside the Company's control. The Company's ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the U. S. and worldwide resulting from the COVID-19 pandemic, the Russian invasion of Ukraine and the unrest in the Middle East. The Company continues to monitor its operating activities in light of these events, and it is possible that these events could result in a variety of risks to the business. The specific impact, if any, is not readily determinable as of the date of these consolidated Financial Statements. The Company has based its estimates on assumptions that may prove to be wrong. The Company may need to obtain additional funds sooner or in greater amounts than it currently anticipates. Potential sources of financing include strategic relationships, public or private sales of the Company's shares or debt, the sale of the Company's New Jersey NOLs and other sources. If the Company raises funds by selling additional shares of common stock or other securities convertible into common stock, the ownership interest of existing stockholders may be diluted. The actual amount of funds the Company will need to operate is subject to many factors, some of which are beyond the Company's control. These factors include the progress of research activities; the number and scope of research programs; the progress of preclinical and clinical development activities; the progress of the development efforts of parties with whom the Company has entered into research and development agreements; the costs associated with additional clinical trials of drug candidates; the ability to maintain current research and development licensing arrangements and to establish new research and development and licensing arrangements; the ability to achieve milestones under licensing arrangements; the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; and the costs and timing of regulatory approvals. The consolidated financial statements have been prepared on the going concern basis. In making this assessment, management conducted a comprehensive review of the Company's business plan including, but not limited to: ● the Company's financial position for the year ended December 31, 2023; ● significant events and transaction the Company has entered into since December 31, 2023; ● the Company's cash flow and cash usage forecasts for the period one year from the issuance date of this Annual Report on Form 10-K; ● the Company's capitalization structure including common stock outstanding and common stock issuable on exercise of warrants and equity awards; and other common stock issuable under equity plans; and ● continued support of the Company's stockholders. As a result of the uncertainties involved in our business, we are unable to estimate the duration and completion costs of our research and development projects or when, if ever, and to what extent we will receive cash inflows from the commercialization and sale of a product. Our inability to complete our research and development projects in a timely manner or our failure to enter into collaborative agreements, when appropriate, could significantly increase our capital requirements and could adversely impact our liquidity. These uncertainties could force us to seek additional, external sources of financing from time to time in order to continue with our business strategy. Our inability to raise additional capital, or to do so on terms reasonably acceptable to us, would jeopardize the future success of our business. Our estimated future capital requirements are uncertain and could change materially as a result of many factors, including the progress of our research, development, clinical, manufacturing, and commercialization activities. Management has determined the Company has suffered recurring losses from operations and has an accumulated deficit that raises substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance date of this Annual Report on Form 10-K. The report of our independent registered public accounting firm for the year ended December 31, 2023 includes an explanatory paragraph, which expresses substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of the uncertainty. A fundamental component of the ability to continue as a going concern is the Company's ability to raise capital as required, as to which no assurances can be provided. To address the additional funding requirements of the Company, management has undertaken the following initiatives: ● it has assessed its current expenditures and will be reducing the current spending requirements where necessary; ● it will pursue additional capital funding in the public and private markets through equity sales and/or debt facilities; ● it will pursue possible partnerships and collaborations; and ● it will pursue potential out licensing for its drug candidates. Our ability to continue as a going concern may depend on our ability to raise additional capital, attain further operating efficiencies, reduce expenditures, and, ultimately, to generate revenue. There are no assurances that these future funding and operating efforts will be successful. If management is unsuccessful in these efforts, our current capital is not expected to be sufficient to fund our operations for the next twelve months. X-ReferencesNo definition available. Details Name: us-gaap_OrganizationConsolidationAndPresentationOffinancialStatementsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionThe entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 205-SubTopic 40-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org//205-40/tableOfContentDetails> Name: us-gaap_SubstantialDoubtAboutGoingConcernTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: durationINVESTMENTS IN DEBT SECURITIES AVAILABLE FOR SALE 12 Months Ended Dec. 31, 2023 Investments, Debt and Equity Securities [Abstract] INVESTMENTS IN DEBT SECURITIES AVAILABLE FOR SALE 3. INVESTMENTS IN DEBT SECURITIES AVAILABLE FOR SALE Investments in debt securities available for sale with a fair value of \$ 9, 857, 087 and \$ 21, 254, 485 as of December 31, 2023 and 2022, respectively, consisted of U. S. Treasury securities and corporate debt securities. These investments are valued at estimated fair value, with unrealized gains and losses reported as a separate component of stockholders' equity in accumulated other comprehensive loss. The Company reviews its debt securities classified as short-term investments on a regular basis for impairment. For debt securities in unrealized loss positions, the Company determines whether any portion of the decline in fair value below the amortized cost basis is due to credit-related factors if it neither intends to sell nor anticipates that it is more likely than not that it will be required to sell prior to recovery of the amortized cost basis. The Company considers factors such as the extent to which the market value has been less than the cost, any noted failure of the issuer to make scheduled payments, changes to the rating of the security and other relevant credit-related factors in determining whether or not a credit loss exists. During fiscal 2023 and 2022, the Company did not recognize an allowance for credit-related losses on any of our investments. A summary of the cost, fair value and maturities of the Company's short-term investments is as follows: SCHEDULE OF COST, FAIR VALUE AND MATURITIES OF SHORT TERM INVESTMENTS December 31, 2023 December 31, 2022 Cost Fair Value Cost Fair Value Short-term investments U. S. Treasury securities \$ 9, 796, 291 \$ 9, 857, 087 \$ - \$ - Corporate debt securities - 21, 227, 991 21, 254, 485 Total \$ 9, 796, 291 \$ 9, 857, 087 \$ 21, 227, 991 \$ 21, 254, 485 December 31, 2023 December 31, 2022 Cost Fair Value Cost Fair Value Short-term investment maturities Within 3 months \$ 2, 467, 518 \$ 2, 490, 775 \$ 4, 005, 559 \$ 3, 994, 590 Between 3-12 months 7, 328, 773 7, 366, 312 17, 222, 422 17, 259, 895 Total \$ 9, 796, 291 \$ 9, 857, 087 \$ 21, 227, 991 \$ 21, 254, 485 The following table shows the Company's investment in debt securities available for sale gross unrealized gains (losses) and fair value by investment category and length of time that individual securities have been in a continuous unrealized loss position at December 31, 2023 and 2022. The Company has reviewed individual securities to determine whether a decline in fair value below the amortizable cost basis is other than temporary. SUMMARY OF INVESTMENT SECURITIES GROSS UNREALIZED GAINS (LOSSES) December 31, 2023 December 31, 2022 Available for sale securities (all unrealized holding gains and losses are less than 12 months at date of measurement) Fair Value Unrealized

Holding Gains (Losses) Fair Value Unrealized Holding Gains (Losses) Investments in debt securities with unrealized gains \$ 9, 857, 087 \$ 60, 796 \$ 13, 278, 505 \$ 43, 508 Investments in debt securities with unrealized losses \$ 7, 975, 980 (17, 014) Total \$ 9, 857, 087 \$ 60, 796 \$ 21, 254, 485 \$ 26, 494 Investment income, which includes net realized losses on sales of available for sale securities and investment income interest and dividends, is summarized as follows: SUMMARY OF NET REALIZED LOSSES ON SALES OF AVAILABLE FOR SALE SECURITIES AND INVESTMENT INCOME INTEREST AND DIVIDENDS 2023-2022 Interest and dividends accrued and paid \$ 725, 824 \$ 502, 578 Realized losses 431, 801 (49, 222) Realized gains (losses) 431, 801 (49, 222) Investment income, net \$ 1, 157, 625 \$ 453, 356 X-References No definition available. Details Name: us-gaap-InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap-Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-Definition The entire disclosure for investments in certain debt and equity securities. References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org//320/tableOfContentReference 2>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 10-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481800/320-10-50-10](http://www.xbrl.org/2003/role/disclosureRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 10-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481800/320-10-50-10) Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6B-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B](http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6B-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B) Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6B-Subparagraph \(e\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B](http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6B-Subparagraph (e)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B) Reference 5:

2, 055, 192 \$ 2, 468, 388 Furniture and fixtures (3–5 year life) 191, 932 350, 481 Leasehold improvements (5–7 year life) 607, 054 373, 194 Property and equipment gross 2, 854, 178 3, 192, 063 Less accumulated depreciation and amortization (2, 102, 272) (2, 643, 762) Total \$ 751, 906 \$ 548, 301 X- ReferencesNo definition available. Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- DefinitionThe entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. ReferencesReference 1:

in 2024 through 2037. The federal NOLs generated for the years ended after 2017 of approximately \$ 78 million can be carried forward indefinitely. As of December 31, 2023, the Company had state net operating loss carryforwards of approximately \$ 44 million, net of net operating losses utilized in prior years, and, if unused, will expire starting in 2029 through 2042. Effective for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental to research and experimentation (“ R & E ”) activities under IRC Section 174. While taxpayers historically had the option of deducting these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R & E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection with R & E activities in the US must be amortized over a 5-year period if incurred, and R & E expenses incurred outside the US must be amortized over a 15-year period. R & E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2023, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R & E expenses. The Company will continue to monitor this issue for future developments, but it does not expect R & E capitalization and amortization to require it to pay cash taxes now or in the near future. The Company’s income tax returns for 2019 to 2022 are still open and subject to audit. In addition, net operating losses arising from prior years are also subject to examination at the time they are utilized in future years. ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. As of December 31, 2023, and 2022, there were no unrecognized tax benefits. The Company recognizes accrued interest and penalties as income tax expense. No amounts were accrued for the payment of interest and penalties at December 31, 2023 and 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position in the next year. Sections 382 and 383 of the Internal Revenue Code provide for a limitation on the annual use of NOL and tax credit carryforwards following certain ownership changes that could limit the Company’s ability to utilize these carryforwards. The Company has completed an analysis to determine if such ownership changes have occurred and concluded it was more likely than not that there were changes in ownership. Due to the existence of full valuation allowance, limitations under Section 382 and 383 will not impact the Company’s effective tax rate. Further analyses will be performed prior to recognizing the benefits of any losses or credits in the financial statements. Sale of New Jersey Net Operating Losses Since 2018, the Company has annually submitted applications to sell a portion of the Company’s New Jersey NOLs as part of the Technology Business Tax Certificate Program sponsored by The New Jersey Economic Development Authority. Under the program, emerging biotechnology companies with unused NOLs and unused research and development credits are allowed to sell these benefits to other New Jersey-based companies. As part of the Technology Business Tax Certificate Program, the Company sold \$ 1.3 million and \$ 1.6 million of its New Jersey NOLs in 2023 and 2022, respectively. The sale of these net operating losses resulted in net proceeds to the Company of approximately \$ 1.3 million in 2023 and \$ 1.6 million in 2022. During 2021, the New Jersey State Legislature increased the maximum lifetime benefit per company from \$ 15 million to \$ 20 million, which will allow the Company to participate in this funding program in future years for up to an additional \$ 0.3 million in net operating losses under this maximum lifetime benefit. X-ReferencesNo definition available. Details Name: us-gaap-IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionThe entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise’s statement of financial position; net change during the year in the total valuation allowance; approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets; utilization of a tax carryback; and tax uncertainties information. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 13-Publisher FASB-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08 \(b\) \(2\)\)-Publisher FASB-URI https://asc.fasb.org//740/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Publisher FASB-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08 (b) (2))-Publisher FASB-URI https://asc.fasb.org//740/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Publisher FASB-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 21-Publisher FASB-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 270-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 17-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 17-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SAB TOPIC 6.1.5-Q1\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SAB TOPIC 6.1.5-Q1)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SAB Topic 11-C\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SAB Topic 11-C)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2)Details Name: us-gaap-IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: textBlockItemType Balance Type: na Period Type: durationSTOCKHOLDERS’ EQUITY 12 Months Ended Dec. 31, 2023 Equity [Abstract] STOCKHOLDERS’ EQUITY 11: STOCKHOLDERS’ EQUITY On March 19, 2021, the Company filed with the SEC a shelf registration statement on Form S-3 (the “ 2021 Registration Statement ”) that allows the Company to issue any combination of common stock, preferred stock or warrants to purchase common stock or preferred stock in an amount up to \$ 100 million. The 2021 Registration Statement was declared effective on March 30, 2021. The 2021 Registration Statement was intended to provide the Company with flexibility to raise capital in the future for general corporate purposes. However, as of the date of these financial statements and so long as the Company’s public float remains below \$ 75 million, it is subject to limitations with respect to the use of the 2021 Registration Statement and any other shelf registration statement that it files with the SEC pursuant to General Instruction I.B. 6 of Form S-3 (the “ Baby Shelf Limitation ”), which limits the amount that the Company can offer to up to one-third of its public float during any trailing 12-month period. The Company would be no longer subject to the Baby Shelf Limitation if its public float exceeds \$ 75 million. On September 19, 2022, the Company announced a corporate name change to Immunon, Inc. The Company’s common stock will continue to trade on the Nasdaq Stock Market under the new ticker symbol “ IMNN ” effective as of the opening of trading on September 21, 2022, and its CUSIP number (15117N602) remained unchanged. The Company filed an amendment to its Articles of Incorporation to effect the new corporate name. Reverse Stock Split On February 28, 2022, the Company effected a 15-for-1 reverse stock split of its common stock which was made effective for trading purposes as of the commencement of trading on March 31, 2022. As of that date, each 15 shares of issued and outstanding common stock and equivalents was consolidated into one share of common stock. All shares have been restated to reflect the effects of the 15-for-1 reverse stock split. In addition, at the market open on March 1, 2022, the Company’s common stock started trading under a new CUSIP number 15117N602 although the Company’s ticker symbol, CLSN, remained unchanged. The reverse stock split was previously approved by the Company’s stockholders at the 2022 Special Meeting held on February 24, 2022, and the Company subsequently filed a Certificate of Amendment to its Certificate of Incorporation to effect the stock consolidation. The primary reasons for the reverse stock split and the amendment were: ● To provide the Company with the ability to support its future anticipated growth and would provide greater flexibility to consider and respond to future business opportunities and needs as they arise, including equity financings and stock-based acquisitions of new technology and product development candidates. The availability of additional shares of common stock would permit the Company to undertake certain of the foregoing actions without delay and expense associated with holding a Special Meeting of Stockholders to obtain stockholder approval each time such an opportunity arises that would require the issuance of shares of common stock; and ● To continue listing on The NASDAQ Capital Market, which requires that the Company comply with the applicable listing requirements under NASDAQ Marketplace Rules, which requirements include, among others, a minimum bid price of at least \$ 1.00 per share. On December 2, 2021, the Company received a letter from NASDAQ indicating that the closing bid price of the Company’s common stock fell below \$ 1.00 per share for the previous 30 consecutive business days, and that the Company was therefore not in compliance with the minimum bid price requirement for continued inclusion on The NASDAQ Capital Market. The Company had 180 calendar days, until May 31, 2022, to regain compliance with this requirement, which occurs when the closing bid price of the Company’s common stock is at least \$ 1.00 per share for a minimum of ten consecutive business days during the 180-day compliance period. Immediately prior to the reverse stock split, the Company had 86,557,736 shares of common stock outstanding which consolidated into 5,770,516 shares of the Company’s common stock. No fractional shares were issued in connection with the reverse stock split. Holders of fractional shares have been paid out in cash for the fractional portion with the Company’s overall exposure for such payouts consisting of a nominal amount. The amount of the Company’s outstanding convertible preferred stock were not affected by the reverse stock split. The number of outstanding options, stock awards and warrants were adjusted accordingly, with outstanding options and stock awards being reduced from approximately 6.6 million to approximately 0.4 million and outstanding warrants being reduced from approximately 2.5 million to approximately 0.2 million. At the Market Offering Agreement On May 25, 2022, the Company entered into an At the Market

Offering Agreement with H. C. Wainwright & Co., LLC, as sales agent (“Wainwright”), pursuant to which the Company may offer and sell, from time to time, through Wainwright, shares of the Company’s common stock having an aggregate offering price of up to \$ 7, 500, 000. During 2022 the Company sold 336, 075 shares of stock for net proceeds of \$ 503, 798. The Company intends to use the net proceeds from the offering, if any, for general corporate purposes, including research and development activities, capital expenditures and working capital. In 2023, the Company has sold 1, 904, 142 shares of stock for net proceeds of \$ 2, 781, 438. Series A and Series B Convertible Redeemable Preferred Stock Offering On January 10, 2022, the Company entered into a Securities Purchase Agreement (the “Preferred Stock Purchase Agreement”) with several institutional investors, pursuant to which the Company agreed to issue and sell, in concurrent registered direct offerings (the “Preferred Offerings”), (i) 50, 000 shares of the Company’s Series A Convertible Redeemable Preferred Stock, par value \$ 0. 01 per share (the “Series A Preferred Stock”), and (ii) 50, 000 shares of the Company’s Series B Convertible Redeemable Preferred Stock, par value \$ 0. 01 per share (the “Series B Preferred Stock” and together with the Series A Preferred Stock, the “Preferred Stock”), in each case at an offering price of \$ 285 per share, representing a 5 % original issue discount to the stated value of \$ 300 per share, for gross proceeds of each Preferred Offering of \$ 14. 25 million, or approximately \$ 28. 50 million in the aggregate for the Preferred Offerings, before the deduction of the Placement Agent’s (as defined below) fee and offering expenses. The shares of Series A Preferred Stock have a stated value of \$ 300 per share and are convertible, at a conversion price of \$ 13. 65 per share, into 1, 098, 901 shares of common stock (subject in certain circumstances to adjustments). The shares of Series B Preferred Stock have a stated value of \$ 300 per share and are convertible, at a conversion price of \$ 15. 00 per share, into 1, 000, 000 shares of common stock (subject in certain circumstances to adjustments). The closing of the Preferred Offerings occurred on January 13, 2022. On March 3, 2022, the Company redeemed for cash at a price equal to 105 % of the \$ 300 stated value per share all of its 50, 000 outstanding shares of Series A Preferred Stock and its 50, 000 Series B Preferred Stock. As a result, all shares of the Preferred Stock have been retired and are no longer outstanding and Imunon’s only class of outstanding stock is its common. In connection with the Preferred Offerings, the Company entered into a placement agent agreement (the “Placement Agent Agreement”) with AGP pursuant to which the Company agreed to pay AGP an aggregate cash fee equal to \$ 1, 000, 000 and reimburse the AGP for certain of their expenses in an amount not to exceed \$ 110, 000. April 2022 Registered Direct Offering On April 6, 2022, the Company entered into a Securities Purchase Agreement (the “April 2022 Purchase Agreement”) with several institutional investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “April 2022 Offering”), an aggregate of 1, 328, 274 shares of the Company’s common stock at an offering price of \$ 5. 27 per share for gross proceeds of \$ 7. 0 million before the deduction of the April 2022 Placement Agent (as defined below) fees and offering expenses. The closing of the April 2022 Offering occurred on April 8, 2022. In connection with the April 2022 Offering, the Company entered into a placement agent agreement with A. G. P. /Alliance Global Partners (the “April 2022 Placement Agent”) pursuant to which the Company agreed to pay the April 2022 Placement Agent a cash fee equal to 6. 5 % of the aggregate gross proceeds raised from the sale of the securities sold in the April 2022 Offering and reimburse the April 2022 Placement Agent for certain of their expenses in an amount not to exceed \$ 50, 000. X-ReferencesNo definition available. Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap Data Type: xbrl:stringItemType Balance Type: na Period Type: durationX-DefinitionThe entire disclosure for equity. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-Subparagraph-\(h\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-Subparagraph-(h)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-14-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-14-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-235-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481062/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-235-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481062/946-235-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-235-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(d\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481062/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-235-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(d)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481062/946-235-50-2)Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-505-Name-Accounting-Standards-Codification-Section-50-Paragraph-6-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481004/946-505-50-6>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic-815-SubTopic-40-Name-Accounting-Standards-Codification-Section-50-Paragraph-6-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480237/815-40-50-6](http://www.xbrl.org/2003/role/disclosureRef-Topic-815-SubTopic-40-Name-Accounting-Standards-Codification-Section-50-Paragraph-6-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480237/815-40-50-6)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.3-04\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.3-04)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480008/505-10-S99-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.4-08\(c\)\(1\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.4-08(c)(1))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 10: <http://asc.fasb.org/us-gaap/role/ref/legacyRef-Topic-505-Name-Accounting-Standards-Codification-Publisher-FASB-URI-https://asc.fasb.org/505/tableOfContentReference-11>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-13>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-Subparagraph-\(g\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-Subparagraph-(g)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-Subparagraph-\(i\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-Subparagraph-(i)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-14-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-14-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-14-Subparagraph-\(c\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-14-Subparagraph-(c)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-16-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-16](http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-16-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-16)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-18-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-18-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-18-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-18-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-18-Subparagraph-\(d\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-18-Subparagraph-(d)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-18)Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dti-types:textBlockItemType Balance Type: na Period Type: durationSTOCK-BASED COMPENSATION 12 Months Ended Dec. 31, 2023 Share-Based Payment Arrangement [Abstract] STOCK-BASED COMPENSATION 12. STOCK-BASED COMPENSATION The Company has long-term compensation plans that permit the granting of equity-based awards in the form of stock options, restricted stock, restricted stock units, stock appreciation rights, other stock awards, and performance awards. At the 2018 Annual Stockholders Meeting of the Company held on May 15, 2018, stockholders approved the Imunon, Inc. 2018 Stock Incentive Plan (the “2018 Plan”). The 2018 Plan, as adopted, permits the granting of 180, 000 shares of Imunon common stock as equity awards in the form of incentive stock options, nonqualified stock options, restricted stock, restricted stock units, stock appreciation rights, other stock awards, performance awards, or in any combination of the foregoing. At the 2019 Annual Stockholders Meeting of the Company held on May 14, 2019, stockholders approved an amendment to the 2018 Plan whereby the Company increased the number of common stock shares available by 80, 000 to a total of 260, 000 under the 2018 Plan, as amended. At the 2020 Annual Stockholders Meeting of the Company held on June 15, 2020, stockholders approved an amendment to the 2018 Plan, as previously amended, whereby the Company increased the number of shares of common stock available by 166, 667 to a total of 426, 667 under the 2018 Plan, as amended. At the 2021 Annual Stockholders Meeting of the Company held on June 10, 2021, stockholders approved an amendment to the 2018 Plan, as previously amended, whereby the Company increased the number of shares of common stock available by 513, 333 to a total of 940, 000 under the 2018 Plan, as amended. At the 2023 Annual Stockholders Meeting of the Company held on June 14, 2023, stockholders approved an amendment to the 2018 Plan, as previously amended, whereby the Company increased the number of shares of common stock available by 1, 030, 000 to a total of 1, 970, 000 under the 2018 Plan, as amended. The Company has issued stock awards to employees and directors in the form of stock options and restricted stock. Options are generally granted with strike prices equal to the fair market value of a share of Imunon common stock on the date of grant. Incentive stock options may be granted to purchase shares of common stock at a price not less than 100 % of the fair market value of the underlying shares on the date of grant, provided that the exercise price of any incentive stock option granted to an eligible employee owning more than 10 % of the outstanding stock of Imunon must be at least 110 % of such fair market value on the date of grant. Only officers and key employees may receive incentive stock options. Option and restricted stock awards vest upon terms determined by the Compensation Committee of the Board of Directors and are subject to accelerated vesting in the event of a change of control or certain terminations of employment. The Company issues new shares to satisfy its obligations from the exercise of options or the grant of restricted stock awards. As of December 31, 2023, the Compensation Committee of the Board of Directors approved the grant of (i) inducement stock options (the “Inducement Option Grants”) to purchase a total of 294, 751 shares of Imunon common stock and (ii) inducement restricted stock awards (the “Inducement Stock Grants”)

totaling 91,350 shares of Immunon common stock. Each award has a grant date of the date of grant. Each Inducement Option Grant has a weighted exercise price of \$ 1.59 per share. Each Inducement Option Grant vests over three years, with one-third vesting on the one-year anniversary of the employee's first day of employment with the Company and one-third vesting on the second and third anniversaries thereafter, subject to the new employee's continued service relationship with the Company on each such date. Each Inducement Option Grant has a ten-year term and is subject to the terms and conditions of the applicable stock option agreement. Each Inducement Stock Grant vested on the one-year anniversary of the employee's first day of employment with the Company is subject to the new employee's continued service relationship with the Company through such date and is subject to the terms and conditions of the applicable restricted stock agreement. As of December 31, 2023, there were a total of 1,975,073 shares of Immunon common stock reserved for issuance under the 2018 Plan, which were comprised of 768,731 shares of Immunon common stock subject to equity awards previously granted under the 2018 Plan and 2007 Plan and 1,206,342 shares of Immunon common stock available for future issuance under the 2018 Plan. As of December 31, 2023, there are a total of 294,751 shares of Immunon common stock subject to outstanding inducement awards. Total compensation cost related to stock options and restricted stock awards was approximately \$ 0.8 million and \$ 2.7 million during 2023 and 2022, respectively. Of these amounts, \$ 0.2 million and \$ 0.9 million were charged to research and development expenses during 2023 and 2022, respectively, and \$ 0.6 million and \$ 1.8 million were charged to general and administrative expenses during 2023 and 2022, respectively. A summary of stock option awards as of December 31, 2023 and changes during the two-year period ended December 31, 2023 is presented below: SUMMARY OF STOCK OPTIONS

Stock Options Number Outstanding	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (years)	Aggregate Intrinsic Value Outstanding at January 1, 2022
441,425	\$ 38.50	2.72	\$ 39.06
760,220	\$ 4.55	1.23	\$ 61.88
Options granted	432,500	1.23	\$ 9.37
Options canceled or expired	(129,238)		\$ 2.61
Options outstanding at December 31, 2023	1,062,482		\$ 8.85
Exercisable at December 31, 2023	453,766		\$ 3.64

A summary of the status of the Company's non-vested restricted stock awards as of December 31, 2023 and changes during the two-year period ended December 31, 2023, is presented below: SUMMARY OF NON-VESTED RESTRICTED STOCK AWARDS

Restricted Stock Number Outstanding	Weighted Average Grant Date Fair Value	Non-vested stock awards outstanding at January 1, 2022
69,650	\$ 1.92	\$ 12.36
Granted	69,650	\$ 1.92
Vested and issued	(1,381)	\$ 12.04
Forfeited	(100)	\$ 9.45
Non-vested stock awards outstanding at December 31, 2022	69,650	\$ 1.92
Granted	22,100	\$ 0.92
Vested and issued	(59,450)	\$ 1.91
Forfeited	(200)	\$ 1.40
Non-vested stock awards outstanding at December 31, 2023	32,100	\$ 1.23

A summary of stock options outstanding at December 31, 2023 by price range is as follows: SUMMARY OF STOCK OPTIONS OUTSTANDING

Options Outstanding	Exercisable	Range of Exercise Prices	Number	Weighted Average Remaining Contractual Term (in years)	Weighted Average Exercise Price
Up to \$ 1.95	689,113	\$ 1.74 - \$ 1.95	315,867	8.8	\$ 1.71
\$ 1.96 to \$ 10.00	347,975	\$ 2.27 - \$ 113.936	8.2	\$ 4.63	\$ 10.01
Above \$ 10.01	26,394	\$ 6.3 - \$ 23.69	23,963	6.1	\$ 24.29

The fair values of stock options granted were estimated at the date of grant using the Black-Scholes option pricing model. The Black-Scholes model was originally developed for use in estimating the fair value of traded options, which have different characteristics from Immunon's stock options. The model is also sensitive to changes in assumptions, which can materially affect the fair value estimate. The Company used the following assumptions for determining the fair value of options granted under the Black-Scholes option pricing model: SCHEDULE OF ASSUMPTIONS USED TO DETERMINE FAIR VALUE OF OPTIONS GRANTED Year Ended December 31, 2023

2022	Risk-free interest rate	3.39%	4.81%	1.74%	3.97%
Expected volatility	100.0% <td>113.6% <td>100.0% <td>113.9% <td>Expected life (in years)</td> </td></td></td>	113.6% <td>100.0% <td>113.9% <td>Expected life (in years)</td> </td></td>	100.0% <td>113.9% <td>Expected life (in years)</td> </td>	113.9% <td>Expected life (in years)</td>	Expected life (in years)
7.5 to 10.0	0.0% <td>0.0% <td>0.0% <td>Expected volatilities utilized in the model are based on historical volatility of the Company's stock price.</td> </td></td>	0.0% <td>0.0% <td>Expected volatilities utilized in the model are based on historical volatility of the Company's stock price.</td> </td>	0.0% <td>Expected volatilities utilized in the model are based on historical volatility of the Company's stock price.</td>	Expected volatilities utilized in the model are based on historical volatility of the Company's stock price.	

As of December 31, 2023, there was \$ 0.4 million of total unrecognized compensation cost related to non-vested stock-based compensation arrangements. That cost is expected to be recognized over a weighted-average period of 1.8 years. X-Definition The entire disclosure for share-based payment arrangement. References Reference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(a\)\(1\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/exampleRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(a)(1)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480429/718-10-50-2) Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic718-NameAccountingStandardsCodification-PublisherFASB-URIhttps://asc.fasb.org//718/tableOfContentReference3:> [http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480429/718-10-50-2) Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(h\)\(2\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(h)(2)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480429/718-10-50-2) Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(h\)\(2\)\(i\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(h)(2)(i)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480429/718-10-50-2) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(l\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(l)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480429/718-10-50-2) Details Name: us-gaap-DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap-Data Type: dtr-types:textBlockItem Type: Balance Type: na-Period-Type: durationX-ReferencesNo definition available. Details Name: us-gaap-DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract Namespace Prefix: us-gaap-Data Type: xbrli:stringItem Type: Balance Type: na-Period-Type: durationEARN-OUT MILESTONE LIABILITY 12 Months Ended Dec. 31, 2023 Earn-out Milestone Liability EARN-OUT MILESTONE LIABILITY 13. EARN-OUT MILESTONE LIABILITY The total aggregate purchase price for the EGEN Acquisition included potential future earn-out payments contingent upon achievement of certain milestones. The difference between the aggregate \$ 30.4 million in future earn-out payments and the \$ 13.9 million included in the fair value of the acquisition consideration at June 20, 2014 was based on the Company's risk-adjusted assessment of each milestone (10% to 67%) and utilizing a discount rate based on the estimated time to achieve the milestone (1.5 to 2.5 years). The earn-out milestone liability is fair valued at the end of each quarter and any change in their value will be recognized in the Financial Statements. On March 28, 2019, the Company and EGWU, Inc., entered into the Amended Asset Purchase Agreement. Pursuant to the Amended Asset Purchase Agreement, payment of the earnout milestone liability related to the Ovarian Cancer Indication of \$ 12.4 million has been modified. The Company had the option to make the payment upon achievement of the milestones as follows: a) \$ 7.0 million in cash within 10 business days of achieving the milestone; or b) \$ 12.4 million in cash, common stock of the Company, or a combination of either, within one year of achieving the milestone. At December 31, 2022, the Company wrote off the earn-out milestone liability as a result of the requirements not being achieved and recognized a non-cash gain of \$ 5.4 million during 2022 as a result of the change in the fair value of the earn-out milestone liability. The Company fair value of the milestone liability is zero at December 31, 2023. The following is a summary of the changes in the earn-out milestone liability for 2022: SCHEDULE OF CHANGES IN EARN-OUT MILESTONE LIABILITY Balance at January 1, 2022 \$ 396,000 Non-cash gain from the adjustment for the change in fair value included in 2022 net loss (5,396,000) Balance at December 31, 2022 \$ X-ReferencesNo definition available. Details Name: IMNN-DisclosureEarnoutMilestoneLiabilityAbstract Namespace Prefix: IMNN-Data Type: xbrli:stringItem Type: Balance Type: na-Period-Type: durationX-Definition Earnout Milestone Liability-Disclosure [Text Block] ReferencesNo definition available. Details Name: IMNN-EarnoutMilestoneLiabilityDisclosureTextBlock Namespace Prefix: IMNN-Data Type: dtr-types:textBlockItem Type: Balance Type: na-Period-Type: durationWARRANTS 12 Months Ended Dec. 31, 2023 Warrants WARRANTS 14. WARRANTS Following is a summary of all warrant activity for the two years ended December 31, 2023: SUMMARY OF WARRANT ACTIVITY Warrants Number of Warrants Issued Weighted Average Exercise Price Warrants outstanding at January 1, 2022 175,792 \$ 20.96 Warrants expired during 2022 (7,273) \$ 48.30 Warrants outstanding and exercisable at December 31, 2022 168,519 \$ 19.78 Warrants expired during 2023 (8,459) \$ 37.29 Warrants outstanding and exercisable at December 31, 2023 160,060 \$ 18.86 Aggregate intrinsic value of outstanding warrants at December 31, 2023 \$ Weighted average remaining contractual terms (years) 2.2 X-ReferencesNo definition available. Details Name: IMNN-DisclosureWarrantsAbstract Namespace Prefix: IMNN-Data Type: xbrli:stringItem Type: Balance Type: na-Period-Type: durationX-Definition Disclosure of warrants. ReferencesNo definition available. Details Name: IMNN-WarrantsTextBlock Namespace Prefix: IMNN-Data Type: dtr-types:textBlockItem Type: Balance Type: na-Period-Type: durationIMUNON EMPLOYEE BENEFIT PLANS 12 Months Ended Dec. 31, 2023 Retirement Benefits [Abstract] IMUNON EMPLOYEE BENEFIT PLANS 15. IMUNON EMPLOYEE BENEFIT PLANS Immunon maintains a defined-contribution plan under Section 401 (k) of the Code. The plan covers substantially all employees over the age of twenty-one. Participating employees may defer a portion of their pretax earnings, up to the IRS annual contribution limit. The Company makes a matching contribution up to a maximum of 3% of an employee's annual salary. The Company's total matching contributions for the year ended December 31, 2023 and 2022 were \$ 142,000 and \$ 117,000, respectively. X-Definition The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans. References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic710-NameAccountingStandardsCodification-PublisherFASB-URIhttps://asc.fasb.org//710/tableOfContentReference2:> <http://fasb.org/us-gaap/role/ref/legacyRef-Topic712-NameAccountingStandardsCodification-PublisherFASB-URIhttps://asc.fasb.org//712/tableOfContentReference3:> <http://fasb.org/us-gaap/role/ref/legacyRef-Topic715-NameAccountingStandardsCodification-PublisherFASB-URIhttps://asc.fasb.org//715/tableOfContentReference4:> <http://fasb.org/us-gaap/role/ref/legacyRef-Topic718-NameAccountingStandardsCodification-PublisherFASB-URIhttps://asc.fasb.org//718/tableOfContent-Details>

Name: us-gaap-CompensationAndEmployeeBenefitPlansTextBlock-namespace-Prefix: us-gaap-Data-Type: dtr-types: textBlockItemType-Balance-Type: na-Period-Type: durationX-ReferencesNo definition available. Details Name: us-gaap-CompensationAndRetirementDisclosureAbstract-namespace-Prefix: us-gaap-Data-Type: xbrli:stringItemType-Balance-Type: na-Period-Type: durationLEASES 12 Months Ended Dec. 31, 2023 Leases LEASES 16-LEASES Lawrenceville, New Jersey Lease In August 2023, the Company renewed its Lawrenceville office lease for a 24-month agreement for 9,850 square feet with monthly rent payments of approximately \$ 22,983 to \$ 23,394. Huntsville, Alabama Lease In January 2023, the Company renewed its Huntsville facility lease for a 60-month lease agreement for 11,420 square feet with monthly rent payments of approximately \$ 28,550 to \$ 30,903. The following is a table of the lease payments and maturity of the Company's operating lease liabilities as of December 31, 2023: SCHEDULE OF LEASE PAYMENTS AND MATURITY OF OPERATING LEASE LIABILITIES For the year ending December 31, 2024 \$ 626,323 2025 543,009 2026 362,976 2027 370,236 2028 and Thereafter 30,903 Subtotal future lease payments 1,933,447 Less imputed interest (308,733) Total lease liabilities \$ 1,624,714 Weighted average remaining life 3.5 years Weighted average discount rate 9.98% For 2023, operating lease expense was \$ 646,633 and cash paid for operating leases included in operating cash flows was \$ 644,593. For 2022, operating lease expense was \$ 587,744 and cash paid for operating leases included in operating cash flows was \$ 601,495. Amortization expense was approximately \$ 472,000 and \$ 535,000 for the years ended December 31, 2023 and 2022, respectively. X-ReferencesNo definition available. Details Name: IMNN-DisclosureLeasesAbstract-namespace-Prefix: IMNN-Data-Type: xbrli:stringItemType-Balance-Type: na-Period-Type: durationX-DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/842-20/tableOfContent-Details> Name: us-gaap-LesseeOperatingLeasesTextBlock-namespace-Prefix: us-gaap-Data-Type: dtr-types: textBlockItemType-Balance-Type: na-Period-Type: durationCOMMITMENTS AND CONTINGENCIES 12 Months Ended Dec. 31, 2023 Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES 17.COMMITMENTS AND CONTINGENCIES On October 29, 2020, a putative securities class action was filed against the Company and certain of its officers and directors (the "Spar Individual Defendants") in the U. S. District Court for the District of New Jersey, captioned Spar v. Celsion Corporation, et al., Case No. 1:20-cv-15228. The plaintiff alleged that the Company and Spar Individual Defendants made false and misleading statements regarding one of the Company's drug candidates, ThermoDox®, and brought claims for damages under Section 10(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and Rule 10b-5 promulgated thereunder against all defendants, and under Section 20(a) of the Exchange Act against the Spar Individual Defendants. On February 6, 2023, the U. S. District Court granted a Motion to Dismiss filed by the Company and Spar Individual Defendants and granted the plaintiff leave to file an amended complaint within 30 days. The plaintiff did not file an amended complaint within the 30-day deadline. In September 2023, the U. S. District Court issued an Order for Dismissal without prejudice. In February 2021, a derivative shareholder lawsuit was filed against the Company, as the nominal defendant, and certain of its directors and officers as defendants in the U. S. District Court for the District of New Jersey, captioned Fidler v. Michael H. Tardugno, et al., Case No. 3:21-cv-02662. The plaintiff alleged breach of fiduciary duty and other claims arising out of alleged statements made by certain of the Company's directors and/or officers regarding ThermoDox®. The Company believes it has meritorious defenses to these claims and intends to vigorously contest this suit. At this stage of the case, neither the likelihood that a loss, if any, will be realized, nor an estimate of possible loss or range of loss, if any, can be determined. X-ReferencesNo definition available. Details Name: us-gaap-CommitmentsAndContingenciesDisclosureAbstract-namespace-Prefix: us-gaap-Data-Type: xbrli:stringItemType-Balance-Type: na-Period-Type: durationX-DefinitionThe entire disclosure for commitments and contingencies. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 440-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482648/440-10-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 440-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482648/440-10-50-4) Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 450-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/450/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 954-SubTopic 440-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480327/954-440-50-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 450-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/450/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 954-SubTopic 440-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480327/954-440-50-1) Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 440-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482648/440-10-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 440-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482648/440-10-50-4) Reference 5: <http://asc.fasb.org/us-gaap/role/ref/legacyRef-Topic 440-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/440/tableOfContent-Details> Name: us-gaap-CommitmentsAndContingenciesDisclosureTextBlock-namespace-Prefix: us-gaap-Data-Type: dtr-types: textBlockItemType-Balance-Type: na-Period-Type: durationTECHNOLOGY DEVELOPMENT AND LICENSING AGREEMENTS 12 Months Ended Dec. 31, 2023 Technology Development And Licensing Agreements TECHNOLOGY DEVELOPMENT AND LICENSING AGREEMENTS 18. TECHNOLOGY DEVELOPMENT AND LICENSING AGREEMENTS On May 7, 2012, the Company entered into a long-term commercial supply agreement with Zhejiang Hisun Pharmaceutical Co. Ltd. ("Hisun") for the production of ThermoDox® in mainland China, Hong Kong and Macau (the "China territory"). In accordance with the terms of the agreement, Hisun is responsible for providing all of the technical and regulatory support services, including the costs of all technical transfer, registration and bioequivalence studies, technical transfer costs, Imunon consultative support costs and the purchase of any necessary equipment and additional facility costs necessary to support capacity requirements for the manufacture of ThermoDox®. Imunon is obligated to repay Hisun for the aggregate amount of these development costs and fees commencing on the successful completion of three registration batches of ThermoDox®. Hisun is also obligated to meet certain performance requirements under the agreement. The agreement was initially limited to a percentage of the production requirements of ThermoDox® in the China territory with Hisun retaining an option for additional global supply after local regulatory approval in the China territory. In addition, the agreement provided that Hisun would collaborate with Imunon around the regulatory approval activities for ThermoDox® with the China State Food and Drug Administration. On January 18, 2013, the Company entered into a technology development contract with Hisun, pursuant to which Hisun paid Imunon a non-refundable research and development fee of \$ 5 million to support development of ThermoDox® in the China territory. Following the Company's announcement on January 31, 2013 that the HEAT study failed to meet its primary endpoint, Imunon and Hisun agreed that the Technology Development Contract entered into on January 18, 2013 would remain in effect while the parties continued to collaborate and evaluate the next steps in relation to ThermoDox®, which include the sub-group analysis of patients in the Phase III HEAT Study for the HCC clinical indication and other activities to further the development of ThermoDox® for the Greater China market. The \$ 5.0 million received as a non-refundable payment from Hisun in the first quarter 2013 was recorded to deferred revenue and was amortized over the 10-year term of the agreement, until such time as the parties would find a mutually acceptable path forward on the development of ThermoDox® based on findings of the ongoing post-study analysis of the HEAT study data. The Hisun agreement has expired. X-ReferencesNo definition available. Details Name: IMNN-DisclosureTechnologyDevelopmentAndLicensingAgreementsAbstract-namespace-Prefix: IMNN-Data-Type: xbrli:stringItemType-Balance-Type: na-Period-Type: durationX-DefinitionDisclosure of licensing transaction. ReferencesNo definition available. Details Name: IMNN-LicensingTransactionTextBlock-namespace-Prefix: IMNN-Data-Type: dtr-types: textBlockItemType-Balance-Type: na-Period-Type: durationRELATED PARTY TRANSACTION 12 Months Ended Dec. 31, 2023 Related Party Transactions [Abstract] RELATED PARTY TRANSACTION 19. RELATED PARTY TRANSACTION On November 16, 2022 the Company entered into a convertible note purchase agreement with Transomic Technologies, Inc. ("Transomic") whereby the Company purchased \$ 375,000 of convertible notes secured by certain assets held by Transomic and warrants. Imunon purchased product from Transomic for research and development purposes—primarily delivery vectors for its vaccine program. As a result of this investment in Transomic, Imunon's executive chairman, Mr. Michael Tardugno, was appointed to the Board of Directors of Transomic. The Company disclosed the notes receivable as a related party transaction. In December 2023, Transomic filed a formal certificate of dissolution of the company resulting in a complete write off of the convertible note and related warrants. X-ReferencesNo definition available. Details Name: us-gaap-RelatedPartyTransactionsAbstract-namespace-Prefix: us-gaap-Data-Type: xbrli:stringItemType-Balance-Type: na-Period-Type: durationX-DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147480990/946-20-50-2> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 5-Publisher FASB-URI https://asc.fasb.org/1943274/2147480990/946-20-50-5> Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147480990/946-20-50-6> Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481062/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481062/946-235-50-2) Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481062/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481062/946-235-50-2) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 850-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483226/850-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 850-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483226/850-10-50-1) Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-07\(2\)\(g\)\(3\)\)-Publisher](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-07(2)(g)(3))-Publisher)

FASB-URI <https://asc.fasb.org/1943274/2147483575/946-220-S99-1Reference-8>; [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-6-07-\(2\)-\(c\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483575/946-220-S99-1Reference-9](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-6-07-(2)-(c))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483575/946-220-S99-1Reference-9); [http://www.xbrl.org/2003/role/disclosureRef-Topic-850-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/850/tableOfContentReference-11](http://www.xbrl.org/2003/role/disclosureRef-Topic-850-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/850/tableOfContentReference-11); [http://www.xbrl.org/2003/role/disclosureRef-Topic-850-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference-12](http://www.xbrl.org/2003/role/disclosureRef-Topic-850-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference-12); [http://www.xbrl.org/2003/role/disclosureRef-Topic-850-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference-13](http://www.xbrl.org/2003/role/disclosureRef-Topic-850-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference-13); [http://www.xbrl.org/2003/role/disclosureRef-Topic-855-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483399/855-10-50-2Details-Name-us-gaap-SubsequentEventsAbstractNamespace-Prefix-us-gaap-Data-Type-xbrli:stringItem-Type-Balance-Type-na-Period-Type-durationX-Definition-The-entire-disclosure-for-significant-events-or-transactions-that-occurred-after-the-balance-sheet-date-through-the-date-the-financial-statements-were-issued-or-the-date-the-financial-statements-were-available-to-be-issued.Examples-include-the-sale-of-a-capital-stock-issue,purchase-of-a-business,settlement-of-litigation,catastrophic-loss,significant-foreign-exchange-rate-changes,loans-to-insiders-or-affiliates,and-transactions-not-in-the-ordinary-course-of-business.ReferencesReference-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-855-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483399/855-10-50-2Details-Name-us-gaap-SubsequentEventsAbstractNamespace-Prefix-us-gaap-Data-Type-xbrli:stringItem-Type-Balance-Type-na-Period-Type-durationX-Definition-The-entire-disclosure-for-significant-events-or-transactions-that-occurred-after-the-balance-sheet-date-through-the-date-the-financial-statements-were-issued-or-the-date-the-financial-statements-were-available-to-be-issued.Examples-include-the-sale-of-a-capital-stock-issue,purchase-of-a-business,settlement-of-litigation,catastrophic-loss,significant-foreign-exchange-rate-changes,loans-to-insiders-or-affiliates,and-transactions-not-in-the-ordinary-course-of-business.ReferencesReference-1);

Comprehensive Income (Loss) ASC 220, Comprehensive Income, establishes standards for the reporting and display of comprehensive income (loss) and its components in the Company's consolidated financial statements. The objective of ASC 220 is to report a measure of comprehensive income (loss) of all changes in equity of an enterprise that result from transactions and other economic events in a period other than transactions with owners. Comprehensive gains (losses) result from changes in unrealized gains and losses from investment in debt securities. Research and Development Research and Development Research and development costs are expensed as incurred. Equipment and facilities acquired for research and development activities that have alternative future uses are capitalized and charged to expense over their estimated useful lives. Net Loss per Share of Common Stock Net Loss per Share of Common Stock Basic and diluted net loss per common share was computed by dividing net loss for the year by the weighted average number of shares of common stock outstanding, both basic and diluted, during each period. The impact of common stock equivalents has been excluded from the computation of diluted weighted average common shares outstanding in periods where there is a net loss, as their effect is anti-dilutive. For the years ended December 31, 2023 and 2022, the total number of shares of common stock issuable upon exercise of warrants and equity awards was 1,255,642 and 988,389, respectively. For the years ended December 31, 2023 and 2022, diluted loss per common share is the same as basic loss per common share as all options and all other warrants that were convertible into shares of the Company's common stock were excluded from the calculation of diluted earnings attributable to common stockholders per common share as their effect would be anti-dilutive. Income Taxes Income Taxes Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in results of operations in the period that the tax rate change occurs. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. In accordance with ASC 740, Income Taxes, a tax position is recognized as a benefit only if it is "more likely than not" that the tax position taken would be sustained in a tax examination, presuming that a tax examination will occur. The Company recognizes interest and/or penalties related to income tax matters in the income tax expense category. As more fully discussed in Note 10, on November 28, 2023, the Company received approval from the New Jersey Economic Development Authority to sell \$ 1.3 million of its New Jersey net operating losses ("NOLs"), recognizing a tax benefit for the year ended December 31, 2023 for the net proceeds (approximately \$ 1.3 million) by reducing the net operating loss valuation allowance. As more fully discussed in Note 10, on November 28, 2023, the Company was notified by the New Jersey Economic Development Authority that its application was approved and the Company entered into an agreement to sell this NOL. On March 22, 2024, the Company received approximately \$ 1.3 million upon completion of the sale of the 2023 NOLs. During 2022, the Company received approval to sell \$ 1.6 million of its New Jersey NOLs, receiving net proceeds of approximately \$ 1.6 million. As part of the Technology Business Tax Certificate Program sponsored by The New Jersey Economic Development Authority, emerging biotechnology companies with unused NOLs and unused research and development credits are allowed to sell these benefits to other New Jersey-based companies. During 2021, the New Jersey State Legislature increased the maximum lifetime benefit per company from \$ 15 million to \$ 20 million, which will allow the Company to participate in this innovative funding program in future years for up to an additional \$ 0.4 million in net operating losses under this maximum lifetime benefit (see Note 2). Stock-Based Compensation Stock-Based Compensation In March 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-09, Compensation-Stock Compensation, which simplifies various aspects of accounting for share-based payments. The areas for simplification involve several aspects of the accounting for share-based payment transactions, including the income tax consequences and classification on the statements of cash flows. The Company recognizes the effect of forfeitures in compensation cost when they occur. Recent Accounting Pronouncements Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued accounting pronouncements will not have a material impact on the Company's consolidated financial position, results of operations, and cash flows, or do not apply to its operations. In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures, which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. ASU No. 2023-09 is effective for fiscal years beginning after December 15, 2024 and allows for adoption on a prospective basis, with a retrospective option. Early adoption is permitted. The Company is currently evaluating the impact of the ASU on the income tax disclosures within the consolidated financial statements. X-DefinitionDisclosure of accounting policy for deposits. ReferencesNo definition available. Details Name: IMNN_DevelopmentsPolicyTextBlock Namespace Prefix: IMNN_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX-DefinitionDisclosure of accounting policy for description of business. ReferencesNo definition available. Details Name: IMNN_DescriptionOfBusinessPolicyTextBlock Namespace Prefix: IMNN_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX-ReferencesNo definition available. Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). ReferencesNo definition available. Details Name: us-gaap_BasisOfAccountingPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX-DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org//1943274/2147482913/230-10-50-1> Details Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX-DefinitionDisclosure of accounting policy for comprehensive income. ReferencesNo definition available. Details Name: us-gaap_ComprehensiveIncomePolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX-DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 260-SubTopic 10-Section 50-Paragraph 1-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 260-SubTopic 10-Section 50-Paragraph 1-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1) Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 260-SubTopic 10-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org//1943274/2147482662/260-10-50-2> Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX-DefinitionDisclosure of accounting policy for determining the fair value of financial instruments. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 60-Paragraph 1-SubTopic 10-Topic 820-Publisher FASB-URI https://asc.fasb.org//1943274/2147482053/820-10-60-1> Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 1-SubTopic 10-Topic 825-Publisher FASB-URI https://asc.fasb.org//1943274/2147482907/825-10-50-1> Details Name: us-gaap_FairValueOfFinancialInstrumentsPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX-DefinitionDisclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 360-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SAB Topic 5-CC\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 360-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SAB Topic 5-CC)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2) Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 05-Paragraph 4-SubTopic 10-Topic 360-Publisher FASB-URI https://asc.fasb.org//1943274/2147482338/360-10-05-4> Details Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX-DefinitionDisclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets. ReferencesNo definition available. Details Name: us-gaap_InProcessResearchAndDevelopmentPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX-DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210-6-03 \(h\) \(1\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482338/946-10-03-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210-6-03 (h) (1))-Publisher FASB-URI https://asc.fasb.org//1943274/2147482338/946-10-03-3)

org//1943274/2147479886/946-10-S99-3Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 17-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 17-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Publisher FASB-URI https://asc.fasb.org//1943274/2147482685/740-10-50-9>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Publisher FASB-URI https://asc.fasb.org//1943274/2147482525/740-10-45-25>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Publisher FASB-URI https://asc.fasb.org//1943274/2147482525/740-10-45-28>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 19-Publisher FASB-URI https://asc.fasb.org//1943274/2147482685/740-10-50-19>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org//1943274/2147482765/220-10-50-1>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 20-Publisher FASB-URI https://asc.fasb.org//1943274/2147482685/740-10-50-20> Details Name: us-gaap_IncomeTaxPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na-Period Type: durationX-DefinitionDisclosure of accounting policy for investment in financial asset. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(3\)\(b\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(3)(b))-Publisher FASB-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-03\(d\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-03(d))-Publisher FASB-URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-03\(f\)\(1\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-03(f)(1))-Publisher FASB-URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-03\(f\)\(2\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-03(f)(2))-Publisher FASB-URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-03\(f\)\(3\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-03(f)(3))-Publisher FASB-URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 12-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-12](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 12-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-12)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 19-Subparagraph \(2\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 19-Subparagraph (2)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19) Details Name: us-gaap_InvestmentPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na-Period Type: durationX-DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. ReferencesNo definition available. Details Name: us-gaap_NewAccountingPronouncementsPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na-Period Type: durationX-DefinitionDisclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. ReferencesReference 1: <http://www.fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 1-SubTopic 10-Topic 360-Publisher FASB-URI https://asc.fasb.org//1943274/2147482099/360-10-50-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-03\(a\)\(8\)\(a\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-03(a)(8)(a))-Publisher FASB-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(d\)-SubTopic 360-Topic 958-Publisher FASB-URI https://asc.fasb.org//1943274/2147480321/958-360-50-1](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (d)-SubTopic 360-Topic 958-Publisher FASB-URI https://asc.fasb.org//1943274/2147480321/958-360-50-1)Details Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na-Period Type: durationX-DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 730-SubTopic 10-Name Accounting Standards Codification-Section 05-Paragraph 1-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483044/730-10-05-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 730-SubTopic 10-Name Accounting Standards Codification-Section 05-Paragraph 1-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483044/730-10-05-1)Details Name: us-gaap_ResearchAndDevelopmentExpensePolicy Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na-Period Type: durationX-DefinitionDisclosure of accounting policy for revenue from contract with customer. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 17-Publisher FASB-URI https://asc.fasb.org//1943274/2147479806/606-10-50-17>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 19-Publisher FASB-URI https://asc.fasb.org//1943274/2147479806/606-10-50-19>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479806/606-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479806/606-10-50-18)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479806/606-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479806/606-10-50-18)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 20-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479806/606-10-50-20](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 20-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479806/606-10-50-20)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 20-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479806/606-10-50-20](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 20-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479806/606-10-50-20)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 20-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479806/606-10-50-20](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 20-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479806/606-10-50-20)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 20-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479806/606-10-50-20](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 20-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479806/606-10-50-20)Reference 9: <http://www.xbrl.org/2003/role/exampleRef-Name Accounting Standards Codification-Section 50-Paragraph 4-Paragraph 4-SubTopic 10-Topic 235-Publisher FASB-URI https://asc.fasb.org//1943274/2147483426/235-10-50-4>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(f\)\(2\)\(i\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Topic 606-Publisher FASB-URI https://asc.fasb.org//606/tableOfContent-Details Name: us-gaap_RevenueFromContractWithCustomerPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na-Period Type: durationX-DefinitionDisclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost. ReferencesReference 1: <a href=)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(f\)\(2\)\(ii\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f)(2)(ii)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(f\)\(2\)\(v\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f)(2)(v)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SAB Topic 14.C.Q3\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SAB Topic 14.C.Q3)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SAB Topic 14.D.1.Q5\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SAB Topic 14.D.1.Q5)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SAB Topic 14.D.3.Q2\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SAB Topic 14.D.3.Q2)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SAB Topic 14.D.2.Q6\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SAB Topic 14.D.2.Q6)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org//718/tableOfContentReference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(f\)\(1\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f)(1)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 11: <http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph>

Outstanding at December 31, 2022 760,220 \$ 4.55 Options granted 432,500 \$ 1.23 Options canceled or expired (129,238) \$ 9.37 Outstanding at December 31, 2023 1,063,482 \$ 2.61 8.8% — Exercisable at December 31, 2023 453,766 \$ 3.64 8.5% — SUMMARY OF NON-VESTED RESTRICTED STOCK AWARDS A summary of the status of the Company's non-vested restricted stock awards as of December 31, 2023 and changes during the two-year period ended December 31, 2023, is presented below: SUMMARY OF NON-VESTED RESTRICTED STOCK AWARDS Restricted Stock Number Outstanding Weighted Average Grant Date Fair Value Non-vested stock awards outstanding at January 1, 2022 1,481 \$ 12.36 Granted 69,650 \$ 1.92 Vested and issued (1,381) \$ 12.04 Forfeited (100) \$ 9.45 Non-vested stock awards outstanding at December 31, 2022 69,650 \$ 1.92 Granted 22,100 \$ 0.92 Vested and issued (59,450) \$ 1.91 Forfeited (200) \$ 4.60 Non-vested stock awards outstanding at December 31, 2023 32,100 \$ 1.23 SUMMARY OF STOCK OPTIONS OUTSTANDING A summary of stock options outstanding at December 31, 2023 by price range is as follows: SUMMARY OF STOCK OPTIONS OUTSTANDING Options Outstanding Options Exercisable Range of Exercise Prices Number Weighted Average Remaining Contractual Term (in years) Weighted Average Exercise Price Number Weighted Average Remaining Contractual Term (in years) Weighted Average Exercise Price Up to \$ 1.95 689,113 9.1 \$ 1.74 315,867 8.8 \$ 1.71 \$ 1.96 to \$ 10.00 347,975 8.4 \$ 3.27 113,936 8.2 \$ 4.63 Above \$ 10.01 26,394 6.3 \$ 23.69 23,963 6.1 \$ 24.29 1,063,482 8.5, 766 SCHEDULE OF ASSUMPTIONS USED TO DETERMINE FAIR VALUE OF OPTIONS GRANTED The fair values of stock options granted were estimated at the date of grant using the Black-Scholes option pricing model. The Black-Scholes model was originally developed for use in estimating the fair value of traded options, which have different characteristics from Imunon's stock options. The model is also sensitive to changes in assumptions, which can materially affect the fair value estimate. The Company used the following assumptions for determining the fair value of options granted under the Black-Scholes option pricing model: SCHEDULE OF ASSUMPTIONS USED TO DETERMINE FAIR VALUE OF OPTIONS GRANTED Year Ended December 31, 2023 2022 Risk-free interest rate 3.39% to 4.81% 1.74% to 3.97% Expected volatility 100.0% to 113.6% 100.0% to 113.9% Expected life (in years) 7.5 to 10.0 7.5 to 10.0 Expected dividend yield 0.0% 0.0% X-References No definition available. Details Name: us-gaap-DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-Definition Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms. References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 10-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2> Details Name: us-gaap-ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: durationX-Definition Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(d\)-SubTopic 10-Topic 718-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 10-Section 50-Paragraph 2-Subparagraph (c)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\)-SubTopic 10-Topic 718-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e)-SubTopic 10-Topic 718-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) Details Name: us-gaap-ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: durationX-Definition Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate (s), and (e) discount for post-vesting restrictions. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 718-SubTopic 10-Subparagraph \(f\)\(2\)-Name Accounting Standards Codification-Paragraph 2-Section 50-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 718-SubTopic 10-Subparagraph (f)(2)-Name Accounting Standards Codification-Paragraph 2-Section 50-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) Details Name: us-gaap-ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: durationX-Definition Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year. References No definition available. Details Name: us-gaap-ScheduleOfShareBasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: durationEARN-OUT MILESTONE LIABILITY (Tables) 12 Months Ended Dec. 31, 2023 Earn-out Milestone Liability SCHEDULE OF CHANGES IN EARN-OUT MILESTONE LIABILITY The following is a summary of the changes in the earn-out milestone liability for 2022: SCHEDULE OF CHANGES IN EARN-OUT MILESTONE LIABILITY Balance at January 1, 2022 5,396,000 Non-cash gain from the adjustment for the change in fair value included in 2022 net loss (5,396,000) Balance at December 31, 2022 \$ X-References No definition available. Details Name: IMNN-DisclosureEarnoutMilestoneLiabilityAbstract Namespace Prefix: IMNN_ Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-Definition Schedule Of Changes In Earn Out Milestone Liabilities Table [TextBlock] References No definition available. Details Name: IMNN-ScheduleOfChangesInEarnOutMilestoneLiabilitiesTableTextBlock Namespace Prefix: IMNN_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration WARRANTS (Tables) 12 Months Ended Dec. 31, 2023 Warrants SUMMARY OF WARRANT ACTIVITY Following is a summary of all warrant activity for the two years ended December 31, 2023: SUMMARY OF WARRANT ACTIVITY Warrants Number of Warrants Issued Weighted Average Exercise Price Warrants outstanding at January 1, 2022 175,792 \$ 20.96 Warrants expired during 2022 (7,273) \$ 48.30 Warrants outstanding and exercisable at December 31, 2022 168,519 \$ 19.78 Warrants expired during 2023 (8,459) \$ 37.29 Warrants outstanding and exercisable at December 31, 2023 160,060 \$ 18.86 Aggregate intrinsic value of outstanding warrants at December 31, 2023 \$ Weighted average remaining contractual terms (years) 2.2 X-References No definition available. Details Name: IMNN-DisclosureWarrantsAbstract Namespace Prefix: IMNN_ Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-Definition Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 10-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 10-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-1) Details Name: us-gaap-ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration LEASES (Tables) 12 Months Ended Dec. 31, 2023 Leases SCHEDULE OF LEASE PAYMENTS AND MATURITY OF OPERATING LEASE LIABILITIES The following is a table of the lease payments and maturity of the Company's operating lease liabilities as of December 31, 2023: SCHEDULE OF LEASE PAYMENTS AND MATURITY OF OPERATING LEASE LIABILITIES For the year ending December 31, 2024 \$ 626,323 2025 543,009 2026 362,976 2027 370,236 2028 and Thereafter 30,903 Subtotal future lease payments 1,933,447 Less imputed interest (308,733) Total lease liabilities \$ 1,624,714 Weighted average remaining life 3.5 years Weighted average discount rate 9.98% X-References No definition available. Details Name: IMNN-DisclosureLeasesAbstract Namespace Prefix: IMNN_ Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-Definition Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. References Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-6> Details Name: us-gaap-LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) USD (\$) 12 Months Ended Dec. 31, 2023 Dec. 31, 2022 Dec. 31, 2021 Mar. 22, 2024 Nov. 28, 2023 Jan. 31, 2022 Property, Plant and Equipment [Line Items] Accounts receivable \$ 0 \$ 0 Depreciation expense 248,000 197,000 Impairment of property or equipment \$ 0 \$ 0 Number of shares of common stock issuable upon exercise of warrants and equity awards 1,255,642 988,389 NEW JERSEY Property, Plant and Equipment [Line Items] Net proceeds from sale of net operating losses \$ 1,600,000 Tax benefits of EDA \$ 1,600,000 NEW JERSEY [New Jersey Division of Taxation [Member] Property, Plant and Equipment [Line Items] Net proceeds from sale of net operating losses \$ 1,300,000 \$ 1,600,000 \$ 1,300,000 NEW JERSEY [New Jersey Division of Taxation [Member]] Subsequent Event [Member] Property, Plant and Equipment [Line Items] Net proceeds from sale of net operating losses \$ 1,300,000 Minimum [Member] Property, Plant and Equipment [Line Items] Property plant and equipment useful life 3 years Minimum [Member]] NEW JERSEY Property, Plant and Equipment [Line Items] Net proceeds from sale of net operating losses \$ 15,000,000 Maximum [Member] Property, Plant and Equipment [Line Items] Property plant and equipment useful life 7 years Maximum [Member]] NEW JERSEY

Property, Plant and Equipment [Line Items] Net proceeds from sale of net operating losses 20,000,000 Direct financing lease, selling loss \$ 400,000 X-
Definition Represents the total number of Shares of common stock issuable upon exercise of warrants and equity awards. References No definition available. Details Name: IMNN_NumberOfSharesOfCommonStockIssuableUponExerciseOfWarrantsAndEquityAwards Namespace Prefix: IMNN_Data Type: xbrli:
sharesItem Type Balance Type: na Period Type: durationX- Definition Tax benefits of EDA References No definition available. Details Name:
IMNN_TaxBenefitsOfEarningsBeforeDepreciationAndAmortization Namespace Prefix: IMNN_Data Type: xbrli: monetaryItem Type Balance Type: debit Period
Type: durationX- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course
of business. References Reference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic-946-SubTopic-310-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph-\(d\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480833/946-310-45-1Reference-2: http://www.xbrl.org/2009/role/commonPracticeRef-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-7-03-\(a\)-\(5\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479440/944-210-S99-1Reference-3: http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-6-04-\(5\)-\(b\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479617/946-210-S99-1Reference-4: http://www.xbrl.org/2003/role/disclosureRef-Topic-954-SubTopic-310-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481058/954-310-45-1](http://www.xbrl.org/2003/role/exampleRef-Topic-946-SubTopic-310-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph-(d)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480833/946-310-45-1Reference-2: http://www.xbrl.org/2009/role/commonPracticeRef-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-7-03-(a)-(5))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479440/944-210-S99-1Reference-3: http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-6-04-(5)-(b))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479617/946-210-S99-1Reference-4: http://www.xbrl.org/2003/role/disclosureRef-Topic-954-SubTopic-310-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481058/954-310-45-1) Details Name:
us-gaap_AccountsReceivableNet Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItem Type Balance Type: debit Period Type: instantX- Definition The
current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize
the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect
consumption during the period of an asset that is not used in production. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-28-Subparagraph-\(b\)-SubTopic-10-Topic-230-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference-2: http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-360-SubTopic-10-Section-50-Paragraph-1-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482099/360-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-28-Subparagraph-(b)-SubTopic-10-Topic-230-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference-2: http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-360-SubTopic-10-Section-50-Paragraph-1-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482099/360-10-50-1) Details Name: us-
gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItem Type Balance Type: debit Period Type: durationX-
Definition Amount of loss recognized at commencement from direct financing lease. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-270-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-6A-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482964/270-10-50-6AReference-2: http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-30-Name-Accounting-Standards-Codification-Section-50-Paragraph-5-Subparagraph-\(a\)-\(1\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479773/842-30-50-5](http://www.xbrl.org/2003/role/disclosureRef-Topic-270-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-6A-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482964/270-10-50-6AReference-2: http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-30-Name-Accounting-Standards-Codification-Section-50-Paragraph-5-Subparagraph-(a)-(1)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479773/842-30-50-5) Details Name: us-
gaap_DirectFinancingLeaseSellingLoss Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItem Type Balance Type: debit Period Type: durationX-
Definition The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.
References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-28-Subparagraph-\(b\)-SubTopic-10-Topic-230-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference-2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic-360-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-15-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482130/360-10-45-15](http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-28-Subparagraph-(b)-SubTopic-10-Topic-230-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference-2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic-360-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-15-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482130/360-10-45-15) Details Name: us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf Namespace Prefix: us-gaap_Data Type: xbrli:
monetaryItem Type Balance Type: debit Period Type: durationX- Definition Amount of operating loss carryforward, before tax effects, available to reduce future
taxable income under enacted tax laws. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-740-SubTopic-10-Section-50-Paragraph-3-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482685/740-10-50-3](http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-740-SubTopic-10-Section-50-Paragraph-3-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482685/740-10-50-3) Details Name:
us-gaap_OperatingLossCarryforwards Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItem Type Balance Type: debit Period Type: instantX-
Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members
defined in one or many axes to the table. References No definition available. Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-
gaap_Data Type: xbrli: stringItem Type Balance Type: na Period Type: durationX- Definition Useful life of long lived, physical assets used in the normal conduct of
business and not intended for resale, in 'PnYmMnDtnHnMns' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen
days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
References No definition available. Details Name: us-gaap_PropertyPlantAndEquipmentUsefulLife Namespace Prefix: us-gaap_Data Type: xbrli:
durationItem Type Balance Type: na Period Type: instantX- Details Name: srt_StatementGeographicalAxis = stpr_NJ Namespace Prefix: Data Type: na Balance
Type: Period Type: X- Details Name: us-gaap_IncomeTaxAuthorityNameAxis = us-gaap_NewJerseyDivisionOfTaxationMember Namespace Prefix: Data Type:
na Balance Type: Period Type: X- Details Name: srt_RangeAxis = srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details
Name: srt_RangeAxis = srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: FINANCIAL CONDITION AND GOING
CONCERN UNCERTAINTY (Details Narrative)- USD (\$) 12 Months Ended Dec. 31, 2023 Dec. 31, 2022 Organization, Consolidation and Presentation of Financial
Statements [Abstract] Net loss \$ 19,514,977 \$ 35,898,234 Fund operation 19,022,148 23,096,895 Cumulated net losses 388,182,802 \$ 368,667,825 Cash and
cash equivalents, short-term investments 15,700,000 Proceeds from sale of net operating losses \$ 1,300,000 X- Definition Proceeds From Sale Of Net Operating
Losses. References No definition available. Details Name: IMNN_ProceedsFromSaleOfNetOperatingLosses Namespace Prefix: IMNN_Data Type: xbrli:
monetaryItem Type Balance Type: debit Period Type: durationX- Definition Cash includes currency on hand as well as demand deposits with banks or financial
institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any
time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include
short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes
in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original
maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased
three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining
maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the
normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as
applicable. References Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-5-02-\(9\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-5-02-(9))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1) Details Name:
us-gaap_CashCashEquivalentsAndShortTermInvestments Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItem Type Balance Type: debit Period Type:
instantX- Definition Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions;
adjustments, and changes in value not defined as investing or financing activities. References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic-230-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-28-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference-2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic-230-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-24-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference-3: http://fasb.org/us-gaap/role/ref/legacyRef-Topic-230-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-25-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-25> Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_Data Type: xbrli:
monetaryItem Type Balance Type: na Period Type: durationX- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the
parent. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-4-08-\(g\)-\(1\)-\(ii\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference-2: http://www.xbrl.org/2003/role/disclosureRef-Topic-323-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-\(e\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference-3: http://www.xbrl.org/2003/role/disclosureRef-Topic-825-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-28-Subparagraph-\(f\)-Publisher-FASB-URI-https://asc.fasb.org/1942274/2147482907/825-10-50-28Reference-4: http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-6-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference-5: http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference-6: http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(b\)-\(2\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference-7: http://www.xbrl.org/2003/role/disclosureRef-Topic-815-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-\(f\)-](http://www.xbrl.org/2003/role/disclosureRef-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-4-08-(g)-(1)-(ii))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference-2: http://www.xbrl.org/2003/role/disclosureRef-Topic-323-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-(e)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference-3: http://www.xbrl.org/2003/role/disclosureRef-Topic-825-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-28-Subparagraph-(f)-Publisher-FASB-URI-https://asc.fasb.org/1942274/2147482907/825-10-50-28Reference-4: http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-6-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference-5: http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference-6: http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(b)-(2)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference-7: http://www.xbrl.org/2003/role/disclosureRef-Topic-815-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-(f)-)

Publisher FASB URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-8-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-9-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 12: <http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 13: <http://www.xbrl.org/2003/role/exampleRef-Topic-946-SubTopic-830-Name-Accounting-Standards-Codification-Section-55-Paragraph-10-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480167/946-830-55-10>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-45-Paragraph-7-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483581/946-220-45-7>Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-7-04-\(18\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483586/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-7-04-(18))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483586/944-220-S99-1)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-22-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-6-07-\(9\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483575/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-6-07-(9))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483575/946-220-S99-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-\(SX-210-6-09-\(1\)-\(d\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483575/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-(SX-210-6-09-(1)-(d))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483575/946-220-S99-3)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-\(SX-210-13-01-\(a\)-\(4\)-\(i\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(4)-(i))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 20: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-\(SX-210-13-01-\(a\)-\(4\)-\(ii\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(4)-(ii))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-\(SX-210-13-01-\(a\)-\(4\)-\(iii\)-\(A\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(4)-(iii)-(A))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-\(SX-210-13-01-\(a\)-\(4\)-\(iv\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(4)-(iv))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-\(SX-210-13-01-\(a\)-\(5\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(5))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-\(SX-210-13-02-\(a\)-\(4\)-\(i\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02-(a)-(4)-(i))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-\(SX-210-13-02-\(a\)-\(4\)-\(ii\)-\(A\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02-(a)-(4)-(ii)-(A))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-\(SX-210-13-02-\(a\)-\(4\)-\(iii\)-\(B\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02-(a)-(4)-(iii)-(B))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-\(SX-210-13-02-\(a\)-\(4\)-\(iv\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02-(a)-(4)-(iv))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-\(SX-210-13-02-\(a\)-\(5\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02-(a)-(5))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-30-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-30-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 30: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-\(f\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-(f)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 31: [http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-60B-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-60B-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 32: <http://www.xbrl.org/2003/role/exampleRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-31-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-31>Reference 33: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-\(c\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-(c)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 34: <http://www.xbrl.org/2003/role/disclosureRef-Topic-205-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-7-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 35: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic-230-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-28-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 36: [http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1A-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1A-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482790/220-10-45-1A)Reference 37: [http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1B-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1B-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482790/220-10-45-1B)Reference 38: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-\(SX-210-5-03-\(20\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-(SX-210-5-03-(20))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 39: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-942-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-9-04-\(22\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483589/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-942-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-9-04-(22))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483589/942-220-S99-1)Details Name: us-gaap_NetIncomeLoss-namespace-Prefix: us-gaap_Data Type: xbrli:monetaryItemType-Balance-Type: credit-Period-Type: durationX-ReferencesNo definition available. Details Name: us-gaap_OrganizationConsolidationAndPresentationOffinancialStatementsAbstract-namespace-Prefix: us-gaap_Data Type: xbrli:stringItemType-Balance-Type: na-Period-Type: durationX-DefinitionAmount of accumulated undistributed earnings (deficit). ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic-852-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-10-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-2-Subparagraph-\(g\)-\(2\)-\(i\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-2-Subparagraph-(g)-(2)-(i)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-2-Subparagraph-\(h\)-\(2\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-2-Subparagraph-(h)-(2)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480990/946-20-50-11>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-7-03-\(a\)-\(23\)-\(a\)-\(4\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479440/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-7-03-(a)-(23)-(a)-(4))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479440/944-210-S99-1)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-6-04-\(17\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479617/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-6-04-(17))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479617/946-210-S99-1)Reference 7: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-3-04\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-3-04)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480008/505-10-S99-1)Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-5-02-\(30\)-\(a\)-\(3\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-5-02-(30)-(a)-(3))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Details Name: us-gaap_RetainedEarningsAccumulatedDeficit-namespace-Prefix: us-gaap_Data Type: xbrli:monetaryItemType-Balance-Type: credit-Period-Type: instantSCHEDULE OF COST, FAIR VALUE AND MATURITIES OF SHORT-TERM INVESTMENTS (Details) USD (\$) Dec. 31, 2023 Dec. 31, 2022Marketable Securities [Line Items] Short-term investments-Cost \$ 9,796,291 \$ 21,227,991Short-term investments-Fair Value \$ 9,857,087,21,254,485Short-term investment maturities-Within 3 months, cost 2,467,518 4,005,559Short-term investment maturities-Within 3 months, fair value 2,490,775 3,994,590Short-term investment maturities-Between 3-12 months, cost 7,328,773 17,222,422Short-term investment maturities-Between 3-12 months, fair value 7,366,312 17,259,895Total, cost 9,796,291 21,227,991Total, fair value 9,857,087 21,254,485US Treasury Securities [Member] Marketable Securities [Line Items] Short-term investments-Cost 9,796,291 Short-term investments-Fair Value 9,857,087 Corporate Debt Securities [Member] Marketable Securities [Line Items] Short-term investments-Cost 21,227,991Short-term investments-Fair Value \$ 21,254,485X-DefinitionThe current amount of amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale). ReferencesNo definition

available. Details Name: IMNN_AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent Namespace Prefix: IMNN_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- Definition Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale), with single maturity date and allocated without single maturity date, maturing in next rolling three to twelve months. References No definition available. Details Name: IMNN_DebtSecuritiesAvailableforSaleMaturityAllocatedAndSingleMaturityDateRollingBetweenThreeAndTwelveMonthsAmortizedCost Namespace Prefix: IMNN_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- Definition Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale), with single maturity date and allocated without single maturity date, maturing in next rolling three to twelve months. References No definition available. Details Name: IMNN_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingBetweenThreeAndTwelveMonthsFairValue Namespace Prefix: IMNN_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- Definition Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale) with single maturity date and allocated without single maturity date, maturing in next rolling three months. References No definition available. Details Name: IMNN_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsAmortizedCost Namespace Prefix: IMNN_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- Definition Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale), with single maturity date and allocated without single maturity date, maturing in next rolling three months. References No definition available. Details Name: IMNN_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsFairValue Namespace Prefix: IMNN_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- Definition Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale), with single maturity date and allocated without single maturity date. References Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3> Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2) Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 942-SubTopic 320-Name Accounting Standards Codification-Section 50-Paragraph 3A-Publisher FASB-URI https://asc.fasb.org/1943274/2147480832/942-320-50-3A> Details Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- Definition Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale), classified as current. References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147481830/320-10-45-2> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 326-SubTopic 30-Name Accounting Standards Codification-Section 45-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147479130/326-30-45-1> Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. References No definition available. Details Name: us-gaap_MarketableSecuritiesLineItems Namespace Prefix: us-gaap_Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- Definition Amount of investments including trading securities, available for sale securities, held to maturity securities, and short-term investments classified as other and current. References Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(8\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(8))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-03\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-03(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1) Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-03\(4\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-03(4))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1) Details Name: us-gaap_ShortTermInvestments Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- Details Name: us-gaap_FinancialInstrumentAxis = us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_FinancialInstrumentAxis = us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: SUMMARY OF INVESTMENT SECURITIES GROSS UNREALIZED GAINS (LOSSES) (Details) USD (\$) Dec. 31, 2022 Investments, Debt and Equity Securities [Abstract] Investments with unrealized gains, Fair Value \$ 9, 857, 087 \$ 13, 278, 505 Investments with unrealized gains, Unrealized Holding Gains (Losses) 60, 796 43, 508 Investments with unrealized losses, Fair Value 7, 975, 980 Investments with unrealized Losses, Unrealized Holding Gains (Losses) (17, 014) Total, Fair Value 9, 857, 087 21, 254, 485 Total, Unrealized Holding Gains (Losses) \$ 60, 796 \$ 26, 494 X- Definition Available for sale securities unrealized gains fair value. References No definition available. Details Name: IMNN_AvailableForSaleSecuritiesUnrealizedGainsFairValue Namespace Prefix: IMNN_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- Definition Available for sale securities unrealized gains less than twelve months. References No definition available. Details Name: IMNN_AvailableForSaleSecuritiesUnrealizedHoldingGainsLessThanTwelveMonths Namespace Prefix: IMNN_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- Definition Available for sale securities unrealized gains (losses) less than twelve months. References No definition available. Details Name: IMNN_AvailableForSaleSecuritiesUnrealizedHoldingGainsLossesLessThanTwelveMonths Namespace Prefix: IMNN_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- Definition Available for sale securities unrealized losses less than twelve months. References No definition available. Details Name: IMNN_AvailableForSaleSecuritiesUnrealizedLossFairValue Namespace Prefix: IMNN_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- Definition Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale), classified as current. References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147481830/320-10-45-2> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 326-SubTopic 30-Name Accounting Standards Codification-Section 45-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147479130/326-30-45-1> Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent Namespace Prefix: us-gaap_Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- Definition Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale). References Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-9](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-9) Details Name: us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities. References Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03.7\(a\),\(b\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03.7(a),(b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) Details Name: us-gaap_InvestmentIncomeInterestAndDividend Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- Definition Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities. References Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03.8\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03.8)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03.7\(a\),\(b\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03.7(a),(b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) Details Name: us-gaap_InvestmentIncomeNet Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- References No definition available. Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_Data Type: xbrli: stringItemType Balance Type: na Period Type:

durationINVESTMENTS IN DEBT SECURITIES AVAILABLE FOR SALE (Details Narrative) USD (\$) Dec. 31, 2023 Dec. 31, 2022Investments, Debt and Equity Securities [Abstract] Investment in debt securities- available for sale, at fair value \$ 9, 857, 087 \$ 21, 254, 485SCHEDULE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH (Details) USD (\$) Dec. 31, 2023 Dec. 31, 2022Receivables [Abstract] Cash and cash equivalents \$ 5, 838, 566 \$ 11, 492, 841Money market investments, restricted 6, 000, 000Total \$ 5, 838, 566 \$ 17, 492, 841X- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short- term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph 1-SX 210-5-02 \(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph 1-SX 210-5-02 (1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/exampleRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483467/210-10-45-1](http://www.xbrl.org/2003/role/exampleRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483467/210-10-45-1)Reference 3: <http://asc.fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 45-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-4>Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short- term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147482913/230-10-50-8>Reference 2: <http://asc.fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 24-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://asc.fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 45-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-4>Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX- ReferencesNo definition available. Details Name: us-gaap_ReceivablesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- DefinitionInvestments which are not defined as or included in marketable (debt, equity, or other) securities whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 954-SubTopic 210-Name Accounting Standards Codification-Section 45-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147480632/954-210-45-4>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 954-SubTopic 210-Name Accounting Standards Codification-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147480602/954-210-50-2>Details Name: us-gaap_RestrictedInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX- DefinitionRESTRICED CASH (Details Narrative) USD (\$) Dec. 31, 2023 Dec. 31, 2022Line of Credit Facility [Line Items] Restricted investments \$ 6, 000, 000Silicon Valley Bank [Member] Line of Credit Facility [Line Items] Restricted investments \$ 6, 000, 000. 0X- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210-4-08 \(f\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210-4-08 (f))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Details Name: us-gaap_LineOfCreditFacilityLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- DefinitionInvestments which are not defined as or included in marketable (debt, equity, or other) securities whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 954-SubTopic 210-Name Accounting Standards Codification-Section 45-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147480632/954-210-45-4>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 954-SubTopic 210-Name Accounting Standards Codification-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147480602/954-210-50-2>Details Name: us-gaap_RestrictedInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX- Details Name: us-gaap_CreditFacilityAxis- IMN- SiliconValleyBankMember Namespace Prefix: Data Type: na Balance Type: Period Type: SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) USD (\$) Dec. 31, 2023 Dec. 31, 2022Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Investment in debt securities- available for sale, at fair value \$ 9, 857, 087 \$ 21, 254, 485Corporate Debt Securities [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Investment in debt securities- available for sale, at fair value 21, 254, 485Fair Value, Recurring [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Earn- out milestone liability Fair Value, Recurring [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Earn- out milestone liability Fair Value, Recurring [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Earn- out milestone liability Fair Value, Recurring [Member] Fair Value, Inputs, Level 3 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Earn- out milestone liability Fair Value, Recurring [Member] Fair Value, Inputs, Level 3 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Investment in debt securities- available for sale, at fair value 9, 857, 087 21, 254, 485Fair Value, Recurring [Member] Corporate Debt Securities [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Investment in debt securities- available for sale, at fair value 9, 857, 087 21, 254, 485Fair Value, Recurring [Member] Corporate Debt Securities [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Investment in debt securities- available for sale, at fair value Fair Value, Nonrecurring [Member] Inprocess R & D [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Investment in debt securities- available for sale, at fair value Fair Value, Nonrecurring [Member] Inprocess R & D [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Investment in debt securities- available for sale, at fair value Fair Value, Nonrecurring [Member] Inprocess R & D [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Investment in debt securities- available for sale, at fair value Fair Value, Nonrecurring [Member] Inprocess R & D [Member] Fair Value, Inputs, Level 3 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Investment in debt securities- available for sale, at fair value X- DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale), classified as current. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147481830/320-10-45-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 326-SubTopic 30-Name Accounting Standards Codification-Section 45-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147479130/326-30-45-1>Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer. ReferencesReference 1: [http://asc.fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 25-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147479668/805-30-25-6](http://asc.fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 805-SubTopic 30-Section 25-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147479668/805-30-25-6)Reference 2: <http://asc.fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 35-Paragraph 1-Subparagraph b-SubTopic 30-Topic 805-Publisher FASB-URI https://asc.fasb.org/1943274/2147479613/805-30-35-1>Details Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-3>Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace

Prefix: us-gaap-Data Type: xbrli:stringItemType-Balance Type: na-Period Type: durationX-Details Name: us-gaap-FinancialInstrumentAxis = us-gaap-CorporateDebtSecuritiesMember-namespace Prefix: Data Type: na-Balance Type: Period Type: X-Details Name: us-gaap-FairValueByMeasurementFrequencyAxis = us-gaap-FairValueMeasurementsRecurringMember-namespace Prefix: Data Type: na-Balance Type: Period Type: X-Details Name: us-gaap-FairValueByFairValueHierarchyLevelAxis = us-gaap-FairValueInputsLevel1Member-namespace Prefix: Data Type: na-Balance Type: Period Type: X-Details Name: us-gaap-FairValueByFairValueHierarchyLevelAxis = us-gaap-FairValueInputsLevel2Member-namespace Prefix: Data Type: na-Balance Type: Period Type: X-Details Name: us-gaap-FairValueByFairValueHierarchyLevelAxis = us-gaap-FairValueInputsLevel3Member-namespace Prefix: Data Type: na-Balance Type: Period Type: X-Details Name: us-gaap-FairValueByMeasurementFrequencyAxis = us-gaap-FairValueMeasurementsNonrecurringMember-namespace Prefix: Data Type: na-Balance Type: Period Type: X-Details Name: us-gaap-FinancialInstrumentAxis = IMNN-InprocessRandDMember-namespace Prefix: Data Type: na-Balance Type: Period Type: SCHEDULE OF FAIR-VALUE OF ASSETS ACQUIRED (Details)-IPR And D [Member]-12 Months Ended Dec. 31, 2022 USD (\$) Impairment Effects on Earnings Per Share [Line Items]-Balance \$ 13,366,234 Impairment charge (13,366,234) Balance X-Definition Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-926-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-5-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483154/926-20-50-5> Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-350-SubTopic-30-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(a\)-\(1\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-350-SubTopic-30-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(a)-(1)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482665/350-30-50-2) Details Name: us-gaap-FiniteLivedIntangibleAssetsNet-namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType-Balance Type: debit-Period Type: instantX-Definition For the asset that is reclassified back to held and used from held-for-sale, the amount of impairment charge that is recognized on the reclassification date. References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-360-SubTopic-10-Section-45-Paragraph-7-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482130/360-10-45-7> Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-360-SubTopic-10-Section-35-Paragraph-44-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482190/360-10-35-44> Details Name: us-gaap-ImpairmentChargeOnReclassifiedAssets-namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType-Balance Type: debit-Period Type: durationX-Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. References No definition available. Details Name: us-gaap-ImpairmentEffectsOnEarningsPerShareLineItems-namespace Prefix: us-gaap-Data Type: xbrli:stringItemType-Balance Type: na-Period Type: durationX-Details Name: us-gaap-FairValueByAssetClassAxis = IMNN-IPRAndDMember-namespace Prefix: Data Type: na-Balance Type: Period Type: INTANGIBLE ASSETS (Details Narrative)-In Process Research and Development [Member]-USD (\$) \$ in Millions 3 Months Ended 12 Months Ended Dec. 31, 2022 Dec. 31, 2023 Dec. 31, 2022 EGEN Inc [Member]-IPR & D Drug Technology Platforms [Member]-Finite-Lived Intangible Assets [Line Items]-Estimated acquisition price \$ 24.2 IPR & D Drug Technology Platforms [Member]-Finite-Lived Intangible Assets [Line Items]-Asset impairment charges \$ 13.4 Non-cash charge \$ 13.4 X-Definition Non-cash charge. References No definition available. Details Name: IMNN-NoncashCharge-namespace Prefix: IMNN-Data Type: xbrli:monetaryItemType-Balance Type: debit-Period Type: durationX-Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-28-Subparagraph-\(b\)-SubTopic-10-Topic-230-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-28-Subparagraph-(b)-SubTopic-10-Topic-230-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-28) Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-360-SubTopic-10-Section-45-Paragraph-4-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482130/360-10-45-4> Details Name: us-gaap-AssetImpairmentCharges-namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType-Balance Type: debit-Period Type: durationX-Definition Purchase price of expected business acquisition prior to consideration being transferred. Excludes asset acquisition. References Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Name-Accounting-Standards-Codification-Section-15-Paragraph-3-SubTopic-10-Topic-805-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479455/805-10-15-3> Details Name: us-gaap-BusinessCombinationPriceOfAcquisitionExpected-namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType-Balance Type: credit-Period Type: durationX-Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-926-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-5-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483154/926-20-50-5> Details Name: us-gaap-FiniteLivedIntangibleAssetsLineItems-namespace Prefix: us-gaap-Data Type: xbrli:stringItemType-Balance Type: na-Period Type: durationX-Details Name: us-gaap-BusinessAcquisitionAxis = IMNN-EGENIncMember-namespace Prefix: Data Type: na-Balance Type: Period Type: X-Details Name: dei-LegalEntityAxis = IMNN-IPRAndDDrugTechnologyPlatformsMember-namespace Prefix: Data Type: na-Balance Type: Period Type: X-Details Name: us-gaap-FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap-InProcessResearchAndDevelopmentMember-namespace Prefix: Data Type: na-Balance Type: Period Type: X-Details Name: us-gaap-BusinessAcquisitionAxis = IMNN-IPRAndDDrugTechnologyPlatformsMember-namespace Prefix: Data Type: na-Balance Type: Period Type: SUMMARY OF PROPERTY AND EQUIPMENT (Details)-USD (\$) Dec. 31, 2023 Dec. 31, 2022 Property, Plant and Equipment [Line Items]-Property and equipment gross \$ 2,854,178 \$ 3,192,063 Less accumulated depreciation and amortization (2,102,272) (2,643,762) Total 751,906 548,301 Machinery and Equipment [Member]-Property, Plant and Equipment [Line Items]-Property and equipment gross 2,055,192 2,468,388 Furniture and Fixtures [Member]-Property, Plant and Equipment [Line Items]-Property and equipment gross 191,932 350,481 Leasehold Improvements [Member]-Property, Plant and Equipment [Line Items]-Property and equipment gross \$ 607,054 \$ 373,194 X-Definition Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-599-Paragraph-1-Subparagraph-\(SX-210-7-03\(a\)-\(8\)\(b\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479440/944-210-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-599-Paragraph-1-Subparagraph-(SX-210-7-03(a)-(8)(b))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479440/944-210-599-1) Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-599-Paragraph-1-Subparagraph-\(SX-210-5-02\(13\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-599-Paragraph-1-Subparagraph-(SX-210-5-02(13))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-599-1) Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-360-SubTopic-10-Section-50-Paragraph-1-Subparagraph-\(c\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482099/360-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-360-SubTopic-10-Section-50-Paragraph-1-Subparagraph-(c)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482099/360-10-50-1) Details Name: us-gaap-AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType-Balance Type: credit-Period Type: instantX-Definition Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-599-Paragraph-1-Subparagraph-\(SX-210-7-03\(a\)-\(8\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479440/944-210-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-599-Paragraph-1-Subparagraph-(SX-210-7-03(a)-(8))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479440/944-210-599-1) Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-599-Paragraph-1-Subparagraph-\(SX-210-5-02\(13\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-599-Paragraph-1-Subparagraph-(SX-210-5-02(13))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-599-1) Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-360-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482099/360-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-360-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482099/360-10-50-1) Details Name: us-gaap-PropertyPlantAndEquipmentGross-namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType-Balance Type: debit-Period Type: instantX-Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. References No definition available. Details Name: us-gaap-PropertyPlantAndEquipmentLineItems-namespace Prefix: us-gaap-Data Type: xbrli:stringItemType-Balance Type: na-Period Type: durationX-Definition Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-SubTopic-10-Topic-360-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482099/360-10-50-1> Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic-852-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-10-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481372/852-10-55-10> Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-599-Paragraph-1-Subparagraph-\(SX-210-7-03\(a\)-\(8\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479440/944-210-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-599-Paragraph-1-Subparagraph-(SX-210-7-03(a)-(8))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479440/944-210-599-1) Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic-942-SubTopic-360-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480842/942-360-50-1> Details Name: us-gaap-PropertyPlantAndEquipmentNet-namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType-Balance Type: debit-Period Type: instantX-Details Name: us-gaap-PropertyPlantAndEquipmentByTypeAxis = us-gaap-MachineryAndEquipmentMember-namespace Prefix: Data Type: na-Balance Type: Period Type: X-Details Name: us-gaap-PropertyPlantAndEquipmentByTypeAxis = us-gaap-FurnitureAndFixturesMember-namespace Prefix: Data Type: na-Balance Type: Period Type: X-Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis = us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: SUMMARY OF PROPERTY AND EQUIPMENT (Details) (Parenthetical) Dec. 31, 2023 Minimum [Member] Property, Plant and Equipment [Line Items] Estimated useful life 3 years Maximum [Member] Property, Plant and Equipment [Line Items] Estimated useful life 7 years Machinery and Equipment [Member] Minimum [Member] Property, Plant and Equipment [Line Items] Estimated useful life 5 years Machinery and Equipment [Member] Maximum [Member] Property, Plant and Equipment [Line Items] Estimated useful life 7 years Furniture and Fixtures [Member] Minimum [Member] Property, Plant and Equipment [Line Items] Estimated useful life 3 years Furniture and Fixtures [Member] Maximum [Member] Property, Plant and Equipment [Line Items] Estimated useful life 5 years Leasehold Improvements [Member] Minimum [Member] Property, Plant and Equipment [Line Items] Estimated useful life 5 years Leasehold Improvements [Member] Maximum [Member] Property, Plant and Equipment [Line Items] Estimated useful life 7 years X-Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. References No definition available. Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-Definition Useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. References No definition available. Details Name: us-gaap_PropertyPlantAndEquipmentUsefulLife Namespace Prefix: us-gaap Data Type: xbrli:durationItemType Balance Type: na Period Type: instantX-Details Name: srt_RangeAxis = srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: srt_RangeAxis = srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis = us-gaap_MachineryAndEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis = us-gaap_FurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis = us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: SCHEDULE OF OTHER ACCRUED LIABILITIES (Details) USD (\$) Dec. 31, 2023 Dec. 31, 2022 Payables and Accruals [Abstract] Amounts due to contract research organizations and other contractual agreements \$ 1,442,659 \$ 2,196,711 Accrued payroll and related benefits 1,693,383 2,139,927 Accrued interest 37,583 Accrued professional fees 234,479 215,402 Other 20,000 205,313 Total \$ 3,390,521 \$ 4,794,936 X-Definition Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name/AccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph\(SX210-5-02-20\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name/AccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph(SX210-5-02-20)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1) Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-Definition Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name/AccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph\(SX210-5-02-20\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name/AccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph(SX210-5-02-20)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1) Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-Definition Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments. References Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic235-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph3-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480678/235-10-S99-3> Details Name: us-gaap_ContractualObligation Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-Definition Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name/AccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph\(SX210-5-02-20\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name/AccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph(SX210-5-02-20)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1) Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-Definition Carrying value as of the balance sheet date of accrued interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name/AccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph\(SX210-5-02-20\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name/AccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph(SX210-5-02-20)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1) Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-References No definition available. Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration SCHEDULE OF DEBT (Details) Horizon Technology Finance Corporation [Member] Apr. 21, 2023 USD (\$) Principal balance at April 21, 2023 \$ 6,000,000 Early termination fees 120,000 End of term charges 300,000 Total payoff amount \$ 6,420,000 X-Definition Early termination fee. References No definition available. Details Name: IMNN_EarlyTerminationFee Namespace Prefix: IMNN Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-Definition End of term charge. References No definition available. Details Name: IMNN_EndOfTermCharges Namespace Prefix: IMNN Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-Definition The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long-term obligation to refinance the short-term obligation on a long-term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long-term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name/AccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210-5-02\(22\)\)-SubTopic10-Topic210-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name/AccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210-5-02(22))-SubTopic10-Topic210-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1) Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic944-SubTopic210-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210-7-03\(a\)\(16\)\(a\)\(2\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479440/944-210-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic944-SubTopic210-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210-7-03(a)(16)(a)(2))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479440/944-210-S99-1) Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic942-SubTopic210-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210-9-03\(16\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479853/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic942-SubTopic210-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210-9-03(16))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479853/942-210-S99-1) Details Name: us-gaap_LineOfCredit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-Definition Fair value of the amount outstanding under the credit facility. References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic825-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph10-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482907/825-10-50-10> Details Name: us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-Details Name: dei_LegalEntityAxis = IMNN_HorizonTechnologyFinanceCorporationMember Namespace Prefix: Data Type: na Balance Type: Period Type: NOTES PAYABLE (Details Narrative) USD (\$) 1 Months Ended 12 Months Ended Jun. 18, 2021 Aug. 31, 2020 Dec. 31, 2023 Dec. 31, 2022 Line of Credit Facility [Line Items] Interest expense debt \$ 197,080 \$ 5,028,618 Silicon Valley Bank [Member] Line of Credit Facility [Line Items] Gain (loss) on contract termination 229,158 Silicon Valley Bank [Member] Line of Credit Facility [Line Items] Line of credit facility, maximum borrowing capacity \$ 10,000,000 Proceeds from lines of credit \$ 6,000,000 Loan amount withdrawn \$ 10,000,000 Repayments of lines of credit \$ 5,000,000 Restricted cash \$ 6,000,000 Final payment percentage 3.00% Long term line of credit \$ 10,000,000 Debt instrument, description Payments under the loan agreement were interest only for the first 24 months after loan closing, followed by a 24-month amortization period of principal and interest through the scheduled maturity date. Financing fees and expenses \$ 243,370 End of term charge percentage 3.00% Interest expense debt \$ 300,000 334,212 Interest expense 197,080 295,792 Amortization of debt issuance costs

\$ 329, 158 \$ 181, 259X—DefinitionEnd of term charge percentage. ReferencesNo definition available. Details Name: IMNN_EndOfTermChargePercentage Namespace Prefix: IMNN_Data Type: dtr—types: percentItem Type Balance Type: na Period Type: durationX—DefinitionFinal Payment Percentage. ReferencesNo definition available. Details Name: IMNN_FinalPaymentPercentage Namespace Prefix: IMNN_Data Type: dtr—types: percentItem Type Balance Type: na Period Type: instantX—DefinitionAmount of amortization expense attributable to debt discount (premium) and debt issuance costs. ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 55-Paragraph 69E-Publisher FASB-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E>Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 55-Paragraph 69F-Publisher FASB-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1F-Subparagraph \(b\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1F-Subparagraph (b)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 835-SubTopic 30-Name Accounting Standards Codification-Section 45-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147482925/835-30-45-3>Details Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItem Type Balance Type: debit Period Type: durationX—DefinitionIdentification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(22\)\)-SubTopic 10-Topic 210-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(22))-SubTopic 10-Topic 210-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(19\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(19))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-03\(13\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-03(13))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1)Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-03\(16\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-03(16))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1)Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 505-SubTopic 10-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3>Reference 6: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 942-SubTopic 470-Section 50-Paragraph 3-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480848/942-470-50-3](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 942-SubTopic 470-Section 50-Paragraph 3-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480848/942-470-50-3)Details Name: us-gaap_DebtInstrumentDescription Namespace Prefix: us-gaap_Data Type: xbrli: stringItem Type Balance Type: na Period Type: durationX—DefinitionGain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Details Name: us-gaap_GainLossOnContractTermination Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItem Type Balance Type: credit Period Type: durationX—DefinitionInterest and debt related expenses associated with nonoperating financing activities of the entity. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 1-SubTopic 20-Topic 835-Publisher FASB-URI https://asc.fasb.org/1943274/2147483013/835-20-50-1>Details Name: us-gaap_InterestAndDebtExpense Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItem Type Balance Type: debit Period Type: durationX—DefinitionAmount of the cost of borrowed funds accounted for as interest expense. ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147480167/946-830-55-10>Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 45-Paragraph 3-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483581/946-220-45-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 45-Paragraph 3-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483581/946-220-45-3)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-07\(3\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-07(3))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 835-SubTopic 30-Section 45-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147482925/835-30-45-3>Reference 6: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-04-9\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483589/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04-9)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483589/942-220-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(210.5-03\(11\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (210.5-03(11))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 835-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483013/835-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 835-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483013/835-20-50-1)Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItem Type Balance Type: debit Period Type: durationX—DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 55-Paragraph 69E-Publisher FASB-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E>Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 55-Paragraph 69F-Publisher FASB-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1F-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1F-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F)Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(8\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(8))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 6-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 6-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481139/470-20-50-6)Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItem Type Balance Type: debit Period Type: durationX—DefinitionThe carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long-term obligation to refinance the short-term obligation on a long-term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long-term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(22\)\)-SubTopic 10-Topic 210-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(22))-SubTopic 10-Topic 210-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-03\(a\)\(16\)\(a\)\(2\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-03(a)(16)(a)(2))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-03\(16\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-03(16))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1)Details Name: us-gaap_LineOfCredit Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItem Type Balance Type: credit Period Type: instantX—DefinitionAmount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02.19\(b\); 22\(b\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph (SX 210.5-02.19(b); 22(b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Details Name: us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity Namespace Prefix: us-gaap_Data Type: xbrli: monetaryItem Type Balance Type: credit Period Type: instantX—DefinitionLine items represent financial concepts included in a table. These

concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 4-08 \(f\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 4-08 (f))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1) Details Name: us-gaap_LineOfCreditFacilityLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph \(SX 210. 5-02. 19 \(b\), 22 \(b\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph (SX 210. 5-02. 19 (b), 22 (b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-DefinitionAmount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 4-08 \(f\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 4-08 (f))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1) Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 45-Paragraph 14-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 45-Paragraph 14-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14) Details Name: us-gaap_ProceedsFromLinesOfCredit Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-DefinitionAmount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 4-08 \(f\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 4-08 (f))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1) Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 45-Paragraph 15-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-15](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 45-Paragraph 15-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-15) Details Name: us-gaap_RepaymentsOfLinesOfCredit Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 7-03 \(a\) \(2\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 7-03 (a) (2))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1) Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 5-02 \(1\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 5-02 (1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147482913/230-10-50-8> Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 9-03 \(1\) \(a\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 9-03 (1) (a))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1) Details Name: us-gaap_RestrictedCash Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-Details Name: us-gaap_TypeOfArrangementAxis = IMNN_SiliconValleyBankMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap_LineOfCreditFacilityAxis = IMNN_SiliconValleyBankMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-SCHEDULE OF INCOME TAX PROVISION (BENEFIT) (Details) USD (\$) 12 Months Ended Dec. 31, 2023 Dec. 31, 2022 Income Tax Disclosure [Abstract] Current Deferred State and Local Current Deferred (1, 280, 385) (1, 567, 026) Total \$ (1, 280, 385) \$ (1, 567, 026) X-DefinitionAmount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 4-08 \(h\) \(1\) \(Note 1\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 4-08 (h) (1) (Note 1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1) Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Name Accounting Standards Codification-Section 50-Paragraph 9-Subparagraph \(a\)-SubTopic 10-Topic 740-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-9](http://www.xbrl.org/2009/role/commonPracticeRef-Name Accounting Standards Codification-Section 50-Paragraph 9-Subparagraph (a)-SubTopic 10-Topic 740-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-9) Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SAB Topic 6. I. 7\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SAB Topic 6. I. 7)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1) Details Name: us-gaap_CurrentFederalTaxExpenseBenefit Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-DefinitionAmount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 4-08 \(h\) \(1\) \(Note 1\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 4-08 (h) (1) (Note 1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1) Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Name Accounting Standards Codification-Section 50-Paragraph 9-Subparagraph \(a\)-SubTopic 10-Topic 740-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-9](http://www.xbrl.org/2009/role/commonPracticeRef-Name Accounting Standards Codification-Section 50-Paragraph 9-Subparagraph (a)-SubTopic 10-Topic 740-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-9) Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SAB Topic 6. I. 7\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SAB Topic 6. I. 7)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1) Details Name: us-gaap_CurrentStateAndLocalTaxExpenseBenefit Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-DefinitionAmount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 4-08 \(h\) \(1\) \(Note 1\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 4-08 (h) (1) (Note 1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1) Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SAB Topic 6. I. 7\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SAB Topic 6. I. 7)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1) Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SAB Topic 6. I. 7\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SAB Topic 6. I. 7)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1) Details Name: us-gaap_DeferredFederalIncomeTaxExpenseBenefit Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-DefinitionAmount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction. ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10> Details Name: us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-DefinitionAmount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 4-08 \(h\) \(1\) \(Note 1\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 4-08 (h) (1) (Note 1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1) Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SAB Topic 6. I. 7\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SAB Topic 6. I. 7)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1) Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SAB Topic 6. I. 7\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SAB Topic 6. I. 7)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1) Details Name: us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-ReferencesNo definition available. Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9> Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10> Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SAB TOPIC 6. I. 7\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SAB TOPIC 6. I. 7)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1) Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph \(h\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph (h)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SAB TOPIC 6. I. 7\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SAB TOPIC 6. I. 7)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1)

Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(9))-Publisher FASB-URI https://asc.fasb.org/1943274/2147482586/944-220-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 45-Paragraph 2-Subparagraph (a)-SubTopic 20-Topic 740-Publisher FASB-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(h))-SubTopic 10-Topic 235-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Details Name: us-gaap-IncomeTaxExpenseBenefitNamespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationSCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details) 12 Months Ended Dec. 31, 2023 Dec. 31, 2022 Income Tax Disclosure [Abstract] Federal statutory rate 21.00% 21.00% State taxes, net of federal tax benefit 7.10% 7.10% Permanent differences (3.10%) 29.80% True-Up (105.00%) Other (2.90%) Change in valuation allowance and deferred rate change, net 89.00% (53.80%) Effective tax rate 6.10% 4.10% X-Definition Effective income tax rate reconciliation permanent differences. References No definition available. Details Name: IMNN-EffectiveIncomeTaxRateReconciliationPermanentDifferences Namespace Prefix: IMNN-Data Type: dtr-types:percentItemType Balance Type: na Period Type: durationX-Definition Effective income tax rate reconciliation time up. References No definition available. Details Name: IMNN-EffectiveIncomeTaxRateReconciliationTimeUp Namespace Prefix: IMNN-Data Type: dtr-types:percentItemType Balance Type: na Period Type: durationX-Definition Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. References Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 12-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Details Name: us-gaap-EffectiveIncomeTaxRateContinuingOperations Namespace Prefix: us-gaap-Data Type: dtr-types:percentItemType Balance Type: na Period Type: durationX-Definition Percentage of domestic federal statutory tax rate applicable to pretax income (loss). References Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(h)(2))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 12-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SAB Topic 6.1.Fact.4)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Details Name: us-gaap-EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Namespace Prefix: us-gaap-Data Type: dtr-types:percentItemType Balance Type: na Period Type: durationX-Definition Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets. References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 12-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SAB Topic 6.1.Fact.4)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Details Name: us-gaap-EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Namespace Prefix: us-gaap-Data Type: dtr-types:percentItemType Balance Type: na Period Type: durationX-Definition Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments. References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 12-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SAB Topic 6.1.Fact.4)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Details Name: us-gaap-EffectiveIncomeTaxRateReconciliationOtherAdjustments Namespace Prefix: us-gaap-Data Type: dtr-types:percentItemType Balance Type: na Period Type: durationX-Definition Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit). References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 12-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SAB Topic 6.1.Fact.4)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Details Name: us-gaap-EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Namespace Prefix: us-gaap-Data Type: dtr-types:percentItemType Balance Type: na Period Type: durationX-References No definition available. Details Name: us-gaap-IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap-Data Type: xbrli:stringItemType Balance Type: na Period Type: durationSCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) USD (\$) Dec. 31, 2023 Dec. 31, 2022 Income Tax Disclosure [Abstract] Net operating loss carryforwards \$ 67,310,000 \$ 79,800,000 Section 174-4,929,000 Other deferred tax assets, net 2,016,000 13,287,000 Subtotal 74,255,000 93,087,000 Valuation allowance (72,974,615) (91,519,974) Total deferred tax asset \$ 1,280,385 \$ 1,567,026 X-Definition Deferred tax assets legal act. References No definition available. Details Name: IMNN-DeferredTaxAssetsLegalAct Namespace Prefix: IMNN-Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. References Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-2Details Name: us-gaap-DeferredTaxAssetsGross Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-Definition Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-2Details Name: us-gaap-DeferredTaxAssetsNet Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards. References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-6Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 740-SubTopic 10-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-8Details Name: us-gaap-DeferredTaxAssetsOperatingLossCarryforwards Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-Definition Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other. References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-6Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 740-SubTopic 10-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-8Details Name: us-gaap-DeferredTaxAssetsOther Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-Definition Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized. References Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-2Details Name: us-gaap-DeferredTaxAssetsValuationAllowance Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-References No definition available. Details Name: us-gaap-IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap-Data Type: xbrli:stringItemType Balance Type: na Period Type: durationINCOME TAXES (Details Narrative) USD (\$) 12 Months Ended Dec. 31, 2023 Dec. 31, 2022 Dec. 31, 2021 Nov. 28, 2023 Jan. 31, 2022 Dec. 31, 2018 Operating Loss Carryforwards [Line Items] [custom: ProceedsFromSaleOfNetOperatingLosses] \$ 1,300,000 Deferred Tax Assets, Operating Loss Carryforwards \$ 67,310,000 \$ 79,800,000 [custom: NetOperatingLossesExpirationDescription] expire starting in 2029 through 2042 Income tax examination, description Expenses incurred in connection with R & E activities in the US must be amortized over a 5-year period if incurred, and R & E expenses incurred outside the US must be amortized over a 15-year period. R & E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2023, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R & E expenses. The Company will continue to monitor this issue for future developments, but it does not expect R & E capitalization and amortization to require it to pay cash taxes now or in the near future. The Company's income tax returns for 2019 to 2022 are still open and subject to audit. In addition, net operating losses arising from prior years are also subject to examination at the time they are utilized in future years Operating

Income (Loss) \$ (21,030,430) (24,921,565) Domestic Tax Authority [Member] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards 307,000,000 Net operating losses, unused 218,000,000 Federal Income Tax [Member] No Expiration [Member] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards \$ 78,000,000 State and Local Jurisdiction [Member] Operating Loss Carryforwards [Line Items] Deferred Tax Assets, Operating Loss Carryforwards 44,000,000 New Jersey [Member] Operating Loss Carryforwards [Line Items] Custom: ProceedsFromSaleOfNetOperatingLosses 1,300,000 Net proceeds from sale of net operating losses 1,300,000 1,600,000 New Jersey [Member] Maximum [Member] Operating Loss Carryforwards [Line Items] Operating Income (Loss) \$ 300,000 New Jersey [Member] State and Local Jurisdiction [Member] Minimum [Member] Operating Loss Carryforwards [Line Items] Net proceeds from sale of net operating losses 15,000,000 New Jersey [Member] State and Local Jurisdiction [Member] Maximum [Member] Operating Loss Carryforwards [Line Items] Net proceeds from sale of net operating losses 20,000,000 NEW JERSEY Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards \$ 1,600,000 NEW JERSEY Minimum [Member] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards 15,000,000 NEW JERSEY Maximum [Member] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards \$ 20,000,000 NEW JERSEY New Jersey Division of Taxation [Member] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards \$ 1,300,000 \$ 1,600,000 \$ 1,300,000 X-Definition Net operating losses expiration, description. References No definition available. Details Name: IMNN_NetOperatingLossesExpirationDescription Namespace Prefix: IMNN Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-Definition Net operating losses, unused. References No definition available. Details Name: IMNN_NetOperatingLossesUnused Namespace Prefix: IMNN Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-Definition Net proceeds from sale of net operating losses References No definition available. Details Name: IMNN_NetProceedsFromSaleOfNetOperatingLosses Namespace Prefix: IMNN Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-Definition Proceeds From Sale Of Net Operating Losses. References No definition available. Details Name: IMNN_ProceedsFromSaleOfNetOperatingLosses Namespace Prefix: IMNN Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards. References Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-6> Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 740-SubTopic 10-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-8> Details Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwards Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-Definition A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 740-SubTopic 10-Section 50-Paragraph 15-Subparagraph \(d\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-15](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 740-SubTopic 10-Section 50-Paragraph 15-Subparagraph (d)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-15) Details Name: us-gaap_IncomeTaxExaminationDescription Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-Definition The net result for the period of deducting operating expenses from operating revenues. References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30) Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) Reference 4: <http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 31-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31> Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(e\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (e)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-Definition Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 740-SubTopic 10-Section 50-Paragraph 3-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-3](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 740-SubTopic 10-Section 50-Paragraph 3-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-3) Details Name: us-gaap_OperatingLossCarryforwards Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. References No definition available. Details Name: us-gaap_OperatingLossCarryforwardsLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-Details Name: us-gaap_IncomeTaxAuthorityAxis = us-gaap_DomesticCountryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap_IncomeTaxAuthorityAxis = IMNN_FederalIncomeTaxMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: srt_StatementScenarioAxis = IMNN_NoExpirationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap_IncomeTaxAuthorityAxis = us-gaap_StateAndLocalJurisdictionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: srt_StatementGeographicalAxis = IMNN_NJMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: srt_RangeAxis = srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: srt_StatementGeographicalAxis = srt_NJ Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap_IncomeTaxAuthorityNameAxis = us-gaap_NewJerseyDivisionOfTaxationMember Namespace Prefix: Data Type: na Balance Type: Period Type: STOCKHOLDERS' EQUITY (Details Narrative) USD (\$) 12 Months Ended May 25, 2022 Apr. 06, 2022 Jan. 10, 2022 Mar. 19, 2021 Dec. 31, 2023 Dec. 31, 2022 Mar. 03, 2022 Feb. 28, 2022 Jan. 13, 2022 Class of Stock [Line Items] Stock issued during period, value, new issues \$ 2,781,438 \$ 6,722,654 Reverse stock split, description On February 28, 2022, the Company effected a 15-for-1 reverse stock split of its common stock which was made effective for trading purposes as of the commencement of trading on March 31, 2022. As of that date, each 15 shares of issued and outstanding common stock and equivalents was consolidated into one share of common stock. All shares have been restated to reflect the effects of the 15-for-1 reverse stock split. In addition, at the market open on March 1, 2022, the Company's common stock started trading under a new CUSIP number 15117N602 although the Company's ticker symbol, CLSN, remained unchanged. Stockholders equity note changes in capital structure description To continue listing on The NASDAQ Capital Market, which requires that the Company comply with the applicable listing requirements under NASDAQ Marketplace Rules, which requirements include, among others, a minimum bid price of at least \$ 1.00 per share. On December 2, 2021, the Company received a letter from NASDAQ indicating that the closing bid price of the Company's common stock fell below \$ 1.00 per share for the previous 30 consecutive business days, and that the Company was therefore not in compliance with the minimum bid price requirement for continued inclusion on The NASDAQ Capital Market. The Company had 180 calendar days, until May 31, 2022, to regain compliance with this requirement, which occurs when the closing bid price of the Company's common stock is at least \$ 1.00 per share for a minimum of ten consecutive business days during the 180-day compliance period. Common stock, shares outstanding 9,399,789 7,436,197 86,557,736 Reverse stock split 5,770,516 Preferred stock, shares issued Preferred stock, stated value \$ 300 \$ 0.01 \$ 0.01 \$ 300 Proceeds from issuance of preferred stock \$ 28,500,000 Preferred stock, shares outstanding Proceeds from issuance under placement \$ 1,000,000 Proceeds from issuance of common stock \$ 2,781,438 \$ 6,722,654 Series A Convertible Redeemable Preferred Stock [Member] Class of Stock [Line Items] Preferred stock, shares issued 50,000 Preferred stock, stated value \$ 0.01 Share price \$ 300 Original issue discount rate 5.00% Preferred stock, conversion price \$ 13.65 Conversion of stock, shares issued 1,098,901 Preferred stock, shares outstanding 50,000 Series B Convertible Redeemable Preferred Stock [Member] Class of Stock [Line Items] Preferred stock, shares issued 50,000 Preferred stock, stated value \$ 0.01 Share price \$ 285 \$ 300 Proceeds from issuance of preferred stock \$ 14,250,000 Preferred stock, conversion price \$ 15.00 Conversion of stock, shares issued 1,000,000 Preferred stock, shares outstanding 50,000 Market Offering Agreement [Member] Class of Stock [Line Items] Stock issued during period, value, new issues \$ 7,500,000 Number of shares sold 1,904,142 336,075 Proceeds from sale of stock \$ 2,781,438 \$ 503,798 Securities Purchase Agreement [Member] April 2022 Registered Direct Offering [Member] Class of Stock [Line Items] Share price \$ 5.27 Stock issued, shares 1,328,274 Proceeds from issuance of common stock \$ 7,000,000 Placement agent fee description In connection with the April 2022 Offering, the Company entered into a placement agent agreement with A. G. P. / Alliance Global Partners (the "April 2022 Placement Agent") pursuant to which the Company agreed to pay the April 2022 Placement Agent a cash fee equal to 6.5% of the aggregate gross proceeds raised from the sale of the securities sold in the April 2022 Offering and reimburse the April 2022 Placement Agent for certain of their expenses in an amount not to exceed \$ 50,000. Maximum [Member] Class of Stock [Line Items] Common stock, shares outstanding 6,600,000 Warrants issued 2,500,000 Proceeds from issuance under placement \$ 110,000 Minimum [Member] Class of Stock [Line Items] Common stock, shares outstanding 400,000 Warrants issued 200,000 2021 Registration Statement [Member] Class of Stock [Line Items] Stock issued during period, value, new issues \$ 100,000,000 Public float 75,000,000 2021 Registration Statement [Member] Baby Shelf Limitation [Member] Class of Stock [Line Items] Public float \$ 75,000,000 X-Definition Original issue discount rate. References No definition available. Details Name: IMNN_OriginalIssueDiscountRate Namespace Prefix: IMNN Data Type:

dtr-types: percentItem Type: Balance Type: na Period Type: instantX-Definition Placement agent-fee-description. ReferencesNo definition available. Details Name: IMNN_PlacementAgentFeeDescription Namespace Prefix: IMNN_Data Type: xbrli:stringItem Type: Balance Type: na Period Type: durationX-Definition Amount of public float. ReferencesNo definition available. Details Name: IMNN_PublicFloat Namespace Prefix: IMNN_Data Type: xbrli:monetaryItem Type: Balance Type: debit Period Type: durationX-Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3](http://www.xbrl.org/2003/role/exampleRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef-Topic 272-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 272-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 4-08 (d))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (h)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 5-02 (27) (b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 5-02 (28))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 5-02 (29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210. 6-03 (i) (2))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210. 6-03 (i) (1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210. 6-03 (i) (2) (i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210. 6-03 (i) (2) (ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type: Balance Type: na Period Type: durationX-Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500, 000 warrants may be converted into 1, 000, 000 shares. ReferencesReference 1: <a href=) Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type: Balance Type: na Period Type: instantX-Definition Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. ReferencesReference 1: <http://asc.fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210. 6-05 \(4\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479617/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210. 6-05 (4))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479617/946-210-S99-2) Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210. 6-09 \(4\) \(b\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210. 6-09 (4) (b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3) Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 6-04 \(16\) \(a\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 6-04 (16) (a))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1) Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210. 6-09 \(7\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210. 6-09 (7))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3) Reference 6: [http://asc.fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 5-02 \(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://asc.fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 5-02 (29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type: Balance Type: na Period Type: instantX-Definition Number of shares of convertible preferred stock that is converted. ReferencesReference 1: [http://asc.fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 5-02 \(27\)\)-SubTopic 10-Topic 210-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://asc.fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 5-02 (27))-SubTopic 10-Topic 210-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) Reference 2: [http://asc.fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 5-02 \(28\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://asc.fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 5-02 (28))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) Reference 3: <http://asc.fasb.org/1943274/2147481112/505-10-50-3> Reference 4: [http://asc.fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-6](http://asc.fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-6) Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 16-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 16-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16) Details Name: us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type: Balance Type: na Period Type: instantX-Definition Per share conversion price of preferred stock. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(e\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (e)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13) Details Name: us-gaap_PreferredStockConvertibleConversionPrice Namespace Prefix: us-gaap_Data Type: dtr-types: perShareItem Type: Balance Type: na Period Type: instantX-Definition Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13) Reference 2: [http://asc.fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 5-02 \(28\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://asc.fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 5-02 (28))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_Data Type: dtr-types: perShareItem Type: Balance Type: na Period Type: instantX-Definition Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13) Reference 2: [http://asc.fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 5-02 \(28\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://asc.fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 5-02 (28))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type: Balance Type: na Period Type: instantX-Definition Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210. 6-05 \(4\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210. 6-05 (4))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)

FASB-URI <https://asc.fasb.org/1943274/2147479617/946-210-S99-2>Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-\(SX-210-6-09-\(4\)-\(b\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483575/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-(SX-210-6-09-(4)-(b))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483575/946-220-S99-3)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-6-04-\(16\)-\(a\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479617/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-6-04-(16)-(a))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479617/946-210-S99-1)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-\(SX-210-6-09-\(7\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483575/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-(SX-210-6-09-(7))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483575/946-220-S99-3)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-5-02-\(28\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-5-02-(28))))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> Details Name: us-gaap-PreferredStockSharesOutstanding Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instantX Definition The cash inflow from the additional capital contribution to the entity. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-14-Subparagraph-\(a\)-SubTopic-10-Topic-230-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-14-Subparagraph-(a)-SubTopic-10-Topic-230-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-14) Details Name: us-gaap-ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: durationX Definition Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-14-Subparagraph-\(a\)-SubTopic-10-Topic-230-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-14-Subparagraph-(a)-SubTopic-10-Topic-230-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-14) Details Name: us-gaap-ProceedsFromIssuanceOfPreferredStockAndPreferenceStock Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: durationX Definition The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-14-Subparagraph-\(a\)-SubTopic-10-Topic-230-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-14-Subparagraph-(a)-SubTopic-10-Topic-230-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-14) Details Name: us-gaap-ProceedsFromIssuanceOfPrivatePlacement Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: durationX Definition Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor. References No definition available. Details Name: us-gaap-SaleOfStockConsiderationReceivedPerTransaction Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: durationX Definition The number of shares issued or sold by the subsidiary or equity method investee per stock transaction. References No definition available. Details Name: us-gaap-SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: durationX Definition Price of a single share of a number of saleable stocks of a company. References No definition available. Details Name: us-gaap-SharePrice Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instantX Definition Number of new stock issued during the period. References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-SubTopic-10-Topic-505-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-505-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481004/946-505-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-505-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481004/946-505-50-2)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-\(SX-210-6-09-\(4\)-\(b\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483575/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-(SX-210-6-09-(4)-(b))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483575/946-220-S99-3)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-\(SX-210-6-03-\(i\)-\(1\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-(SX-210-6-03-(i)-(1))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479886/946-10-S99-3)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-5-02-\(28\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-5-02-(28))))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 6: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-3-04\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-3-04)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480008/505-10-S99-1)Reference 7: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-5-02-\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-5-02-(29))))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> Details Name: us-gaap-StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: durationX Definition Reduction in the number of shares during the period as a result of a reverse stock split. References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-SubTopic-10-Topic-505-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-2> Details Name: us-gaap-StockIssuedDuringPeriodSharesReverseStockSplits Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: durationX Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-SubTopic-10-Topic-505-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic-946-SubTopic-830-Name-Accounting-Standards-Codification-Section-55-Paragraph-11-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480167/946-830-55-11>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-205-Name-Accounting-Standards-Codification-Section-45-Paragraph-4-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480767/946-205-45-4](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-205-Name-Accounting-Standards-Codification-Section-45-Paragraph-4-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480767/946-205-45-4)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-505-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481004/946-505-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-505-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481004/946-505-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-\(SX-210-6-09-\(4\)-\(b\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483575/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-(SX-210-6-09-(4)-(b))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483575/946-220-S99-3)Reference 6: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-5-02-\(28\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-5-02-(28))))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 7: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-3-04\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-3-04)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480008/505-10-S99-1)Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-5-02-\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-5-02-(29))))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> Details Name: us-gaap-StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: durationX Definition Description of the total capital structure change due to a stock dividend, stock split and reserve split occurring after the balance sheet date but prior to the later of the issuance of financial statement or the effective date of registration statement. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-4-Subparagraph-\(SAB-Topic-4-C\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480008/505-10-S99-4](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-4-Subparagraph-(SAB-Topic-4-C)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480008/505-10-S99-4) Details Name: us-gaap-StockholdersEquityNoteChangesInCapitalStructureRetroactiveImpact Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: durationX Definition Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-4-Subparagraph-\(SAB-Topic-4-C\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480008/505-10-S99-4](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-4-Subparagraph-(SAB-Topic-4-C)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480008/505-10-S99-4) Details Name: us-gaap-StockholdersEquityReverseStockSplit Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: durationX Details Name: us-gaap-StatementClassOfStockAxis = IMNN-SeriesAConvertibleRedeemablePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X Details Name: us-gaap-StatementClassOfStockAxis = IMNN-SeriesBConvertibleRedeemablePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X Details Name: us-gaap-TypeOfArrangementAxis = IMNN-MarketOfferingAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X Details Name: us-gaap-TypeOfArrangementAxis = IMNN-SecuritiesPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X Details Name: us-gaap-SubsidiarySaleOfStockAxis = IMNN-AprilRegisteredDirectOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X Details Name: srt-RangeAxis = srt-MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X Details Name: srt-RangeAxis = srt-MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X Details Name: us-gaap-AwardTypeAxis = IMNN-TwentyTwentyOneRegistrationStatementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X Details Name: dei-LegalEntityAxis = IMNN-BabyShelfLimitationMember Namespace Prefix: Data Type: na Balance Type: Period Type: SUMMARY OF STOCK OPTIONS (Details)-USD (\$) 12 Months Ended Dec. 31, 2023 Dec. 31, 2022 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Number Outstanding, Outstanding, Ending balance 1,063,482 Number Outstanding, Exercisable, Ending balance 453,766 Share-Based Payment Arrangement, Option [Member] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Number Outstanding, Outstanding, Beginning balance 760,220 441,

425Weighted Average Exercise Price, Outstanding, Beginning balance \$ 4.55 \$ 38.50Number Outstanding, Options granted 432,500 716,156Weighted Average Exercise Price, Options granted \$ 1.23 \$ 2.72Number Outstanding, Options canceled or expired (129,238) (397,361) Weighted Average Exercise Price, Options canceled or expired \$ 9.37 \$ 39.06Number Outstanding, Outstanding, Ending balance 1,063,482 760,220Weighted Average Exercise Price, Outstanding, Ending balance \$ 2.61 \$ 4.55Weighted Average Remaining Contractual Term (years), Outstanding, Ending balance 8 years 9 months 18 days Aggregate Intrinsic Value, Outstanding, Ending balance Number Outstanding, Exercisable, Ending balance 453,766 Weighted Average Exercise Price, Exercisable, Ending balance \$ 3.64 Weighted Average Remaining Contractual Term (years), Exercisable, Ending balance 8 years 6 months Aggregate Intrinsic Value, Exercisable, Ending balance X-DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. ReferencesReference 1:

gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type: Balance Type: debit Period Type: instantX-Definition Number of options outstanding, including both vested and non-vested options. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\) \(1\) \(i\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e) (1) (i)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\) \(1\) \(ii\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e) (1) (ii)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type: Balance Type: na Period Type: instantX-Definition Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\) \(1\) \(i\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e) (1) (i)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\) \(1\) \(ii\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e) (1) (ii)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap Data Type: xbrli:dtr-types:perShareItem Type: Balance Type: na Period Type: instantX-Definition Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\) \(1\) \(iv\) \(01\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e) (1) (iv) (01)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type: Balance Type: na Period Type: durationX-Definition Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2>Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type: Balance Type: debit Period Type: instantX-Definition Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDtnHnMns' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2>Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap Data Type: xbrli:durationItem Type: Balance Type: na Period Type: durationX-Definition Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDtnHnMns' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2>Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap Data Type: xbrli:durationItem Type: Balance Type: na Period Type: durationX-Details Name: us-gaap_AwardTypeAxis = us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: SUMMARY OF NON-VESTED RESTRICTED STOCK AWARDS (Details) - \$ / shares 12 Months Ended Dec. 31, 2023 Dec. 31, 2022 Share-Based Payment Arrangement [Abstract] Number Outstanding, Non-vested stock awards, Outstanding, Beginning balance 69, 650 1, 481 Weighted Average Grant Date Fair Value, Non-vested stock awards, Outstanding, Beginning balance \$ 1.92 \$ 12.36 Number Outstanding, Non-vested stock awards, Granted 22, 100 69, 650 Weighted Average Grant Date Fair Value, Non-vested stock awards, Granted \$ 0.92 \$ 1.92 Number Outstanding, Non-vested stock awards, Vested and issued (59, 450) (1, 381) Weighted Average Grant Date Fair Value, Non-vested stock awards, Vested and issued \$ 1.91 \$ 12.04 Number Outstanding, Non-vested stock awards, Forfeited (200) (100) Weighted Average Grant Date Fair Value, Non-vested stock awards, Forfeited \$ 4.60 \$ 9.45 Number Outstanding, Non-vested stock awards, Outstanding, Ending balance 32, 100 69, 650 Weighted Average Grant Date Fair Value, Non-vested stock awards, Outstanding, Ending balance \$ 1.23 \$ 1.92X-ReferencesNo definition available. Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type: Balance Type: na Period Type: durationX-Definition The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\) \(2\) \(iii\) \(03\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (2) (iii) (03)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type: Balance Type: na Period Type: durationX-Definition Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\) \(2\) \(iii\) \(03\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (2) (iii) (03)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type: Balance Type: na Period Type: durationX-Definition The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\) \(2\) \(iii\) \(01\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (2) (iii) (01)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type: Balance Type: na Period Type: durationX-Definition The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\) \(2\) \(iii\) \(01\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (2) (iii) (01)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type: Balance Type: na Period Type: durationX-Definition The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\) \(2\) \(i\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (2) (i)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\) \(2\) \(ii\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (2) (ii)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type: Balance Type: na Period Type: instantX-Definition Per share or unit weighted average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\) \(2\) \(i\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (2) (i)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\) \(2\) \(ii\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (2) (ii)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type: Balance Type: na Period Type: instantX-Definition The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\) \(2\) \(iii\) \(02\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (2) (iii) (02)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type: Balance Type: na Period Type: durationX-Definition The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance

requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. ReferencesReference 1:

gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Namespace Prefix: us-gaap-Data Type: dtr- types: percentItem Type Balance Type: na-Period Type: durationX-Definition The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. References No definition available. Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Namespace Prefix: us-gaap-Data Type: dtr- types: percentItem Type Balance Type: na-Period Type: durationX-Definition The maximum risk-free interest rate assumption that is used in valuing an option on its own shares. References No definition available. Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Namespace Prefix: us-gaap-Data Type: dtr- types: percentItem Type Balance Type: na-Period Type: durationX-Definition The minimum risk-free interest rate assumption that is used in valuing an option on its own shares. References No definition available. Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Namespace Prefix: us-gaap-Data Type: dtr- types: percentItem Type Balance Type: na-Period Type: durationX-Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 35-Paragraph 1D-Publisher FASB-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 35-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3> Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\) \(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a) (1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\) \(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a) (2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\) \(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a) (3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\) \(1\) \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e) (1) (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\) \(1\) \(ii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e) (1) (ii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\) \(1\) \(iii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e) (1) (iii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\) \(1\) \(iv\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e) (1) (iv)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\) \(1\) \(iv\) \(01\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e) (1) (iv) (01)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\) \(1\) \(iv\) \(02\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e) (1) (iv) (02)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\) \(1\) \(iv\) \(03\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e) (1) (iv) (03)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\) \(1\) \(iv\) \(04\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e) (1) (iv) (04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\) \(2\) \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e) (2) (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\) \(2\) \(ii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e) (2) (ii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\) \(2\) \(iii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e) (2) (iii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\) \(2\) \(iii\) \(01\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e) (2) (iii) (01)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\) \(2\) \(iii\) \(02\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e) (2) (iii) (02)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\) \(2\) \(iii\) \(03\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e) (2) (iii) (03)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) Reference 20: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(d\) \(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d) (1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(d\) \(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d) (2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\) \(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e) (1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) Reference 23: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\) \(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e) (2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) Reference 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(f\) \(2\) \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f) (2) (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) Reference 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(f\) \(2\) \(ii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f) (2) (ii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) Reference 26: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(f\) \(2\) \(iii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f) (2) (iii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) Reference 27: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(f\) \(2\) \(iv\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f) (2) (iv)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) Reference 28: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(f\) \(2\) \(v\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f) (2) (v)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap-Data Type: xbrli:stringItem Type Balance Type: na-Period Type: durationX-Definition Expected term of award under share-based payment arrangement, in 'PnYnMnDtnHnMns' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(f\) \(2\) \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f) (2) (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap-Data Type: xbrli:durationItem Type Balance Type: na-Period Type: durationX-Details Name: srt-RangeAxis = srt-MinimumMember Namespace Prefix: Data Type: na-Balance Type: X-Details Name: srt-RangeAxis = srt-MaximumMember Namespace Prefix: Data Type: na-Balance Type: Period Type: STOCK-BASED COMPENSATION (Details Narrative) USD (\$) \$ / shares in Units, \$ in Millions 12 Months Ended Dec. 31, 2023 Dec. 31, 2022 Jun. 14, 2022 Jun. 10, 2021 Jun. 15, 2020 May 14, 2019 May 15, 2018 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Unrecognized compensation cost \$ 0.4 Cost recognized over a weighted-average period 1 year 9 months 18 days Equity Stock Awards [Member] Granted Under 2018 Plan and 2007 Plan [Member] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Common stock, reserved for future issuance 768, 731 Inducement Awards [Member] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Common stock, reserved for future issuance 294, 751 Stock Options and Restricted Stock Awards [Member] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share based compensation \$ 0.8 \$ 2.7 Stock Options and Restricted Stock Awards [Member] Research and Development Expense [Member] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share based compensation 0.2 0.9 Stock Options and Restricted Stock Awards [Member] General and Administrative Expense [Member] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share based compensation \$ 0.6 \$ 1.8 2018 Stock Incentive Plan [Member] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-based payment award, shares authorized 180, 000 Shares available for issuance 1, 206, 342 Stock options, strike price description Options are generally granted with strike prices equal to the fair market value of a share of Imunon common stock on the date of grant. Incentive stock options may be granted to purchase shares of common stock at a price not less than 100% of the fair market value of the underlying shares on the date of grant, provided that the

exercise price of any incentive stock option granted to an eligible employee owning more than 10% of the outstanding stock of Imunon must be at least 110% of such fair market value on the date of grant. Only officers and key employees may receive incentive stock options. Common stock, reserved for future issuance 1, 975, 073 2018 Stock Incentive Plan [Member] Minimum [Member] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Shares available for issuance 1, 030, 000 513, 333 166, 667 80, 000 2018 Stock Incentive Plan [Member] Maximum [Member] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Shares available for issuance 1, 970, 000 940, 000 426, 667 260, 000 Inducement Option Grants [Member] Five New Employees [Member] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Exercise price per share \$ 1. 59 Inducement Option Grants [Member] Five New Employees [Member] Restricted Stock [Member] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Restricted stock 91, 350 Inducement Option Grants [Member] Five New Employees [Member] Common Stock [Member] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Restricted stock 294, 751 X-Definition Stock options, strike price description. ReferencesNo definition available. Details Name: IMNN-StockOptionsStrikePriceDescription Namespace Prefix: IMNN-Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-Definition Amount of expense for award under share-based payment arrangement. Excludes amount capitalized. ReferencesReference 1:

[gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized](#) Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instantX-Definition The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic718-SubTopic10-Section50-Paragraph2-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480429/718-10-50-2> Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instantX-Definition Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(c\)\(1\)\(iv\)\(01\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(c)(1)(iv)(01)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480429/718-10-50-2) Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap Data Type: dti-types:perShareItem Type Balance Type: na Period Type: durationX-Definition Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph2-SubTopic10-Topic505-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147481112/505-10-50-2> Details Name: us-gaap_SharesIssued Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instantX-Details Name: us-gaap_AwardTypeAxis = IMNN_EquityStockAwardsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: srt_StatementScenarioAxis = IMNN_GrantedUnderTwoThousandAndEighteenPlanAndTwoThousandSevenPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap_AwardTypeAxis = IMNN_InducementAwardsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap_AwardTypeAxis = IMNN_EmployeeStockOptionAndRestrictedStockAwardsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap_IncomeStatementLocationAxis = us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap_IncomeStatementLocationAxis = us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap_PlanNameAxis = IMNN_TwoThousandAndEighteenStockIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: srt_RangeAxis = srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: srt_RangeAxis = srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap_PlanNameAxis = IMNN_InducementOptionGrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: srt_TitleOfIndividualAxis = IMNN_FiveNewEmployeesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap_AwardTypeAxis = us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: SCHEDULE OF CHANGES IN EARN-OUT MILESTONE LIABILITY (Details) 12 Months Ended Dec. 31, 2022 USD (\$) Earn-out Milestone Liability Earn-out liabilities, beginning balance \$ 5,396,000 Non-cash gain/loss from the adjustment for the change in fair value (\$ 5,396,000) Earn-out liabilities, ending balance X-References No definition available. Details Name: IMNN_DisclosureEarnoutMilestoneLiabilityAbstract Namespace Prefix: IMNN Data Type: xbrli:stringItem Type Balance Type: na Period Type: durationX-Definition Earn-out liabilities, beginning balance. References No definition available. Details Name: IMNN_EarnoutMilestoneLiability Namespace Prefix: IMNN Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instantX-Definition The amount of gain (loss) from the change in the fair value of earn-out milestone liability. References No definition available. Details Name: IMNN_GainLossFromChangeInFairValueOfEarnOutMilestoneLiability Namespace Prefix: IMNN Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration EARN-OUT MILESTONE LIABILITY (Details Narrative) USD (\$) \$ in Millions 12 Months Ended Jun. 20, 2014 Dec. 31, 2022 Mar. 28, 2019 EGWC, Inc [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Earnout payment options description each milestone (10% to 67%) and utilizing a discount rate based on the estimated time to achieve the milestone (1.5 to 2.5 years). Non-cash charge on earnout milestone liability \$ 5.4 Amended Asset Purchase Agreement [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Earnout milestone liability \$ 13.9 \$ 12.4 Amended Asset Purchase Agreement [Member] Within One Year of Achieving Milestone [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Earnout milestone liability \$ 30.4 Amended Asset Purchase Agreement [Member] 10 Business Days of Achieving Milestone [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Earnout milestone liability \$ 7.0X-Definition Earnout milestone liability. References No definition available. Details Name: IMNN_EarnoutMilestoneLiability1 Namespace Prefix: IMNN Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instantX-Definition Earn-out payment options, description. References No definition available. Details Name: IMNN_EarnoutPaymentOptionsDescription Namespace Prefix: IMNN Data Type: xbrli:stringItem Type Balance Type: na Period Type: durationX-Definition Non-cash charge on earnout milestone liability. References No definition available. Details Name: IMNN_NoncashChargeOnEarnoutMilestoneLiability Namespace Prefix: IMNN Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: durationX-Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic808-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph\(d\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147479402/808-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic808-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph(d)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147479402/808-10-50-1) Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: durationX-Details Name: us-gaap_BusinessAcquisitionAxis = IMNN_EGWCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap_TypeOfArrangementAxis = IMNN_AmendedAssetPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap_RelatedPartyTransactionAxis = IMNN_AchievingMilestoneWithinOneYearMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap_RelatedPartyTransactionAxis = IMNN_CertainBusinessDaysOfAchievingMilestoneMember Namespace Prefix: Data Type: na Balance Type: Period Type: SUMMARY OF WARRANT ACTIVITY (Details) USD (\$) 12 Months Ended Dec. 31, 2023 Dec. 31, 2022 Warrants Number of Warrants Issued, Warrants outstanding, Beginning balance 168,519 175,792 Weighted Average Exercise Price, Warrants outstanding, Beginning balance \$ 19.78 \$ 20.96 Number of Warrants Issued, warrants expired (8,459) (7,273) Weighted Average Exercise Price, Warrants expired \$ 37.29 \$ 48.30 Number of Warrants Issued, Warrants outstanding, Ending balance 160,060 168,519 Weighted Average Exercise Price, Warrants outstanding, Ending balance \$ 18.86 \$ 19.78 Aggregate intrinsic value of outstanding warrants Weighted average remaining contractual terms (years) 2 years 2 months 12 days X-References No definition available. Details Name: IMNN_DisclosureWarrantsAbstract Namespace Prefix: IMNN Data Type: xbrli:stringItem Type Balance Type: na Period Type: durationX-Definition Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan. References No definition available. Details Name: IMNN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice Namespace Prefix: IMNN Data Type: dti-types:perShareItem Type Balance Type: na Period Type: instantX-Definition Sharebased compensation arrangement by sharebased payment award non options outstanding intrinsic value. References No definition available. Details Name: IMNN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue Namespace Prefix: IMNN Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instantX-Definition Weighted average remaining contractual term for non-option awards outstanding, in 'PnYnMdTnInMns' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. References No definition available. Details Name: IMNN_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: IMNN Data Type: xbrli:durationItem Type Balance Type: na Period Type: durationX-Definition Number of shares under non-option equity instrument agreements for which rights to exercise lapsed. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(c\)\(1\)\(iv\)\(4\)-SubTopic10-Topic718-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(c)(1)(iv)(4)-SubTopic10-Topic718-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480429/718-10-50-2) Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: durationX-Definition Number of equity instruments other than options outstanding, including both vested and non-vested instruments. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(c\)\(1\)\(i\)-SubTopic10-Topic718-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(c)(1)(i)-SubTopic10-Topic718-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480429/718-10-50-2) Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(c\)\(1\)\(ii\)-SubTopic10-Topic718-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(c)(1)(ii)-SubTopic10-Topic718-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480429/718-10-50-2) Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instantX-Definition Weighted average price at which grantees could have acquired the underlying shares

with respect to stock options of the plan that expired. ReferencesReference 1:

disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 5-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (g)(1)-Publisher FASB-URI https://asc.fasb.org//1943274/2147478964/842-20-50-4

Details-Name: us-gaap-OperatingLeasePayments-namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-Definition Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.

References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (b)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 360-SubTopic 10-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482099/360-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210. 5-03.3)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Details-Name: us-gaap-OtherDepreciationAndAmortization-namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-Definition Cash payments to lessor's for use of assets under operating leases.

References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph (g)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-25

Details-Name: us-gaap-PaymentsForRent-namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-Details-Name: us-gaap-TypeOfArrangementAxis = IMNN-LeaseAgreementMember-namespace Prefix: Data Type: na Balance Type: Period Type: X-Details-Name: srt-RangeAxis = srt-MinimumMember-namespace Prefix: Data Type: na Balance Type: Period Type: X-Details-Name: srt-RangeAxis = srt-MaximumMember-namespace Prefix: Data Type: na Balance Type: Period Type: TECHNOLOGY DEVELOPMENT AND LICENSING AGREEMENTS (Details Narrative)-Hisun [Member] \$ in Millions Jan. 18, 2013 USD (\$) Accounts, Notes, Loans and Financing Receivable [Line Items] Proceeds from license fees received \$ 5.0 Deferred revenue \$ 5.0 Deferred revenue amortization period 10 yearsX-Definition The amortization period for deferred revenue.

References No definition available.

Details-Name: IMNN-DeferredRevenueAmortizationPeriod-namespace Prefix: IMNN-Data Type: xbrli:durationItemType Balance Type: na Period Type: durationX-Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

References No definition available.

Details-Name: us-gaap-AccountsNotesAndLoansReceivableLineItems-namespace Prefix: us-gaap-Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.

References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 5-02 (26) (c))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Details-Name: us-gaap-DeferredRevenue-namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-Definition Cash received from licensees for license fees during the current period.

References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 45-Paragraph 25-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-25

Details-Name: us-gaap-ProceedsFromLicenseFeesReceived-namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-Details-Name: us-gaap-AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis = IMNN-HisunMember-namespace Prefix: Data Type: na Balance Type: Period Type: RELATED PARTY TRANSACTION (Details Narrative) Nov. 16, 2022 USD (\$) Convertible Note Purchase Agreement [Member] Transomic Technologies, Inc. [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Convertible and warrants \$ 375,000X-Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

References Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 808-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1

Details-Name: us-gaap-CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems-namespace Prefix: us-gaap-Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-Definition Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.

References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 5-02 (22))-SubTopic 10-Topic 210-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 7-03 (a) (16) (a) (2))-Publisher FASB-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 9-03 (16))-Publisher FASB-URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1

Details-Name: us-gaap-ConvertibleNotesPayable-namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-Details-Name: us-gaap-TypeOfArrangementAxis = IMNN-ConvertibleNotePurchaseAgreementMember-namespace Prefix: Data Type: na Balance Type: Period Type: X-Details-Name: dei-LegalEntityAxis = IMNN-TransomicTechnologiesIncMember-namespace Prefix: Data Type: na Balance Type: Period Type: